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Investigation of CCN1 role(s) in Mantle Cell Lymphoma (MCL) 
Afak Rasheed Salman Zaidi 
Abstract: 
Mantle Cell Lymphoma (MCL) is a comparatively rare non-Hodgkin`s lymphoma which 
is characterised by the overexpression of cyclin D1.  Many patients present with or 
progress to advanced stage disease within three years. Disease progression involves down 
regulation of cyclin D1. Moreover, MCL is broadly considered as an incurable disease 
with median survival of patients being 3-4 years. CCN1, a matricellular protein involved 
in stem cell signalling within the haematopoietic microenvironment is highly expressed 
in early stage MCL cells and down-regulated in advanced stage disease.   
We have used the human MCL cell lines REC1<G519<JVM2 as a model for disease 
aggression. We have investigated the role(s) of CCN1, cyclin D1 and cyclin dependent 
kinase inhibitors in MCL progression. CCN1 dysregulation is identified in MCL 
progression whereby the magnitude of CCN1 expression in human MCL cells is 
REC1˃G519˃JVM2 cells by RQ-PCR, depicting a decrease in CCN1 expression with 
disease progression. Further investigation of CCN1 protein expression by western 
blotting showed that whilst expression of full–length CCN1 (42kDa) barely altered 
through the cell lines, expression of the truncated form (20kDa) was high in REC1 cells 
(OD:1.0) reduced in G519 cells (OD:0.5) and barely detected in JVM2 cells depicting 
decreased with disease progression.   
We have then demonstrated that cyclin D1 and cyclin dependent kinase inhibitors 
(p21CIP1and p27KIP1) are also involved in disease progression using the above MCL cell 
line model. Cyclin D1 was highly expressed in REC1 cells (OD: 1.0), reduced to one fifth 
in G519 cells (OD: 0.2) and not detected by western blotting in JVM2 cells. p27KIP1 
followed a similar profile of expression as cyclin D1. Conversely, p21CIP1 was absent in 
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the REC1 cells and showed increasing expression in G519 and JVM2 cells. Subcellular 
localization detected p21CIP1/ p27KIP1 primarily within the cytoplasm and absent from the 
nucleus, consistent with altered roles in treatment resistance. Mitochondrial detection of 
p21 in the JVM2 cell line supports an additional anti-apoptotic role.  
CCN1 likely plays a key role in B cell development; dysregulation of CCN1 may support 
MCL progression with p21CIP1 and p27kIP1 forming molecular signatures associated with 
progressive disease. 
REC1 cells and JVM2 cells were genetically modified using lentivirus to identify the 
potential pathways associated with CCN1. CCN1 knockdown was performed in REC1 
cells (REC1 KD) and CCN1 overexpression in JVM2 cells (CCN1 OE). Proteomics 
analysis of JVM2 OE and REC1 KD revealed interesting results showing regulation of 
44 proteins. 19 proteins regulated by CCN1 that simultaneously downregulated in the 
CCN1 KD model and up-regulated in CCN1 OE model. 25 proteins modulated by CCN1 
that simultaneously up-regulated in CCN1 KD model and down-regulated in CCN1 OE 
model.  
Our results suggest novel roles for CCN1. Whilst CCN1 roles are substantial in solid 
tumour research, CCN1 role(s) within the haematopoietic compartment are less well 
defined or investigated.  CCN1 may have potential role(s) as a novel pro-inflammation 
regulator by modulating macrophage migration inhibitory factor (MIF) and within 
regulation of haematopoiesis via pre-B cell colony enhancing factor (PBEF1). CCN1 was 
shown to modulate calcium ion signalling by targeting intracellular calcium receptor 
protein Calmodulin 3 (CALM 3). CCN1 altered Apolipoprotein M (ApoM) and Talin 1 
(TLN1) expression and could potentiate new targets to supplement treatment for MCL. 
However, these novel pathways would need further investigation to identify the role(s) of 
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CCN1 in B cell development and within the bone marrow microenvironment where 
regulation of haematopoiesis ensues.   
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Chapter 1 
1.1 Mantle Cell Lymphoma (MCL) 
Mantle cell lymphoma (MCL) is a distinct subset of B-cell Non Hodgkinʼs Lymphoma 
(NHL) characterised by overexpression of cyclin D1 as a result of t(11;14) chromosomal 
translocation (Perez-Galan, Dreyling & Wiestner, 2011). This translocation juxtaposes 
the cyclin D1 (CCND1) gene on chromosome 11q13 with the immunoglobulin heavy 
chain (IgH) gene on 14q32 which leads to cyclin D1 overexpression and the dysregulation 
of the cell cycle (O’Connor, 2007; Zucca & Bertoni, 2013). Disease progression often 
involves down regulation of cyclin D1 (Peng, Chou & Hsu, 1998).  In 1992, MCL was 
considered as a distinct entity (Banks et al., 1992) and in 1994, accepted by the Revised 
European American Classification for Lymphoma (REAL) (Wang & Ma, 2014). MCL 
accounts for 3-10% of all NHL (Marco & Lorenzo, 2012). Median age of onset for MCL 
is 60, with a bias for males to females in the order of 4:1 and it is often diagnosed at 
advanced stage (Ahrens et al., 2013). Patmore et al., (2016) have found in the study of 
MCL management and outcome in the United Kingdom population that in the period of 
2004-15 patients diagnosed with MCL were 327 with a median diagnostic age of 74 years 
(range 39-96) and 66% patients were male. In the United States (U.S.), (Wang & Ma, 
2014) have found that racial differences have seen among patients with MCL and these 
patients were caucasian, male, and elderly. Furthermore, the incidence of MCL had 
increased between 1992-2007 (Howlader et al., 2012: Zhou et al., 2008). MCL is 
considered an aggressive and incurable B-cell malignancy with poor prognosis with 
median survival being 3-4 years from diagnosis (Fisher et al., 2006; Habermann et al., 
2009). Many studies have indicated that the pathogenesis of MCL depends on epigenomic 
and genomic lesions which result in pathway dysregulation including cell cycle 
progression, protein homeostasis, DNA damage response, cell proliferation and apoptosis 
(Parekh, Weniger & Wiestner, 2011). In MCL, the genomic mutations involved in B-cell 
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development and maintenance, contribute to disrupt these gene pathways and epigenetic 
regulatory frameworks (Ahmed et al., 2016). Epigenetic changes in DNA methylation 
and histone modifications in MCL can lead to either aberrant expression of oncogenes or 
inhibition of tumour suppressor genes (Leshchenko et al., 2010; Sharma, Kelly & Jones, 
2010). Hutter et al. (2006) have found that the genetic mutation and a rare promoter of 
methylation of p16 (9% MCL cases) were associated with enhanced cell proliferation and 
can be considered as additional molecular mutations that are involved in MCL cell cycle 
dysregulation. Mutations in the cell cycle regulator p53, correlated with high levels of 
proliferation and shortened survival associated with the aggressive variants of MCL 
(Hernandez et al., 1996). Many gene alterations involved in the PI3K/AKT, WNT and 
TGF beta signalling pathways, which are also aberrantly expressed in MCL correlated 
with pathogenesis of this disease and may be useful as therapeutic targets (Rizzatti et al., 
2005). World Health Organization classification of haematopoietic and lymphoid 
tumours indicated that the diagnosis of MCL depends on “different clinicopathological 
manifestations and molecular pathogenetic pathways”. Classical MCL which consists of 
IGHV-unmutated or minimally mutated B cells expressing SOX11 involves lymph nodes 
and other extranodal sites. Additional molecular / cytogenetic aberrations can lead to a 
more aggressive blastoid or pleomorphic MCL. Other MCL develop from IGHV-mutated 
SOX11- B cells which leads to leukemic non-nodal MCL, usually involving the Peripheral 
Blood (PB), bone marrow, and often spleen. These are often indolent unless additional 
molecular /cytogenetic aberrations have occurred (Swerdlow et al., 2016) (Figure 1.1). 
 Classical MCL is derived from a mutated naïve B cell (Cyclin D1 translocation or those 
that are CCND1 negative frequently have aberrations in cyclin D2 or D3) (Schieber, 
Gordon & Karmali, 2018). Whilst various reports show conflicting evidence of cyclin D1 
status by RNA or protein levels, SOX11 positivity or negativity is a much more reliable 
marker and is independent of Cyclin D1 status (Campo & Rule, 2015: Schieber, Gordon 
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& Karmali, 2018). Transient transition of cells through the mantle zone with SOX11+ 
causes sustained PAX5 expression which represses BLIMP-1 required for plasma cell 
differentiation, hence these tumours are unable to differentiate further (Nutt et al., 2015: 
Swerdlow et al., 2016) (Figure 1.1 B & D). In contrast, cells that are SOX11 negative 
traverse the germinal centre where somatic mutation of VDJ genes occur to enable 
repertoires of high affinity antibody producing cells to develop (Heesters, Myers & 
Carroll, 2014: Swerdlow et al., 2016) (Figure 1.1 B & C). These cells then become 
hypermutated and give rise to leukaemic non-nodal MCL with plasmablast like cells 
(Figure 1.1 B).  
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Figure 1.1 Origins of Mantle Cell Lymphoma.  
(A) MCL is characterised by the t(11;14) (q13;q32) 
gene translocation which arises from Cyclin D1 
(CCND1) on chromosome 11 being translocated and 
juxtaposed to the Immunoglobulin Heavy Chain 
(IgHC) between the J and D components for VDJ 
rearrangement required for antibody diversity.  
 
(B) Classical MCL arises from naïve B cells with 
SOX11+ plus unmutated / minimally mutated IGHV 
which are transiently within the mantle zone of the 
lymph node, accrual of additional mutations give rise 
to more aggressive blastoid or pleomorphic 
phenotypes. Leukaemic non-nodal MCL arises from 
cells that are SOX11 negative traversing the germinal 
centre where somatic mutation of Ig occurs for 
antibody diversity giving rise to hypermutated IGHV 
presenting in the Peripheral Blood (PB), Bone 
Marrow (BM) and spleen (Swerdlow et al., 2016).  
 
(C) The germinal centre of the lymph node: B cells 
present antigen to T helper cells and receive co-
stimulatory signals, selected cells enter the dark zone 
of the GC and undergo somatic hypermutation (SHM) 
by upregulating components of the SHM machinery, 
including activation-induced deaminase (AID). After 
one cycle (or possibly more cycles) of proliferation 
and SHM, the B cells migrate to the light zone; the 
mutated BCRs that are the product of SHM are now 
exposed to antigens that are incorporated into immune 
complexes on the follicular dendritic cells (FDCs). If 
the affinity of the BCR is very low, the B cell will not 
receive survival signals and will undergo apoptosis. 
The remaining B cells need to compete for limited T 
cell help, which favours the higher affinity B cells and 
forces the others to undergo apoptosis. Surviving B 
cells can re-enter the dark zone for further affinity 
maturation and SHM, they can exit the GC as plasma 
cells or they can exit as memory B cells. (Heesters, 
Myers & Carroll, 2014) 
A 
 
 
 
 
 
B 
 
 
 
 
 
 
 
C 
 
 
 
 
 
 
 
D (D) SOX11 + cells in the 
marginal zone of the lymph 
node induce sustained 
PAX5 expression. PAX 5 
inhibits BLIMP1 which is 
required for maturation of 
plasmablasts to plasma 
cells. In contrast, Follicular 
B cells require PAX5 and 
PU.1 for maturation of 
Memory B cells  (Nutt et 
al., 2015) 
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Cyclin D1 status in MCL has conflicting reports depending on whether mRNA or protein 
levels were evaluated and disparity between RNA and protein evaluations exist (Amin et 
al., 2003: Weinstein et al., 2012). This may in part be explained by compartmentalisation 
of the protein in either nuclear or cytoplasmic fractions in MCL (Body et al., 2017). 
Cytoplasmic Cyclin D1 expression results in increased invasive capacity and aggressive 
behaviour; increased engraftment into the bone marrow, spleen and brain in 
immunodeficient mice. Or perhaps, disparity in reports occur by lack of reporting on 
Cyclin D1a and b isoforms (Marzec at al., 2006). Subsequently, SOX11 has been 
identified as a much better clinical marker for classical and blastoid MCL (Campo & Rule, 
2015: Schieber, Gordon & Karmali, 2018).  
IGHV mutation status can therefore be useful clinically; the presence of IGHV mutation 
shows transition through the germinal centre with usual somatic hypermutation occurring 
corresponding to a more favourable prognosis in MCL. However, MCL is derived from 
a naïve B cell whereas Chronic Lymphocytic Leukaemia (CLL) is derived from an 
antigen experienced mature B cell (Figure 1.2). IGHV status is a prognostic indicator in 
CLL whereby unmutated IGHV dictates a poor clinical course with reduced response to 
chemotherapy and progression free survival rates (Rozovski, Keating & Estrov, 2018). 
Mutated IGHV correlates with good responses to chemotherapy and good overall survival 
rates. The rationale for this has been elusive over many years. The current theory in CLL 
proposes that in high proliferating tumours DNA breaks are repaired by efficient high 
fidelity homology directed DNA repair mechanisms resulting in low or no IGHV 
mutation, whilst slowly dividing tumours are repaired by inefficient and low fidelity non-
homologous end joining mechanisms resulting in IGHV mutation (Rozovski, Keating 
& Estrov, 2018) and better response to chemotherapy. This is consistent with Patten et 
al., 2012, who identified that activation induced deaminase (AID) which is required for 
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‘class switching’ and IGHV mutation in B cells, showed a better overall survival rate for 
AID+ patients versus AID- patients (Fig 1.1 C). 
 
Figure 1.2 Origins of B cell disorders. Mantle cell lymphoma is derived from aberrations in naïve B 
cells either transiently transitioning across the mantle zone of the lymph node forming classical MCL 
or through the germinal centre forming non-nodal MCL. Chronic Lymphocytic Leukaemia is derived 
aberrations in antigen experienced mature B cells within the germinal centres of the lymph node 
required for production of high affinity antibodies by clonal selection and memory B cells. Frequently, 
de-regulated programming occurs within B cell malignancies for cell cycle regulation, DNA damage 
response mechanisms, differentiation, somatic mutation and class switching programmes required for 
antibody responses. Image taken from 
http://www.ufrgs.br/imunovet/molecular_immunology/pathohomotissueblood_WBCneoplasm.html 
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MCL is one of the most challenging of all NHL to treat, according to the poor overall 
survival post-treatment with conventional chemotherapy (Romaguera et al., 2010). Many 
studies have suggested that the microenvironment plays an important role in the 
pathogenesis of several B-cell malignancies and indicated that tumour host interactions 
in MCL may be more important than was previously thought. The microenvironmental 
factors are potentially responsible for determination of disease localization or progression 
of malignant cell expansion or both (Kurtova et al., 2009). MCL can involve bone marrow, 
secondary lymphoid organs and gastrointestinal tissue at advanced stages. The cross talk 
between MCL cells and their microenvironment can contribute to disease progression by 
enhancing tumour survival, growth and drug resistance (Burger & Ford, 2011; Kurtova 
et al., 2009). Several aberrant signalling pathways are involved in growth of MCL cell 
including AKT, phosphatidylinositol 3-kinase (PI3K), mammalian target of rapamycin 
(mTOR), nuclear factor kappaB (NFkB), WNT, and Notch (Kridel et al., 2012; Noel, 
Friedberg & Barr, 2012; Rizzatti et al., 2005). Consequently, novel approaches are 
urgently needed to effectively treat MCL patients by targeting specifically the MCL 
associated signalling pathways. 
 
1.2 Stages of Mantle Cell Lymphoma (MCL) 
MCL is a tumour derived from immature peripheral B lymphocytes, classified by stage 
of disease according to distinct morphologic, immunologic and genetic phenotype (Leitch 
et al., 2003; Pervez, Haroon & Awan, 2015). MCL is characterised by classic (common 
variant) associated with early stage and blastoid and pleomorphic (aggressive and rare 
variants) associated with advanced stage of disease (Pervez, Haroon & Awan, 2015). The 
‘classic’ variant has relatively favourable characteristics, with the ‘blastoid’ variant being 
aggressive with high proliferative capacity. The ‘pleomorphic’ variant mimicks diffuse 
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large B cell lymphoma (DLBCL) and is characteristically cyclin D1 negative with poor 
survival rates of under 1 year (Chuang et al., 2017). The classic variant of MCL which 
carries t(11;14) chromosomal translocation leading to cyclin D1 overexpression have 
longer-survival than patients that are cyclin D1 negative (Yatabe et al., 2000). Patients 
with cyclin D1 negative present aggressive behaviour (blastoid and pleomorphic), poor 
prognosis and short-survival with cyclin D2 translocation leading to cyclin D2 
overexpression (Bernard et al., 2001; Seto, 2013; Tiemann et al., 2005). Recently, SOX11, 
a transcription factor, which is overexpressed in MCL cyclin D1 negative phenotype is 
considered as a biomarker (Narurkar, Alkayem & Liu, 2016). In 2009, (Mozos et al.) 
found overexpression of protein and mRNA of SOX11 in cyclin D1 negative cases as 
well as cases of cyclin D1 positive. All most all stages of MCL (except rare cases of 
blastoid and pleomorphic variants) present with CD20+, CD5+, cyclin D1+ and Bcl+ 
however, secondary genetic alterations are found in progressive MCL (aggressive 
blastoid and pleomorphic variants) (Kwatra et al., 2016). For example, mutation in ATM, 
TP53, c-myc and BCL6 genes have been associated with MCL progression (Beà et al., 
1999; Hao et al., 2002; Jares, Colomer & Campo, 2012; Royo et al., 2011; Setoodeh et 
al., 2013). In a rare case, CD5- with CCND1/IGH and myc alterations which were 
identified in patient with blastoid MCL associated with resistance to conventional 
treatment, poor prognosis and poor-survival (1 month after diagnosis) (Seok et al., 2012). 
Each stage of MCL has specific molecular characteristics associated with resistance to 
treatment, however subclassification of MCL is essential to infer  prognostic indicators 
and potential beneficial treatment strands (Zhou et al., 2015).                               
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1.3 Treatment of Mantle Cell Lymphoma (MCL) 
MCL is considered an aggressive disease and has one of the worst outcomes among B-
cell lymphomas due to the dysregulation of the DNA damage response pathways 
accompanied with abnormal cell survival mechanisms suppressing apoptosis (Campo & 
Rule, 2015; Moros et al., 2014). MCL is characterised by clinical course where variants 
are subdivided into indolent form (classic morphology) and aggressive (blastoid or 
pleomorphic appearance) (Kridel et al., 2012). The MCL International Prognostic Index 
(MIPI) stratifies MCL patients into low, intermediate and high risk groups depending on 
age, Eastern Cooperative Oncology Group (ECOG) performance status, white blood cell 
counts and lactate dehydrogenase level (Hoster et al., 2008). The heterogeneous biology 
and aggressive behaviour of MCL present a challenge for designing standard therapies 
(Smith, 2011). Moreover, patients with MCL who initially responded to first-line 
immunochemotherapy, but have shown chemoresistance in relapses are associated with 
poor outcome (Goy et al., 2015). Similarly, short-term remissions are predominant with 
conventional chemotherapy and median survival is usually 3-6 years (Vose, 2015). High 
dose chemotherapy followed by autologous stem-cell transplantation shows improved 
outcomes with event free survival (EFS) >60% at 6 years however, the potential for cure 
resides within allogeneic bone marrow transplants, but this procedure is only feasible for 
younger patients (Avivi & Goy, 2015: Campo & Rule, 2015: Ghielmini & Zucca, 2009) 
(Figure 1.3). Recently, four novel agents have been approved for patients with MCL: 
Temsirolimus (mTOR inhibitor), Lenalidomide (anti-angiogenesis), Ibrutinib (Bruton`s 
Tyrosine Kinase inhibitor), and Bortezomib (NFkB inhibitor) (Avivi & Goy, 2015: 
Campo & Rule, 2015). The mechanism of action of each are reviewed in the subsequent 
sections.  
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Figure 1.3 Mantle cell lymphoma first line treatment strands and clinical trials for refractory 
disease. (A) Schematic of first line treatment schedules for MCL including autograft and variations of 
CHOP (HyperCVAD alternating with high-dose methotrexate/cytarabine alternating with high-dose 
methotrexate/cytarabine regimen), R-Rituximab anti-CD20 monoclonal antibody (Campo & Rule, 2015). 
(B) Clinical trials for novel targeting agents used in MCL. ORR-Overall Response Rate, CR- Complete 
Response, PFS-Progression Free Survival, MTP- Months to Progression, AST – alanine amino 
transferase, ALT – aspartate amino transferase (Chen, Sanchez & Rosen, 2016). 
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1.3.1 Temsirolimus 
Cell cycle inhibitor-779 (CCI-779) currently known as temsirolimus is derived from 
rapamycin and is a selective inhibitor of mammalian target of rapamycin (mTOR) 
signalling protein which is dysregulated in MCL (Galimberti & Petrini, 2010; Müller et 
al., 2013). In the United States, temsirolimus has been approved to treat advanced renal 
cell carcinoma (RCC), in the European Union (EU) it has been approved to treat RCC 
and relapsed or refractory MCL.  
mTOR is a downstream mediator in the phosphoinositide-3-kinase-protein kinase B 
(PI3K/Akt) pathway which is activated by growth factor receptor signalling, activation 
of PI3K/AKT pathways, and other cell stimuli. mTOR which structurally and functionally 
contains 2 distinct complexes mTORC1 and mTORC2 plays a central role in cell growth 
and proliferation, regulation of apoptosis, and angiogenesis by regulating synthesis of 
several proteins including cyclin D1, c-myc  and HIF α (Kim, Cook & Chen, 2017; Le 
Tourneau et al., 2008). In cancer, hyper activation of mTOR leads to stimulate the 
translation of mRNA encoding for cell cycle regulatory proteins (Morita et al., 2015; Rini, 
2008). Temsirolimus prevents the activation of mTOR through binding with FK506-
binding protein (FKBP) and the protein-drug complex supresses the kinase activity of 
mTORC1 (Figure 1.4). However, the mTORC2 isoform can be still activated even in the 
presence of temsirolimus (Le Tourneau et al., 2008). In 2015, (Campo & Rule) have 
reviewed four drugs (Ibrutinib, Bortezomib, Lenalidomide, and Temsirolimus) which 
have been recently approved for MCL.  The overall response rate (ORR) was 68%, 33%, 
28%, and 22% and the duration of response (DOR) was 17.5, 9.2, 16.6, 7.1 months. 
Temsirolimus was the least active of these drugs, showing limited effect when used as a 
single agent.                              
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Figure 1.4 Mechanism of action of Temsirolimus and mTOR signalling: Temsiromas inhibits mTOR 
signalling pathway by targeting mTOR Complex1 (mTORC1) that consists of regulatory-associated protein 
of mTOR (raptor), mLST8 and GβL. Activated mTORC1 which finds in cytoplasm phosphorylates p70S6K 
leading to induce cell growth and angiogenesis through promote translation and production of hypoxia-
inducible factor α (HIFα). Furthermore, mTORC1 phosphorylates 4E-binding protein-1 (4E-BP1) leading 
to regulation of cell growth and apoptosis by regulating synthesis of several proteins including cyclin D1, 
c-myc. Temsirolimus prevents the activation of mTOR through binding with FK506-binding protein (FKBP) 
and protein-drug complex supresses the kinase activity of mTORC1. Image from (Rini, 2008).       
 
 
1.3.2 Bortezomib 
Bortezomib, a reversible proteasome inhibitor (PI) was approved to treat patients with 
MCL by Food and Drug Administration (FDA, 2006) (Kane et al., 2007). It is a boronic 
acid derivative which binds and suppresses the 26S proteasome that regulates critical 
cellular functions for example, inhibition of nuclear factor-kB (NFkB), inhibition of 
angiogenesis, apoptosis and regulation of cell cycle proteins (Figure 1.5) (Crawford & 
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Irvine, 2013). The 26S proteasome which composes of a core particle 20S and 2 
regulatory particles 19S is a proteolysis part of ubiquitin proteasome system (UPS) 
(Wehmer & Sakata, 2016). In normal cells, the UPS regulates intracellular protein 
homeostasis (protein synthesis and degradation) leading to degradation of damaged, 
oxidized, or misfolded proteins. UPS plays a pivotal role in regulation of cell cycle control, 
transcription, DNA damage repair, antigen presentation and apoptosis (Streich Jr & Lima, 
2014). In MCL, many studies have shown that the bortezomib has an anti-tumour impact 
with responses between 30%-50% of patients (Fisher et al., 2006; Leshchenko et al., 
2015). It induced cell cycle halt and apoptosis through inhibition of NFkB activation 
which is aberrantly active in MCL (Pham et al., 2003). Furthermore, preclinical 
researches have shown that the anti-tumour effect of bortezomib has conducted through 
down regulation of anti-apoptotic proteins, up-regulation of pro-apoptotic proteins, and 
down regulation of proteins that implicated in DNA damage response (Mujtaba & Dou, 
2011). However, Noxa, a pro-apoptotic BCL-2 family member, is hypomethylated is 
regulated in response to Bortezomib inducing drug resistance (Leshchenko et al., 2015). 
Subsequently, increasing resistance to bortezomib has been shown in the large proportion 
of patients with MCL impeding its therapeutic activity (Zhao et al., 2015). 
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Figure 1.5 Mechanism of action of Bortezomib. Bortezomib inhibits NF-KB nuclear localization that 
enables the transcription of target genes for cell proliferation and survival. Activation of NF-KB translocated 
into the nucleus occurs by degradation of IKB kinase in the cytoplasm. The 26S proteasome is responsible 
for degradation of damaged, oxidized, or misfolded proteins. Suppression the 26S proteasome by 
bortezomib inhibits IKB degradation leading to inactivate NF-KB which in turn prevents transcription of 
genes necessary for tumour cell proliferation and survival. Image from (Sánchez-Serrano, 2006) 
 
1.3.3 Ibrutinib 
In 2013, Ibrutinib was approved for treatment of relapsed MCL by FDA. Ibrutinib targets 
Bruton's Tyrosine Kinase (BTK) which is an intracellular signalling molecule 
downstream of the B cell receptor (BCR) (Figure 1.6) (Pan et al., 2007; Roskoski Jr, 
2016). Stimulation of the BCR is essential for B cell function including cell proliferation, 
apoptosis, differentiation, cell migration, and cell survival (Callard & Hodgkin, 2007; Del 
Nagro et al., 2005; Richards et al., 2008). Constitutive activation of signalling molecules 
downstream of the B-cell receptor, contributes to tumour proliferation and survival of 
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malignant B cells in several types of NHL including MCL (Maffei et al., 2015; Tucker & 
Rule, 2015). BTK is essential mediator in the BCR signalling pathway by activating cell 
proliferation and survival (Byrd et al., 2013). Ibrutinib inhibits phosphorylation of BTK 
leading to irreversible inactivation of B-cell proliferation and survival (Tucker & Rule, 
2015). Furthermore, preclinical models have shown that the inactivation of downstream 
BTK pathways by ibrutinib leads to enhance tumour cell apoptosis and inhibits tumour 
cell proliferation (Akinleye et al., 2013; Raedler, 2015). In vivo, Herman et al. (2014) 
have found that ibrutinib prevents activation of BCR and NFkB signalling pathways 
resulting in inhibition of chronic lymphocytic leukaemia (CLL) cells proliferation. 
However, ibrutinib has antitumor activity in several types of NHL and resistance to 
ibrutinib has been observed in patients with CLL (Woyach et al., 2014; Young & Staudt, 
2014). Recently, Cheah et al. (2015) found that the MCL patients treated with Ibrutinib 
have a limited increased survival of around 8 months and a poor outcome for salvage 
therapy after treatment with ibrutinib. Resistance to ibrutinib predominantly implicates 
mutation of a cysteine residue C481S, within the ibrutinib binding site, causing reversible 
inhibition rather than irreversible inhibition of BCR signalling (Tucker & Rule, 2015).                                              
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Figure 1.6 The mechanism of Ibrutinib blocking BTK signalling in hairy cell leukaemia. After 
stimulation of BCR receptors, LYN and SYK are phosphorylated leading to activate downstream BTK 
signalling which is phosphorylated leading to calcium release and induction of cell proliferation and 
survival. Ibrutinib inhibits BTK signalling reducing proliferation and survival. In conjunction with 
chemokine receptor CXCR4, Ibrutinib inhibits cell migration. Image from (Sivina et al., 2012).      
 
1.3.4 Lenalidomide      
Lenalidomide is an immunomodulatory drug (lMiD) which has been used therapeutically 
(Dawar & Hernandez-Ilizaliturri, 2012). The mechanism of action of lenalidomide is not 
completely understood, but includes both immunomodulatory and non-
immunomodulatory effects (Figure 1.7) (Habermann et al., 2009). Lenalidomide has been 
found to increase tumour cell apoptosis by inhibiting the production of pro-inflammatory 
cytokines (TNF-α, IL-1, IL-6, and IL-12) and enhancing expression of the anti-
inflammatory cytokine (IL-10) (Kotla et al., 2009; Reddy et al., 2008).   Lenalidomide 
also inhibits CDK2 activity which led to induce G0-G1 cell cycle arrest (Qian et al., 2011). 
Lenalidomide has also appeared to play a strong immunomodulating role through 
41 
 
activation of natural killer (NK) cells and improving the formation of so-called “immune 
synapses” between MCL cells and NK cells (Gaidarova et al., 2009). Moreover, treatment 
of patients with refractory/relapsed MCL with lenalidomide after failing response to 
ibrutinib was affective with 27% overall response rate and 13% complete response (Wang 
et al., 2016a). However, advanced stage MCL usually involves resistance to lenalidomide. 
Lenalidomide showed synergy when used in combination with dexamethasone by 
decreasing proliferation in cells taken from relapsed and refractory MCL patients and also 
within mouse models (Qian et al., 2011).   
 
Figure 1.7 Mechanism of action of lenalidomide. Lenalidomide has immunomodulatory and non-
immunomodulatory effects (anti-proliferative and anti-angiogenic) in lymphoid malignancies. 
Lenalidomide is considered as an anti-angiogenic, in part by decreasing microvessel density and inhibiting 
tumour growth and metastasis through depletion of monocytes/macrophages accompanied with 
lymphangiogenesis. Lenalidomide has anti-proliferative capacity through inhibition of cell cycle by 
ubiquitinating and degradation of the lymphoid transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos) 
leading to a decrease in NF-KB, decreased MYC and IRF4 (interferon regulatory factor 4) levels whilst 
increasing p21. Decreased IRF4 levels increase interferon production leading to enhanced apoptosis. The 
immunomodulatory effects of lenalidomide in lymphoid malignancies involve improvement of anti-tumour 
activity of T-cell and NK-cells. Image from (Kritharis et al., 2015).                          
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1.4 Combination treatment 
MCL presents clinically and biologically a heterogeneous disease with combination of an 
indolent and aggressive characterisations (Maddocks & Blum, 2015). Whilst recent 
therapies are an improvement in the treatment of MCL patients who are mostly >60 yrs, 
the development of therapy-resistance is inevitable and considered a huge problem 
(Ahrens et al., 2013). Patients with MCL initially respond to first line therapy but relapse, 
disease progression is frequent and considered a challenge to treat (Campo & Rule, 2015; 
Hitz et al., 2013). (Zhao et al.) (2015) suggested that combination therapy could improve 
the outcome of patients; using a combination of arsenic trioxide with low dose bortezomib 
was beneficial in MCL cell lines and primary cells to avoid the toxicity associated using 
higher doses of bortezomib alone. Rituximab, an anti-CD20 monoclonal antibody, was 
used as a therapeutic agent to treat MCL alone or in combination with other therapies 
(Foran et al., 2000; Wang et al., 2016b). In clinical trial, combination of rituximab with 
ibrutinib was effective to treat patients with relapse or refractory MCL (Wang et al., 
2016b). Similarly, rituximab used in combination with lenalidomide was active against 
relapsed or refractory MCL with a median progression–free survival of 11.1 months and 
median overall survival of 24.3 months (Wang et al., 2012). The combination of 
rituximab with lenalidomide was proposed as an initial therapy for MCL, improving the 
quality of life in vivo (Ruan et al., 2015). Studies using rituximab plus lenalidomide 
inhibited cell growth and enhanced apoptosis in MCL cell lines and in primary MCL cells 
(Zhang et al., 2009). The combination of rituximab with chemotherapy improved 
response rates and progression-free survival better than using chemotherapy alone in 
indolent MCL patients (Schulz et al., 2007). However, irrespective of all of these 
promising regimens currently in use, MCL is still an incurable disease where patients 
succumb to progressive disease.      
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1.5 CCN1 protein   
1.5.1 CCN family of matricellular proteins 
Tumour development and progression of cancer is dependent on the interaction between 
the tumour cells and their microenvironment (Chong et al., 2012). During this interaction 
the tumour cells and adjacent stromal cells abnormally secrete matricellular proteins 
which regulate cell-cell and cell-matrix interactions (Chong et al., 2012). CCN1, a 
matricellular protein is involved in stem cell signalling within the haematopoietic 
microenvironment (Wells et al., 2015). CCN1, also known as CYR61, belongs to CCN 
family of proteins named using acronym of the first three founding members CYR61 
(cysteine-rich protein 61), CTGF (connective tissue growth factor) and NOV 
(nephroblastoma overexpressed gene). To date, another three members of the CCN 
protein family have been discovered; WISP-1 (CCN4), WISP-2 (CCN5) and WISP-3 
(CCN6) (Wnt- induced secreted proteins) (Brigstock, 2003). All CCN proteins share 
about 40%-60% amino acid homology and comprise an N-terminal signal peptide 
followed by the four discrete domains with 38 conserved cysteine residues (Planque & 
Perbal, 2003). The discrete domains comprise an insulin-like growth factor binding 
protein domain (IGFBP), von Willebrand type C repeat (VWC), thrombospondin type 1 
domain (TSP-1) and cysteine knot carboxyl terminal (CT) (McCallum & Irvine, 2009) 
Apart from CCN5, which is deficient of the C-terminal module, the other CCN proteins 
include the 4 structural modules (Figure 1.8) (Holbourn, Acharya & Perbal, 2008). The 4 
structural domains of CCN1 may illustrate the diverse functions of the protein (McCallum 
& Irvine, 2009).  
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Figure 1.8 Structure of the CCN family protein. All CCN proteins share about 60% amino acid 
homology and comprise an N-terminal signal peptide followed by the four discrete domains with 38 
conserved cysteine residues which shown in dark grey and sequences required for protein function in light 
grey. The discrete domains comprise an insulin-like growth factor binding protein domain (IGFBP), von 
Willebrand type C repeat (VWC), thrombospondin type 1 domain (TSP-1) and cysteine knot carboxyl 
terminal (CT). Apart from CCN5, which is deficient of the C-terminal module, CCN1, CCN2, CCN3, 
CCN4 and CCN6 contain the four structural domains. Image from (McCallum & Irvine, 2009). IGF-
Insulin- like Growth Factor, BMP-4 Bone Morphogenic Protein 4, TGF-B Transforming Growth Factor 
Beta, LRP-1 low density lipoprotein receptor related 1, HSPG Heparan sulphate proteoglycans. Adapted 
from (Malik, Liszewska, & Jaworski, 2015)       
 
1.5.2 CCN1 protein 
CCN1 was originally considered as being a classic growth factor but later studies 
demonstrated that CCN1 induces expression of other growth factors for example, 
fibroblast growth factor and platelet-derived growth factor (Kireeva et al., 1996). Results 
accumulated over the past decade have indicated that CCN1 is involved in a diverse array 
of cellular processes including regulation of cell migration, cell adhesion, proliferation, 
differentiation, apoptosis and angiogenesis through direct binding to cell surface 
receptors such as integrins and heparan sulfate proteoglycans (HSPGs) (Jandova et al., 
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2012; Kireeva et al., 1996) (Figure 1.8). CCN1 is a ligand for integrins (via the IGFBP 
domain) and acts through direct binding to integrins and HSPGs in order to enhance 
specific functions (Leu et al., 2004). Increasing evidence has shown that CCN1 promotes 
cell adhesion by binding to integrin α6β1-HSPG co-receptors in fibroblasts (Todorovicç 
et al., 2005), αMβ2 in murine macrophages (Bai, Chen & Lau, 2010), αDβ2 in 
macrophage foam cells (Yakubenko, Yadav & Ugarova, 2006), αbβ3 in activated 
platelets (Jedsadayanmata et al., 1999). CCN1 enhances cell migration in fibroblasts, 
smooth muscle cells, endothelial cells and certain cancer cells for example, CCN1 
mediates tumour cell migration via integrin αvβ5 in oesophageal squamous carcinoma 
(OSC) cell lines (Jandova et al., 2012; Leu et al., 2004). CCN1 has also specific non-
canonical binding sites for a diverse set of integrins and these sites within CCN1 can 
function independently of one another (Chen et al., 2004; Leu et al., 2004). Some studies 
have shown that CCN1 mutants which disrupt its α6β1-HSPG abolish α6β1-HSPG-
dependent activities while, αvβ3-mediated functions are not affected (Leu et al., 2004). 
Furthermore, when CCN1 interaction with αvβ3 is disrupted, this abolished αvβ3 activity 
without affecting α6β1-mediated activities (Chen et al., 2004). On the other hand, the 
cooperative interaction between CCN1 and TNFα is dependent on its interaction with 
both αvβ5 and α6β1 (Chen et al., 2007). Thus, all these results suggest that CCN1 can 
independently bind specific integrins on the same cell and generate multiple signalling 
pathways (Lau, 2011). In addition to integrins and HSPG, CCN1 may interact with other 
growth factors such as bone morphogenetic proteins (BMP), transforming growth factor 
β (TGF-β) and vascular endothelial growth factor (VEGF) which need more thorough 
investigation (Lau, 2011).                           
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1.5.3 Roles of CCN1 proteins in cancer 
Recently, Lau has described the role of CCN1 in cancer as “a double-edged sword” (Lau, 
2011). CCN1 expression was altered in various cancers, depending on the cancer type, 
CCN1 may induce or suppress tumour growth (Feng, Wang & Ren, 2008; Holloway et 
al., 2005). Consistent with these results, CCN1 plays unique roles in different cancers; it 
is a tumour promoter in cancers of the breast (Menendez et al., 2005), prostate (Sun et al., 
2008), pancreatic (Maity et al., 2014), gastric carcinogenesis (Cheng et al., 2014), ovarian 
carcinoma (Gery et al., 2005), colorectal (Jeong et al., 2014), myeloma (Roodman, 2014) 
and acute myeloid leukaemia (AML)  (Niu et al., 2014) due to either overexpression of 
CCN1 or expression of truncated protein. Recent results have shown that full-length CCN 
proteins can play an anti-proliferative role, whilst CCN1 truncated proteins may induce 
tumour proliferation (Planque & Perbal, 2003). For example, CCN1 is cleaved by plasmin 
and releases a truncated protein of CCN1 (28kDa) which may support endothelial cell 
migration in breast cancer (Pendurthi et al., 2005). This study also indicated that the 
truncated isoform has wider biological functions owing to the CCN1 partition into the 
soluble phase (28kDa) diffusing freely within tissue and may act as an antagonist towards 
the full-length form in the insoluble matrix (42kDa). In 2013, (Choi et al.) found CCN1 
in the vitreous fluid secretome of proliferative diabetic retinopathy patients, these  
truncated proteins ranged from 11-23kDa rather than full-length protein 42kDa. 
Furthermore, a truncated protein of CCN1 which includes complete or partial length 
forms of the two-modules from IGFBP-VWC is generated by proteolytic cleavage by 
MMPs (Choi et al., 2013). Additional to proteolytic activity generating various CCN1 
truncated proteins  in disease, a truncated isoform of CCN1 can also arise due to 
alternative mRNA splicing (Perbal, 2009). The gene structure of the CCN family of 
proteins comprises of five exons and four introns, however loss of one exon results in the 
production of a truncated CCN isoform, for example deletion of exon 4 leads to CCN1 
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lacking the TSP1 domain (Leng et al., 2002; Zuo et al., 2010). Paradoxically, CCN1 is a 
tumour suppressor in melanoma (Dobroff et al., 2009), non-small cell lung cancer (Tong 
et al., 2001) and endometrial adenocarcinoma (Chien et al., 2004). The role of CCN1 in 
mantle cell lymphoma has not previously been investigated. 
Increasing evidence suggests that CCN1 plays important roles in tumour development, 
including migration, survival, proliferation and metastasis (Sun et al., 2008). In AML, 
CCN1 induces tumour survival through activation of the Ras/Raf/Mitogen-activated 
protein kinase/ERK kinase (MEK)/extracellular-signal-regulated kinase (ERK) 
(MEK/ERK pathway) by up regulating c-Myc and Bcl-xL (Bcl-2, Bcl-xL, and Mcl-1 are 
important inhibitors of apoptosis) and by down regulating Bax (apoptosis promoter) (Niu 
et al., 2014). Similarly, CCN1 confers resistance to chemotherapeutic agent-induced 
apoptosis in human breast cancer and suppresses apoptosis by activating integrins and the 
NF-kB/XIAP signalling pathway (Lin et al., 2004). CCN1 has been found in sites of bone 
remodelling, involvement in enhancing osteoblast differentiation, whilst suppressing 
osteoclast formation (Crockett et al., 2007). Furthermore, CCN1 has been implicated in 
Wnt3A-induced osteoblast differentiation of mesenchymal stem cells (Si et al., 2006). In 
a preclinical model of myeloma, mesenchymal stromal cells in the multiple myeloma 
(MM) microenvironment produced CCN1 that has opposing function to myeloma cells 
which secrete and stimulate osteoclast activating factors (OAFs) and decrease osteoblast 
inhibitors (OBIs) (Roodman, 2014). Thus, high expression of CCN1 in the MM 
microenvironment can decrease MM tumour cell growth and osteoclast activity and 
promote osteoblast differentiation (Roodman, 2014) (Figure 1.9). However, CCN1 may 
enhance myeloma cell viability through supporting survival of the INA-6 myeloma cell 
line lacking interleukin-6 (IL-6) (Dotterweich et al., 2014). Zoledronic acid (ZOL) an 
aminobisphosphonate and  TGF-β inhibitor known to disrupt CCN1 signalling (Espinoza 
et al., 2011), has a direct anti-tumour activity in skeletal complications secondary to bone 
48 
 
metastases including lymphoma, breast cancer, hormone-refractory prostate cancer, lung 
cancer and renal cell carcinoma (Lipton, Seaman & Zheng, 2004; Saad et al., 2004; 
Westin et al., 2010). In newly diagnosed lymphoma patients, treatment with ZOL blocks 
the bone mineral density loss that is commonly seen in lymphoma patients and causative 
to patient demise (Westin et al., 2010). In triple negative breast carcinoma (TNBC) which 
has a high tendency for metastasis to bone, most patients receive ZOL as a companion to 
chemotherapy to reduce loss of bone density and reduce tumour spread (Espinoza et al., 
2011).  Similarly, treatment of prostate cancer cells with ZOL decreased CCN1 
expression which led to inhibition of proliferation (Marra et al., 2009). Moreover, ZOL 
is considered a new therapeutic approach for cancer by targeting CCN1 overexpression 
on tumour cells through FOXO3a (forkhead box O3), suppressing bone resorption and 
blocking osteoclast activity. However, the mechanism of ZOL is not completely clear 
(Espinoza et al., 2011). 
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Figure 1.9 CCN Stem cell signalling network. CCN1 is involved in regulating stem cell signalling 
cascades including TGFB, BMP, Notch and Wnt-Beta catenin that are important in haematopoiesis 
including the B and T cell development lineages. Adapted from (McCallum & Irvine, 2009). 
 
1.6 Cell cycle signalling 
1.6.1 Stem cell signalling pathways 
Stem cells are undifferentiated cells with the ability to  self-renew and develop into other 
cell types during embryonic life or growth (Mishra, Derynck & Mishra, 2005). 
Embryonic stem cells (ES) and adult stem cells (also known somatic stem cells) are two 
kinds of stem cells. Human embryonic stem cells (hESCs) originated from the inner cell 
masses of a blastocyst. hESCs are considered pluripotent due to have the capacity to 
differentiate into cells from the three germ layers ectoderm, mesoderm and endoderm 
(Guo & Chen, 2015). Many studies have shown that the multiple signalling networks 
regulate the development and differentiation of ES and adult somatic stem cells into 
functional haematopoietic, neuronal, mesenchymal, and epithelial lineages (Mishra, 
Derynck & Mishra, 2005; Zhang & Crumpacker, 2015). The signalling pathways include 
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those of transforming growth factor beta (TGF-β), bone morphogenetic protein (BMP), 
Notch, and Wnt-β catenin.  Aberrant expression of one of these signalling components 
leads to disruption within the complex co-ordination of signalling, resulting in 
carcinogenesis including that of the haematological malignancies (Harrison et al., 2010; 
Rizzatti et al., 2005; Watabe & Miyazono, 2009). Recently, many studies have focused 
on targeting of stem cell signalling pathways to provide more effective therapeutic 
strategies for different cancers.                             
 
1.6.1.a TGF-β family signalling 
The Transforming growth factor β (TGF-β) signalling pathway and its ligands act as 
potent regulators of cellular processes such as proliferation, differentiation, migration and 
survival (Marino, Risbridger & Gold, 2015). It has essential roles in stem cell regulation 
by maintaining undifferentiated cells and initiating of differentiation (Mishra, Derynck & 
Mishra, 2005). The TGF-β superfamily includes TGF-βs, bone morphogenetic proteins 
(BMPs), growth and differentiation factors (GDFs), Mullerian inhibitory factor (MIF), 
nodal, activins, and inhibins (Krstic, Maslovaric & F Santibanez, 2014; Santibañez, 
Quintanilla & Bernabeu, 2011).  TGF-β mediates downstream intracellular signalling by 
the Smad family of proteins which functionally subdivided into three groups: the receptor 
regulated Smads (R-Smad), which contain Smad 1, 2, 3, 5, 8; the common mediator Smad 
(Co-Smad), Smad4; and the inhibitory Smads (I-Smad), Smad6 and 7 (Heldin, Miyazono 
& Ten Dijke, 1997). TGF-β signalling is initiated by the three types of TGFβ receptor 
(TGFβR); TGFβI, II and III. To date, seven TGFβRI, five TGFβRII and two TGFβRIII 
are known. TGFβRIs include activin receptor-like kinase 1-7 (ALK1-7). TGFβRIIs 
contain the TGFβRII, bone morphogenetic protein receptor II (BMPRII), activin receptor 
II (ACTRII), while betaglycan and endoglin belong to the TGFβRIIIs and predominantly 
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acting as co-receptors to promote activin signalling (Bierie & Moses, 2006; Lewis et al., 
2000). The mechanism of TGF-β signalling starts by binding of ligands to two (type II) 
receptors and two (type I) receptors leading to form a stable receptor complex which 
consist of two receptors of each type. Binding of TGF-β ligands to TGFβRII leads to 
phosphorylation of the TGFβRI. Consequently, the activated TGFβRI phosphorylated 
Smad 2, 3 and bind with Smad 4 to make complex that accumulation in the nucleus  to 
regulate the expression of target genes (Figure 1.10) (Derynck & Zhang, 2003). TGF-β 
signalling is essential in regulating tumorigenesis in human cancer; in early stage disease 
its acts as a tumour inhibitor through proliferation suppression but in advanced disease, it 
is often a tumour promoter through regulation of migration and invasion (Dai et al., 2012; 
Derynck, Akhurst & Balmain, 2001; Roberts & Wakefield, 2003). Recently, it has seen 
that ALK5 suppression prevents TGF-β-induced CCN1 expression in human dermal 
fibroblasts (Thompson, Murphy-Marshman & Leask, 2014). More importantly, CCN1 is 
a transcriptional target of TGF-β and may potentiate an autocrine regulatory mechanism 
in tumourigenesis (Bartholin et al., 2007). Further investigations of the relationship 
between CCN1 and TGF-β protein are required.   
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Figure 1.10 Schematic diagram illustrates the TGFβ signalling pathway. Binding of TGF-β ligands to 
TGFβRII at the cell surface leads to phosphorylation of the TGFβRI by TGFβRII. Consequently, the 
activated TGFβRI phosphorylates Smad 2, 3 and binding with Smad 4 to make a complex which 
accumulates in the nucleus interacts with general transcription factors (GTF) and mediates transcriptional 
activation of genes. The inhibitory Smads (I-Smad), Smad6 and 7 inhibit  R-Smad that is activated by 
TGFβRI in the cytoplasm. Image taken from (Akhurst & Derynck, 2001).      
 
1.6.1.b BMP signalling 
Bone Morphogenetic Proteins (BMPs) are secreted extracellular signalling molecules 
belonging to the TGF-β superfamily (Sartori & Sandri, 2015). BMPs are initially 
identified by their ability to stimulate endochondral bone formation (Chen et al., 2014). 
Recently, more than 20 subgroups of BMPs have identified in the human body in a wide 
range of biological functions such as embryogenesis, skeletal formation, haematopoiesis 
and neurogenesis (Yang et al., 2014). BMPs act an unique role in the formation of bone 
tissue through stimulating differentiation of bone marrow mesenchymal stem cells into 
osteoblastic lineage and then promoting the proliferation of osteoblasts and chondrocytes 
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(Yang et al., 2014). Furthermore, they play important roles in regulation of variance of 
cellular responses including cell proliferation, differentiation, adhesion, migration and 
apoptosis (David, Feige & Bailly, 2009; Feng & Derynck, 2005; Wagner et al., 2010). 
BMP pathways are activated by either a Smad-dependent pathway (canonical) or Smad-
independent mitogen activated protein kinase (MAPK) pathway depending on signal 
transduction (Sánchez-Duffhues et al., 2015; Yang et al., 2014). In canonical Smad-
dependent signalling, BMPs ligands bind BMPRI and BMPRII resulting in the activation 
of BMPRII which subsequently phosphorylates and activates of BMPRI (Miyazono, 
Kamiya & Morikawa, 2010). The activated BMPRI in the cytoplasm binds to R-Smad 1, 
5, and Smad 8/9 that mediate BMPs signalling (Peng et al., 2016). This complex leads to 
phosphorylate R-Smad 1, 5, 8/9, which in turn, complexes with co-Smad 4 enabling 
transduction into the nucleus where the complex collaborates with other transcription 
factors and accessory components to regulate the transcription of the target genes 
(Miyazono, Maeda & Imamura, 2005). While the non-canonical  Smad-independent 
MAPK pathway, after binding of BMPs with either BMPRI or BMPRII, this complex 
activates BMPs-MAPKs signalling pathway which in turn migrate into the nucleus via 
JNK-1 and 2/3, ERK1/2, NF-kB and p38 signalling pathways to regulate the expression 
of target genes (Figure 1.11) (Yang et al., 2014). On the other hand, the aberrant 
expression of BMP members have been involved in the  progression of various cancers 
including breast cancer (Davies et al., 2008), prostate carcinoma (Si, Feng & Yang, 2010), 
colon cancer (Kim et al., 2015), lung squamous cell carcinoma and adenocarcinoma 
(Deng et al., 2015). For example, the high expression of BMP2, BMP4 and BMP7 has 
found in gastric cancer associated with poor prognosis (Aoki et al., 2011; Katoh & Terada, 
1996; Park et al., 2008). Clinical trials show various  attempts to treat  cancers by targeting 
the BMP signalling pathways (Peng et al., 2016). However, the role of BMPs in MCL 
remains unknown.  
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Figure 1.11 Schematic diagram overview of canonical Smad-dependent and Smad-independent BMP 
signalling. In canonical Smad-dependent signalling, BMPs ligands bind BMPRI and BMPRII resulting in 
the phosphorylation and activation of BMPRI that binds and activates R-Smad 1, 5, and Smad 8 which in 
turn complex with co-Smad 4 and transduce into the nucleus and mediate transcriptional activation of 
osteogenic genes Dlx5, Osterix and Runx2. While in the Smad-independent pathway, after binding of BMP 
ligand with BMP receptor, this complex phosphorylates TGF-β activation kinase (TAK1) leading to 
activation of the BMPs-MAPKs signalling pathway which in turn migrate into the nucleus via p38 MAP 
signalling to regulate the expression of Runx2. Image taken from (Chenard et al., 2012).   
 
1.6.1.c Notch signalling 
Notch signalling is implicated in different cellular functions including cell fate 
specification, differentiation, proliferation and apoptosis (De Falco et al., 2015). The 
notch family comprises of four notch receptors (notch 1-4) which consist of extracellular 
and intracellular domains. The extracellular domain (ECD) contains 29-36 epidermal 
growth factor (EGF) like repeats and three Lin-notch repeats (LNR). The intracellular 
domain (ICD) contains the RBP-J-associated molecule (RAM) domain, six ankyrin 
repeats (ANK), nuclear localization sequences (NLS), a transactivation domain (TAD) 
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and a proline-, glutamate-, serine- and threonine-rich sequence (PEST). The (TAD) is 
necessary to activate transcription while (PEST) is responsible to regulate notch 
degradation. Notch3 and notch4 are considered smaller proteins due to having fewer EGF 
repeats and absence of TAD. On the other hand, notch ligands consists of five canonical 
ligands belonging to Delta (Delta like 1, 3, and 4) and Jagged (Jag 1 and 2) which  also 
having multiple EGF-like repeats and cysteine rich sequences known as the Delta-
Serrate-Lag2 (DSL) motif (D'souza, Miyamoto & Weinmaster, 2008). Recently, many 
groups have shown that the notch  activation can be performed by non-canonical ligands 
such as CCN3 (Suresh et al., 2013) or the Wnt pathway (Andersen et al., 2012) which 
signal independent of CSL transcription factors.                  
Notch signalling starts by ligands binding to the extracellular domain of notch receptors 
(NECD), this interaction allows series proteolytic cleavages of the receptors which 
termed S1, S2, S3, and S4. S1 is mediated by furin proteases (in the Golgi apparatus) and 
S2 is mediated by ADAM metalloproteases (anchored to the plasma membrane) (Brou et 
al., 2000; Suresh & Irvine, 2015). Moreover, S3/S4 cleavage is mediated by the 
presenilin-dependent ỵ-secretase (De Strooper et al., 1999; Okochi et al., 2002). These 
proteolytic cleavages  result in liberation and translocation of the intracellular domain of 
the notch receptor (NICD) to the nucleus, that in turn, binds to the DNA transcription 
factors and activates subsequent expression of Notch target genes (Figure 1.12) (Kovall, 
2008). Recently, increasing evidence has demonstrated that abnormal notch signalling is  
implicated in tumour progression (Yuan et al., 2015) including MCL. In 2012, (Kridel et 
al.) demonstrated that the 12% of cases and 20% of MCL cell lines had a notch  mutation 
in the PEST domain. They also demonstrated that suppression of proliferation and 
promotion of apoptosis can be achieved by inhibiting the notch signalling pathway. 
Similarly, in colorectal cancer (CRC), reduced cell viability and cell cycle arrest has 
achieved by down-regulation of Jagged 1 which led to reduced expression of cyclin D1, 
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cyclin E, and c-Myc (Dai et al., 2014). Furthermore, notch1 and notch2 signalling is 
involved in the resistance to apoptosis in chronic lymphocytic leukemia (CLL) (Rosati et 
al., 2013; Rosati et al., 2009). In cancer, it has been clear that the notch signalling blocks 
apoptosis by cell cycle and survival pathways such as the inhibition of p53 (Beverly, 
Felsher & Capobianco, 2005). Notch enhances the activation of the pro-survival 
PI3K/AKT pathway (Palomero, Dominguez & Ferrando, 2008) and  notch suppresses the 
pro-apoptotic proteins Bax, Bim, and Noxa (Konishi et al., 2010; Rizzo et al., 2008) and 
increases the expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL  (Konishi et al., 
2010). Overall, dysregulation of notch signalling or notch mutations have been involved 
in many cancers including MCL. Targeting this pathway may be beneficial as a novel 
therapeutic strategy but would need more investigation. 
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Figure 1.12 Schematic overview of the notch signalling pathway. The Notch signalling pathway starts 
in the Golgi apparatus when the notch receptor starts proteolytic cleavage 1 (S1) mediated by Furin 
proteases before the receptor can be released to the membrane. Notch ligands, Delta, Jagged and Serrate 
produced by neighbouring cells bind with notch-ECD leading to stimulate the S2 cleavage by ADAM 
metalloproteases. Once activated S3/S4 cleavage is mediated by the presenilin-dependent ỵ-secretase 
resulting in liberation and translocation of the notch intracellular domain (NICD) into the nucleus, binding 
to CSL protein resulting in the activation of complex with MAML and subsequent expression of Notch 
target genes including HES and HEY. Image taken from (Suresh & Irvine, 2015). 
  
1.6.1.d Wnt-β catenin signalling 
Wnt proteins are secreted glycoproteins that act as growth factors by regulating different 
cellular functions including cell proliferation, differentiation, migration and cell division 
(Willert et al., 2003). In mammals, Wnts comprise a large family of cysteine rich secreted 
protein ligands that play essential roles in developmental and physiological processes 
(Katoh, 2002; Logan & Nusse, 2004). The Wnt signalling mechanisms are subdivided 
into canonical pathway (cell fate determination) or via the non-canonical pathway 
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(control of cell movement and tissue polarity) (Sharma et al., 2015). For the canonical 
pathway, Wnt ligands bind with seven pass transmembrane receptors of the Frizzled (Fzd) 
family (Vinson, Conover & Adler, 1989) and with single pass transmembrane co-
receptors lipoprotein-receptor-related protein5/6 (LPR5/6) leading to activation of the β-
catenin signalling cascade (Pinson et al., 2000). In the lack of Wnt signalling, 
ubiquitination and degradation of β-catenin is conducted through phosphorylation of β-
catenin interaction with GSK-3β and axin-1 (Aberle et al., 1997). Activation of the Wnt 
pathway blocks β-catenin phosphorylation-induced degradation, and accumulation of β-
catenin in the nucleus, where it forms active transcription complexes with the T cell 
factor/lymphoid enhancer binding factor (TCF/LEF) family of DNA-binding 
transcription factors (Behrens et al., 1996; Polakis, 2012). In the non-canonical pathway, 
Wnt ligands bind and complex with the receptors of FZD family and receptor tyrosine 
kinase-like orphan receptor 2/receptor tyrosine kinase (ROR2/RYK) (Oishi et al., 2003). 
Additionally, Dickkopf (DKK) is considered another class of proteins family that 
interacts with Wnt receptor complex (Sharma et al., 2015) and WISP-1/CCN4, WISP-
2/CCN5, WISP-3/CCN6 are Wnt ligands that activate β-catenin signalling (Stephens et 
al., 2015). Activation of canonical and non-canonical Wnt signalling pathways lead to 
expression of Wnt induced target genes (Figure 1.13).  For example, Wnt proteins have 
essential roles in different types of stem cells including neural, mammary and embryonic 
stem cells (Nusse et al., 2008). Recently, emerging evidence has shown that Wnt 
signalling has an important role in cancer stem cells (Holland et al., 2013; Malanchi et 
al., 2008). Cancer stem cells and haematopoietic stem cells have Wnt and Notch 
signalling pathways, which are essential for their growth and self-renewal (Holland et al., 
2013; Reya et al., 2001). Dysregulation of Wnt signalling  enhances tumourigenesis 
(Grady & Markowitz, 2002; Salahshor & Woodgett, 2005). Recently, many studies have 
shown that dysregulation of Wnt signalling pathway leads to lymphomagenesis of MCL 
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through maintenance and survival of MCL-initiating cells (MCL-ICs) (Kimura et al., 
2013; Mathur et al., 2015). Similarly, Wnt increases chemotherapy resistance of high-
grade serous ovarian cancer (HGSOC) by activation of Wnt/β-catenin signalling pathway 
(Nagaraj et al., 2015). Furthermore, inhibition of this pathway in ovarian CICs leads to 
eliminate cancer initiating cells (CIC) and sensitize cells to platinum-based therapies.  
Also, this study referred to using iCG-001, an inhibitor of Wnt/β-catenin signalling 
pathway, “sensitized cells to cisplatin and decreased stem-cell frequency in platinum 
resistant cells” (Nagaraj et al., 2015) . 
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Figure 1.13 Schematic overview of canonical WNT signalling pathway.  To activate transduction 
signalling for the canonical pathway, Wnt ligands bind with Frizzled (Fzd) receptor and with single pass 
transmembrane co-receptors lipoprotein-receptor-related protein5/6 (LPR5/6) leading to activate β-catenin 
signalling cascade (Right). In the lack of Wnt signalling, ubiquitination and degradation of β-catenin is 
conducted through phosphorylation of β-catenin and interaction with GSK-3β and axin-1 (Left). Activation 
of the Wnt pathway blocks β-catenin phosphorylation-induced degradation, and accumulation of β-catenin 
in the nucleus, where it forms active transcription complexes with the TCF/LEF family of DNA-binding 
transcription factors. Image taken from (Staal, Chhatta & Mikkers, 2016).  
 
 
1.6.2 Cell cycle  
The cell cycle of eukaryotic cells comprises of four sequential phases; two gap phases, 
G1 and G2 , DNA synthesis phase (S phase) which comprising the replication of DNA in 
the nucleus and mitosis phase (M phase) which comprising the division of nucleus and 
cytoplasm (Zetterberg, Larsson & Wiman, 1995). The transition from one phase to the 
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next occurs in a precise consecutive pattern. It is controlled by cooperation of cyclins and 
cyclin dependent kinases (CDK’s) which are found at G1 and G2 checkpoints (Bonelli et 
al., 2014). Cell cycle progression is halted by cyclin dependent kinase inhibitors (CDKI’s) 
in response to DNA damage, low levels of oxygen or nutrients Figure 1.14 (Zhang & Yan, 
2012). 
Several diseases and also tumorigenesis are associated with dysregulation of cell cycle 
checkpoints. In cancer, the cell cycle is dysregulated leading to loss differentiation and 
abnormal cell growth. Recently, more than 90% of cancers have been identified by 
oncogenic alteration of CDKs, and CDKIs which are frequently linked to the G1 phase 
(Bonelli et al., 2014). The molecular mechanisms which may be associated are gene 
overexpression, chromosomal translocation, point mutations, insertions and deletions, 
missense and frame shift mutation, splicing, or methylation. Moreover, the dysregulation 
of cell cycle associated with tumour relapse and treatment resistance is conferred by 
increasing proliferation. Recently, attention has focused on the restoration of cell cycle 
by therapeutic agents that act by modulating molecular targets in the cell (Bonelli et al., 
2014).                 
  
1.6.2.a Cyclin D1 and cell cycle progression 
Overexpression of cyclin D1 (CCND1) as a result of t(11;14) chromosomal translocation 
is the hallmark feature of MCL (Cassaday et al., 2015). Cyclin D1 plays a central role in 
the cell cycle regulation by binding to either cyclin-dependent kinase 4 (CDK4) or CDK6. 
The CCND1-CDK4 or CCND1-CDK6 complex phosphorylates the retinoblastoma 
protein (pRb) which leads to degradation of CCND1 suppressor effect on cell cycle 
progression. This process leads to release of the E2F family of transcription factors and 
then S-phase entry (Cassaday et al., 2015). E2F transcription factor regulates genes that 
62 
 
encode for DNA replication and cell cycle control  (Figure 1.14) (Nevins, 2001). In G1 
phase, there are some hormones, growth factors, and cytokines that regulate cell cycle. 
For example, CALMODULIN (CaM) which is an intracellular Ca2+ receptor protein 
regulates cell cycle by nuclear translocation of CDK4 and cyclin D1, activation of CDK4 
and phosphorylation of pRb (Berchtold & Villalobo, 2014:  Taulés et al., 1999).  
In MCL, CCND1 overexpression leads to hyperphosphorylation of pRb and accumulation 
of E2F which facilitates the G1/S transition and uncontrolled cell proliferation (Cassaday 
et al., 2015). CCND1 is upregulated in almost all MCL patients, however cyclin D1 alone 
is insufficient to promote MCL. Additional oncogenic aberrations have been implicated 
in the generation of MCL, including, c-Myc overexpression, lack of the ataxia 
telangiectasia mutated (ATM) gene or p53 dysregulation (Müller et al., 2013). 
Furthermore, many secondary genetic events are involved in MCL lymphomagenesis and 
include inactivation of the DNA damage response pathways, activation of cell-survival 
pathways and suppression of apoptosis. Additional oncogenic aberrations are likely to 
contribute to the development of MCL involving cell proliferation, survival, and 
interactions with the microenvironment (Jares, Colomer & Campo, 2012; Müller et al., 
2013). Recently, stem cell signalling mutations have been identified in MCL that may 
contribute to the development or pathology of this disease. For example, Notch1 
mutations are found in 12% of MCL and are associated with poor survival; suppression 
of the Notch pathway in MCL decreased cell proliferation and increased apoptosis (Kridel 
et al., 2012). Similarly, the deregulation of the Wnt canonical pathway was found in MCL 
by  inactivation of  phospho-GSK3B which suggests that the Wnt pathway may also 
contribute to the pathogenesis of MCL (Gelebart et al., 2008). However, these 
observations need further investigation toward developing novel, effective therapeutic 
agents for MCL. 
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In addition to overexpression of cyclin D1 by chromosomal translocation, additional 
mechanisms that lead to increased  expression of cyclin D1 have also been observed in 
MCL (Jares, Colomer & Campo, 2012). These mechanisms include aberrant expression 
of PI3-K/AKT/mTOR signalling pathway which is implicated in tumour progression and 
responsible in part, to increased cyclin D1 expression in MCL (Rini, 2008). Moreover, 
cyclin D1 overexpression correlates with poor prognosis and mirrors the fact that 
prognosis of patients with MCL is the poorest of all B-cell lymphoma patients (Ghielmini 
& Zucca, 2009).   
 
Figure 1.14 Cell cycle. Cyclin D1 is involved in promotion and progression of G1 phase. p21 and p27 are 
cyclin-dependent kinase inhibitors (CDKI’s) responsible for blocking G1 phase progression. The Restriction 
checkpoint (R) is located at the end of the G1 phase is responsible for assessing the integrity of the DNA. 
Updated from (Dehay & Kennedy, 2007) and (Zhang & Yan, 2012). 
 
1.6.2.b P21 
P21CIP1 (p21) belongs to the CIP/KIP family of proteins that regulate cell cycle 
progression.  The CIP/KIP family comprises three members; p21CIP1 (Cdk Interacting 
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Protein 1), p27KIP1 (Kinase Inhibitory Protein 1) and p57KIP2 (Kinase Inhibitory Protein 2) 
(Bretones, Delgado & León, 2015). They bind and inhibit most cyclin-CDK complexes.  
The CIP/KIP family of proteins, particularly p21, plays an essential role in cell cycle 
control, halting the transition from G1 phase to S phase (Pérez-Sayáns et al., 2013) (Figure 
1.14).  
There are two different pathways to regulate p21, through (i) a p53-dependent pathway 
in response to DNA damage which activates p53 leading to upregulation of p21 and 
repression of cell growth in G1 phase with potential DNA repair or stimulation of 
programmed cell death or (ii) a p53-independent pathway, in which cellular growth 
factors regulate p21 expression (Brennan et al., 2002; Ciccarelli et al., 2005). P21 binds 
to CCND-CDK4 or -CDK6 complex and inhibits the kinase activity of CDKs in response 
to many stimuli leading to regulation G1/S progression, at a specific stage named the 
restriction point. This process leads to repression of phosphorylation of pRb protein 
which in turn prevents the expression of E2F transcription factor and blocks G1/S 
transition (Figure 1.14) (Zhang & Yan, 2012). In addition to negative regulation of the 
cell cycle, p21 regulates gene transcription; for example, p21 suppresses E2F 
transcription factor through a pathway independent of CDKs or Rb (Perkins, 2002). P21 
is involved in controlling cellular growth by suppressing of E2F1 transcription factor via 
Wnt4 expression through Notch 1 activation (Devgan et al., 2005). However, p21 
stimulates NFkB-mediated transcription by activation of transcriptional 
cofactors/deacetylases p300 and CBP (Perkins, 2002). Moreover, p21 is up-regulated in 
response to DNA damage which correlates with cell growth arrest and senescence (Chang 
et al., 2000). Many studies have identified additional roles for p21, in cancer it is a tumour 
suppressor through cell cycle arrest and blocking DNA synthesis by binding to 
proliferating cell nuclear antigen (PCNA) (Abbas & Dutta, 2009 ; Ando et al., 2001 ; 
Waga et al., 1994). P21 can be observed as an oncogenic factor, where various functions 
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including enhanced proliferation and delocalisation of p21 from the nucleus are involved 
in promoting carcinogenesis and tumour development (Gartel, 2009; Roninson, 2002). 
Furthermore, the expression of p21 varies in different cancers, it is down regulated in 
small-cell lung (Komiya et al., 1997), colorectal (Zirbes et al., 2000), cervical (Lu et al., 
1998a), and head and neck cancers (Kapranos et al., 2000) that associated with tumour 
progression. In contrast, it is upregulated in prostate (Baretton et al., 1999), ovarian 
(Ferrandina et al., 2000), breast, oesophageal squamous cell carcinomas, and in brain 
tumours (Roninson, 2002). For example, in patients with breast cancer, high expression 
of p21 is associated with disease progression, lymph node metastasis and short survival 
(Wei et al., 2015).  
The function of p21 in different cell types depends on localization, either in the nucleus 
or the cytoplasm. However p21 regulates cell proliferation and differentiation by 
localizing in the nucleus (in all normal cells except monocytes). In various cancers and 
in monocytes, it inhibits proteins essential for apoptosis and therefore enhances  
tumourigenesis by localisation to the cytoplasm (de Renty, DePamphilis & Ullah, 2014). 
Recently, it has been evident that p21 expression is entirely nuclear in some cancers which 
are associated with high proliferation rates, for example, oral squamous cell carcinoma 
(OSCC) (Nemes, Nemes & Márton, 2005; Queiroz et al., 2010). Expression of p21CIP1 
has not yet been investigated fully in MCL.  
           
1.6.2.c P27 
As mentioned above, p27KIP1 (p27) is one of the CIP/KIP family of cyclin dependent 
kinase inhibitors (CDKIs). Initially p27 and other members of CIP/KIP family have been 
identified as cell cycle inhibitors leading to growth inhibition. In G1, p27 binds to CCNE-
CDK2 complex and inhibits the catalytic activity of CDK2 resulting in cell cycle arrest 
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at the restriction point in response to DNA damage or anti-mitogenic signals (Hirama & 
Koeffler, 1995). As a result, this prevents the phosphorylation of pRb which leads to block 
in the transcription of genes required for G1/S progression (Figure 1.14) (Toyoshima & 
Hunter, 1994). Beyond the G1 restriction point in cell cycle, cell cycle progression can 
continue  independent of mitogenic signals (Coats et al., 1996). Interestingly, p27KIP1 and 
p21CIP1 have important roles in promotion of the assembly of CCND-CDK4/6 complexes 
(LaBaer et al., 1997). This interaction leads to sequestration of p27 in CCND-CDK4 
complex which blocks inhibition of the CCNE-CDK2 complex (Perez‐Roger et al., 1999). 
Furthermore, binding of p27KIP1 with CCND-CDK4 complex supresses the kinase activity 
of CDK4 (Ray et al., 2009). The regulation of p27KIP1 has been found primarily governed 
by transcriptional and translational mechanisms (Hengst & Reed, 1996). Many 
transcriptional factors such as FKHR-LI, AFX, FOXO, SPI, E2FI and BRCAI have been 
observed in promotion of its transcription (Andrés et al., 2001; Dijkers et al., 2000; 
Medema et al., 2000; Stahl et al., 2002; Wang et al., 2008; Williamson, Dadmanesh & 
Koeffler, 2002). Simultaneously, c-myc, Id3 and Ap-1 have been observed to inhibit the 
transcription of p27KIP1 (Chassot et al., 2007; Garrett-Engele et al., 2007b; Khattar & 
Kumar, 2010; Yang et al., 2001). Moreover, p27KIP1 degradation has emerged to control 
p27 expression (Pagano et al., 1995). For example, degradation of p27KIP1 by CCNE-
CDK2 complex which mediated phosphorylation of p27KIP1 in Thr187 makes it a target 
to the ubiquitin-proteasome pathway by the ubiquitin ligase F-box protein SKp2 (Lu & 
Hunter, 2010). However, there is no evidence to link involvement of activated CCND-
CDK4 complex in the degradation of p27KIP1(Sheaff et al., 1997; Sherr & Roberts, 1999).  
In cancer, loss of cell growth regulation and enhanced proliferation are often involved in 
aberrant expression of the cell cycle regulators which control the transition from G1 to S 
phase of the cell cycle. P27KIP1 which is one of these cell cycle regulators, in cancers, is 
aberrantly expressed by transcriptional and post-transcriptional mechanisms, genetic 
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alterations of p27KIP1 are rare (Chu, Hengst & Slingerland, 2008; Garrett-Engele et al., 
2007b). Similarly, the expression of p27KIP1 is reduced in several types of cancer that are 
associated with poor prognosis including breast, prostate, lung, and colon cancer (He et 
al., 2012; Hershko, 2008; Shapira et al., 2005; Tian et al., 2013; Timmerbeul et al., 2006). 
However, p27KIP1 is overexpressed in hepatocellular carcinoma (HCC) which is 
associated with longer disease free survival (Qin & Ng, 2001). In MCL, Quintanilla-
Martinez et al. (2003) suggested that overexpression of cyclin D1 contributed to a buffer 
change in p27KIP1 levels leading to inhibition of cellular growth. Furthermore, the role of 
p27KIP1 in the pathogenesis of MCL remains controversial.          
In addition of cell cycle regulation, there is some evidence that p27KIP1 has important 
roles in apoptosis, transcriptional activation, and migration depending on its localization. 
In the nucleus, it has an essential role to inhibit cell growth and is considered as a tumour 
suppressor. However, phosphorylation of specific sites of p27KIP1 lead to its export into 
the cytoplasm where it can act as a tumour promotor (Besson, Dowdy & Roberts, 2008). 
Recently, many studies have shown that the cytoplasmic p27KIP1 is involved in many 
cancers including melanoma, ovarian carcinoma, renal cell carcinoma, osteosarcoma, 
acute myelogenous leukemia and breast cancer leading to cell migration, high tumour 
grade, poor prognosis, survival and metastasis (Chen et al., 2011; Denicourt et al., 2007; 
Duncan et al., 2010; Liang et al., 2002; Min et al., 2004; Rosen et al., 2005). Moreover, 
cytoplasmic p27KIP1 has been contributed to treatment resistance by suppressing apoptosis 
in Her2+ breast cancer cells. However, the mechanism of p27KIP1 in oncogenesis is not 
fully  understood (Zhao et al., 2014).  
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1.6.2.d p57  
P57KIP2 together with p21 and p27 are members of CIP/KIP family of cyclin dependent 
kinase inhibitor proteins that regulate cell cycle progression by binding and inhibiting 
cyclin-CDK complexes and halting the transition from G1 phase to S phase (Figure 1.14) 
(Vidal & Koff, 2000). p57 is considered a tumour suppressor protein. However, in 
different types of human cancers, p57 has seen inactivated resulting in implication in 
promoting cancer cell growth instead of cancer cell suppression (Vlachos et al., 2007).  
Moreover, down regulation of p57KIP2 in different tumours involved in tumorigenesis 
(Hatada et al., 1996: Kobatake et al., 2004: Li et al., 2003:  Nakai et al., 2002: Pateras et 
al., 2006: Shin et al., 2000: Sui et al., 2002). For example, in Wilm's tumours, down 
regulation of p57 involved in increasing invasiveness and metastasis suggesting a role of 
p57 in tumorigenesis (Orlow et al., 1996). Importantly, no somatic mutations in p57 gene 
have seen in these tumours (Li et al., 2003: Nakai et al., 2002: Shin et al., 2000: Sui et 
al., 2002). p57KIP2 has an anti-proliferation function in the nucleus (Lee, Reynisdottir & 
Massague, 1995), however p57KIP2 may accumulate in the cytoplasm playing a role in the 
regulation of the cytoskeletal dynamics (Yokoo et al., 2003). In 2007, (Vlachos et al.,) 
have seen that p57KIP2 translocated to mitochondria and activated the intrinsic apoptotic 
pathway. Furthermore, p57 play a role in maintain haematopoietic stem cells (HSCs) 
quiescence by retaining Cyclin D into the cytoplasm (Matsumoto et al., 2011; Zou et al, 
2011).  However, functions of p57 need more investigations to detect its role in cancer 
development (Joaquin et al., 2012).  
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1.7 Aims and objectives this study  
1.7.1 Aims: 
  This study aims to: 
(1) Establish CCN1 roles in cell cycle regulation of progressive MCL.  
(2)  Establish stable overexpression and knockdown cell line models using the REC1 and 
JVM2 cell lines which depict CCN1 driven disease progression: 
(3) Identify signalling pathways associated with CCN1 driven disease progression using 
proteomic technology and IPA / other software. 
1.7.2 Objectives:  
CCN1 expression is dysregulated in progressive Mantle Cell Lymphoma (MCL). This 
study will characterise the role of CCN1 in cell cycle regulation and develop stable CCN1 
overexpression and knockdown cell line models in human MCL cells through viral 
infection. The stable cell lines will then be utilised to conduct proteomic investigation of 
the pathways affected; IPA / other software will be used to delineate the data sets 
generated and aid identification of novel small molecule inhibitors that may be useful 
clinically. We will screen a small number of compounds for efficacy on the human MCL 
cell lines and select those that may be useful for further detailed investigation.   
1.7.3 Hypothesis: 
Mantle cell lymphoma (MCL) is a distinct subset of B-cell non Hodgkin lymphoma (NHL) 
characterised by overexpression of cyclin D1 as a result of t(11;14) chromosomal 
translocation. Disease progression often involves down regulation of cyclin D1. We 
hypothesize that the CCN1 may play an active role in regulating MCL cells by altering B 
cell development via the stem cell signalling pathways.   
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2. Materials and methods 
2.1 Cell culture 
All cell lines used in this study were cultured in vitro in biological safety cabinet class II 
(Holten LaminAir, UK) under sterile conditions. The cells were maintained at 37 ˚C in 
95% humidified atmosphere and 5% CO2.       
 
2.1.1 Human Mantle cell lymphoma (MCL) cell lines 
2.1.1.a MCL cell lines  
Human Mantle Cell Lymphoma cell lines REC1, G519 and JVM2 were purchased from 
the Deutsche Sammlung von Mikroorganismen and Zellkulturen (DSMZ; Germany). 
REC1, was established from a man 61 years old, human B cell lymphoma progressing to 
transformed mantle cell lymphoma blastoid variant (Raynaud et al., 1993; Rimokh et al., 
1994) and is considered as early stage MCL. GRANTA-519 (G519), human B cell 
lymphoma, established from a Caucasian woman 58 years old derived from the peripheral 
blood at relapse of a high grade B-NHL (leukemic transformation of MCL, stage IV) with 
previous history of cervical cancer (Amin et al., 2003; Drexler & MacLeod, 2002; Jadayel 
et al., 1997; Rudolph et al., 2004) is considered as an aggressive stage of MCL. JVM2, 
human chronic B cell leukaemia, established from a woman 63 years old with B-
prolymphocytic leukaemia (B-PLL) derived from the peripheral blood (Melo et al., 1988; 
Melo et al., 1986) is considered as an advanced stage of MCL. All cell lines were cultured 
in Roswell Park Memorial Institute (RPMI 1640; Gibco, UK) supplemented with 10% 
Fetal Bovine Serum (FBS; Gibco, UK), and were incubated at 37 °C in a humidified 
atmosphere of 5% CO2.  
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2.1.1.b REC1<G519<JVM2 model of MCL progression 
In this study, we used three MCL cell lines which are REC1, G519 and JVM2 as a model 
for disease progression. The  2016  revision  of  World  Health  Organisation classification  
of  lymphoid  neoplasms  describes  the  variants  of  MCL  in  addition  to  the 
characteristic  Cyclin  D1  rearrangement (i)  2  types  of  clinically indolent  forms  with  
either Immunoglobulin  heavy  chain  variable region gene (IGHV) unmutated  or 
minimally mutated and  usually  with  expression  of  SOX11  typically  involving  lymph  
nodes  or  extranodal  sites, (ii) acquisition  of additional molecular  or cytogenetic 
abnormalities  leading  to an aggressive blastoid or pleomorphic phenotype and (iii) 
leukaemic non-nodal MCL develops from IGHV mutated  and  SOX11  negative  B  cells  
with  usual  bone  marrow  and  /  or  spleen  involvement where  abnormalities  in  TP53  
contributes to  enhance  aggressive  nature  (Swerdlow et  al., 2016).  REC1 cells display 
unmutated IGHV with expression of SOX11 (Beà et al., 2013) consistent with the classic 
indolent forms of MCL. We used REC1 as early stage of MCL because it behaves like 
primary MCL in many studies in terms of sensitivity to conventional therapy in contrast 
to G519 and JVM2 cell lines which behave like aggressive stages (Nordgren, Hegde & 
Joshi, 2012; Rauert‐Wunderlich et al., 2016). However, data which are available for the 
cell line REC1 are limited (Drexler & MacLeod, 2002). G519 cells display blastoid 
phenotype with SOX11 positivity and amplification of BCL2 gene leading to Bcl2 
overexpression enhancing cell survival associated with the aggressive blastoid variant 
forms (Queirós et al., 2016; Rudolph et al. ,2004). G519 was established from peripheral 
blood of a patient with high grade of MCL in leukaemic transformation (Drexler & 
MacLeod, 2002) and we observed this as an intermediate stage in comparison to indolent 
and aggressive disease. In a comparative study between G519 and primary tumour of 
MCL, they found this cell line genetically similar to primary MCL in terms of expressing 
genes that upregulated in primary MCL when compared to normal B cells (Ek, Ortega & 
73 
 
Borrebaeck, 2005). G519 cell line carries t(11;14) chromosomal translocation, 
overexpressed cyclin D1 but it is un-similar to classic MCL (that is CD5+ and CD23-) in 
terms of having CD5- and CD23+ (Amin et al., 2003). In mouse models, Klanova et al. 
(2014) have found that the overall survival of immunodeficient NSG mice xenografted 
with REC1 and G519 separately was 54 ± 3 days and 22 ± 1 days respectively. The 
authors reported that G519 is more aggressive from REC1 cells and the other cell lines 
that were used in this study which are Jeko, Mino and Hbl-2 according to overall short 
survival time.                    
JVM2 cells are IGHV unmutated and SOX11 negative, expressing low levels of cyclinD1 
with increased expression of cyclin D2, BCL2 positive (Tucker et al., 2006) and is 
considered a blastoid variant (Camps et al., 2006) consistent   with   the   aggressive   
blastoid   variant, SOX11   negativity   overlaps   with   the aggressive leukaemic non-
nodal MCL forms. In 2005, (Tiemann et al.) have found that additional to classic, small 
cell, pleomorphic and blastic subtypes of MCL there is cytological variants of MCL 
classified pleomorphic subgroups with mixtures of cells classical with pleomorphic cells. 
In 2006, (Tucker et al.) reported that JVM2 cell line harbouring both classic and variant 
characterisations of MCL. All the three cell lines carry t(11;14)(q13;32) chromosomal 
translocation and overexpressed cyclin D1 (Salaverria et al., 2006) except JVM2 that 
expressed cyclin D2 instead (Tucker et al., 2006). In addition, the cell lines show 
increasing resistance to lenalidomide in the order of REC1<G519<JVM2 (Zhang et al., 
2008) with G519 and JVM2 cells also showing increased resistance to Ibrutinib (Balsas 
et al., 2017). REC1 cells are observed as  early  stage/  indolent  MCL  showing  sensitivity  
to  conventional therapy  in  contrast  to  G519  and  JVM2  cell  lines  which  behave  
consistently  with  aggressive stages (Nordgren, Hegde & Joshi, 2012; Rauert‐Wunderlich 
et al., 2016). 
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2.1.2 HEK293 cell line 
The human embryonic kidney 293 (HEK 293) cells were kindly provided by Professor 
David Parkinson (Biomedical Research-Institute of Translational & Stratified Medicine, 
Faculty of Medicine and Dentistry, Plymouth University, UK) and used in transfection 
experiments. Cells were maintained at 37 °C in 5% CO2 in Dulbeccos Modified Eagle 
Medium [+] 4.5g/L DMEM (1x) (DMEM; Gibco, UK) containing 10% FBS (Gibco, UK).  
 
2.2 Maintenance, cryopreservation and reconstitution 
REC1, G519 and JVM2 have been maintained in RPMI 1640 supplemented with 10% 
FBS and they were passaged twice weekly to maintain log phase. Experiments were 
conducted within 10 passages from cell recovery and cells were seeded at 2x105 cells per 
ml for experimental procedures. Cells were counted using a haemocytometer and cell 
viability assessed using the trypan blue dye exclusion assay as described at (4.3). HEK293 
cells were maintained in DMEM supplemented with 10% FBS and were split three times 
a week. Adherent HEK293 cells were grown up to 80-90% confluence and then the 
medium was discarded, cells were passaged using 1-3 ml of Trypsin-EDTA (0.25%) with 
Phenol Red (Gibco, UK), incubated for 2-3 minutes in the cell culture incubator. DMEM 
supplemented with 10% FBS was added to stop trypsin and cells were centrifuged at 1300 
rpm for 5 minutes, the supernatant was discarded and the pellet was re-suspended in 
culture medium and aliquoted 1:4 in 75 cm2 tissue culture flasks. Cell morphology and 
cell density were checked using inverted microscopy (Olympus CK30, Japan). The colour 
and turbidity of the medium were also monitored. 
For long-term storage, cells were prepared for cryopreservation; MCL cells were 
centrifuged at 1600 rpm for 5 minutes and the cell pellet was re-suspended in 90% FBS 
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and 10% dimethyl sulphoxide (DMSO) (Sigma-Aldrich, Germany) at a density 4-5x106 
cells/vial. Vials were placed in cryopreservation stacks and stored at -80 °C until required. 
Similarly, HEK293 cells were centrifuged at 1300 rpm for 5 minutes re-suspended in 45% 
DMEM, 45% FBS and 10% DMSO at a density 4-5x106 cells/vial. Vials were placed in 
cryopreservation racks and stored at -80 °C until required. To reconstitute cells, vials were 
removed from -80 °C and thawed at 37 °C. Cells were transferred to a 15 ml tube with 10 
ml supplemented medium. The cells centrifuged at 1600 rpm for 5 minutes for MCL cell 
lines and at 1300 rpm for 5 minutes for HEK293 cells and the cell pellet was re-suspended 
in 5 ml culture medium and placed in a 25 cm2 tissue culture flask. The cells incubated 
as described above.   
 
2.3 Cell viability assay  
Cell viability was assessed by trypan blue (Sigma-Aldrich, UK) using a haemocytometer. 
The trypan blue dye exclusion assay was performed at 1:2 dilution and the percentage of 
unstained cells (live cells) counted and used to seed cells for each experiment. The stained 
cells (dead cells) were excluded by viewing the cells using inverted microscope at 400X 
magnification.           
2.4 Lentiviral system 
2.4.1 Characteristics of lentiviral vectors 
Lentivirus-based vectors have been used as a robust tool for gene delivery. Lentiviruses 
are a complex subclass of retroviruses derived from human immunodeficiency virus 1 
(HIV-1). In contrast to simple subclasses of retroviruses which are onco (γ-) retroviruses 
such as murine leukaemia viruses (MLV), they have the ability to stably integrate with 
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dividing and non-dividing genome. A comparative study between viral transduction 
vectors (using lentiviral vectors, adenovirus and adeno-associated vectors) and non-viral 
transduction vectors and ability to transduce rat mesenchymal stem cells showed that the 
lentivirus was an effective transduction tool with 95% of transgene incorporated and “low 
levels of cell toxicity” (McMahon et al., 2006). Table 2.1 shows the summarised 
characteristics of lentiviral vectors compared with some other viral transgene systems.   
 
 
 
 
 
Transgene 
capacity 
4.8kb 1  38kb 5  8kb 9  8kb 11  
Infect cells Dividing and non-
dividing cells 2  
Dividing and non-
dividing cells 6   
Dividing and non-
dividing cells 9  
Dividing cells 11  
Gene expression Long-term gene 
expression 3  
Too short term 
gene expression 7  
Long-term stable 
gene expression 10  
Long-term gene 
expression 12   
Side effects (In 
vivo) 
It has not 
associated with 
disease 4   
It has caused 
death of some 
patients 8  
No side effects 11  It has developed 
leukaemia by 
integrating with 
LMO2 proto-
oncogene 
promoter that 
leads to aberrantly 
transcription and 
expression of 
LMO2 13  
Table 2.1: Characteristics of lentiviral vectors and comparison with some other viral transgenes 
system.  Summary of transgene capacity and advantages / disadvantages for a number of vector delivery 
systems. Information collated from 1 (Grieger & Samulski, 2005), 2 (Daya & Berns, 2008), 3 (Haberman, 
McCown & Samulski, 1998), 4 (Lai, Lai & Rakoczy, 2002), 5 (Vorburger & Hunt, 2002), 6 (Kafri et al., 
1998), 7 (Crystal, 2014), 8 (Reid, Warren & Kirn, 2002), 9 (Zufferey et al., 1998),  10 (Mao et al., 2015), 11 
(Nayerossadat, Maedeh & Ali, 2012), 12 (Vargas et al., 2016), 13 (Hacein-Bey-Abina et al., 2003; Zhang et 
al., 2008b).  
Since lentiviral transduction will provide long-term expression and with no side effects, 
we have chosen to use the lentivirus system for CCN1/ CYR61 gene (1.146kb) in MCL 
cell lines. Furthermore, lymphoma cells are difficult cells to modify gene expression 
(Anastasov et al., 2009). In 1998, (Huang et al.) have found that the primary T-helper 
Characteristics Adeno-associated 
vectors 
Adenoviral 
vectors 
Lentiviruses 
vectors 
γ-retroviral 
vectors 
Retroviruses 
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cells were resistant to transfection by conventional methods. Lentiviral vectors can 
deliver up to 10 kilobases (kb) of transgenes and leading to a naturally long-term 
expression of the transgene (Mátrai, Chuah & VandenDriessche, 2010) which makes the 
lentiviral system an attractive technique to use in lymphoma (Lois et al., 2002).  
   
2.4.2 The Lentivirus Expression System 
Applied Biological Materials Inc (abm®) plasmids used in this study to overexpress and 
knockdown CCN1/CYR61 protein. pLenti and piLenti lentivirus expression system 
utilize 3rd generation system with replication-incompetent according to limited relation 
to the wild type (HIV-1 virus) through some safety characteristics that make using 
lentivirus expression system is safe. All lentiviral expression systems provided from Abm 
Inc. include the following safety features: 
 Self-inactivation (SIN) recombinant according to deleting enhancer in the U3 
region of the 3` Long Terminal Repeat (LTR) that making all lentivirus expression 
systems provided by abm Inc. replication-incompetent after transduction and 
integration with DNA of the targeted cells.  
 By using Rous Sarcoma Virus (RSV) which is promoter upstream of 5` LTR Tet-
independent to produce of viral RNA. 
  The replication of virus is prevented (replication-incompetent) by deleting all 
accessory genes of wild type virus (HIV-1) and using necessary genes of Gag, Pol, 
and Rev for packaging, replication and transduction. The expression of these 
genes come from different (separate) plasmids that are losing packaged viral 
genome.            
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Lentivirus system that provided from abm Inc. is stable system to gene delivery, easy to 
grow in DH5α competent cells and using “convergent promoters to avoid hairpin loop 
structure design” which helps to insert of 27-29 bp oligos. All pLenti and piLenti 
lentiviruses that used in this study depended on green fluorescence protein (GFP) 
expression as indicator to insert CCN1/CYR61 genes as well as including puromycin 
resistance gene in mammalian cells and kanamycin resistance in bacteria. For pLenti-
GIII-CMV-hCYR61-GFP-2A-Puro, cytomegalo virus CMV promotor was used to 
express CCN/CYR61 overexpression. SV40 promoter was used to express GFP and 
kanamycin/puromycin resistance. For piLenti-siRNA-GFP, U6 and H1 promotors were 
used to direct CCN/CYR61 knockdown system. CMV promoter was used to express GFP 
and kanamycin/puromycin resistance (figure 2.1) (Lenti-siRNA-Expression-05-2014 
(2).pdf). 
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Using lentivirus system in gene modification contains two parts which are lentivirus 
packaging and lentivirus infection. Lentivirus packaging includes recombination 
plasmids in packaging cells and lentivirus infection involves transcription viral RNA to 
double stranded DNA in targeted cells and integration with DNA cells leading to 
translation of targeted protein ( Figure 2.2) (Durand & Cimarelli, 2011).          
 
 
Figure 2.2: Schematic overviews lentivirus packaging using packaging cell line and infection of 
targeted cells. a, transfection of transfer vector which is part of HIV provirus carrying gene of interest, the 
packaging plasmid coding for gag-pol and the envelope glycoprotein coding for the env. The three plasmids 
transfected into packaging cells. b, the viral RNA, envelope, reverse transcriptase integrase enzymes 
package in lentivirus in supernatant  that uses to infect targeted cells. c, infection lentivirus of targeted cells 
which started with engagement of specific targeted cellular-lentivirus ENV receptor triggering the fusion 
between plasma cells and viral membrane leading to release of viral RNA and enzymes into the cells. d, 
viral RNA reverse transcripted to double stranded DNA (dsDNA) utilizing viral transcriptase. e, integration 
of dsDNA with DNA of targeted cells in the nucleus leading to modify gene of interest. Image taken from 
http://biology.kenyon.edu/slonc/gene-web/Lentiviral/Lentivi2.html.          
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2.5 Bacterial techniques 
2.5.1 Bacterial broth, agar and reagents 
 2.5.1.a Luria Bertani broth (LB) 
20g of LB broth (Sigma-Aldrich, USA) was dissolved in 1 litre of distilled water and 
autoclaved at 121 ˚C for 20 minutes with pressure 151bs/in2. Antibiotics ampicillin 
(Sigma-Aldrich, Belgium) or kanamycin (Sigma-Aldrich, UK)) was added to LB broth to 
a final concentration of 50µg/ml as required.   
2.5.1.b Antibiotic-Luria Bertani agar 
According to manufacturer's protocol 35g of LB agar (Sigma-Aldrich, UK), was 
dissolved in 1 litre of distilled water and autoclaved as described at (2.5.1.a). LB agar was 
cooled at room temperature (approximately 50-45 ˚C), appropriate antibiotic was added 
to a final concentration of 50 µg/ml. The mixture of LB agar and antibiotic was mixed, 
plated in a 94mm petri dish and stored at 4 ˚C until required.  
          
2.5.1.c 1mg/ml of PEI reagent 
To prepare 1 mg/ml polyethleneimine (PEI), 0.01 µl of PEI (Sigma-Aldrich, UK) was 
dissolved in 8 ml molecular grade distilled water and mixed in a 37°C water bath. The 
pH was adjusted to 8.0 by adding HCl (4M) and topped up by distilled water to 10 ml 
final volume. The solution was filter sterilised using 0.2 µm pore filter (Fisher Scientific, 
UK) and aliquoted in 1 ml vials and stored at -20 C˚ until required. 
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2.5.2 Bacterial transformation  
Escherichia coli (E. coli) DH5α was purchased from Invitrogen and was used as the 
recipient for the plasmids. Vials of competent E. coli (50 µl/vial) were thawed on ice. 100 
ng of DNA was added to one vial of competent cells and mixed by gentle shaking. Cells 
were incubated on ice for 30 minutes, heat shocked at 42 ˚C for 30 seconds and recovered 
on ice for 5 minutes. 250 µl of pre-warmed LB broth was added to the vial and incubated 
at 30 ˚C for 2 hours with shaking. 4 LB agar plates were used to sub clone each plasmid, 
1 control plate without antibiotic was used to culture control E. coli. Another plate with 
appropriate antibiotic cultured with E. coli and 2 plates with relevant antibiotic as 
prepared at (2.5.1.b) cultured with 30 µl and 270 µl (respectively) using the mixture of 
bacteria and plasmid. All plates were incubated overnight at 30 ˚C with agitation at 230 
rpm. LB agar plate was supplemented with 50 µg/ml ampicillin or kanamycin (2.5.1.b) 
for VSV-G, pΔ8.9 and lentiviral vectors respectively were used (Figure 2.3).    
 
Figure 2.3 Sub-cloning a plasmid with E. coli DH5α. A LB agar without antibiotic cultured with 
DH5α without plasmid. B LB agar with antibiotic cultured with DH5α without plasmid. C LB agar 
with antibiotic cultured with 30 µl of DH5α and plasmid. D LB agar with antibiotic cultured 270 µl 
DH5α and plasmid.  
     
2.5.3 Preparation of Long-term glycerol stocks  
For long-term storage, a single colony of bacteria was transferred from LB agar (2.5.2) 
in to 5 ml LB broth supplemented with appropriate antibiotic and incubated overnight at 
30 ˚C with agitation at 230 rpm. 800 µl of overnight culture has added to 800 µl of sterile 
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glycerol (Fisher Scientific, UK) and mixed by pipetting up and down many times. 
Glycerol stocks were stored at -80 C˚ until required.          
 
2.5.4 Purification of plasmids (DNA) 
The plasmid was isolated by using MiniPrep Genelute HP plasmid (Sigma-Aldrich, UK) 
following the supplier instructions. A single colony was transferred from LB agar (2.5.2) 
or using glycerol stock (2.5.3) (by scraping) into 5 ml LB broth supplemented with 
appropriate antibiotic and incubated (VWR, West Sussex, UK) overnight as described at 
(2.5.2). The culture was then centrifuged at 3,500 rpm for 15 minutes at room temperature 
and the supernatant was discarded. The bacterial pellet was re-suspended by adding 200 
µl of resuspension solution containing RNase and gently pipetting up and down. To lyse 
the bacteria, 200 µl of alkaline lysis buffer was added and mixed by inversion 6-8 times. 
To precipitate the cell debris, 350 µl of neutralization/Binding buffer was added and 
mixed by inversion 4-6 times before centrifugation at 10,000 rpm (12,000 x g) for 10 
minutes at room temperature. The clear solution is now absent of cell debris containing 
proteins, lipid and chromosomal DNA. The clear supernatant was transferred to the DNA 
binding column and centrifuged at 10,000 rpm for 1 minute at room temperature. The 
supernatant was discarded and the column was washed twice with wash solution 1 and 2. 
To remove excess ethanol from wash solution 2, the column was centrifuged for 1 minute 
at 10,000 rpm. 100 µl of Elution buffer was added to the column and centrifuged at 10,000 
rpm for 1 minute to elute DNA. DNA quantity and purity was measured using a nanodrop 
spectrophotometer using A260/A280 ratios (Thermo-Fisher scientific, Waltham, MA, 
USA). Good quality DNA was regarded as 1.7-1.9 using A260/A280 ratio. The three 
sequences of CYR61 siRNA (i005683a, i005683b and i005683c) targeting three different 
sequences in CCN1 (Table 2.2) and pLenti-GIII-CMV-hCYR61-GFP-2A-Puro 
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(LV110412) (appendix 1) were purchased from Applied Biological Materials Inc (abm®) 
and were used for knockdown and overexpression of the target gene CCN1 respectively. 
Scrambled siRNA EGFP (LV015-G) and pLenti-III-CMV-GFP-2A-Puro-Blank Control 
Lentiviral Vector (LV590) were purchased from abm® and used for positive controls of 
knockdown and overexpression models respectively. VSV-G and pΔ8.9 plasmids were 
kindly provided by Dr Dan Rocca (University of Bristol).  
System / Use P-lenti vector Sequence 
 
CCN1 
Knockdown 
Vectors and 
Control 
Scrambled siRNA EGFP GGGTGAACTCACGTCAGAA 
 
CYR61-288 
siRNA/shRNA/RNAi 
Lentivector (Human) 
(Target a) 
GGGCAGACCCTGTGAATATAACTCCAGA 
CYR61-582 
siRNA/shRNA/RNAi 
Lentivector (Human) 
(Target b) 
AAACAATGAATTGATTGCAGTTGGAA 
CYR61-676 
siRNA/shRNA/RNAi 
Lentivector (Human) 
(Target c) 
GGCCAGAAATGTATTGTTC 
 
CCN1 
Overexpression 
Vector and 
Control 
pLenti-III-CMV-GFP-2A-
Puro-Blank Control 
(LV590) 
Empty Vector 
pLenti-GIII-CMV-
hCYR61-GFP-2A-Puro 
(LV110412) 
Vector containing full length human CCN1 
sequence 
Table 2.2: Composition of lentiviral vectors used in CCN1 overexpression and knockdown 
experiments. 
 
2.5.5 Lentiviral production 
The pLenti lentiviral vector was used to produce virus through transfection of HEK293 
cells using 20 µg lentiviral vector, 10 µg VSV-G vector (envelope glycoprotein), 15 µg 
pΔ8.9 vector (packaging constructs) and 100 µl PEI (1 mg/ml) (2.5.1.c). In the present 
study, we used a three-plasmid expression system to generate lentivirus carrying 
CCN1/CYR61 gene. Two helper plasmids which are packaging and envelope plasmids 
and the transfer plasmid. The packaging plasmid was pΔ8.9 coding for gag-pol and the 
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envelope glycoprotein was VSV-G glycoprotein of the vesicular stomatitis virus coding 
for the env. The gag gene encodes for structural proteins which are matrix, capsid and 
nucleocapsid. pol gene encodes for the enzymes reverse transcriptase, integrase and 
protease that involved in reverse-transcription, integration, maturation and replication 
(Liechtenstein, Perez-Janices & Escors, 2013). VSV-G glycoprotein has broad tropism 
making the lentivirus a good transducer in a broad range of cell types. All the three 
plasmids were mixed in the following order (media, DNA and PEI) using 3 ml DMEM 
free serum. They were then incubated at 37 °C for 30 minutes to allow complex formation 
and then applied to the HEK293 packaging cells. Medium was changed to DMEM 
supplemented with 10% FBS 4-6 hours post transfection. After 48 hours, transfection was 
checked for fluorescence using a Lumascope. Supernatant containing lentivirus was 
collected and stored at 4 °C. Cells were maintained in fresh DMEM with 10% FBS. A 
second harvest of lentivirus was performed at 72 hours after the initial harvest. 
Supernatant containing lentivirus was spun down for 5 minutes at 1500 rpm to remove 
any cells or cell debris. The supernatant was then centrifuged for 2.5 hours at 48000 x g. 
Supernatant was discarded and the pellet was re-suspended in RPMI free serum and was 
then aliquoted and snap frozen in liquid nitrogen and stored at -80 °C until required. 
 
2.5.6 Kill Curve  
This experiment was performed to determine the optimal antibiotic concentration that 
enabled selection of transduced clones for the stable overexpression and knockdown 
models.  JVM2 and REC1 cells were seeded separately at 0.3x105, 1.5x104, 7.5x103, 
3.5x103, 2x103 and 1x103 in a 200 µl RPMI media supplemented with 10% FBS using 
96-well plates in duplicate. After 2 days incubation, various concentrations of puromycin 
(10, 9, 8, 7, 6, 5, 4, 3, 2, 1, 0.5 and 0.1 µg/ml) were added. For each cell number, a negative 
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control in duplicate was included that did not have addition of puromycin. Cell viability 
was checked every two days as described in 2.3, the medium was changed and fresh 
puromycin was added. 
 
2.5.7 JVM2 preparation for single cell sorting by using Cell Trace Cell 
Proliferation Kit (CFSE) 
 Single cell sorting was performed for the JVM2 overexpression model to select clones 
with similar levels of CCN1 expression. JVM2 parent cells were harvested and 
centrifuged at 1600 rpm for 5 minutes. The supernatant discarded and the pellet re-
suspended to 5x105 cells/ml and 1x106 cells/ml in PBS. Cell Trace CFSE Cell 
Proliferation Kit, for flow cytometry (ThermoFisher, USA) which contains 2 components 
(component A and B) was used. According to the manufacturer's protocol 18 µl of 
component B (DMSO) was added to component A (5 mM STOCK CellTrace reagent) to 
make 5 µM working concentration. 1 µl of CellTrace reagent working concentration was 
added to each 1 ml of cell suspension and cells were incubated for 20 minutes at 37 °C 
with protection from light. RPMI supplemented with 10% FBS in a volume five times the 
original staining volume was added to the cells and incubated for 5 minutes. The cells 
were centrifuged to discard the supernatant, the pellet was re-suspended in culture 
medium and the cells were incubated for 10 minutes and applied to flow cytometry 
(Beckman Coulter FACS ARIA). To prepare a culture plate for cells post sorting, 200 µl 
of culture medium was added into each well of a fresh 96-well plate. Single cells were 
sorted to each well of the 96-well plate and the plate was incubated at 37°C in a 
humidified atmosphere of 5% CO2 to enable clones to grow.     
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2.5.8 Establishment of Stable CCN1/CYR61 expression models using 
MCL cell lines 
2.5.8.1 CYR61 (CCN1) overexpression in JVM2 cells 
JVM2 cells were seeded at 2 different cell densities 1.5 x 105 and 2.5 x 105 in 2 ml pure 
RPMI 1640 (Gibco, UK) using 3x 6-well plates. Two-wells of first plate were infected 
by 30µl of CYR61 lentivirus and two-wells of second plate by 30µl of empty lentivirus 
(blank) for positive control with two-wells of third plate as a negative control in the 
presence of polybrene (Merck Millipore,UK)(4 µg/ml). Cells were incubated for 24 hours 
and then collected/spun down at 1600 rpm for 5 minutes at room temperature and re-
suspended using 3 ml of fresh RPMI 1640 supplemented with 10% FBS. All three plates 
were incubated at 37 °C in 5% CO2. After detection of green fluorescence protein (GFP) 
production, cells were sorted using flow cytometry (Beckman Coulter) to collect only 
GFP-positive cells which have CCN1 /CYR61overexpression.  
2.5.8.2 CYR61 knockdown model in REC1 cells 
To generate a stable CYR61 knockdown model using REC1cells, three different CYR61-
siRNA/shRNA/RNAi Lentiviruses targeting three different sequences (a-c) were used 
(Table 2.2). After production of piLenti lentiviruses carrying siRNA sequences (section 
2.5.5), REC1 cells were seeded at cell densities of 5.0 x 105 and 7.5 x 105 in 3ml of pure 
RPMI 1640 medium in 25 cm2 tissue culture flask. The cells were infected by CYR61-
R288, CYR61-582, CYR61-676 and scrambled lentiviruses in the presence of polybrene 
(4 µg/ml) in duplicate (Table 2.2). Two flasks were left without infection to serve as a 
negative control and all the flasks incubated overnight. Cells were collected, spun down 
to discard the supernatant and the pellet re-suspended in 5 ml of RPMI 1640 
supplemented with 10% FBS in 25 cm2 tissue culture flasks. After detection of green 
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fluorescence protein (GFP) production, cells were selected by adding puromycin (0.1-3 
µg/ml) to obtain CCN1 knockdown clones and 0.5 µg/ml was used to maintenance the 
cells.   
          
2.5.8.3 CCN1 overexpression and knockdown models maintenance and 
long-term storage 
Stable overexpression JVM2+CYR61 and knockdown REC1-CYR61models were cultured in 
RPMI 1640 (Gibco, UK) supplemented with 10% Fetal Bovine Serum (Gibco, UK) 
incubated at 37 °C in 5% CO2. Cells were passaged between 1 to 5 weeks to collect 
protein samples and were used to check gene expression changes associated with CCN1 
models and correct modification before proceeding to proteomics.  
For long-term storage, the cells were centrifuged at 1600 rpm for 5 minutes at room 
temperature. The cell pellet was re-suspended in 90% FBS and 10% DMSO and placed 
in a cryopreservation tube using a density 4-5x106 cells/vial and stored at -80 °C until 
required. 
 
2.5.8.4 Confirmation of CCN1 overexpression and knockdown  
pLenti and piLenti lentiviral vectors contain green fluorescence protein (GFP) gene 
within the plasmid therefore enabling visualisation as an indicator of transfection efficacy 
using cell fluorescence using Lumascope. Within each weekly passage of the modified 
cell lines, 1 X 106 cells were retained and used to extract mRNA for RQ-PCR (2.7.2) and 
3-5 X 106 cells were retained and used to extract protein lysate for western blotting 
(2.6.5.2) and proteomics (2.8).      
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2.6 Molecular biology techniques 
2.6.1 RIPA buffer preparation 
Radioimmune Precipitation Assay buffer (RIPA) was prepared by: Tris 50 mM, NaCl 
150 mM, Triton X-100 1%, Na-Deoxycholate 0.5%, SDS 0.1%. To prepare 50 ml of 
RIPA buffer, 0.302 g Tris Base, 0.438 g NaCl, 0.05 g SDS, 0.25 g NaDeoxycholate, 0.5 
ml TritonX 100 dissolved in ddH2O in a 50 ml tube using a water bath at 37°C. The pH 
was adjusted to 7.8 and topped up to 50 ml by adding ddH2O and stored at 4˚C until 
required. 
 
2.6.2 Total Protein Extraction and Subcellular Fractions 
Total cell lysates for human MCL cell lines (REC1, G519 and JVM2) were prepared in 
RIPA buffer (2.6.1) supplemented with CompleteTM protease inhibitor (Roche, UK) 
which used according to manufacturer instructions and stored at -20 °C until required. 
Cells at density (1x106 cells/ml) were collected and centrifuged at 1600 rpm for 5 minutes 
at RT. The supernatant was discarded and the pellet was re-suspended in 500-1000 µl of 
RIPA buffer with CompleteTM protease inhibitor. The suspension was incubated on ice 
for 10 minutes and sonicated by using a probe sonicator for 10 seconds at 4 °C and then 
centrifuged at 1400 rpm for 10 minutes at 4 °C. The supernatant was stored at -20 °C until 
required. 
Nuclear, mitochondrial and cytoplasmic proteins from cell lines were extracted using Cell 
Fraction Kit-Standard (Abcam, UK) according to manufacturer instructions with some 
modifications. 1X buffer A was prepared using 5 ml 2X buffer A, 4900 µl dH2O and 100 
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µl PI (Halt Protease Inhibitor Single-Use Cocktail EDTA-Free, ThermoScientific, UK). 
Cells were collected, counted using trypan blue dye exclusion, centrifuged and the cell 
pellet (1x106 cells/ml) was re-suspended with 500 µl of 1X buffer A. Buffer B was 
prepared by diluting Detergent I 1000-fold in 1X buffer A to extract cytoplasmic protein. 
500 µl of buffer B was added to the cell suspensions and the cells were incubated for 6-7 
minutes on a rotator at room temperature. The cells were then centrifuged twice at 5000 
x g and 10,000 x g for 1 minute at 4 °C each time. Supernatants were collected in a fresh 
tube and labelled cytoplasmic fraction. Buffer C was prepared by diluting Detergent II 
25-fold in 1X buffer A. The pellet was then re-suspended by pipetting with 500 µl of 1X 
buffer A and then buffer C was added. The cells were incubated for 8-9 minutes at room 
temperature on a rotator. After incubation, the cells were centrifuged twice at 5000 x g 
and 10,000 x g for 1 minute at 4 °C each time. Supernatants were collected in fresh tubes 
and labelled mitochondrial fraction. The pellet was then re-suspended in 1 ml of 1X buffer 
A, sonicated by using a probe sonicator for 2 minutes at 4 °C, centrifuged at 10,000 x g 
for 4 minutes at 4 °C. The supernatant was collected in a fresh tube and labelled nuclear 
fraction.  All fractions were stored at -80 °C until required.  
 
2.6.3 Protein quantification 
The protein in each sample was quantified using micro BCA Assay Kit (Thermo 
Scientific, USA) following the supplier instructions. Micro BCA TM Protein Assay Kit 
contains 3 buffer components MA, MB and MC. Micro BCA working reagent (WR) was 
prepared by mixing 25:24:1 parts of reagent MA, MB and MC respectively. 10 µl of each 
sample or standard (2.6.4) was pipetted into replicates in each well of Nunc 96-well 
microplate (Thermo Scientific, UK) and then 90 µl of WR was added. The plate was 
mixed by a plate shaker for 30 seconds and incubated at 37 ˚ C for 2 hours. The absorbance 
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was measured at 562 nm on a plate reader. A standard curve (BSA standards) was used 
to detect the protein concentration of known standards and calculate / estimate protein 
concentration of experimental samples.  
 
2.6.4 Bovine Serum Albumin (BSA) standard 
Bovine serum albumin stock solution (Sigma-Aldrich, USA) (2 mg/ml) was prepared in 
deionised water ddH2O. A dilution series was prepared to have BSA standards ranging 
from 2mg/ml to 0.1 mg/ml as described at Table 2.3 below.  
Table 2.3 BSA standards 
Standard Stock ddH2O Final 
volume 
           2 mg/ml                   500 µl              0 µl     500 µl 
           1.5 mg/ml                   375 µl             125 µl   500 µl 
           1 mg/ml                   250 µl             250 µl   500 µl 
           0.75 mg/ml                   187.5 µl              312.5 µl   500 µl 
           0.5 mg/ml                   125 µl             375 µl   500 µl 
           0.25 mg/ml                   62.5 µl             437.5 µl   500 µl 
           0.1 mg/ml                   25 µl             475 µl   500 µl 
           0 mg/ml                   0 µl              500 µl   500 µl 
 
 
2.6.5 Immunoblotting detection 
2.6.5.1 Immunoblotting solutions 
2.6.5.1.a MOPS SDS Running Buffer(1X) 
To prepare running buffer (1X), 25 ml of MOPS (20X) (ThermoFisher Scientific, USA) 
placed in 500 ml cylinder and topped up to 500 ml by adding ddH2O. 
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2.6.5.1.b NuPAGE® Transfer buffer (1X) 
The transfer buffer was prepared by mixing 50 ml of transfer buffer NUPAGE® (20X) 
(ThermoFisher Scientific, USA), 50 ml of methanol (VWR, chemical, France) and 450 
ml of ddH2O and stored at 4 ˚C until required. 
 
2.6.5.1.c 2.5% Milk Blocking buffer 
2.5 g of skimmed milk was dissolved in 10 ml of phosphate buffer saline (PBS) (1X) 
(Fisher chemical, UK) and topped up to 100 ml by using distilled water.    
 
2.6.5.1.d Washing buffer (0.05% PBS-T) 
1 tablet of phosphate buffer saline (100XPBS) (Fisher chemical, UK) was dissolved in 
100 ml of distilled water to prepare 1XPBS final concentration. 50 ml of 1X PBS was 
mixed with 500 µl of Tween® 20 (FisherScientific, UK) and topped up to 500 ml by 
distilled water and stored at room temperature until required.   
 
2.6.5.1.e Membrane Stripping solution 
Guanidine HCL 28.659 g (Fisher BioReagents, UK) was dissolved in 20 mM Tris-HCl 
pH 7.5 (Sigma-Aldrich, UK) which was prepared by weight 12.11 g of Tris Base 
(Molecular Weight 121.14) in 40 ml of distilled water, pH was adjusted and stored at 4 
˚C until required. Triton X-100 0.2% and β-Mercaptoethanol 0.1 M were added and 
topped up to 50 ml by adding distilled water.                   
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2.6.5.2 SDS-PAGE and western blotting             
Protein samples (10 µg) were placed in 1.5 ml sterilised Eppendorf tubes with one part of 
sample reducing sample buffer (5X SDS-PAGE) (ThermoFisher Scientific,USA) and 
denatured at 95 ˚C for 5 minutes. The protein samples were loaded on a 10% NuPAGE® 
Bis-Tris Gel (Invitrogen, USA) using the XCell SureLockTM Mini-cell system (Invitrogen, 
UK) and MOPS running buffer (1X) (2.6.5.1.a). Gels were run at 200V for 50 minutes at 
room temperature. Proteins were transferred onto a polyvinylidene difluoride PVDF 
membrane (Millipore, UK) by using transfer buffer (2.6.5.1.b) and current applied at 30V, 
300 mA for 1 hour at room temperature. Membranes were then blocked using 2.5% 
skimmed milk (2.6.5.1.c) for 30 minutes and were then incubated overnight at 4 °C with 
antibody raised to detect the various human proteins. Specific antibodies used are as 
follows: rabbit anti-p21CIP1 (1:1000, Cell Signalling Technology) (2947S), rabbit anti-
p27KIP1 (1:1000, New England Biolabs) (3688s), rabbit cyclin D1 (1:1000, Cell Signalling 
Technology) (2922s), rabbit anti-CCN1 (1:2000, Abcam) (ab24448,  Lot  #  GR26258-
7), rabbit anti-GAPDH (1:2500, Abcam) (ab9485), mouse anti-COX IV (1:1000, Abcam) 
(ab33985), rabbit anti Histone H3 (1:1000, New England Biolabs) (9717s) and mouse 
anti-beta actin (1:5000, proteingroup) ( 60008-1-Ig). Membranes were washed with 0.05% 
PBS-T (2.6.5.1.d) three times for 5 minutes each time to remove excess unbound primary 
antibody. Membranes were then incubated with an appropriate secondary antibody 
conjugated to horseradish peroxidase (HRP) (anti-rabbit-HRP (Cell Signalling 
Technology) or anti-mouse-HRP (Abcam) for 30 minutes at room temperature. All the 
incubations of membranes were performed using a shaker platform. Membranes were 
washed again with 0.05% PBS-T 3 times for 5 mins as described above. Bands were 
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detected using chemiluminesence (Thermo Scientific SuperSignal®West Dura Extended 
Duration Substrate, USA) and viewed using the Image Quant LAS4000 software.  
 
2.6.5.3 Stripping and Re-probing membrane 
This procedure was performed inside the fume cabinet. To re-probe membranes with 
loading control antibody, 25 ml of stripping solution buffer (2.6.5.1.e) was added to the 
membrane and incubated for 5 minutes at room temperature. Solution was discarded and 
another 25 ml stripping solution was used with incubation for 5 minutes at room 
temperature. The membrane was washed by 0.05% PBS-T (2.6.5.1.d) four times for 5 
minutes each. Blocking buffer 2.5% skimmed milk (5.2.1.c) was added to the membrane 
for 30 minutes at room temperature with shaking. The membrane was then incubated with 
primary antibody overnight at 4 ˚C and procedures completed as detailed in (2.6.5.2).  
  
2.7 RNA extraction and RQ-PCR  
2.7.1 RNA extraction and cDNA synthesis 
Total RNA was extracted using Trizol® reagent (Fisher Scientific, UK). Trizol® (1ml 
per 1x106 cells) was pipetted up and down several times until the samples were 
homogenised. 200 µl of chloroform was added per initial 1ml of Trizol®, shaken 
vigorously for 15 seconds and incubated at room temperature for 2-3 minutes. Samples 
were centrifuged at 13,000 rpm for 15 minutes at 4 °C. The upper layer was decanted to 
new tubes and 500 µl isopropanol added (per initial 1ml of Trizol®) and incubated at 
room temperature for 10 minutes. Samples were centrifuged at 13,000 rpm for 15 minutes 
at 4 °C. Supernatant was discarded and the white RNA pellet washed three times with 70% 
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ethanol. RNase free water was used to re-suspend the pellet. Samples were stored at -
80 °C until required. RNA quantity and purity was measured using a nanodrop 
spectrophotometer using A260/A280 ratios (Thermo-Fisher scientific, Waltham, MA, 
USA). cDNA was synthesised using 2 µg of total RNA in 20 µl volume using the High 
Capacity RNA to cDNA kit (Applied Biosystems, UK). According to the manufacturer’s 
instructions, the samples were heated at 37 °C for 60 minutes to perform reverse 
transcription and reaction stopped by heating at 95°C for 5 minutes to denature the 
enzyme. cDNA samples were stored at -20 °C until required. Negative template controls 
consisting of RT reaction without cDNA were run for all experiments.  
 
2.7.2 RQ-PCR 
Quantitative real-time PCR was performed by using Step One Plus and Software v2.3 for 
analyses (Applied Biosystems, USA). Reactions had a final volume of 12.5 µl containing 
1µl cDNA (100ng), 0.625 µl primer primer probe set, 6.25 µl 2x Master Mix (Prime time 
Master Mix, Integrated DNA technologies). The PCR reaction conditions were 95 °C for 
3 minutes, followed by 40 cycles comprising denaturation at 95 °C for 5 seconds and 
annealing and extension at 60 °C for 30 seconds. Predesigned assay reagents with FAM/ 
TAMRA fluorescence were used for CCN1 (PT.58.827217), GAPDH (PT.39a.22214836) 
(Integrated DNA Technologies), p21 (00355782-M1), p27 (01597588-M1) and cyclin D1 
(00765553-M1) (Applied Biosystems). GAPDH used as an endogenous control, gene 
expression levels were reported using the ∆∆CT method with experimental samples run 
in triplicate.  Independent replicates of N=3 experiments were used for reporting.  
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2.8 Proteomics 
2.8.1 Sample preparation for Mass Spectrometry 
Cell pellets were lysed with RIPA buffer as described at (2.6.2). Protein estimation was 
performed by BCA Assay as described at (2.6.3). A total of 50ug of protein was digested 
using the Filter Aided Sample Preparation (FASP) procedure as described previously 
(Bouyer et al., 2016). In day 1, 200 µl of Buffer A (8 M Urea in 0.1 M Tris-HCl pH 8.5 
which made fresh) was added to Amicon Ultra-0.5 centrifugal filter device (Millipore, 
UK) and centrifuged at 14000 rpm for 5 minutes at room temperature to check the 
column. The samples were added to the column, topped up to 400 µl by buffer A and 
centrifuged for 5 minutes. 2 µl of DTT (final concentration 10mM) was added to the 
peptide concentrate and topped up to 200 µl with buffer A. The solution was incubated at 
room temperature for 30 minutes and centrifuged for 5 minutes at 14000 rpm and then 
the flow through was discarded. 20 µl of 50 mM chloroacetamide (CAA) (prepared in 
buffer A final concentration 500 mM) was added and topped up to 200 µl with buffer A. 
The column was incubated at room temperature in the dark for 20 minutes, centrifuged 
for 5 minutes at 14000 rpm and the flow through was discarded. 400 µl of buffer B (8M 
of urea in 0.1M Tris-HCl pH 8) was added, centrifuged for 5 minutes at 14000 rpm and 
the flow through was discarded. 400 µl of buffer ammonium bicarbonate (ABC) (50 mM 
prepared in water, the final concentration was 500 mM in ddH2O and stored at -20 °C) 
was added, centrifuged for 10 minutes at 13300 rpm and the flow through was discarded. 
5 µl of trypsin was added and incubated overnight at room temperature.  
On day 2, collection tubes were changed and the column was centrifuged for 15 minutes 
at 14000 rpm with the flow through containing the proteins after digestion by trypsin. 50 
µl of 500 mM sodium chloride was added to wash the column and centrifuged for 10-15 
minutes at 14000 rpm. For acidity, 5% of trifluoroacetic acid (TFA) 100 µl was added to 
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each sample and 2 µl taken from each sample on to pH paper to check the acidity which 
was 2/3. The samples were stored at -80 °C until required. 
In stage-tip assembly; a high performance extraction disk (C18) was placed in a petri dish. 
A piece of the disk was picked using the picking tool (a cut off p200 tip and pushed down 
with Hamilton syringe plunger). The disk was transferred via pipet tip to a 2ml Eppendorf 
tube with a hole pierced in middle of the cap.  The home-made stage-tip  was pushed into 
the tube by pushing through lid. 
For purification, 100 µl of methanol was added and centrifuged for 10-15 minutes at 5000 
rpm. Then 100 µl of buffer C (80% of ACN 20% H2O (0.5% acetic acid) was added and 
centrifuged until all the volume of fluid has passed the filter. 100 µl of buffer D (aqueous 
phase 0.5% acetic acid prepared in water) was added and centrifuged for 10-15 minutes 
for 5000 rpm. 40 µl of protein was added into the column and centrifuged until all the 
fluid has passed through the filter. Collection tubes were changed, 25 µl of buffer C was 
added and centrifuged for 10-15 minutes at 5000 rpm. 400 µl of buffer D was added, then 
transferred into glass vials for LC-MS analysis and stored at -20 °C until required.  
                
 
2.8.2 Proteome analysis:  
Peptides were separated on a Dionex Ultimate 3000 RSLC nano flow system (Dionex, 
Camberley, UK). 3 μl of sample was loaded in 0.1% trifluoroacetic acid (TFA) and 
acetonitrile (2% acetonitrile in 0.1% TFA) onto an Acclaim Pep Map, 3 μm C18 nano 
trap column, at a flow rate of 5 μl/min, bypassing the analytical column. Elution of bound 
peptides was performed with the trap column in line with an Acclaim PepMap C18 nano 
column, 100 Å (Analytical Column) with a linear gradient of 96% buffer A and 4% buffer 
B to 60% buffer A and 40% buffer B, (Buffer A: 0.5% Acetic Acid, Buffer B: 80% 
acetonitrile in 0.5% acetic acid) at a constant flow rate of 300nl/min over 120 minutes. 
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The sample was ionized in positive ion mode using a Proxeon nano spray ESI source 
(Thermo Fisher Hemel UK) and analyzed in an Orbitrap Velos Pro FTMS (Thermo 
Finnigan, Bremen, Germany). MS spectra of intact peptides (m/z 350-1600) with an 
automated gain control accumulation target value of 1000000 ions were acquired with a 
resolution of 30000. The ten most intense ions were sequentially isolated and fragmented 
in the C trap by Higher Energy Dissociation (HCD) at a resolution of 7500. All the singly 
charged and unassigned charge state ions were excluded from sequencing. Typical mass 
spectrometric conditions were: spray voltage, 2.3 kV; no sheath and auxiliary gas flow; 
heated capillary temperature, 275˚C; normalized HCD collision energy 45 for MS2 in C 
trap. The ion selection threshold was 50000 counts for MS2. An activation q = 0.25 and 
activation time of 20 ms were used. 
 
 
2.8.3 Data Analysis by Max Quant  
Peptides and proteins were identified by Andromeda via automated database searching of 
all tandem mass spectra against a curated target/decoy database (forward and reversed 
version of the Human protein sequence database (http://www.uniprot.org/, UniProt. 
Release May 2017) containing all Human protein entries from Swiss-Prot and TrEMBL. 
Spectra were initially searched with a mass tolerance of 6 ppm in MS mode and 0.5 Da 
in MS/MS mode and strict trypsin specificity and allowing up to 2 missed cleavage sites. 
Cysteine carbamidomethylation was searched as a fixed modification, whereas N-acetyl 
protein, deamidated NQ, oxidized methionine were searched as variable modification. 
The resulting Andromeda peak list-output files were automatically loaded into inbuilt 
MaxQuant software modules for further processing, label free quantitation (LFQ) and a 
maximum false discovery rate of 1% was fixed for the result output files (Cox et al.,  
2014). Recent progress in the field has led to development of robust software tools for 
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analysis of label free proteomics datasets. Furthermore, label free offers a higher dynamic 
range and simplicity of analysing large datasets (Cox et al., 2014). We performed 
proteomics analysis of samples in three biological replicates. Data analysis was 
performed on log 2 normalised LFQ intensities and ANOVA with permutation based 
FDR (>0.05) was used to determine significantly altered proteins. Gene Ontology (GO) 
Enrichment analysis was performed using DAVID webtool (Huang da, Sherman & 
Lempicki, 2009a: Huang da, Sherman, Lempicki, 2009b). Enrichment of GO terms was 
considered statistically significant, corrected for multiple testing by the Benjamini-
Hochberg method with adjusted p-values < 0·05. 
We performed ANOVA to look for significantly altered proteins across multiple 
conditions. However, individual t tests or post hoc analysis could be performed before 
carrying out further validation studies in future. 
 
2.9 Statistics 
Statistical analysis was performed on data from at least 3 independent experiments. For 
RQ-PCR samples were run in triplicate and then independent sample replicates performed 
in triplicate for publication. Students t-test was performed to identify significance 
between samples where p<0.05 was deemed significant. 
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Chapter 3 
Role(s) of CCN1 (CYR61) protein and cell cycle regulators in MCL 
progression 
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Chapter 3 
3. CCN1 (CYR61) protein and cell cycle regulators in MCL 
progression  
3.1 Introduction 
Mantle cell lymphoma (MCL) is a rare subset of B-NHL combines the poor-risk features 
of both indolent lymphoma with its incurability and aggressive lymphoma with its ability 
to proliferate and disseminate rapidly (Deng, Lee & O'Connor, 2012). It is characterised 
by cyclin D1 overexpression as a result of chromosomal translocation of t(11;14) (Bertoni, 
Zucca & Cotter, 2004). However, cyclin D1-Negative expression has been identified in 
blastoid MCL (Zeng et al., 2012). Furthermore, lack of cyclin D1 expression has been 
observed in a rare case of MCL but with cyclin D2 overexpression. In 2013, (Igawa et 
al.,) have found that cyclin D2 overexpressed in 98% of de novo CD5-positive DLBCLs 
(50/51) and in 28% of CD5-negative DLBCLs (14/51) and suggested that “this insight 
may be useful for overcoming the inferior survival of this aggressive lymphoma”. Cyclin 
D2 expression protein could plays a role in pathogenesis of MCL instead of cyclin D1 but 
the mechanism is not clear (Fu et al., 2005). On the other hand, MCL lack cyclin D1 
expression is considered difficulty to identify this type of NHL (Mozos et al., 2009). 
However, SOX11 has been identified as a reliable biomarker for MCL with cyclin D1− 
patients which prognosis aggressive variants (Narurkar, Alkayem & Liu, 2016). 
Moreover, patients with cyclin D1-/SOX11+ MCL presented advanced stage of disease 
and poor outcome (5 year OS, 48%) (Salaverria et al., 2013). Additionally, SOX11+ 
expression has seen in patients with MCL and not expressed in other low-grade B-cell 
NHL which making SOX11 transcriptional factor a valuable tool to distinguish cyclin D1 
negative MCL from other type of lymphoma (Carvajal-Cuenca et al., 2012: Dictor et al., 
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2009: Ek et al., 2008: Fernandez et al., 2010: Hsiao et al., 2012:  Mozos et al., 2009: 
Zeng et al., 2012).  While cyclin D2 expression was identified in small B-cell lymphoma 
additionally to patients with MCL which indicating that this type of cyclin is not useful 
to identify patients with cyclin D1 negative MCL (Metcalf et al., 2010: Mozos et al., 
2009).       
Increasing evidence refers to association of deregulated cyclin D1 expression with 
secondary genetic alterations involved in MCL progression (Sander et al., 2016). For 
example, mutations of CDKN2A and TP53 associated with high proliferation rate of 
lymphoid neoplasms are common in blastoid and aggressive MCL but not in indolent 
MCL (Fernàndez et al., 2010; Royo et al., 2011). In 2007, (Salaverria et al.) reported that 
overexpression and down regulation of cyclin D1 in progressive MCL “share the same 
secondary genetic alterations”. 
 In MCL, as a result of dysregulation of cyclin D1, the cell cycle and DNA damage 
responses are disrupted (Fernàndez et al., 2005). p21 and p27 which are  inhibitors of the 
cell cycle progression through binding to CDK-cyclin D complex have observed 
dysregulated in MCL (Muñoz-Alonso et al., 2005; Pinyol et al., 1997). p27 expression 
has correlated with high rate of survival in typical MCL (Kremer et al., 2001)  
Furthermore, p27 down expression associated with low rate of survival of patients with 
aggressive MCL variant (Chiarle et al., 2000). It was suggested that the lack of p27 
expression results from enhanced proteasome degradation of p27 protein in aggressive 
MCL when they have seen that normal mRNA of p27 was expressed (Chiarle et al., 2000). 
Conversely, Izban et al. (2000) have reported that there was no difference in p21 
expression at early and advanced stages of MCL. 
The goal of therapy in patients with MCL, is to prolong survival while minimizing both 
disease-related and treatment-related side effects (Martin, Ghione & Dreyling, 2017). 
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Increasing evidence focuses on the extrinsic signalling from surrounding cells in 
microenvironment of MCL to overcome treatment resistance that is correlated with 
disease progression (Chiron et al., 2017; Papin, Le Gouill & Chiron, 2018). Treatment 
resistance in MCL is produced from the surrounding cells in the microenvironment, 
specifically stromal cells have been identified as responsible or partially responsible for 
recurrence/relapse in  MCL (Pham et al., 2014). CCN1 (CYR61) which belongs to CCN 
family of proteins is involved in tumour microenvironment and has a role in potentiating 
chemoresistance (Long et al., 2015). CCN1 is involved in many stem cell signalling 
pathways and active within the bone marrow microenvironment where haematopoiesis 
ensues; CCN1 can activate the Wnt-β catenin-TCF4 signalling pathway in glioma cells 
(Xie et al., 2004a) and induces Wnt3A osteoblast differentiation of mesenchymal stem cells 
(Si et al., 2006).  CCN1 in some cancers plays important roles in enhancing apoptosis, 
suppressing tumour growth, such as non-small-cell lung cancer (NSCLC) cell lines 
through activating the β-catenin-c-myc-p53-p21 signalling pathway (Tong et al., 2004). 
Moreover, CCN1 enhances pancreatic cancer cell motility in vitro and cell tumorigenic 
growth in vivo by regulating sonic-Hedgehog through integrin-Notch-signalling pathway 
(Haque et al., 2012). In this chapter, we have investigated the expression of CCN1 and 
cell cycle regulators Cyclin D1, p21 and p27 in progressive MCL.  
                                          
3.2 Results 
3.2.1 CCN1 expression is inversely correlated with MCL aggressiveness  
In order to assess the potential role(s) of CCN1 in MCL, we have investigated CCN1 
expression using RQ-PCR and Western blotting.  REC1, G519, JVM2 human MCL cell 
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lines were used as a model for MCL disease progression in the order from indolent to 
aggressive disease REC1<G519<JVM2 respectively.  
RQ-PCR for CCN1 expression showed that JVM2 cells had the lowest CCN1 expression 
with a CT value 32.14573288. JVM2 expression was then set to a fold change of 1.0 to 
enable calculation of fold change for REC1 and G519 cells using the CT method. 
CCN1 expression was high in REC1 cells and sequentially decreased in progressive G519 
and JVM2 cells. The fold change of CCN1 in MCL cell lines REC1, G519 and JVM2 
was 23.5, 7.0 and 1.0 respectively (Figure 3.1).  
Investigation of CCN1 total protein expression using western blot analysis showed CCN1 
protein expression at the following approximate molecular weights; 42kDa consistent 
with expression of full length CCN1, 28-30kDa and 18-20kDa consistent with expression 
of truncated isoforms. Expression of full–length CCN1 barely altered through the cell 
lines however, expression of the truncated isoform (18-20kDa) was high in REC1 cells 
(OD:1.0) reduced in G519 cells (OD:0.5) and barely detected in JVM2 cells (Figure 3.2A 
and B). Reports from a previous study (Choi et al., 2013) suggests the 28-30kDa moiety 
could comprise the SP, IGFBP, VWC and TSP-1 domains whilst the 18-20 kDa moiety 
could be either the SP, IGFBP, VWC fragment or TSP-1 and CT fragment, or potentially 
a mix of both (Figure 3.3). 
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Figure 3.1: RQ-PCR screen of MCL cell lines for CCN1 expression shows that CCN1 expression is 
upregulated in the low-aggression phenotype (REC1) and down regulated in aggressive disease (G519 and 
JVM2). The fold change of CCN1 expression in MCL cell lines was 23.5 in REC1, 7.0 in G519 and 1.0 in 
JVM2. GAPDH is the housekeeping gene, data generated were normalised against GAPDH control (n=3 
independent samples). 
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Figure 3.2: Western blot analysis of CCN1 expression for the MCL cell lines, REC1, G519 and JVM2 
(A) Western blot showed full length CCN1 protein expression with 42 kDa barely altered in MCL 
progression. However, expression of truncated isoforms 28-30kDa and 18-20kDa were high in early stage 
REC1 and decreased in advanced stages G519 and JVM2. (B) Optical densitometry for CCN1 band pattern 
by Western Blotting expression shown expression of full–length CCN1 barely altered through the cell lines 
however, expression of the truncated isoform (18-20kDa) was high in REC1 cells (OD:1.0) reduced in 
G519 cells (OD:0.5) and barely detected in JVM2 cells. GAPDH was used as a loading control, data 
generated were normalised against GAPDH control (n=3 independent samples).  
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Figure 3.3: CCN1 domain structure of full length and potential truncated CCN1 proteins. The 
molecular weight (Mwt) of full length of CCN1 protein is 42 kDa that involves 5 kDa of an insulin-like 
growth factor binding protein domain (IGFBP), 7 kDa of von Willebrand type C repeat (VWC), 5 kDa of 
thrombospondin type 1 domain (TSP-1) and 10 kDa of cysteine knot carboxyl terminal (CT). Furthermore, 
8 kDa of Hinge that contacts the N-terminus and C-terminus and 3 kDa of signal peptide (SP). The potential 
truncated CCN1 isoforms include C-terminus (IGFBP and VWC) with 19 kDa, N-terminus (TSP-1 and CT) 
with 18 kDa and C-terminus plus TSP-1 with 30 kDa. Adapted from (Choi et al., 2013). 
 
3.2.2 Cyclin D1 is downregulated in progressive MCL  
We have investigated cyclin D1 expression using RQ-PCR and Western blotting using 
total protein extracts from the three MCL cell lines; REC1, G519 and JVM2. RQ-PCR 
shows cyclin D1 expression is high in REC1 cells and decreased in G519 and JVM2 cells 
consistent with deregulation of cyclin D1 in aggressive disease.  Fold changes in cyclin 
D1 expression were 10.1, 4.6 and 1.0 for REC1, G519 and JVM2 respectively (Figure 
3.4).        
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Cyclin D1 total protein expression mirrored that of the gene expression where cyclin D1 
was highly expressed in the REC1 cells (OD: 1.0), reduced to one fifth in the G519 cells 
(OD: 0.2) and not detected by western blotting in the JVM2 cell line (Figure 3.5A and B). 
  
 
Figure 3.4: RQ-PCR screen of Cyclin D1 expression in MCL progression shown fold change in cyclin 
D1 expression in early stage of MCL (REC1) and down regulation in advanced stage of disease (G519 and 
JVM2). Fold changes in cyclin D1 expression were 10.1, 4.6 and 1.0 for REC1, G519 and JVM2 
respectively. GAPDH was the housekeeping gene and data generated were normalised against GAPDH 
control (n=3 independent samples).    
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Figure 3.5: Western blotting for expression of total protein for cyclin D1 in MCL cell lines. (A) 
Western blot depicts high expression of cyclin D1 in REC1, decreases in G519 and barely detected in 
JVM2. (B) Optical densitometry for western blotting presents the expression of cyclin D1 total protein 
was highly expressed in the Rec1 cells (OD: 1.0), reduced to one fifth in the G519 cells (OD: 0.2) and not 
detected by western blotting in the JVM2 cell line. Optical densitometry was performed on banding and 
data generated normalised against GAPDH loading control (n=3 independent replicates). 
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3.2.3 High expression of p21CIP1 and down regulation of p27KIP1 in 
aggressive MCL   
Cyclin dependent kinase inhibitors, p21CIP1 and p27KIP1, were also investigated for an 
involvement in disease progression.  
RQ-PCR shows increasing expression of p21 with disease progression (Figure 3.6) whilst 
expression levels of p27 are decreased with disease progression in G519 and JVM2 cells 
(Figures 3.8).  Total cell lysates showed that p21CIP1 was not detected in REC1 cells but 
had increasing expression in G519 (OD: 0.6) and JVM2 cells (OD: 1.0) (Figure 3.7A and 
B). Whilst RQ-PCR and western blotting show that p27KIP1 expression was high in the 
REC1 and decreased with disease progression in G519 and JVM2 cells (Figures 3.8 and 
3.9A). Total cell lysates showed that p27KIP1 was high expressed in REC1 (OD: 1.5) and 
decreased in G519 (OD: 1.0) and not detected in JVM2 cells (Figure 3.9B).  
 
Figure 3.6: RQ-PCR screen p21 expression in MCL cell lines shown disease progression involved 
upregulation of p21 expression in the high-aggressive MCL and down regulation in low-aggressive disease. 
Fold change of p21 expression was 12.8 in JVM2 and reduced to 8.0 in G519 and 1.0 in REC1 mirrors 
association of p21 expression with progression disease. GAPDH was used the housekeeping gene and data 
generated were normalised against GAPDH control (n=3 independent samples).          
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Figure 3.7: Western blotting for expression of total protein for p21 in MCL cell lines. (A) Western 
blot shows high expression of p21 in JVM2, decreases in G519 and not detected in REC1. (B) Optical 
densitometry for western blotting presents the expression of p21 total protein was highly expressed in the 
JVM2 cells (OD: 0.6), reduced in the G519 cells (OD: 1.0) and not detected by western blotting in the 
REC1 cell line. Optical densitometry was performed on banding and data generated normalised against 
GAPDH loading control (n=3 independent replicates).     
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Figure 3.8: RQ-PCR screen p27 expression in MCL cell lines shown p27KIP1 expression was high in the 
REC1 and decreased with disease progression in G519 and JVM2 cells. Fold change of p27 was 10.6 in the 
REC1 decreased to 1.5 in G519 and 1.0 in JVM2 cells. GAPDH was used the housekeeping gene, data 
generated were normalised against GAPDH control (n=3 independent samples).         
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Figure 3.9: Western blot of total protein of p27 expression in MCL cell lines REC1, G519 and JVM2. 
(A) Western blot shown that p27 expression total protein decreased with disease progression and increased 
with early stage of disease. (B) Total cell lysates showed that p27KIP1 was high expressed in REC1 (OD: 
1.5) and decreased in G519 (OD: 1.0) and not detected in JVM2 cells. Optical densitometry was performed 
on banding and data generated normalised against GAPDH loading control (n=3 independent replicates).              
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3.2.4 Altered subcellular localization of p21CIP1 and p27KIP1 portray 
resistance in progressive MCL  
To investigate the subcellular localization of p21CIP1 and p27KIP1 in MCL, we extracted 
cytoplasmic, mitochondrial and nuclear protein from cells and performed western blotting.  
Expression of p21CIP1 was not detected in any fraction for early stage REC1 cells. For the 
progressive G519 and JVM2 cells, p21CIP1 was primarily expressed in the cytoplasm and 
was not detected in the nucleus. Expression of p21CIP1 was detected in the mitochondrial 
fraction for JVM2 cells (Figure 3.10 A). Blotting for GAPDH (cytoplasmic), COX IV 
(Mitochondrial) and Histone 3 (Nuclear) markers were used as controls for each fraction.  
For p27KIP1, expression was only detected in the cytoplasmic fraction and not in 
mitochondrial or nuclear fractions (figure 3.10 B). GAPDH (cytoplasmic), COX IV 
(Mitochondrial) and Histone 3 (Nuclear) markers were used as loading controls and to 
ensure clean fractions were obtained for each, without cross contamination during the 
fractionation process.  
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Figure 3.10: Subcellular localisation of p21 and p27 in MCL. (A) Western blot for p21 cellular content 
for cytoplasmic, mitochondrial and nuclear fractions for REC1, G519 and JVM2 cells. P21 was not detected 
in nuclear of all MCL cell lines. It is disappeared in early stage disease REC1, detected in the cytoplasm of 
advanced stage G519 and JVM2 and in mitochondria of JVM2. (B) Western blot for p27 cellular content 
for cytoplasmic, mitochondrial and nuclear fractions for REC1, G519 and JVM2 cells. P27 expression was 
detected in cytoplasm of MCL cell lines with decreased in expression with disease progression. It is 
disappeared in nucleus and mitochondria of all stages of MCL cell lines. GAPDH, Histone 3 and COXIV 
were used as a loading control and to ensure clean fractions free from cross contamination during the 
fractionation process were obtained (n=3 independent samples). 
116 
 
3.3 Discussion 
MCL is considered an aggressive disease and has one of the worst outcomes among B-
cell lymphomas due to the dysregulation of the DNA damage response pathways 
accompanied with abnormal cell survival mechanisms suppressing apoptosis (Campo & 
Rule, 2015; Moros et al., 2014). MCL characterised by overexpression of cyclin D1 as a 
result of t(11;14) chromosomal translocation that leads to dysregulation of the cell cycle 
(O’Connor, 2007; Zucca & Bertoni, 2013). Furthermore, MCL is characterised by clinical 
course where variants are subdivided into indolent form (classic morphology) and 
aggressive (blastoid or pleomorphic appearance) (Kridel et al., 2012). The heterogeneous 
biology and aggressive behaviour of MCL present a challenge for designing standard 
therapies (Smith, 2011) and therefore require further investigation to identify more 
effective treatment strategies.  
In this study, we have investigated the role(s) of CCN1 in MCL and investigated cell 
cycle regulation using expression of cyclin D1, p21CIP1 and p27KIP1 in the a cell line model 
representing disease progression in MCL where the magnitude of aggressive behaviour 
is in the order REC1<G519<JVM2. CCN1 dysregulation was identified in MCL 
progression where CCN1 was highly expressed in the REC1 cells and reduced in the 
aggressive G519 and JVM2 cells. CCN1 expression decreases with disease progression. 
We found that the lower expression of CCN1 in aggressive MCL cell lines (G519 and 
JVM2) is additional risk factor for disease progression. However, many studies have 
indicated that the high expression of CCN1 is implicated in disease progression, 
tumorigenesis and invasion of hepatocellular carcinoma (HCC) (Li et al., 2012), breast 
cancer (O'Kelly et al., 2008), prostatic carcinoma (D'Antonio et al., 2010), gliomas (Xie 
et al., 2004b) and gastric cancer (Lin et al., 2007). 
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Further investigation demonstrated that whilst full-length CCN1 remains relatively 
constant within the cells lines, the 18-20 kDa truncated form is decreased within 
aggressive G519 and JVM2 cells. Previous reports identify that this truncated form could 
potentially be a fragment consisting of the SP-IGFBP-VWC domains or the TSP-1-CT 
domains (Choi et al., 2013), the latter would infer that CCN1 transcriptional control is 
lost within aggressive MCL. In 2006, (Planque et al.) have found that full length of CCN3 
inhibited cell growth while truncated isoform induced “morphological transformation of 
chicken embryo fibroblast” and suggested a role in oncogenic activities. Moreover, 
truncated isoform of CCN3 translocated to the nucleus of cancer cell lines which is 
supporting of CT-CCN3 being involved in transcriptional regulation. Increasing evidence 
indicates the Nuclear Localisation Signal (NLS), a short peptide motif mediates nuclear 
localisation of proteins, located at the CT module in the CCN3 (lysine-rich 
PTDKKGKKCLRTKKSLKA) which is responsible for CT-translocated in the nucleus 
(Planque, 2006). Perbal (1999) found nuclear localisation of truncated isoform of NOV 
protein (31/32kDa) in the nucleus of 143 and HeLa cells. Furthermore, it is suggested the 
truncated isoform may be N-terminus which probably has a role in the gene expression 
of target cells because it is used antibodies against the C-terminus of NOV protein 
(KKGKKCLRTKKS). CCN1 (CYR61) and CCN3 (NOV) are members in the CCN cell 
growth regulators family sharing 40%-60% amino acid homology suggesting that the 
truncated isoform of CCN1 may be targeted to the nucleus and playing a role in the gene 
regulation (Perbal, 1999; Planque & Perbal, 2003). Furthermore, the CCN3 NLS region 
is highly conserved in CCN1 KKGKKCSKTKKS (Planque, 2006) which suggests the 
CT-CCN1 truncated isoform may translocate to the nucleus of MCL cell lines. This is 
consistent with CCN1 found in the nucleus of bladder smooth muscle cells (Chen & Du, 
2007; Tamura et al., 2001).  
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Full length CCN proteins can play an anti-proliferative role, while truncated isoforms 
may induce tumour proliferation (Planque & Perbal, 2003). The truncated isoform has 
wider biological functions owing to the CCN1 partition into the soluble phase (28kDa) 
diffusing freely within tissue and may act as an antagonist towards the full-length form 
in the insoluble matrix (42kDa) (Pendurthi et al., 2005). For example, CCN1 is cleaved 
by plasmin and released a truncated isoform of CCN1 (28kDa) which may support 
endothelial cell migration in breast carcinoma cells (Pendurthi et al., 2005). In 2013, 
(Choi et al.), found the CCN1 truncated isoform (11-23kDa) expressed in diabetic 
retinopathy patients instead of the full-length protein 42kDa. It is also postulated that the 
truncated form of CCN1 can also arise due to alternative mRNA splicing (Perbal, 2009).  
In this study, Cyclin D1 was also deregulated in MCL and our findings are consistent 
with previous reports of cyclin D1 down regulation and disease progression (Peng, Chou 
& Hsu, 1998). Interestingly, Saglam et al. (2014) have demonstrated that the up regulation 
of cyclin D1 and p53 are activated by the CCN1 pathway in high-grade ductal carcinoma 
in situ (DCIS). Consistent with these findings, we showed a positive association between 
CCN1 and cyclin D1 expression in all MCL cell lines. In other solid tumours, where 
cyclin D1 is overexpressed; breast, liver, lung, and brain cancer (Gillett et al., 1996; Hall 
& Peters, 1996; Molenaar et al., 2008) requires consistent signalling from the 
extracellular matrix and growth factors (Assoian & Klein, 2008).  
MCL progression involving down regulation of cyclin D1 and the up regulation of p21CIP1 
may contribute to treatment resistance (Abukhdeir & Park, 2008). We have shown that 
p21CIP1 levels increase with disease progression.  This is consistent with other studies that 
report overexpression of p21CIP1 was correlated with tumour progression; in breast 
(Ceccarelli et al., 2001) and  ovarian carcinoma (Ferrandina et al., 2000) and in brain 
tumours (Jung et al., 1995). 
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We have shown that p27KIP1 levels decrease with disease progression also consistent with 
findings from Izban et al. (2000), where p27KIP1  was overexpressed in early stage disease 
(typical MCL) and down regulated in aggressive stage (blastoid variants) where it was 
associated with a high proliferation rate of blastoid MCL. Conversely, in 1998 
(Quintanilla-Martinez et al.) showed expression of p27KIP1 was inversely associated with 
the proliferation rate of MCL cells; undetected in typical MCL cells (classic disease) 
associated with low proliferation rate but was overexpressed in the blastic variant of MCL 
cells (aggressive disease) with higher proliferation rate. 
P27KIP1 and p21CIP1 have important roles in promotion of assembly of CCND-CDK4/6 
complexes (LaBaer et al., 1997). This interaction leads to sequestration of p27KIP1 in 
CCND-CDK4 complex which blocks inhibition of the CCNE-CDK2 complex (Perez‐
Roger et al., 1999). Furthermore, investigation of p21CIP1 expression in MCL progression 
showed down regulation at early stage disease and overexpression at advanced stage that 
mirrors its roles in MCL progression.  
More importantly, in cancer, the tumour suppressor function of p21CIP1 and p27KIP1 
depends on their nuclear localization (Jeannot et al., 2015; Romanov, Pospelov & 
Pospelova, 2012). Many studies have found that phosphorylation of specific sites of 
p27KIP1 and p21CIP1 lead to their export into the cytoplasm where they can act as a tumour 
promotors and induce drug resistance (Ohkoshi, Yano & Matsuda, 2015; Zhao et al., 
2014). Furthermore, calmodulin plays important role in p21 accumulation in the nucleus 
but not p27 by binding to p21 and prevents phosphorylation of p21 at Ser153 (Rodríguez-
Vilarrupla et al., 2005: Taulés et al., 1999). In this study, p21CIP1 and p27KIP1 were found 
in the cytoplasmic fractions and absent in nuclear fractions of all three cell lines (REC1, 
G519 and JVM2). This suggests in MCL, p21CIP1 and p27KIP1 have lost their tumour 
suppressor roles and acquired tumour promoter roles by localisation to the cytoplasm.  
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Whilst mutation of p21CIP1 has not been investigated here, mutation of the p21CIP1 gene 
frequently occurs in cancer cells leading to inactivation of p21CIP1 with loss of function 
to block the cell cycle, even when overexpressed (Lu et al., 1998b; Lukas et al., 1997). 
While regulation of p27KIP1 is different from other cell cycle inhibitors, p27KIP1 gene 
mutation is rare (Garrett-Engele et al., 2007a).  
CCN1 likely plays key role(s) in haematopoiesis and in B cell development through 
modulation of stem cell signalling pathways, TGF β, BMP, Notch, Wnt-β catenin 
(McCallum & Irvine, 2009; Wells et al., 2015). CCN1 roles within haematological 
malignancy show CCN1 promotes survival and inhibits apoptosis in AML (Niu et al., 
2014) and overexpression of CCN1 in multiple myeloma (MM) postponed tumour growth 
and suppressed bone destruction (Johnson et al., 2014). Recently, in 2018, (Niu et al.,) 
have found the “genetic polymorphisms in the CYR61 gene may be considered potential 
AML risk factors in the Han Chinese population”. Additionally, CCN1 expression 
associated with osteosarcoma progression by promoting cell migration and metastasis 
through Raf-1/MEK/ERK/Elk-1/TWIST-1 signaling pathway (Hou et al., 2014). CCN1 
involved in the pathogenesis of acute lymphoblastic leukemia (ALL) by overexpression 
in the plasma and bone marrow samples from ALL patients compared with samples from 
normal control.  Resulting in promoting tumour survival through the AKT/NF-κB 
pathway by up-regulating Bcl-2 (Zhu et al., 2016). CCN1 also decreases bone resorption 
by inducing osteoblastogenesis and suppressing osteoclastogenesis (Roodman, 2014).  
CCN1 may interact with other growth factors such as bone morphogenetic proteins 
(BMP), transforming growth factor β (TGF-β) and vascular endothelial growth factor 
(VEGF) which need more investigation (Lau, 2011).  Recently, it has seen that ALK5 
suppression prevents TGF-1β-induced CCN1 expression in human dermal fibroblasts 
(Thompson, Murphy-Marshman & Leask, 2014). More importantly, CCN1 is a 
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transcriptional target of TGF-β and may potentiate an autocrine regulatory mechanism in 
tumourigenesis (Bartholin et al., 2007).  
In conclusion, CCN1 appears to have a role in cell cycle regulation in progressive MCL. 
However, low expression of the truncated CCN1 protein in progressive MCL together 
with p21 / p27 changes in expression and subcellular localisation of p21 and p27 may 
contribute to aggressive disease and treatment resistance.  
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CCN1 stable overexpression and knockdown models in 
MCL cell lines 
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Chapter 4 
4. CCN1 overexpression and knockdown models in MCL cell lines 
CCN1 expression is high in REC1 cells and reduced in aggressive JVM2 cells (Figure 
3.1). In order to assess the role of CCN1 in disease progression, we used genetic 
modification of the cells lines as follows; knockdown CCN1 sequence in REC1 cells and 
CCN1 overexpression in JVM2 cells by lentivirus.  
Western blot analysis of CCN1 expression for the MCL cell lines, REC1, G519 and JVM2 
showed full length CCN1 protein expression with 42 kDa barely altered in MCL 
progression. However, expression of truncated isoforms 28-30kDa and 18-20kDa were 
high in early stage REC1 and decreased in advanced stages G519 and JVM2 as described 
at chapter 3 (Figure 3.2).  
 
4.1 Introduction 
Lentivirus expression has been chosen to transduce notoriously difficult to genetically 
modify haematopoietic cell lines, as this system has a higher efficacy of transduction with 
less toxicity.  
In first attempt, JVM2 cells were seeded in 6 flasks 2 of them were infected by pLenti-
hCYR61 lentivirus, 2 were infected by pLenti-Empty vector or Blank Control and 2 of 
flasks were used as negative control as described at (2.5.8.1). After successfully forming 
fluorescence, puromycin was added gradually on concentrations (0.1, 0.25, 0.5, 1, 2, 4, 8, 
10 and 20) µg/ml. After 2 months adding puromycin to select transduced cells we noticed 
the negative control cells still viable and increased in number, so we stopped adding 
puromycin and cells were left to grow. After 1 month all the cells were dead, even 
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transduced cells were died. This problem occurred in second and third attempt with parent 
JVM2 (wild type) cells resistant to puromycin, therefore requiring further optimisation. 
 
4.2 Optimisation of lentivirus delivery system  
To identify the optimal antibiotic concentration that enabled selection of transduced 
clones for the stable overexpression and knockdown models, kill curves for REC1 and 
JVM2 cells were performed as described at (2.5.6). For REC1, cells were resistant to 
puromycin on concentration 0.1-2 µg/ml and sensitive to 6-10 µg/ml in the first dose of 
adding puromycin. Cells were sensitive to 4-5 µg/ml concentration of puromycin after 25 
days adding antibiotic. 3 µg/ml of puromycin concentration was the minimum antibiotic 
concentration that killed the cells in all cell densities that used in this study (Figure 4.1).  
For JVM2 cells, the cells were sensitive to 8, 9 and 10 µg/ml of puromycin in the first 
dose and then resistance appeared in all concentrations after 25 days adding puromycin 
(Figure 4.2).               
Since JVM2 cell line is resistant to antibiotic selection (puromycin) we have chosen single 
cell sorting to select transduced cells. This experiment was performed with parent JVM2 
cells (without lentivirus infection) using CFSE kit as described at (2.5.7) to optimise the 
cell density and flow cytometry setting. The parameters for flow cytometry were 
Forward-scattered light (FSC), Side-scattered light (SSC) and Fluorescein isothiocyanate 
(FITC) were 155, 500 and 220 nm respectively (Figure 4. 3 A and B).  
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Figure 4.1: Kill curve of REC1 cells: Seeding density for REC1 cells was titred against puromycin concentration to ensure CCN1 knock down clones were obtained. 
Cell viability after addition of puromycin at 2 days (blue) and after 25 days (red) compared to cell seeding density (grey).   
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Figure 4.2 Kill curve of JVM2 cells: Seeding density for JVM2 cells was titred against puromycin concentration to ensure CCN1 overexpression clones were 
obtained. Cell viability after addition of puromycin at 2 days (blue) and after 25 days (red) compared to cell seeding density (grey). 
 
     2 days 
      25 days 
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Figure 4.3: Flow cytometry of single cell sorting of JVM2 cells. (A) Wild type of JVM2 cells display 
negative fluorescence of JVM2 cells. (B) JVM2 cells stained using CFSE kit display high fluorescence of 
cells that sorted.           
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4.2.1 Efficient lentivirus production 
Lentivirus production was performed as described in (2.5.5). High green fluorescence 
indicated that high efficient lentivirus production because GFP is a reporter marker to 
package of lentiviral vector provided from abm® (Figure 4.4). In this study, lentiviral 
plasmid and two helper plasmids were used to generate lentivirus carrying CCN1/CYR61 
gene. A three-plasmid expression system including two helper plasmids which are 
packaging and envelope plasmids and the transfer plasmid was used. The packaging 
plasmid was pΔ8.9 coding for gag-pol and the envelope glycoprotein was VSV-G 
glycoprotein of the vesicular stomatitis virus coding for the env. The gag gene encodes 
for structural proteins which are matrix, capsid and nucleocapsid that used to package the 
virus. pol gene encodes for the enzymes reverse transcriptase, integrase and protease that 
involved in reverse-transcription, integration, maturation and replication (Liechtenstein, 
Perez-Janices & Escors, 2013).          
 
Figure 4.4: GFP expression after lentiviral production in HEK293 cells. A and E are scrambled and 
blank for CYR61 overexpression and knockdown respectively B, C and D are CYR61 siRNA 
lentiviruses. F is CYR61-overexpression lentivirus. 
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4.2.2 Effective transduction of MCL cell lines 
JVM2 cells were seeded at 2 different cell densities 1.5 x 105 /well and 2.5 x 105 /well as 
described at (2.5.8.1) to generate CYR61/CCN1 overexpression (OE). High Green 
Fluorescence Protein (GFP) expression in both of cell densities reflected effective 
lentiviral transduction of JVM2 cells (figure 4,5 i and v). GFP is a reporter marker of 
insertion gene in to the DNA of targeted cells. After transduction of lentivius carrying 
CYR61/CCN1 gene in MCL cells, the virus uncovered and released virus RNA and 
enzymes necessary for reverse transcription and integration into cells. In the cytoplasm 
of JVM2 cells, RNA transcribed to dsDNA which in turn was transported to nucleus 
integrated with DNA leading to translated CCN1 protein and gene modification.  
GFP expression is highly expressed in picture B and C which are JVM2 cells infected by 
pLenti-III-CMV-GFP-2A-Puro-Blank Control as empty (blank) vector and pLenti-GIII-
CMV-hCYR61-GFP-2A-Puro as vector containing full length human CCN1 sequence 
respectively (Figure 4.5 i and v). In comparison with wild type JVM2 cells which are 
GFP expression negative (figure 4.5 i and v picture A). However, during lentiviral 
transduction, not all cells will become transduced and there may be varying levels of gene 
transduction observed within the cell population displayed by a heterogenous GFP signal 
(figure 4.5 i and v picture B and C). Single cell sorting was used to identify GFP positive 
clones and enable growth of a more homogenous population of cells with the gene 
transduced to similar levels within the population (Figure 4.5 i and v picture D and E).      
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To generate a stable CYR61/CCN1 knock down in REC1, three different CYR61-
siRNA/shRNA/RNAi Lentiviruses targeting three different sequences (a-c) were used 
(Table 2.2). REC1 cells were seeded at cell densities of 5.0 x 105 /25 cm2 tissue culture 
flask and 7.5 x105 /25 cm2 tissue culture flask as described at (2.5.8.2). High green 
fluorescence protein expression in both of cell densities referring to effective transduction 
of REC1. GFP is a reporter marker of insertion gene in to DNA of targeted cells. After 
detection of green fluorescence protein (GFP) production, cells were selected by adding 
puromycin (0.1-3 µg/ml) to obtain CCN1 knockdown clones and 0.5 µg/ml was used to 
maintain the cells.            
GFP expression is highly expressed in picture B, C, D, and E in both of cell densities 
(Figure 4.6 i and v) which are infected by scrambled siRNA EGFP, CYR61-288 
siRNA/shRNA/RNAi Lentivector (Human), CYR61-582 siRNA/shRNA/RNAi 
Lentivector (Human) and CYR61-676 siRNA/shRNA/RNAi Lentivector (Human) 
respectively. Comparing with wild type of REC1 which is negative to GFP expression 
(figure 4.6.i and v picture A). 
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Single cell sorting for selecting transduced JVM2 with CCN1/CYR61 gene that express 
fluorescence was performed (Figure 4.7).  
Figure 4.7: Flow cytometry of sorting of JVM2-CCN1/CYR61 cells. (A) Negative control of JVM2 cells 
(wild type). (B) JVM2-Empty cells, P1 (red) to sort cells with empty gene. (C) JVM2-CCN1 OE cells, P1 
(red) to sort cells with CCN1/CYR61 gene.     
 
A 
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4.2.3 Characterisation of CCN1 OE and KD cell line models 
Western blots of samples taken forward for Proteomics 
Western blotting as described at (2.6.5.2) was performed to confirm CYR61/CCN1 
protein expression in OE and KD models of three sequential passages in JVM2 and REC1 
cells respectively. High green fluorescence protein (GFP) expression was detected in both 
cell densities of OE and KD models but western blotting shows variations in bands in 
these models compared with positive controls (blank for OE and scrambled for KD). For 
CYR61/CCN1 OE model, western blotting has showing full length (42 kDa) and 
truncated forms (28-30 and 18-20 kDa) of CCN1 protein were overexpressed which 
means CYR61/CCN1 gene successfully inserted at cell densities 1.5 x 105 and 2.5 x 105 
compared with positive control (blank vector). Protein was extracted from transduced 
CCN1-JVM2 cells with cell density 2.5 x 105 where CCN1 was highly expressed 
compared with empty vector or blank (positive control) and used for proteomics analysis 
in Chapter 5. Samples selected for proteomics were Blank b, CCN1 OEb1 passage 1, 
CCN1 OE b2 passage 2 and CCN1 OEb1 passage 3 (Figure 4.8). 
For CYR61/CCN1 KD model, full length (42 kDa) and truncated forms 28-30 and 18-20 
kDa of CCN1 protein were down regulated in REC1 cells at 7.5 x 105 cell density 
compared with positive control (scrambled). However, CCN1 protein (42kDa) at cell 
density 5.0 x 105 cells was still up-regulated compared with scrambled sequence. Protein 
was extracted from transduced siRNA/CCN1-REC1 from cell density 7.5 x 105  where 
CCN1 was down regulated compare with scrambled sequence (positive control) and used 
for proteomics analysis in chapter 5. Samples selected for proteomics were from passage 
1; scrambled b, CCN1 KD R288b, CCN1 KD Y582b, CCN1 KD G676b; passage 2 
scrambled b, CCN1 KD G676b, passage 3; scrambled b and CCN1 KD G676b (Figure 
4.9). 
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Figure 4.8: Western blot of transduced JVM2 cells with CYR61/CCN1 protein of three sequential passages. Blank a, CCN1 OE a1 and 2 are protein extracted from transduced 
JVM2 with pLenti-III-CMV-GFP-2A-Puro-Blank Control and pLenti-GIII-CMV-hCYR61-GFP-2A-Puro lentivirus respectively at cell densities 1.5 x 105.  Blank b, CCN1 OE b1 
and 2 are protein extracted from transduced JVM2 with pLenti-III-CMV-GFP-2A-Puro-Blank Control and pLenti-GIII-CMV-hCYR61-GFP-2A-Puro lentivirus respectively at cell 
density 2.5 x 105 . Full length (42 kDa) and truncated forms (28-30 and 18-20 kDa) of CCN1 protein were overexpressed at cell densities 1.5 x 105 and 2.5 x 105 compared with positive 
control (blank vector). However, in passages 1, 2 and 3 Blank b, CCN1 OE b1 and CCN1 OE b2 which are cell density 2.5 x 105 CCN1 full length and truncated forms were strongly 
overexpressed compare with  Blank a, CCN1 OE a1 and 2 which are cell densities 1.5 x 105. GAPDH was used as loading control. 
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Figure 4.9: Western blot of transduced REC1 cells with CYR61/CCN1 protein of three sequential passages. scrambled a, CCN1 KD R288 a, CCN1 KD Y582 a and CCN1 
G676 a are protein extracted from transduced REC1 with scrambled siRNA, CYR61-288, CYR61-582 and CYR61-676- si RNA lentivirus respectively at cell densities 5.0 x 105.  
scrambled b, CCN1 KD R288 b, CCN1 KD Y582 b and CCN1 G676 b are protein extracted from transduced REC1 with scrambled siRNA, CYR61-288, CYR61-582 and CYR61-
676- si RNA lentivirus respectively at cell densities 7.5 x 105. Full length (42 kDa) and truncated forms 28-30 and 18-20 kDa of CCN1 protein were down regulated in REC1 cells at 
7.5 x 105 cell density compared with scrambled. However, CCN1 protein (42kDa) at cell density 5.0 x 105 cells was still up-regulated compared with scrambled in three passages. 
GAPDH, B-Actin, H3 and COXIV were used as loading control. 
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4.3 Conclusion 
 Lentiviral vectors have been used as an effective transfer gene tool and optimisation of 
effective lentiviral transduction conditions are important for effective gene modification 
to occur experimentally (Denning et al., 2013). Developing stable OE or KD cell lines 
require the optimal cell density and antibiotic concentration for selection to be evaluated 
(Delrue et al., 2018). Kill curves were performed for wild type JVM2 and REC1 cells to 
optimise the optimal puromycin concentration and cell densities for effective CCN1 OE 
and CCN1 KD cells lines to be gained. The optimal puromycin concentration for REC1 
was 3 µg/ml which was the minimum puromycin concentration that optimally killed the 
cells in all cell densities used in this study. Cells were sensitive to 4-5 µg/ml and resistant 
to 0.1-2 µg/ml concentration of puromycin after 25 days adding antibiotic (figure 4.1). In 
2011, Jones et al., have used 2 µg/ml puromycin to select transduced REC1 lentiviral 
shRNA knockdown of RRM2 to generate stable cell lines. However, 0.5 µg/ml 
puromycin concentration was used to select REC1 infected with lentiviral 
shRNA/pLOK.1 targeting rictor in mantle cell lymphoma (Liao et al., 2019).  
CCN1 OE in advanced stage JVM2 cells was particularly challenging because of the 
antibiotic resistance of JVM2 wild type cells which was observed in the kill curve 
experiments. In this study, we found that the JVM2 cells were resistant to all the 
recommended puromycin concentrations which are 0.1-10 µg/ml puromycin (Figure 4.2), 
so we used single cell sorting by flow cytometry to select CCN1 OE transduced cells 
(figure 4.3 A and B).  Flow cytometry is rapid and reliable tool to select gene transferred 
cells (Nunez et al., 2001: Wang et al., 2015).  
After optimisation of antibiotic concentration and cell densities of JVM2 and REC1 cells 
we have used lentivirus system for CCN1 OE and CCN1 KD respectively (figure 4.8 and 
4.9). Lentiviral transduction has been found to be an attractive technique to deliver up to 
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10 kilobases of transgenes, naturally long-term expression with no side effects in 
lymphoma cells (Lois et al., 2002: Mátrai, Chuah & VandenDriessche, 2010). In 
particular, lymphoma cells are difficult cells to modify gene expression (Anastasov et al., 
2009). In 1998, (Huang et al.) found that the primary T-helper cells were resistant to 
transfection by conventional methods. Protein was then extracted from CCN1 OE and 
CCN1 KD cell lines and western blotting performed to confirm gene insertion / deletion 
in the MCL cell lines.  Protein was then extracted from three independent passages of the 
cell lines and used for proteomics analysis in chapter 5 (Figure 4.8 and 4.9). 
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Chapter 5 
5.1 Proteomics Analyses 
We have genetically modified MCL cell lines in order to assess the role of CCN1 in MCL. 
We have used CCN1 knockdown in REC1 cells (parental: CCN1 high) and CCN1 
overexpression in JVM2 cells (parental CCN1 low) as a model for investigating CCN1 
potential roles and function(s). Proteomics was completed at the new Derriford Research 
Facility in conjunction with Dr Vikram Sharma.   
Investigation of proteins in the knockdown model (REC1 KD) quantified changes in 559 
proteins of which 112 proteins were downregulated to a value of less than 0.5. DAVID 
analyses was conducted to identify interactions within the network and Bonferoni was 
used to perform multiple testing correction and establish significance for p<0.05.  
(Appendix 2). Similarly, 105 proteins were upregulated in this sample set greater than 2.0 
fold, DAVID analyses was completed using Bonferoni to identify significance for 
pathways where p<0.05 (Appendix 3).  
Unfortunately the overexpression system did not yield many results with only 25 
pathways associated using DAVID and will need further investigation (Appendix 4).  
Proteomics has emerged as a promising tool to contribute to the prevention and treatment 
of cancer as it unravels protein modifications and networks enabling identification of 
biomarkers and treatment targets (Koomen et al., 2008). Proteomics is the study of 
proteome and beyond genomics to identify protein-protein, protein-nucleic acid 
interactions, and post-translational modifications that affect protein function (Cho, 2007; 
Wu, Hu & Kavanagh, 2002).  Many studies have found that Mass spectrometry (MS)-
based proteomics is a useful technology to identify cancer biomarkers for diagnostic as 
well as therapeutic purposes (Elliott et al., 2009; Lou et al., 2007; Schirle, Bantscheff & 
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Kuster, 2012; Zhang, Chen & Huang, 2012; Zhu, Zhang & Humphreys, 2011). MS is an 
accurate measurement of mass (m) of a molecule to its charge (z) (m/z) ratio after ionizing 
to a gas phase (Savaryn, Toby & Kelleher, 2016). Protein ionization is performed by using 
two techniques which are electrospray ionization (ESI) and matrix-assisted laser 
desorption ionization (MALDI) enabling proteins to be identified by a peptide mass 
‘finger print’ (Huang et al., 2017). In this study, we used ESI method to ionize protein 
samples of MCL cell lines of CYR61/CCN1 genetically modified models; CCN1 OE in 
JVM2 cells and CCN1 KD in REC1 cells. The principle of this technique described at 
Figure 5.1.  
 
Figure 5.1 Overview of ESI-MS; sample comes out from the needle and generated charged 
droplets which in turn applying heat to desolvate, nebuliser gas and produce ions. Mass analyser 
separates the ions depending on m/z ratio and then the detector registers the ion resolved. Image 
from (Paul et al., 2013).   
 
Over last decade, mantle cell lymphoma prognosis has improved because of developing 
new treatment strategies but still MCL is more than a chronic disease with recurrent 
relapses and high morbidity (Sharma & Sweetenham, 2018). For young and fit patients 
with early stage MCL, there are many treatment options such as chemoimmunotherapy 
and stem cell transplantation are available. However, for elderly patients there is an urgent 
need for effective treatment (Sharma & Sweetenham, 2018). Investigation of CCN1 
dependent pathways in MCL may lead to novel linkages within signalling pathways that 
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are specific to MCL or B cells and more importantly, provide novel targeting agents for 
MCL with higher selectivity and efficacy to target the disease effectively.  
CCN1, a matricellular protein is involved in stem cell signalling within the 
haematopoietic microenvironment and involving in many cellular functions including cell 
adhesion, proliferation, migration, differentiation and survival (Franzen et al., 2009: 
Wells et al., 2015). Dysregulation of matricellular proteins have seen involving in the 
pathogenesis of disease and cancer generation and detection of the molecular mechanisms 
contributing to reveal new therapeutic regimes (Roberts, Kaur & Isenberg, 2017). 
CCN1/CYR61 implicates in the adhesion of prostatic carcinoma cells by binding to 
integrins and HSPGs and KD of CCN1/CYR61 expression in prostate cancer cells (PC-3 
and DU-145) suppressed cells growth without causing apoptosis which reflects a role for 
CCN1 in promoting cell proliferation (Franzen et al., 2009). Also, KD of CCN1 protein 
expression in gastric cells inhibited their migration and invasion indicating a role for 
CCN1 in metastasis (Wei et al., 2016). Furthermore, expression of CCN1 associated 
inversely with the aggressiveness of NSCLC and addition of CCN1 in these cells which 
prompted cancer cell senescence provided a novel therapeutic strategy for lung cancer 
(Jim Leu et al., 2013). Thus, utilising gene modification strategies for CCN1 expression 
in MCL could provide new therapeutic strategies for effective treatment (Chen et al., 
2017: Lau, 2011: Wei et al., 2016).  
 
5.2 Results 
In this study, we used MS-based proteomics technology to identify protein changes in the 
MCL CCN1 OE and KD cell line models. Unfortunately, this technique could not detect 
CYR61/CCN1 protein which was genetically modified in REC1 and JVM2 cells but was 
detected by western blot (Figure 4.9). Specialists at the DRF proteomics laboratory have 
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suggested this is due to other proteins in the samples being of higher abundance than 
CCN1 itself. This consistent with studies that found the detection of low abundant 
proteins need depletion methodologies to deplete the high abundant proteins and 
enrichment approach to enhance the detection of low abundant protein (Millioni et al., 
2011; Qian et al., 2008; Thulasiraman et al., 2005). Protein concentrations should be at 
range 3-4 of magnitude to enable proteomics technology to analyse them, protein 
amplification cannot be performed like DNA and requires more complex processing 
(Cho, 2007). In the past decade, proteomics emerged as robust tool to detect biomarkers 
for cancer but has been hampered with the problem of difficult detection of low 
abundance of proteins (Srinivas et al., 2001). Low-abundance proteins are often be 
hindered by the highly abundant ones, which mask them, requiring an increase in 
sensitivity to enhance information capture (Chandramouli & Qian, 2009; Srinivas et al., 
2001). For example in plasma, studies have found that highly abundant proteins in a 
sample mask low abundant proteins but depletion of high concentration proteins such as 
albumin in human blood plasma led to loss of low concentration protein and some 
cytokines which in turn confounded proteomic analysis (Granger et al., 2005). Therefore 
the process of accessing data for low abundant protein remains complicated.           
We have therefore investigated proteins that could be already associated with CCN1 from 
published literature to ensure CCN1 pathways were being affected in our genetically 
modified models. Many studies have found that integrins are receptors for the CCN1 
protein to mediate diverse functions in cancer (Chai et al., 2012; Espinoza et al., 2014; 
Jandova et al., 2012). In humans, there are 18 α subunit, 8 β subunit genomes and 24 
different α-β combinations that have discovered at protein expression (Humphries, Byron 
& Humphries, 2006).  
Using a STRING protein-protein search for Cyr61 (CCN1) (https://string-db.org/) for 
CCN1 UniProt ID O00622 showed various known  interactions for CCN1. The String 
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database is useful to detect known ‘shells’ of protein interactions that have been 
determined theoretically, experimentally or thought to be possible by data mining.  
Interaction of CYR61/CCN1 protein with integrins ITGB2 (integrin subunit β2), ITGB3 
(integrin subunit β3), ITGB5 (integrin subunit β5), ITGAM (integrin subunit αM), 
ITGA2B (integrin subunit α2b) and ITGAV (integrin subunit αV) are known by 
experimental determination (Figure 5.2). Interaction of integrins with ligands drives 
normal cellular and pathologies functions such as cell adhesion, metastasis, tumour cell 
proliferation, migration and tumour cell survival (Gahmberg et al., 2009; Ganguly et al., 
2013). In breast cancer, CCN1 drives pro-metastasis pathway leading to disease 
progression through binding to αvβ3 integrin in a paracrine manner and supporting VEGF 
secretion, an angiogenesis factor, in an autocrine manner (Espinoza et al., 2014). 
Furthermore, CCN1-αvβ3 signalling pathway is driving breast cancer angiogenesis 
through acting like an angiogenic promotor of endothelial cells (Brigstock, 2002; 
Espinoza et al., 2014; Leu, Lam & Lau, 2002). Increasing evidence has shown that 
integrin αvβ5 mediated CCN1 promoting tumour cell migration (Jandova et al., 2012) 
and enhancing resistance to apoptosis in breast cancer (Lin et al., 2004). In fact, integrin 
subunit β5 is a receptor of CCN1 (Chen, Mo & Lau, 2001; Grzeszkiewicz et al., 2001) 
and integrin subunit β2 is considered a receptor of ICAM1, ICAM2 and ICAM3 (Long, 
2011; Yun et al., 2014).  
Also, in Figure 5.2, STRING protein-protein interaction program shown that an 
interaction between CYR61/CCN1 protein and MAPK and APC. CCN1 is a ligand for 
integrins and acts through direct binding to integrins to enhance specific functions 
downstream signalling pathway including the PI3K and MAPK (Holbourn, Acharya & 
Perbal, 2008; Lin et al., 2012; Sun et al., 2015; Zhang et al., 2009). In 2017, (Sun et al.) 
have found CCN1 protein as a novel pro-inflammatory regulator through binding to 
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integrin α6β1 and activation of p38/MAPK signalling leading to enhance IL-1β 
expression.          
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Figure 5.2 CCN1 (CYR61) associated proteins. STRING search identified a number of known CCN1 associated proteins including ITGB2, ITGA2B, ITGB3, ITGB5, ITGAV, 
ITGAM (Known experimentally determined interactions shown in Pink / Turquoise). Other components that may be involved in the CCN1 (CYR61) pathway are APC, AXIN2, 
AXIN1, CTNNA1, CTNNB1, JUN, JUND, JUNB, MAPK9, MAPK8, FOS,SRF, MKL1 and ATF3 (as determined by databases).    
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Furthermore, STRING network shown CYR61/CCN1 regulates integrins (ITGB5, 
ITGA5, ITGAV, ITGA2B, ITGA7, ITGA6, ITGA8 and ITGAP) and TLN1 (Figure 5.3). 
Integrin/ECM adhesion occurs through binding of TLN1 to the cytoplasmic part of  β 
subunit of integrin (Anthis et al., 2010) that suggest TLN1 is essential player in integrins 
activation to promote interaction between the cell and ECM leading to regulation of cell 
adhesion, proliferation, survival and cancer progression (Alam et al., 2007; Das et al., 
2014; Fornaro, Manes & Languino, 2001).      
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Figure 5.3: CYR61/CCN1 regulates integrins (ITGB5, ITGA5, ITGAV, ITGA2B, ITGA7, ITGA6, ITGA8, ITGAP and Talin1 (TLN1). TLN1 was upregulated in KD model 
of CCN1 in REC1 and down regulated in OE model of CCN1 in JVM2.  
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5.2.1 REC1 CCN1 Knockdown model 
112 proteins were down regulated and 107 proteins were up-regulated in REC1 KD model 
(Green 676 (G676) sequence compared to scrambled control). 418 pathways were down 
regulated (Appendix 2) and 252 pathways were up-regulated in REC1 CCN1 model 
(Appendix 3) using DAVID. By applying STRING protein-protein interaction program, 
intercellular adhesion molecules 1, and 3 (ICAM 1 and ICAM 3) were involved in three 
different adhesion pathways with other groups of proteins and were down regulated in 
REC1 KD model. These include cell adhesion molecule binding, cell-cell adhesion and 
cell adhesion. Gene Ontology (GO) analysis of CYR61/CCN1 KD and OE models was 
completed using DAVID functional analysis Cell adhesion molecule binding 
(GOTERM_BP_FAT   GO:0050839) contains 17 proteins including MSN, ENO1, 
PARK7, P4HB, ACTN4, CAPZB, PDLIM1, PAICS, PRDX1, ANXA2, YWHAZ, 
YWHAE, HIST1H3B and EEF1D. P value was 1.17E-08, Bonferroni and Benjamini 
values were 0.0000 for both and was down regulated in REC1 KD (Figure 5.4). 
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Figure 5.4: Cell adhesion molecule binding. STRING protein-protein interaction network shows ICAM 1 and ICAM 3 involved in cell adhesion molecule interacting with different 
proteins including MSN, ENO1, PARK7, P4HB, ACTN4, CAPZB, PDLIM1, PAICS, PRDX1, ANXA2, YWHAZ, YWHAE, HIST1H3B and EEF1D.   
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Cell-cell adhesion proteins (GOTERM_BP_FAT GO:0098609) which involved 17 proteins 
ICAM 1, ICAM 3, MSN, ENO1, PRDX1, PARK7, DOD1, HLA-A, PAICS, EEF1D, ANXA2, 
CAPZB, YWHAE, YWHAZ, HIST1H3B, TMPO and PDIM1, were down expressed in KD 
model. The P value was 5.93E-04, Bonferroni and Benjamini were 0.7740 and 0.0207 
respectively (Figure 5.5).
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Figure 5.5: Cell-cell adhesion. STRING protein-protein net shown down regulation of ICAM 1 and ICAM 3 which involved in cell-cell adhesion with 15 proteins containing 
MSN, ENO1, PRDX1, PARK7, DOD1, HLA-A, PAICS, EEF1D, ANXA2, CAPZB, YWHAE, YWHAZ, HIST1H3B,TMPO and PDIM1.    
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Cell adhesion proteins (GOTERM_BP_FAT GO:0007155) which contain 21 proteins, ICAM 
1, ICAM 3, HLA-A, MSN, ACTN4, CAPZB, PDLIM1, ARHGDIA, ENO1, PRDX1, SOD1, 
NME1-NME2, PAICS, PARK7, ANXAZ, ENTPD1, YWHAE, YWHAZ, HIST1H3B, EEF1D 
and TMPO down regulated in CCN1 KD model of MCL disease. The P value was 8.35E-04, 
Bonferroni and Benjamini were 0.8769 and 0.0241 respectively (Figure 5.6). 
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Figure 5.6: Cell adhesion. 21 proteins which involved in cell adhesion contains ICAM 1, ICAM 3, HLA-A, MSN, ACTN4, CAPZB, PDLIM1, ARHGDIA, 
ENO1, PRDX1, SOD1, NME1-NME2, PAICS, PARK7, ANXAZ, ENTPD1, YWHAE, YWHAZ, HIST1H3B, EEF1D and TMPO.     
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In this study, proteomics analysis data by using DAVID bioinformatics resources shows that 
CYR61/CCN1 KD in REC1 cells identified ribosome biogenesis associated proteins, some of 
which were down-regulated and some that were increased expression. Ribosome biogenesis 
(GOTERM_BP_FAT GO:0042254) was down regulated in KD G676 compare with 
scrambled. Ribosome biogenesis involved 7 proteins RPL26, RPL8, RPS18, RPLP2, RPL30, 
RPS20 and RPL35A was in core of this interaction. The P value was 0.011, Bonferroni and 
Benjamini were 1.0000 and 0.1323 respectively (Figure 5.7).   
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Figure 5.7: STRING protein-protein interaction shows ribosome biogenesis which is down regulated in CYR61/CCN1 KD model in REC1 involved 
RPL35A in core of this interaction that interacted with 6 proteins RPL26, RPL8, RPS18, RPLP2, RPL30 and RPS20.   
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Proteomics analysis of KD model of CYR61/CCN1 in REC1 cells had also shown 107 proteins 
that were up-regulated and involved in different pathways. 252 pathways were up-regulated in 
REC1 CCN1 model using DAVID (Appendix 3). Ribosome biogenesis proteins were 
overexpressed may be as response to KD of CYR61/CCN1 in this model. Because CCN1 
involves in various signalling to perform many cellular function, REC1 cells struggled to resist 
genetic modification in this dynamic protein. Ribosome biogenesis (GOTERM_BP_FAT 
GO:0042254) contains 8 proteins, DDX21, RPS23, RPL14, RPL9, EIF4A3, RPL32, RPS4X 
and RPL4. The P value was 8.34E-04, Bonferroni and Benjamini were 0.8279 and 0.0280 
respectively (Figure 5.8).   
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Figure 5.8: Ribosome biogenesis which were upregulated in KD model of CCN1 in REC1 contains 8 proteins, DDX21, RPS23, RPL14, RPL9, EIF4A3, 
RPL32, RPS4X and RPL4 
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 DNA repair proteins (GOTERM_BP_FAT GO:0006281) were also identified and were 
potentially upregulated in CCN1 KD model but didn’t reach significance. This data set 
contained 6 proteins, RECQL, RPKDC, RUVBL2, SSRP1, SFPQ and PRPF19. The P value 
was 0.095, Bonferroni and Benjamini were 1.0000 and  0.7547 respectively (Figure 5.9).  
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Figure 5.9: DNA repair proteins in CCN1 KD model and contained 6 proteins, RECQL, RPKDC, RUVBL2, SSRP1, SFPQ and PRPF19. 
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 5.2.2 JVM2 CCN1 overexpression model 
Unfortunately the overexpression system did not yield many results with only 25 pathways 
associated using DAVID and will need further investigation. JVM2 CCN1 OE model did not 
have up-regulated associated pathways, but showed 25 down regulated pathways using DAVID 
analyses (Appendix 3). Extracellular region part (GOTERM_CC_FAT GO:0044421) was 
down regulated in CCN1 OE model and contained 8 proteins. Macrophage migration inhibitory 
factor (MIF) was down regulated in CCN1 OE model and involved with 7 proteins which are 
HINT1, RPL35A, RPL10A, ATP6V1A, HSPA1A, APOM, and PRDX1. The P value was 
0.005227832, Bonferroni and Benjamini were 0.345945849 and  0.191263856 respectively 
(Figure 5.10).      
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Figure 5.10: Extracellular region part. Macrophage migration inhibitory factor (MIF) was down regulated in CCN1 OE mode and involved with 7 proteins 
which are HINT1, RPL35A, RPL10A, ATP6V1A, HSPA1A, APOM, and PRDX1.        
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 5.2.3 Protein expression simultaneously modulated in OE and KD models 
To identify proteins that were regulated in both the overexpression and knockdown models, we 
set parameters of fold change to less than 0.7 and over 1.5 fold. Rationale for choosing 0.7 and 
1.5 were to ensure that we could identify more subtle changes in protein expression that may 
be associated with transcriptional components rather than only the larger changes in protein 
expression usually associated with cytoskeletal  / cytoplasmic proteins using a 0.5/2 fold cut 
off. Simultaneously, 19 proteins were down-regulated in KD model and up-regulated in OE 
model (Table 5.1) and 25 proteins up-regulated in KD model and down-regulated in OE model 
(Table 5.2). 
Some novel and interesting proteins have been identified in response to modulation of CCN1 
expression in our MCL cell line models. In table 5.1, Pre-B cell enhancing colony factor 1 
(Uniprot Accession:  A0A024R718) was down regulated in CYR61/CCN1 KD in REC1 model 
(fold change: 0.489262) and up-regulated in CYR61/CCN1 OE in JVM2 model (fold change: 
1.688939). ANOVA q-value was 0.002763. CALM 3 protein, calcium ion binding, (Uniprot 
Accession: Q9BRL5) was down expressed in CYR61/CCN1 KD model (fold change: 
0.091035) and overexpressed in CYR61/CCN1 OE model (fold change: 2.086001). ANOVA 
q-value was  0.009052. 
In table 5.2, 3 proteins were selected; apolipoprotein M, macrophage migration inhibitory 
factor and Talin-1. Apolipoprotein M (Uniprot Accession: I2D5J2) was overexpressed in 
REC1/CYR61/CCN1 KD model (fold change: 7.107762) and down expressed in 
JVM2/CYR61/CCN1 OE model (fold change: 0.251444). ANOVA q-value was 0.001623. 
Macrophage migration inhibitory factor (Uniprot Accession: I4AY87) was up-regulated in 
REC1/CYR61/CCN1 KD model (fold change: 3.795844) and down expressed in 
JVM2/CYR61/CCN1 OE model (fold change: 0.364793). ANOVA q-value was 0.389875. 
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Talin-1 (Uniprot Accession: Q9Y490) was up-regulated in REC1/CYR61/CCN1 KD model 
(fold change: 1.581185) and down expressed in JVM2/CYR61/CCN1 OE model (fold change: 
0.650002) ANOVA q-value was  0.0066.
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Table 5.1 Proteins simultaneously downregulated in KD model and up-regulated in OE model 
(CCN1 KD676/SCRAMBLED less than 0.7 and OE/ EMPTY VECTOR greater than 1.5 fold) 
Uniprot 
Accession 
Fold 
Change 
KD 
676/Scrm 
Fold 
Change 
OE/Empty 
ANOVA 
Significant 
ANOVA 
q-value 
Protein details 
Q567R0 0.632598 1.634836 + 0.007845 
UQCRH protein, ubiquinol-cytochrome-c reductase activity, Ubiquinol-Cytochrome C 
Reductase Hinge Protein, related pathways are Metabolism and Respiratory electron 
transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling 
proteins. 
B2RE46 0.659792 1.508077 + 0.004197 
cDNA, FLJ96923, highly similar to Homo sapiens ribophorin II (RPN2), mRNA; 
protein N-linked glycosylation 
H0YFI1 0.545737 1.50759 + 0.018239 
Ragulator complex protein LAMTOR1, REGULATION of MAPK and TOR, Late 
Endosomal/Lysosomal Adaptor, MAPK And MTOR Activator 1, As part of the 
Ragulator complex it is involved in amino acid sensing and activation of mTORC1, a 
signaling complex promoting cell growth in response to growth factors, energy levels, 
and amino acids. Activated by amino acids through a mechanism involving the 
lysosomal V-ATPase, the Ragulator functions as a guanine nucleotide exchange factor 
activating the small GTPases Rag. Activated Ragulator and Rag GTPases function as a 
scaffold recruiting mTORC1 to lysosomes where it is in turn activated. LAMTOR1 is 
directly responsible for anchoring the Ragulator complex to membranes. Also required 
for late endosomes/lysosomes biogenesis it may regulate both the recycling of receptors 
through endosomes and the MAPK signaling pathway through recruitment of some of 
its components to late endosomes. May be involved in cholesterol homeostasis 
regulating LDL uptake and cholesterol release from late endosomes/lysosomes. May also 
play a role in RHOA activation. 
B4DDF7 0.589661 1.596185 + 0.003659 
cDNA FLJ53296, highly similar to Serine/threonine-protein phosphatase 2A 65 kDa 
regulatory subunit A alpha isoform, protein phosphatase regulator activity 
H6VRG2 0.407092 3.52698 + 0.031124 
Keratin 1, KRT1, structural molecule activity, The type II cytokeratins consist of basic 
or neutral proteins which are arranged in pairs of heterotypic keratin chains coexpressed 
during differentiation of simple and stratified epithelial tissues 
V9HWC6 0.46461 1.559968 + 0.002677 
Peptidyl-prolyl cis-trans isomerase, peptidyl-prolyl cis-trans isomerase activity, 
protein folding. 
H9ZYJ2 0.502747 1.674899 + 0.00169 
Thioredoxin, TXN, peptide disulfide oxidoreductase activity, cell redox homeostasis, 
The protein encoded by this gene acts as a homodimer and is involved in many redox 
reactions. The encoded protein is active in the reversible S-nitrosylation of cysteines in 
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certain proteins, which is part of the response to intracellular nitric oxide. This protein is 
found in the cytoplasm. Two transcript variants encoding different isoforms have been 
found for this gene, Diseases associated with TXN include Adult T-Cell Leukemia and 
Myocarditis. Among its related pathways are Gene Expression and Protein repair; 
Nitrosylates the active site Cys of CASP3 in response to nitric oxide (NO), and thereby 
inhibits caspase-3 activity.  
A0A024R718 0.489262 1.688939 + 0.002763 
Pre-B-cell colony enhancing factor 1, isoform CRA_a, PBEF1, NAMPT, 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648259/ 
B4E2Z3 0.375945 1.802968 + 0.01138 
cDNA FLJ54090, highly similar to 4F2 cell-surface antigen heavy chain, catalytic 
activity, (ie Similar to SL3A2) 
A8KAQ5 0.425042 1.701171 + 0.002331 
cDNA FLJ77404, highly similar to Homo sapiens small nuclear ribonucleoprotein 
70kDa polypeptide (RNP antigen) (SNRP70), transcript variant 1, mRNA. U1 snRNA 
binding 
A0A024R3W7 0.375636 1.94946 + 0.003863 
Eukaryotic translation elongation factor 1 beta 2, isoform CRA_a, EEF1B2, 
translation elongation factor activity 
F4ZW64 0.38961 1.583634 + 0.003639 
NF90a, double-stranded RNA binding, This gene encodes a double-stranded RNA 
(dsRNA) binding protein that complexes with other proteins, dsRNAs, small noncoding 
RNAs, and mRNAs to regulate gene expression and stabilize mRNAs. This protein 
(NF90, ILF3) forms a heterodimer with a 45 kDa transcription factor (NF45, ILF2) 
required for T-cell expression of interleukin 2. This complex has been shown to affect 
the redistribution of nuclear mRNA to the cytoplasm. Knockdown of NF45 or NF90 
protein retards cell growth, possibly by inhibition of mRNA stabilization. In contrast, an 
isoform (NF110) of this gene that is predominantly restricted to the nucleus has only 
minor effects on cell growth when its levels are reduced. Alternative splicing results in 
multiple transcript variants encoding distinct isoforms.[provided by RefSeq, Dec 2014] 
A0A024QZ42 0.219351 1.73697 + 0.001867 
HCG1985580, isoform CRA_c, PDCD6, calcium ion binding, Programmed cell 
death protein 6 
V9HW98 0.25155 1.672154 + 0.003377 
Epididymis luminal protein 2, HEL2, E3 ubiquitin-protein ligase HEL2, Probable 
ubiquitin-protein ligase involved in the degradation-related ubiquitination of histones. 
Contributes to the post-translational regulation of histone protein levels by 
polyubiquitination of excess histones for subsequent degradation 
Q496I0 0.186965 1.797549   0.102643 
COX7A2 protein, COX7A2, This protein is one of the nuclear-coded polypeptide 
chains of cytochrome c oxidase, the terminal oxidase in mitochondrial electron 
transport., Diseases associated with COX7A2 include Barrett's Adenocarcinoma. 
Among its related pathways are Respiratory electron transport, ATP synthesis by 
chemiosmotic coupling, and heat production by uncoupling proteins. and Cardiac muscle 
contraction 
A0A024RCA7 0.111717 1.637925 + 0.001714 Ribosomal protein, large, P2, isoform CRA_a, RPLP2.  
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Q9BRL5 0.091035 2.086001 + 0.009052 
CALM3 protein, calcium ion binding, CALMODULIN 3, This gene encodes a 
member of a family of proteins that binds calcium and functions as a enzymatic co-factor. 
Activity of this protein is important in the regulation of the cell cycle and cytokinesis 
J3KTF8 0.074175 1.556524 + 0.001739 
Rho GDP-dissociation inhibitor 1, ARHGDIA, Rho GDP Dissociation Inhibitor 
Alpha, This gene encodes a protein that plays a key role in the regulation of signaling 
through Rho GTPases. The encoded protein inhibits the disassociation of Rho family 
members from GDP (guanine diphosphate), thereby maintaining these factors in an 
inactive state. Activity of this protein is important in a variety of cellular processes, and 
expression of this gene may be altered in tumors. 
Q76LA1 0.065526 1.662608 + 0.008658 
CSTB protein, Cystatin B, The cystatin superfamily encompasses proteins that contain 
multiple cystatin-like sequences. Some of the members are active cysteine protease 
inhibitors, while others have lost or perhaps never acquired this inhibitory activity. There 
are three inhibitory families in the superfamily, including the type 1 cystatins (stefins), 
type 2 cystatins and kininogens. This gene encodes a stefin that functions as an 
intracellular thiol protease inhibitor. The protein is able to form a dimer stabilized by 
noncovalent forces, inhibiting papain and cathepsins l, h and b. The protein is thought to 
play a role in protecting against the proteases leaking from lysosomes 
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Table 5.2 Proteins simultaneously up-regulated in KD model and down-regulated in OE model 
(CCN1 KD676/SCRAMBLED greater than 1.5 and OE/ EMPTY VECTOR less than 0.7 fold) 
Uniprot 
Accessi
on 
Fold 
Change 
KD 
676/Scrm 
Fold 
Change 
OE/Emp
ty 
ANOVA 
Significa
nt 
ANOVA 
q-value 
Protein details 
A8K5I0 20.57224 0.455629 + 0.00168 Epididymis secretory protein Li 103, HSPA1A, HSPA1B, Proteosome P45 like ATPase 
I2D5J2 7.107762 0.251444 + 0.001623 Apolipoprotein M, links with Rheumatoid Arthritis 
H7BXH
6 5.258516 0.542395 + 0.009607 Chitinase, CHIA, hydrolase, lysozyme activity 
Q8TE92 3.96974 0.249509 + 0.001945 cDNA FLJ23782 fis, clone HEP20947 
B4E266 3.70062 0.663747  0.390382 cDNA FLJ58466, highly similar to Leucyl-tRNA synthetase, cytoplasmic 
A0A024
RAM0 3.962813 0.639955   0.690141 Transportin 1, isoform CRA_a, for intracellular transport 
A8K517 3.931517 0.69856  0.082126 Ribosomal protein S23, isoform CRA_a 
I4AY87 3.795844 0.364793   0.389875 
Macrophage migration inhibitory factor, links with Rheumatoid Arthristis and T cell 
development / disorders 
M0QXS
5 3.154703 0.691388  0.145811 Heterogeneous nuclear ribonucleoprotein L 
P53621 2.693598 0.666542 + 0.040847 Coatomer subunit alpha, intracellular transport, ER Golgi vesicle mediated transport 
P48047 3.030063 0.654179   0.270884 ATP synthase subunit O, mitochondrial, drug binding, ATP synthase activity 
B4DDZ
5 2.675871 0.674476  0.419119 
DNA FLJ53969, highly similar to Trifunctional enzyme subunit alpha, mitochondrial, fatty acid 
beta-oxidation 
V9HW2
4 2.673619 0.306314  0.168792 Epididymis secretory protein Li 73, HEL-S-73,  
Q9NTK
5 2.662313 0.688177  0.08092 , OLA1, ATPase requires Mg, binds cadherin 
A0A140
VK70 2.513442 0.684032 + 0.014443 
Testis secretory sperm-binding protein Li 197a,  ATP binding, cytoplasmic ribnucleoprotein 
granule 
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B8ZZI4 2.117774 0.5837 + 0.004156 
Coiled-coil domain-containing protein 150, CCDC150, Transcription factor / promoter / 
enhancer. Links with having transcription factor bindings sites for FOXO3b FOXO3a FOXO3 
Pax-5 Ik-2 RORalpha2 TBP POU2F1c POU2F1b POU2F1a and upstream PKNOX1, SMAD1, 
FOXA2, TAF9B, CREB1, PKNOX1, CLOCK, JUN, CEBPB. Links to NOX4 potential oxygen 
sensor in response to HIF1a and also RAI1 retinoic acid induced gene regulated by CLOCK.  
Q08ES8 1.765457 0.310873  0.777221 Cell growth-inhibiting protein 34, Ribonucleoprotein, Ribosomal protein 
Q5TFA
5 1.643095 0.635322   0.218866 
GINM1, glycoprotein integral membrane 1 , single pass type I membrane protein 
https://www.genecards.org/cgi-bin/carddisp.pl?gene=GINM1 
D3YTB
1 2.076259 0.661053 + 0.026776 60S ribosomal protein L32 
C9JXZ7 1.655766 0.585244  0.259281 RFC4, Replication factor 4, plasma protein, predicted intracellular protein  
Q4ZG5
7 1.642209 0.666008 + 0.00156 
DNA helicase, MCM6, 
https://www.sciencedirect.com/science/article/pii/S2211124717301778?via%3Dihub 
Q9Y490 1.581185 0.650002 + 0.0066 
Talin-1, TLN1, involved in connections of major cytoskeletal structures to the plasma 
membrane. High molecular weight cytoskeletal protein concentrated at regions of cell-substratum 
contact and, in lymphocytes, at cell-cell contacts, Talin-1 functions to mediate cell-cell adhesion 
via the linkage of integrins to the actin cytoskeleton and in the activation of integrins, required for 
lymphocyte homing and developmenthttps://www.ncbi.nlm.nih.gov/pubmed/20923969 
P30084 1.56129 0.574221  0.213159 
ECHS1 Straight-chain enoyl-CoA thioesters from C4 up to at least C16 are processed, although 
with decreasing catalytic rate. Belongs to the enoyl-CoA hydratase/isomerase family.Amino Acid 
Metabolism - lysine degradation; Amino Acid Metabolism - tryptophan; Amino Acid Metabolism 
- valine, leucine and isoleucine degradation; Carbohydrate Metabolism - butanoate; Carbohydrate 
Metabolism - propanoate; EC 4.2.1.17; Lipid Metabolism - fatty acid; Lipid Metabolism - fatty 
acid elongation in mitochondria; Lyase; Mitochondrial; Other Amino Acids Metabolism - beta-
alanine; Secondary Metabolites Metabolism - limonene and pinene degradation 
V9HWF
5 1.543778 0.694702  0.218976 Peptidyl-prolyl cis-trans isomerase, protein folding activity 
A0A024
RDH8 1.517251 0.664698 + 0.021775 Ribosomal protein L34, isoform CRA_a, RPL34, required for translation 
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5.3 Discussion 
Despite the advances in understanding of the molecular pathogenesis of MCL, treatment 
remains inadequate (Weisenburger et al., 2000). Proteomics is a robust tool to examine protein 
changes between samples. In this study, proteomics showed that in the CYR61/CCN1 KD in 
REC1 cells 112 proteins were down regulated. Intercellular adhesion molecules 1, and 3 
(ICAM 1 and ICAM 3, which are ligands for integrins) were down regulated in KD model and 
are associated with adhesion pathways.  
ICAM 1 belongs to the immunoglobulin superfamily mediating cell-cell adhesion (Lawson & 
Wolf, 2009; Zimmerman & Blanco, 2008) and was expressed by bladder high grade tumour 
cell line and played a role in cancer migration (Roche et al., 2003). Many studies have found 
that CCN family proteins such as NOV and CCN6 involved in enhancing migration and 
metastasis of different types of cancer through up-regulation of ICAM 1 expression protein 
(Chen et al., 2012; Fong et al., 2012; Liu et al., 2015). Furthermore, in vivo, CCN1 knock down 
mice showed less lung injury compared with wild type, CCN1 promoted ICAM 1 expression 
and mediated endothelial cell adhesion (Ringo et al., 2011). CCN1 increased adhesion and 
interaction of thymic epithelial cells as well as thymocytes through binding to ICAM 1 and 
integrin α6 (Emre et al., 2013). These findings support our result that CCN1 KD in REC1 cells 
downregulated ICAM 1, which suggests a role in cancer migration cells and may be involved 
metastasis. ICAM 3, is an adhesion molecule and has been found playing an important role in 
enhancing adhesion of T lymphocytes to endothelial cells and extracellular matrix proteins 
supporting immune activation (Cid et al., 1994). However, high expression of ICAM 3 is 
related to increase treatment resistance in cancer cells and enhanced migration and invasion of 
human non-small cell lung cancer cells (Park et al., 2010). Many studies suggested that down 
regulation of ICAM 1 and ICAM 3 can be anticancer therapy in different types of cancer (Di 
et al., 2016; Park et al., 2010). ICAM 1 is a ligand for the receptors CD11a (ITGAL) CD18 
174 
 
(ITGB2) and CD11b (ITGAM) and ICAM 3 is a ligand for integrin alpha D (ITGAD), Integrin 
beta 2 / CD18 (ITGB2), integrin alpha L (ITGAL).  ITGAM and ITGB2 are known to be 
regulated by CCN1 (Figure 5.2). Whilst most studies to date have been completed in solid 
tumour investigations, our results suggest that CCN1 regulates the ligands ICAM 1 and ICAM3 
in MCL and this regulatory network may be specific to MCL or potentially within B cell 
signalling. Further investigation is required to investigate the role of CCN1 modulating ICAM1 
and ICAM3 expression.  
The human ribosome which is essential for protein synthesis by translation of messenger RNA 
(mRNA) to protein comprises of 4 ribosomes (rRNAs) and 80 different ribosomal proteins 
(RPs) (Mao-De & Jing, 2007). Eukaryotic ribosome consists of 2 subunits which are large L 
(60S) and small S (40S) are responsible for different types of rRNAs and RPs (Chakraborty, 
Uechi & Kenmochi, 2011) as well as accessory factors named proteins associated with 
ribosome (PAR) for instance initiation factors (IFs) and elongation factors (EFs) (Mao-De & 
Jing, 2007). Ribosome biogenesis is the process of ribosome production and up-regulated in 
cancer in response to extracellular or intracellular stimuli stimulates ribosomal stress leading 
to an accumulation of free RPs (Montanaro, Treré & Derenzini, 2012; Zhang & Lu, 2009; Zhou 
et al., 2012). In 2015, this was  reviewed by (Zhou et al.) who identified potential reasons for 
ribosomal stress are “chemical agents or radiation that inevitably perturb rRNA production or 
mediates RP degradation, lack of nutrients, including serum or glucose starvation, hypoxia and 
gene deregulation e.g. malfunction of genes required for ribosome biogenesis resulting from 
genetic alterations or experimental manipulation” (Zhou et al., 2015). In additional to protein 
synthesis, RPs have functions beyond the ribosome named extra ribosomal functions which are 
DNA replication, transcription, DNA repair, RNA splicing, regulation of cell growth and 
apoptosis and development of cellular transformation (Mao-De & Jing, 2007). Increasing 
evidences of dysregulation of RPs in cancer shown that individual RPs can play a tumour 
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promotor or tumour suppressor in tissue or disease specific (Zhou et al., 2015). For example, 
the expression of numerous RPs was highly expressed at mRNA or protein level in various 
human cancers (Artero-Castro et al., 2011; Kondoh et al., 1992; Kondoh et al., 2001; Shuda et 
al., 2000). Additionally, in nude mice, overexpression of RPS3A enhanced transformation of 
NIH-3T3 cells and promoted tumour growth (Naora et al., 1998). The expression level of RPL9 
at mRNA was high in small-cell lung carcinoma, decreased in Adenocarcinoma, Large cell 
carcinoma and low expression in squamous cell lung carcinoma where it is associated with 
playing an important role in tumour development and cell proliferation (Dlamini & Mphahlele, 
2006). Knockdown of RPL9 expression has found to inhibit colorectal cancer cell growth 
through decrease activation of Id-1/NF-κB signalling in nude mice experiment (Baik et al., 
2016). On the other hand, knockdown of RPS4X decreased tumour cell growth but increased 
tumour cell resistance-treatment in ovarian cancer and breast cancer cell lines (Garand et al., 
2011; Tsofack et al., 2013). Our result shown that 8 ribosomal proteins DDX21, RPS23, 
RPL14, RPL9, EIF4A3, RPL32, RPS4X and RPL4 involved in ribosome biogenesis were up-
regulated in CYR61/CCN1 KD model (Figure 5.8). This result needs more investigation to 
reveal if these RPs overexpressed in response to gene modification or may have specific 
functions in regulation of treatment resistance, regulation of cell proliferation and apoptosis. 
However, some RPs are considered tumour suppressors through activation of tumour inhibitors 
or inactivation of oncoproteins (de Las Heras-Rubio et al., 2014; Zhou et al., 2015). For 
example, many studies have found that different RPs such as RPL26, RPS20, RPS14 and 
RPS27A have involved in suppression of cancer cell proliferation through regulation of the 
MDM2/MDMX-p53 signalling (Daftuar et al., 2013; Sun et al., 2011; Zhang et al., 2010; Zhou 
et al., 2013). STRING protein-protein interaction network shows ribosome biogenesis which 
is down regulated in CYR61/CCN1 KD model in REC1 involved RPL35A in core of this 
interaction that interacted with 6 proteins RPL26, RPL8, RPS18, RPLP2, RPL30 and RPS20 
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(Figure 5.7). Down regulation of RP35A in CCN1 KD may suggest a role in increased 
apoptosis and regulation of cell growth. Furthermore, RPL35A was down regulated in the 
JVM2 CCN1 OE model in extracellular region part pathway (Figure 5.10) that could be a 
promising target in enhancing apoptosis and regulation of proliferation of MCL at early and 
advance stages of disease. RPL35A-deficient hematopoietic cell lines shown decreased 
proliferation and enhanced apoptosis 45%-55% compared with control (Farrar et al., 2008). 
Furthermore,  low expression of RPL35A  is associated with reduced cellular proliferation, 
enhanced apoptosis and defective ribosome biogenesis in Diamond Blackfan Anaemia 
(Caywood et al., 2009).             
 In this study, RECQL, RPKDC, RUVBL2, SSRP1, SFPQ and PRPF19 were up-regulated in 
CCN1 KD model in a DNA repair pathway (Figure 5.9). RECQL, an ATP-dependent DNA 
helicase enzyme, plays crucial roles in DNA repair, recombination, replication and 
transcription by interaction with a unique set of protein partners (Croteau et al., 2014). In 2018, 
(Xu et al.) have found that down regulation of RECQL protein associated with poor survival 
in breast cancer patients more than those with overexpression.  Moreover, RECQL-deficient 
cancer cells were sensitive to treatment with DNA-toxic drug that reflects its role in DNA 
repair pathway for genomic integrity (Sharma & Brosh Jr, 2007; Sharma et al., 2007; Wu & 
Brosh, 2010). This is consistent with our result that shows RECQL protein expression up-
regulated in REC1-CCN1 KD model in response to the DNA repair process. 
Pre-B-cell colony enhancing factor 1, (PBEF1 also known NAMPT) which is pro-
inflammatory cytokine expresses by various cells lymphoid and non-lymphoid cells and 
contains 2 forms intracellular and extracellular (Rongvaux et al., 2002; Sun, Lei & Zhang, 
2013). Intracellular acts as cytokine-like molecule (PBEF) and extracellular has as enzymatic 
function in nicotinamide phosphoribosyl transferase (NAMPT) and both function in immune 
modulation, cell metabolism and inflammation (R Moschen, R Gerner & Tilg, 2010; Roberts 
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et al., 2013; Sun, Lei & Zhang, 2013). Several studies have demonstrated that overexpression 
of pre-B-cell colony enhancing factor involved in different tumour malignancies including 
breast, prostate, colorectal, ovarian, well-differentiated thyroid, endometrial carcinomas, 
myeloma, melanoma, and in malignant lymphomas (Folgueira et al., 2005; Hufton et al., 1999; 
Maldi et al., 2013; Olesen, Hastrup & Sehested, 2011; Patel et al., 2010; Shackelford et al., 
2013; Shackelford et al., 2010; van Beijnum et al., 2002; Venkateshaiah et al., 2013; Wang et 
al., 2011). In studying 53 samples of malignant lymphoma including diffuse large B‐cell 
lymphoma, follicular B‐cell lymphoma, Hodgkin’s lymphoma and peripheral T‐cell 
lymphoma, the NAMPT was overexpressed in the aggressive lymphoma malignancy more than 
indolent follicular lymphoma. Depletion of NAMPT by NAMPT inhibitor, APO866 which is 
in clinical phase II trials in lymphomas, revealed that follicular lymphoma was a promising 
target for inhibition of NAMPT while aggressive lymphoma particularly Hodgkin’s lymphoma 
needed a combination treatment of NAMPT inhibitor with nicotinic acid (Olesen, Hastrup & 
Sehested, 2011). Reduced expression of pre-B-cell colony enhancing factor 1 in the REC1 
CCN1 KD model could indicate a promising target for CCN1 positivity in early stage MCL.    
CALMODULIN (CaM) is an intracellular Ca2+ receptor protein encoded by 3 genes CALM 1, 
CALM 2, and CALM 3 and regulates cell proliferation, cell cycle and apoptosis (Berchtold & 
Villalobo, 2014; Boczek et al., 2016; Chen et al., 2013; Monteith, Davis & Roberts-Thomson, 
2012). CaM has been seen to regulate various intracellular enzymes including 
phosphodiesterases, adenylyl cyclases, ion channels, protein kinases, and protein phosphatases 
(Chin & Means, 2000). In cell cycle regulation, calcium/calmodulin (Ca+2/CaM) complex 
regulates the phosphorylation of retinoblastoma protein at early G1 stage of cell cycle.  
Inhibition of CaM by antagonists enhanced arrest of the cell cycle at the G1 stage through 
inhibition of cdk4 and cdk2 resulting in hypophosphorylation of retinoblastoma protein (Taulés 
et al., 1998).   Many studies have demonstrated that overexpression of CaM in different tumour 
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cells and in cancer progression resulting in tumour metastasis (Berchtold & Villalobo, 2014; 
Karp et al., 2007; Mishra, Siddique & Saleem, 2012). CaM has been reported to be involved 
in the initiation and progression of ductal cancers through activation of PI3Kα/Akt and 
Raf/MEK/ERK pathways (Nussinov et al., 2015). Blocking of calmodulin/PI3Kα binding in a 
K-Ras4B/calmodulin/PI3Kα model is considered a promising treatment strategy (Nussinov et 
al., 2015). Furthermore, depletion of CaM by N-(6-aminohexyl)-5-chloro-1-
naphthalenesulfonamide (W-7) prevented the metastasis development of primary lewis lung 
carcinoma in a mouse model (Ito, Wang & Shimura, 1991). Our result demonstrated that CaM 
(CALM 3) was down regulated in CCN1 KD model and up-regulated in CCN1 OE model 
(Table 5.1). Interestingly, a study revealed for the first time that CCN3 has a role in calcium 
ion signalling when it found CCN3 interacted with S100A4 (which is a calcium binding 
protein) in glioblastoma and neuroblastoma cells leading to S100A4 being considered as a 
partner of CCN3 (Li et al., 2002). This interaction may associated with carcinogenesis and in 
normal tissues and addition of CCN2 and CCN3 enhanced intracellular calcium concentrations 
involved in regulation of the calcium flux which is associated with cell growth control and 
motility. These results indicated a role for CCN3 and all CCN family protein members in 
calcium ion signalling (Li et al., 2002). This is consistent with our results that show knock 
down of CCN1 in REC1 results in depletion of intracellular Ca2+ receptor protein 
(CALMODULIN) and overexpression of CCN1 in JVM2 results in upregulation of 
CALMODULIN. 
Additionally, CCN family proteins bind to other receptors such as the lipoprotein receptor-
related proteins (LRPs) to mediate biological functions (Segarini et al., 2001). For example, 
CCN2 which is a member of CCN family proteins modulated cell adhesion and Wnt signalling 
in different cells by binding to LRP1 and LRP6 respectively (Gao & Brigstock, 2003; Mercurio 
et al., 2004). Apolipoprotein M (ApoM), which is a novel lipoprotein plasma protein of the 
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apolipoprotein family normally expressed in liver and kidney and is expressed in the human 
colorectal adenocarcinoma cell line (Caco-2 cells) (Calayir et al., 2008; Luo et al., 2010). In 
2010, (Luo et al.) have found that the expression level of mRNA ApoM was substantially 
higher in the patients having colorectal cancer with lymph node metastasis than the patients 
without lymph node metastasis. Furthermore, they have reported that the expression level of 
mRNA ApoM was significantly increased in the patients with advanced stage of Dukes (stages 
3 and 4) than the patients with early stage of Dukes (stage 1 and 2) and suggested that ApoM 
expression level could play a role in cancer progression (Luo et al., 2010). Recently, another 
study has shown that the expression of ApoM protein level was increased in the non-small cell 
lung cancers tissues compare with adjacent tissue which suggested a role in tumour cell 
proliferation and invasion through activation of ERK1/2 and PI3K/AKT pathways (Zhu et al., 
2018). In the present study, overexpression of apolipoprotein M was detected in REC1 
CYR61/CCN1 KD model and down regulation in JVM2 CYR61/CCN1 OE model. HIF1 alpha 
binds to the ApoM and drives ApoM expression (Huang et al., 2015). This suggests ApoM 
levels may be modulated in a complex network with CCN1 in response to oxygen sensing in 
B cells and the Bone marrow microenvironment. 
Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine secreted by T 
lymphocytes, epithelial cells, endothelial cells and macrophages and participates in many 
cellular functions including carcinogenesis (Conroy, Mawhinney & Donnelly, 2010; Richard, 
Kindt & Saussez, 2015). Many studies have demonstrated that MIF overexpression in solid 
tumours such as lung, colorectal, breast, cervical and prostate cancers playing a critical role in 
cancer progression through enhancing tumour cell proliferation and invasion (Guo et al., 2015; 
He et al., 2009; Meyer-Siegler et al., 2006; Rendon et al., 2007; Richard et al., 2014). Up-
regulation of MIF was correlated with enhanced tumour invasion and metastasis to the liver, 
spleen, lymph nodes and intestine in pancreatic cancer cells (in vivo and in vitro) (Funamizu et 
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al., 2013). Inhibition of MIF activation by ISO-1(an inhibitor of MIF) attenuated tumour cell 
migration through activation of JNK pathway in adenoid cystic carcinoma (ACC) cells (Liu et 
al., 2013). There is growing evidence that indicates knock down of MIF expression could be a 
therapeutic target in cancer treatment by enhancing apoptosis and decreasing tumour 
proliferation (Conroy, Mawhinney & Donnelly, 2010; Huang et al., 2014). Moreover, 
inhibition of the ATPase activity of heat shock protein 90 (HSP90) in different cancer cells 
resulted in the down regulation of MIF (Schulz & Moll, 2014) which makes targeting HSP90 
a novel strategy for the inhibition of MIF in cancer (Kindt et al., 2016). Kindt et al. (2013) have 
revealed a role for MIF in head and neck squamous cell carcinoma (HNSCC) treatment when 
they have seen that the MIF-knock down cells grew slowly and were more sensitive to anti-
cancer treatment than control cells. In this study, MIF was down regulated in the JVM2 CCN1 
OE model (Figure 5.9) and up-regulated in the CCN1 KD model. This suggests that MIF has 
an inverse relationship with CCN1 expression in MCL.   
Talin-1 (TLN1), is a cytoskeleton protein involved in cell migration and plays an important 
role in tumour formation and tumour migration through regulation of cell-cell adhesion by 
binding to different receptors such as integrins and actin (Desiniotis & Kyprianou, 2011; 
Sakamoto et al., 2010). Overexpression of talin-1 has been reported in prostate cancer with 
enhanced tumour migration, invasion and mediates bone and lymph node metastasis (Jin et al., 
2015; Xu et al., 2016; Zhang et al., 2015). Moreover, high expression of talin-1 correlated with 
short-survival patients particularly in advanced stage of disease in nasopharyngeal carcinoma 
(NPC) patients (Xu et al., 2015). Recently, talin-1 was found to regulate genes-associated 
hepatocellular carcinoma (HCC) progression; this study reported that knock down of talin-1 
dysregulated 3099 genes (1924 genes up-regulated and 2175 down regulated (CYR61 which 
is a growth factor-inducible gene was down regulated) (Chen et al., 2017)). Gene ontology 
(GO) profiled that TLN1 enhanced transcription of genes associated with cell-adhesion, ion 
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transport and cell growth which suggested a promising therapeutic targets (Chen et al., 2017). 
Whilst the ligands ICAM 1 and 3 are downregulated in the CCN1 KD model, the cell is possibly 
trying to compensate by up-regulation of the TLN1.  
In present study, overexpression of ApoM, MIF and TLN1 in the CCN1 KD model and down 
regulation in CCN1 in the OE model may identify novel pathways / approaches for more 
effectively targeting MCL.  
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Chapter 6 
6.1 General Conclusion and future work  
CCN1 expression has not been investigated in MCL to our knowledge to date. CCN1 full 
length protein and truncated proteins were identified in a human cell line model for MCL 
progression; REC1, G519 and JVM2 where REC1 cells are consistent with early stage 
disease, G519 and JVM2 representative of aggressive disease. The magnitude of CCN1 
expression by RQ-PCR in the cell lines is REC1>G519>JVM2 cells, depicting a decrease 
in CCN1 expression with disease progression. This is consistent with findings for Cyclin 
D1 levels associated with early stage disease and down-regulation in aggressive MCL 
(Zeng et al., 2012). CCN1 mirrors Cyclin D1 expression in MCL. Investigation of CCN1 
protein expression by Western blotting showed that whilst expression of full-length 
CCN1 was barely altered across the cell lines, expression of a truncated form (20kDa) 
was decreased in aggressive G519 and JVM2 cells. For future work, further investigations 
of the role(s) of the 20kDa protein in MCL would help elucidate the significance of this 
truncated form.  
We investigated the expression of cell cycle regulators p21 and p27 in the cell line model. 
Whilst p21 expression was barely detectable in REC1 cells, increased expression was 
detected in G519 and JVM2 cells by RQ-PCR and Western blotting. Conversely, p27 was 
detected in REC1 cells and reduced in expression in G519 and JVM2 cells by RQ-PCR 
and Western Blotting. The subcellular localisation of both proteins have not been reported 
to date.  This study detected expression of p21 and p27 in cytoplasm of the three MCL 
cell lines; absence from the nuclear compartment mirrors the loss of roles in cell cycle 
inhibition and further acquisition of tumour promoting roles via suppression of apoptosis, 
contributing to enhanced tumour proliferation and treatment resistance (Besson, Dowdy 
& Roberts, 2008; Gartel, 2009; Min et al., 2004; Roninson, 2002).  Mitochondrial 
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detection of p21 in the JVM2 cell line supports an additional anti-apoptotic role (Suzuki 
A, 1999).       
Many studies have indicated that activation or upregulation of cell cycle regulators, p21, 
p27 and  cyclin  D1  are  induced  through CCN1  signalling  (Sawai et  al.,  2007;  Tong 
et  al.,  2004),  whilst  the  functional  effect  or  output  appears  to  be  cell  type  specific.  
In 2014, (Saglam et al.) have found that induction of cyclin D1 expression in grade ductal 
carcinoma in situ (DCIS) can occur through CCN1 signalling   leading to cell cycle 
progression. CCN1 protein promoted cell cycle arrest by increased cell senescence at 
G0/G1 phase through activation notch-1-p21 pathway and reduced   proliferation of 
human trophoblast cells (Kipkeew et al., 2016). Similarly, CCN1 signalling induced 
accumulation of p53 and p21 driving cell senescence leading to suppression of lung 
cancer cell proliferation (Jim Leu et al., 2013). A future work of investigation of 
cytoplasmic subcellular localisation of p21 and p27 proteins in REC1, G519 and JVM2 
cells and mitochondrial subcellular of p21 protein in JVM2 cells signalling pathways 
would be interesting to study their roles in apoptosis and treatment resistant.   
Stable overexpression and knockdown cell lines modules were completed in JVM2 
(JVM2 OE) and REC1 (REC1 KD) cells respectively. Proteomics analysis of JVM2 OE 
and REC1 KD revealed interesting results showing regulation of 44 proteins (Table 5.1 
and Table 5.2). Table 5.1 shows proteins simultaneously downregulated in the CCN1 KD 
model and up-regulated in CCN1 OE model and comprised of 19 proteins regulated by 
CCN1. Table 5.2 shows proteins simultaneously up-regulated in CCN1 KD model and 
down-regulated in CCN1 OE model and comprised of 25 proteins modulated by CCN1.  
Our results suggest novel roles for CCN1. Whilst CCN1 roles are substantial in solid 
tumour research, CCN1 role(s) within the haematopoietic compartment are less well 
defined or investigated.  CCN1 may have potential role(s) as a novel pro-inflammation 
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regulator by modulating macrophage migration inhibitory factor (MIF) and within 
regulation of haematopoiesis via pre-B cell colony enhancing factor (PBEF1). Liu et al. 
(2008) have suggested a role for CCN1 (CYR61) in contributing in MIF-mediated pro-
inflammation, angiogenesis, cell proliferation and tumourgenesis when they have seen 
that the MIF knockdown cells led to downregulation of CCN1 expression in both mRNA 
and protein levels which inhibit CCN1 dependent signalling pathway (Figure 6.1).  
 
 
 
 
 
 
186 
 
 
Figure 6.1: Schematic diagram overview of MIF knockdown led to down regulation of CCN1 
(CYR61) and inhibition of CCN1-dependent signalling pathway. Image taken from (Liu et al., 
2008).  
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CCN1 was shown to modulate calcium ion signalling by targeting intracellular calcium 
receptor protein Calmodulin 3 (CALM 3). CCN1 altered Apolipoprotein M (ApoM) and 
Talin 1 (TLN1) expression and could potentiate new targets to supplement treatment for 
MCL. However, these novel pathways would need further investigations to identify the 
role(s) of CCN1 in B cell development and within the bone marrow microenvironment 
where regulation of haematopoiesis ensues.   
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Appendices    
Appendix 1: Full length of DNA CCN1/CYR61 from gene bank, yellow colour is Y582, green colour is G676 and red colour is R288. Taken from 
https://www.ncbi.nlm.nih.gov/nuccore/NC_000001.11?report=genbank&from=85580761&to=85583967 
ORIGIN       
        1 agaccgcgag cgagagcgcc cccgagcagc gcccgcgccc tccgcgcctt ctccgccggg 
       61 acctcgagcg aaagacgccc gcccgccgcc cagccctcgc ctccctgccc accgggccca 
      121 ccgcgccgcc accccgaccc cgctgcgcac ggcctgtccg ctgcacacca gcttgttggc 
      181 gtcttcgtcg ccgcgctcgc cccgggctac tcctgcgcgc cacaatgagc tcccgcatcg 
      241 ccagggcgct cgccttagtc gtcacccttc tccacttgac caggctggtg agttggactc 
      301 tccttttgcc acctattccc cgtccgctct ccagcccctt cccctggtcc cagattgccc 
      361 acggcaggaa aagttaaaaa gttcgcgatc gtttgcgggt agccgtttct ttaagcactc 
      421 tccccctccc cccgaagacg tgtcgggacc tcttggtggg agcagccttc cgaggtggcc 
      481 gggctggacg agatcagagg ctccccgtcg atagggtcgg agacccccgt ccctcactgc 
      541 ggcagccgcg gcgcccctcc tgcgcaccgc gccgagtctc acgcgtatct tctccccctt 
      601 ccaggcgctc tccacctgcc ccgctgcctg ccactgcccc ctggaggcgc ccaagtgcgc 
      661 gccgggagtc gggctggtcc gggacggctg cggctgctgt aaggtctgcg ccaagcagct 
      721 caacgaggac tgcagcaaaa cgcagccctg cgaccacacc aaggggctgg aatgcaactt 
      781 cggcgccagc tccaccgctc tgaaggggat ctgcagaggt aagatgcttg tggtttggcc 
      841 cctttaaaaa aaatactagt ccccatagtc cagaagttta gtaattctga gaccatgtat 
      901 ggtgatgctt tgttgttggt agcttggcag aaaggcacat gatttcagca gtctggaatg 
      961 caattcagtg tgtctgggcc caacgaaagc gcatacggaa aagtgattcc tgactaactt 
     1021 attgttctgg tctggagtct ccggggaatt gtagggaact ttaccataaa ttgaatttaa 
     1081 cagcagaaaa tatgtatgag tttcaggcgg tggtttggaa tcttaacttt atccccttct 
     1141 acctttctct tttggtgatc tttgcagctc agtcagaggg cagaccctgt gaatataact 
     1201 ccagaatcta ccaaaacggg gaaagtttcc agcccaactg taaacatcag tgcacatgta 
     1261 ttgatggcgc cgtgggctgc attcctctgt gtccccaaga actatctctc cccaacttgg 
     1321 gctgtcccaa ccctcggctg gtcaaagtta ccgggcagtg ctgcgaggag tgggtctgtg 
     1381 acgaggatag tatcaaggac cccatggagg accaggacgg cctccttggc aaggagctgg 
     1441 gattcgatgc ctccgaggtg gagttgacga gaaacaatga attgattgca gttggaaaag 
     1501 gcagctcact gaagcggctc cctggtaagt ggagactgag cacttcagac actgtactga 
     1561 gatgcatttc tggtctaaat ctttgtagaa atgagtgctt gagcctgttt gtgtcggtat 
     1621 gcctctgaga agtcttccct cttatatgtc tctagttttt ggaatggagc ctcgcatcct 
     1681 atacaaccct ttacaaggcc agaaatgtat tgttcaaaca acttcatggt cccagtgctc 
     1741 aaagacctgt ggaactggta tctccacacg agttaccaat gacaaccctg agtgccgcct 
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     1801 tgtgaaagaa acccggattt gtgaggtgcg gccttgtgga cagccagtgt acagcagcct 
     1861 gaaagtaagt tccttcaggg acgtgtagac tgttgcctgg caggtgggtg ggatgtgaac 
     1921 atctttttga agaaagagaa atatcacccc taactttcct tctctccttt ctcttacaga 
     1981 agggcaagaa atgcagcaag accaagaaat cccccgaacc agtcaggttt acttacgctg 
     2041 gatgtttgag tgtgaagaaa taccggccca agtactgcgg ttcctgcgtg gacggccgat 
     2101 gctgcacgcc ccagctgacc aggactgtga agatgcggtt ccgctgcgaa gatggggaga 
     2161 cattttccaa gaacgtcatg atgatccagt cctgcaaatg caactacaac tgcccgcatg 
     2221 ccaatgaagc agcgtttccc ttctacaggc tgttcaatga cattcacaaa tttagggact 
     2281 aaatgctacc tgggtttcca gggcacacct agacaaacaa gggagaagag tgtcagaatc 
     2341 agaatcatgg agaaaatggg cgggggtggt gtgggtgatg ggactcattg tagaaaggaa 
     2401 gccttgctca ttcttgagga gcattaaggt atttcgaaac tgccaagggt gctggtgcgg 
     2461 atggacacta atgcagccac gattggagaa tactttgctt catagtattg gagcacatgt 
     2521 tactgcttca ttttggagct tgtggagttg atgactttct gttttctgtt tgtaaattat 
     2581 ttgctaagca tattttctct aggctttttt ccttttgggg ttctacagtc gtaaaagaga 
     2641 taataagatt agttggacag tttaaagctt ttattcgtcc tttgacaaaa gtaaatggga 
     2701 gggcattcca tcccttcctg aagggggaca ctccatgagt gtctgtgaga ggcagctatc 
     2761 tgcactctaa actgcaaaca gaaatcaggt gttttaagac tgaatgtttt atttatcaaa 
     2821 atgtagcttt tggggaggga ggggaaatgt aatactggaa taatttgtaa atgattttaa 
     2881 ttttatattc agtgaaaaga ttttatttat ggaattaacc atttaataaa gaaatattta 
     2941 cctaatatct gagtgtatgc cattcggtat ttttagaggt gctccaaagt cattaggaac 
     3001 aacctagctc acgtactcaa ttattcaaac aggacttatt gggatacagc agtgaattaa 
     3061 gctattaaaa taagataatg attgctttta taccttcagt agagaaaagt ctttgcatat 
     3121 aaagtaatgt ttaaaaaaca tgtattgaac acgacattgt atgaagcaca ataaagattc 
     3181 tgaagctaaa tttgtgattt aagaaaa 
// 
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Appendix 2: Down regulated proteins in REC1 CYR61/CCN1 KD model. 
Category Term GO TERM Count % PValue Genes List 
Total 
Pop 
Hits 
Pop 
Total 
Fold 
Enrichment 
Bonferroni Benjamini FDR 
GOTERM_BP_FAT GO:0070972 protein 
localization to 
endoplasmic 
reticulum 
9 9.474 5.31E-07 29082, 6181, 2923, 6132, 6224, 6222, 
6154, 6165, 6156 
93 128 16650 12.5882 0.0013 0.0013 0.0009 
GOTERM_BP_FAT GO:0002474 antigen processing 
and presentation 
of peptide antigen 
via MHC class I 
8 8.421 7.46E-07 5687, 5688, 2923, 5243, 5721, 5685, 
3105, 5684 
93 92 16650 15.5680 0.0019 0.0009 0.0013 
GOTERM_BP_FAT GO:0090150 establishment of 
protein 
localization to 
membrane 
13 13.684 8.41E-07 6181, 302, 6132, 6154, 6165, 6156, 
29082, 6224, 6222, 7534, 7532, 7531, 
26520 
93 368 16650 6.3245 0.0021 0.0007 0.0015 
GOTERM_BP_FAT GO:0045047 protein targeting 
to ER 
8 8.421 1.72E-06 29082, 6181, 6132, 6224, 6222, 6154, 
6165, 6156 
93 104 16650 13.7717 0.0043 0.0011 0.0030 
GOTERM_BP_FAT GO:0072599 establishment of 
protein 
localization to 
endoplasmic 
reticulum 
8 8.421 2.21E-06 29082, 6181, 6132, 6224, 6222, 6154, 
6165, 6156 
93 108 16650 13.2616 0.0055 0.0011 0.0039 
GOTERM_BP_FAT GO:0033238 regulation of 
cellular amine 
metabolic process 
7 7.368 3.31E-06 11315, 5687, 5688, 3251, 5721, 5685, 
5684 
93 74 16650 16.9355 0.0083 0.0014 0.0058 
GOTERM_BP_FAT GO:0009117 nucleotide 
metabolic process 
16 16.842 3.50E-06 3251, 654364, 1329, 4190, 4710, 
11315, 2079, 7167, 51727, 10606, 
10135, 808, 7086, 2023, 1345, 3945 
93 667 16650 4.2946 0.0087 0.0013 0.0062 
GOTERM_BP_FAT GO:0006753 nucleoside 
phosphate 
metabolic process 
16 16.842 4.05E-06 3251, 654364, 1329, 4190, 4710, 
11315, 2079, 7167, 51727, 10606, 
10135, 808, 7086, 2023, 1345, 3945 
93 675 16650 4.2437 0.0101 0.0013 0.0071 
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GOTERM_BP_FAT GO:0045454 cell redox 
homeostasis 
7 7.368 4.17E-06 10130, 9601, 2923, 10935, 9352, 
5034, 5052 
93 77 16650 16.2757 0.0104 0.0012 0.0074 
GOTERM_BP_FAT GO:0016032 viral process 19 20.000 4.70E-06 6181, 6132, 6154, 293, 6165, 5034, 
5685, 5684, 8665, 3383, 6156, 29082, 
2224, 5688, 6224, 6222, 2023, 7531, 
3105 
93 966 16650 3.5213 0.0117 0.0012 0.0083 
GOTERM_BP_FAT GO:0044764 multi-organism 
cellular process 
19 20.000 5.20E-06 6181, 6132, 6154, 293, 6165, 5034, 
5685, 5684, 8665, 3383, 6156, 29082, 
2224, 5688, 6224, 6222, 2023, 7531, 
3105 
93 973 16650 3.4960 0.0129 0.0012 0.0092 
GOTERM_BP_FAT GO:0006605 protein targeting 16 16.842 6.39E-06 6181, 302, 6132, 2923, 6154, 293, 
6165, 5052, 6156, 29082, 6224, 6222, 
7534, 7532, 7531, 26520 
93 701 16650 4.0863 0.0159 0.0013 0.0113 
GOTERM_BP_FAT GO:0044403 symbiosis, 
encompassing 
mutualism 
through parasitism 
19 20.000 7.38E-06 6181, 6132, 6154, 293, 6165, 5034, 
5685, 5684, 8665, 3383, 6156, 29082, 
2224, 5688, 6224, 6222, 2023, 7531, 
3105 
93 998 16650 3.4084 0.0183 0.0014 0.0130 
GOTERM_BP_FAT GO:0044419 interspecies 
interaction 
between 
organisms 
19 20.000 7.38E-06 6181, 6132, 6154, 293, 6165, 5034, 
5685, 5684, 8665, 3383, 6156, 29082, 
2224, 5688, 6224, 6222, 2023, 7531, 
3105 
93 998 16650 3.4084 0.0183 0.0014 0.0130 
GOTERM_BP_FAT GO:0006886 intracellular 
protein transport 
19 20.000 9.95E-06 6181, 302, 6132, 2923, 10961, 6154, 
293, 6165, 5052, 6156, 29082, 11315, 
10016, 6224, 6222, 7534, 7532, 7531, 
26520 
93 1020 16650 3.3349 0.0246 0.0018 0.0176 
GOTERM_BP_FAT GO:0055086 nucleobase-
containing small 
molecule 
metabolic process 
16 16.842 1.01E-05 3251, 654364, 1329, 4190, 4710, 
11315, 2079, 7167, 51727, 10606, 
10135, 808, 7086, 2023, 1345, 3945 
93 728 16650 3.9348 0.0249 0.0017 0.0177 
GOTERM_BP_FAT GO:0006612 protein targeting 
to membrane 
9 9.474 1.02E-05 29082, 6181, 302, 6132, 6224, 6222, 
6154, 6165, 6156 
93 190 16650 8.4805 0.0252 0.0016 0.0180 
GOTERM_BP_FAT GO:1901566 organonitrogen 
compound 
22 23.158 1.48E-05 1936, 6181, 3251, 654364, 1933, 
6132, 1329, 6154, 293, 6165, 8665, 
93 1375 16650 2.8645 0.0363 0.0022 0.0260 
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biosynthetic 
process 
6156, 11315, 2079, 6224, 51727, 
10606, 6222, 10135, 808, 5859, 6576 
GOTERM_BP_FAT GO:0006614 SRP-dependent 
cotranslational 
protein targeting 
to membrane 
7 7.368 1.50E-05 6181, 6132, 6224, 6222, 6154, 6165, 
6156 
93 96 16650 13.0544 0.0369 0.0021 0.0265 
GOTERM_BP_FAT GO:0072657 protein 
localization to 
membrane 
13 13.684 1.55E-05 6181, 302, 6132, 6154, 6165, 6156, 
29082, 6224, 6222, 7534, 7532, 7531, 
26520 
93 489 16650 4.7595 0.0381 0.0020 0.0273 
GOTERM_BP_FAT GO:0072594 establishment of 
protein 
localization to 
organelle 
15 15.789 1.64E-05 6181, 6132, 2923, 6154, 293, 6165, 
5052, 6156, 29082, 6224, 6222, 7534, 
7532, 7531, 26520 
93 666 16650 4.0323 0.0404 0.0021 0.0290 
GOTERM_BP_FAT GO:0006613 cotranslational 
protein targeting 
to membrane 
7 7.368 2.24E-05 6181, 6132, 6224, 6222, 6154, 6165, 
6156 
93 103 16650 12.1672 0.0547 0.0027 0.0396 
GOTERM_BP_FAT GO:0002223 stimulatory C-type 
lectin receptor 
signaling pathway 
7 7.368 2.50E-05 5687, 5688, 7334, 3385, 5721, 5685, 
5684 
93 105 16650 11.9355 0.0609 0.0029 0.0442 
GOTERM_BP_FAT GO:0002479 antigen processing 
and presentation 
of exogenous 
peptide antigen 
via MHC class I, 
TAP-dependent 
6 6.316 2.52E-05 5687, 5688, 5721, 5685, 3105, 5684 93 63 16650 17.0507 0.0612 0.0027 0.0445 
GOTERM_BP_FAT GO:1902582 single-organism 
intracellular 
transport 
15 15.789 2.64E-05 6181, 6647, 302, 6132, 1329, 2923, 
6154, 6165, 5052, 6156, 29082, 6224, 
6222, 26520, 81 
93 695 16650 3.8640 0.0640 0.0028 0.0466 
GOTERM_BP_FAT GO:0002220 innate immune 
response 
activating cell 
surface receptor 
signaling pathway 
7 7.368 2.79E-05 5687, 5688, 7334, 3385, 5721, 5685, 
5684 
93 107 16650 11.7124 0.0675 0.0028 0.0492 
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GOTERM_BP_FAT GO:0033365 protein 
localization to 
organelle 
17 17.895 3.14E-05 6181, 6132, 2923, 6154, 293, 6165, 
5052, 6156, 29082, 11315, 4478, 
6224, 6222, 7534, 7532, 7531, 26520 
93 902 16650 3.3742 0.0757 0.0030 0.0554 
GOTERM_BP_FAT GO:0042590 antigen processing 
and presentation 
of exogenous 
peptide antigen 
via MHC class I 
6 6.316 3.16E-05 5687, 5688, 5721, 5685, 3105, 5684 93 66 16650 16.2757 0.0762 0.0029 0.0558 
GOTERM_BP_FAT GO:0019882 antigen processing 
and presentation 
9 9.474 3.67E-05 5687, 5688, 2923, 5243, 5721, 5685, 
3105, 5684, 3383 
93 227 16650 7.0982 0.0880 0.0033 0.0648 
GOTERM_BP_FAT GO:0044106 cellular amine 
metabolic process 
7 7.368 4.19E-05 11315, 5687, 5688, 3251, 5721, 5685, 
5684 
93 115 16650 10.8976 0.0997 0.0036 0.0739 
GOTERM_BP_FAT GO:0046907 intracellular 
transport 
23 24.211 4.25E-05 6181, 6647, 302, 2923, 6132, 1329, 
10961, 6154, 293, 6165, 5052, 6156, 
29082, 11315, 4478, 10016, 6224, 
6222, 7534, 7532, 81, 7531, 26520 
93 1594 16650 2.5833 0.1011 0.0035 0.0750 
GOTERM_BP_FAT GO:0051438 regulation of 
ubiquitin-protein 
transferase 
activity 
7 7.368 5.07E-05 11315, 5687, 5688, 7334, 5721, 5685, 
5684 
93 119 16650 10.5313 0.1195 0.0041 0.0895 
GOTERM_BP_FAT GO:0015031 protein transport 25 26.316 5.20E-05 6181, 9601, 6165, 29082, 10016, 
4678, 81, 302, 2923, 6132, 10961, 
293, 6154, 5052, 6156, 11315, 4082, 
6224, 2665, 6222, 7534, 7532, 7531, 
26520, 5878 
93 1860 16650 2.4063 0.1222 0.0041 0.0917 
GOTERM_BP_FAT GO:0048002 antigen processing 
and presentation 
of peptide antigen 
8 8.421 5.99E-05 5687, 5688, 2923, 5243, 5721, 5685, 
3105, 5684 
93 179 16650 8.0014 0.1396 0.0045 0.1057 
GOTERM_BP_FAT GO:0000184 nuclear-
transcribed 
mRNA catabolic 
process, nonsense-
mediated decay 
7 7.368 6.11E-05 6181, 6132, 6224, 6222, 6154, 6165, 
6156 
93 123 16650 10.1888 0.1420 0.0045 0.1077 
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GOTERM_BP_FAT GO:0006979 response to 
oxidative stress 
11 11.579 6.30E-05 11315, 654364, 9124, 6647, 10935, 
3848, 9352, 5034, 5052, 5660, 4710 
93 394 16650 4.9984 0.1461 0.0045 0.1111 
GOTERM_BP_FAT GO:0009308 amine metabolic 
process 
7 7.368 6.39E-05 11315, 5687, 5688, 3251, 5721, 5685, 
5684 
93 124 16650 10.1067 0.1480 0.0044 0.1127 
GOTERM_BP_FAT GO:0051444 negative 
regulation of 
ubiquitin-protein 
transferase 
activity 
6 6.316 8.00E-05 11315, 5687, 5688, 5721, 5685, 5684 93 80 16650 13.4274 0.1819 0.0054 0.1412 
GOTERM_BP_FAT GO:0006413 translational 
initiation 
8 8.421 8.44E-05 6181, 6132, 6224, 6222, 6154, 6165, 
8665, 6156 
93 189 16650 7.5781 0.1908 0.0056 0.1488 
GOTERM_BP_FAT GO:0019080 viral gene 
expression 
8 8.421 9.31E-05 6181, 6132, 6224, 6222, 6154, 6165, 
8665, 6156 
93 192 16650 7.4597 0.2083 0.0060 0.1642 
GOTERM_BP_FAT GO:1902580 single-organism 
cellular 
localization 
18 18.947 9.89E-05 6181, 6647, 302, 6132, 1329, 2923, 
6154, 6165, 5052, 6156, 29082, 6224, 
6222, 7534, 7532, 7531, 26520, 81 
93 1102 16650 2.9243 0.2197 0.0062 0.1744 
GOTERM_BP_FAT GO:0044248 cellular catabolic 
process 
22 23.158 1.56E-04 6181, 3251, 302, 6132, 6154, 6165, 
5721, 5052, 5685, 5684, 6156, 5687, 
11315, 4478, 5688, 7167, 6224, 7334, 
10935, 6222, 808, 1632 
93 1616 16650 2.4373 0.3244 0.0095 0.2755 
GOTERM_BP_FAT GO:0044033 multi-organism 
metabolic process 
8 8.421 1.83E-04 6181, 6132, 6224, 6222, 6154, 6165, 
8665, 6156 
93 214 16650 6.6928 0.3673 0.0108 0.3216 
GOTERM_BP_FAT GO:0045184 establishment of 
protein 
localization 
25 26.316 1.92E-04 6181, 9601, 6165, 29082, 10016, 
4678, 81, 302, 2923, 6132, 10961, 
293, 6154, 5052, 6156, 11315, 4082, 
6224, 2665, 6222, 7534, 7532, 7531, 
26520, 5878 
93 2021 16650 2.2146 0.3822 0.0111 0.3383 
GOTERM_BP_FAT GO:0019058 viral life cycle 11 11.579 2.05E-04 29082, 6181, 6132, 6224, 6222, 6154, 
6165, 5034, 8665, 3383, 6156 
93 455 16650 4.3283 0.4020 0.0116 0.3611 
GOTERM_BP_FAT GO:0006412 translation 13 13.684 2.08E-04 1936, 6181, 1933, 6132, 6224, 6222, 
6154, 293, 6165, 5859, 6576, 8665, 
6156 
93 641 16650 3.6309 0.4058 0.0115 0.3656 
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GOTERM_BP_FAT GO:0002181 cytoplasmic 
translation 
5 5.263 2.08E-04 6181, 6132, 6154, 6165, 8665 93 53 16650 16.8898 0.4062 0.0113 0.3661 
GOTERM_BP_FAT GO:0019693 ribose phosphate 
metabolic process 
12 12.632 2.17E-04 11315, 3251, 654364, 1329, 7167, 
10606, 51727, 808, 7086, 2023, 1345, 
4710 
93 549 16650 3.9133 0.4204 0.0115 0.3830 
GOTERM_BP_FAT GO:0006521 regulation of 
cellular amino 
acid metabolic 
process 
5 5.263 2.23E-04 5687, 5688, 5721, 5685, 5684 93 54 16650 16.5771 0.4291 0.0116 0.3937 
GOTERM_BP_FAT GO:0009161 ribonucleoside 
monophosphate 
metabolic process 
9 9.474 2.37E-04 11315, 3251, 1329, 7167, 10606, 
51727, 2023, 1345, 4710 
93 297 16650 5.4252 0.4485 0.0121 0.4179 
GOTERM_BP_FAT GO:0051443 positive regulation 
of ubiquitin-
protein transferase 
activity 
6 6.316 2.64E-04 5687, 5688, 7334, 5721, 5685, 5684 93 103 16650 10.4291 0.4840 0.0131 0.4645 
GOTERM_BP_FAT GO:0034599 cellular response 
to oxidative stress 
8 8.421 2.69E-04 11315, 654364, 6647, 10935, 9352, 
5034, 5052, 5660 
93 228 16650 6.2818 0.4906 0.0131 0.4734 
GOTERM_BP_FAT GO:0044802 single-organism 
membrane 
organization 
15 15.789 2.73E-04 6181, 6647, 302, 6132, 5243, 6154, 
6165, 6156, 29082, 6224, 6222, 7534, 
7532, 7531, 26520 
93 866 16650 3.1010 0.4961 0.0131 0.4811 
GOTERM_BP_FAT GO:0002478 antigen processing 
and presentation 
of exogenous 
peptide antigen 
7 7.368 2.77E-04 5687, 5688, 5243, 5721, 5685, 3105, 
5684 
93 162 16650 7.7360 0.5003 0.0130 0.4869 
GOTERM_BP_FAT GO:0044265 cellular 
macromolecule 
catabolic process 
16 16.842 2.79E-04 6181, 302, 6132, 6154, 6165, 5721, 
5685, 5684, 6156, 11315, 5687, 4478, 
5688, 6224, 7334, 6222 
93 976 16650 2.9350 0.5035 0.0129 0.4915 
GOTERM_BP_FAT GO:0043043 peptide 
biosynthetic 
process 
13 13.684 2.99E-04 1936, 6181, 1933, 6132, 6224, 6222, 
6154, 293, 6165, 5859, 6576, 8665, 
6156 
93 667 16650 3.4894 0.5271 0.0135 0.5256 
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GOTERM_BP_FAT GO:0055114 oxidation-
reduction process 
16 16.842 3.01E-04 6647, 1329, 2923, 9352, 4190, 5052, 
4710, 11315, 7167, 10935, 2665, 808, 
2023, 1632, 1345, 3945 
93 983 16650 2.9141 0.5304 0.0134 0.5305 
GOTERM_BP_FAT GO:0038061 NIK/NF-kappaB 
signaling 
6 6.316 3.15E-04 5687, 5688, 81, 5721, 5685, 5684 93 107 16650 10.0392 0.5460 0.0138 0.5542 
GOTERM_BP_FAT GO:0019674 NAD metabolic 
process 
5 5.263 3.15E-04 7167, 10135, 4190, 2023, 3945 93 59 16650 15.1722 0.5461 0.0135 0.5543 
GOTERM_BP_FAT GO:0009123 nucleoside 
monophosphate 
metabolic process 
9 9.474 3.24E-04 11315, 3251, 1329, 7167, 10606, 
51727, 2023, 1345, 4710 
93 311 16650 5.1810 0.5558 0.0137 0.5694 
GOTERM_BP_FAT GO:0019637 organophosphate 
metabolic process 
17 17.895 3.45E-04 3251, 654364, 1329, 4190, 4710, 
2224, 11315, 2079, 7167, 51727, 
10606, 10135, 808, 7086, 2023, 1345, 
3945 
93 1108 16650 2.7469 0.5786 0.0143 0.6063 
GOTERM_BP_FAT GO:0019884 antigen processing 
and presentation 
of exogenous 
antigen 
7 7.368 3.47E-04 5687, 5688, 5243, 5721, 5685, 3105, 
5684 
93 169 16650 7.4155 0.5812 0.0142 0.6106 
GOTERM_BP_FAT GO:0006796 phosphate-
containing 
compound 
metabolic process 
32 33.684 3.66E-04 5660, 5685, 5684, 3383, 2224, 7167, 
51727, 10135, 7086, 1345, 3945, 
3251, 654364, 6647, 302, 1329, 
10961, 4190, 476, 5721, 5052, 4710, 
5687, 11315, 5688, 2079, 10935, 
10606, 808, 2023, 7532, 7531 
93 3083 16650 1.8583 0.6008 0.0147 0.6440 
GOTERM_BP_FAT GO:0006793 phosphorus 
metabolic process 
32 33.684 3.79E-04 5660, 5685, 5684, 3383, 2224, 7167, 
51727, 10135, 7086, 1345, 3945, 
3251, 654364, 6647, 302, 1329, 
10961, 4190, 476, 5721, 5052, 4710, 
5687, 11315, 5688, 2079, 10935, 
10606, 808, 2023, 7532, 7531 
93 3089 16650 1.8547 0.6137 0.0150 0.6670 
GOTERM_BP_FAT GO:0051649 establishment of 
localization in cell 
24 25.263 4.45E-04 6181, 6647, 302, 2923, 6132, 1329, 
10961, 6154, 293, 6165, 5052, 6156, 
29082, 11315, 4478, 10016, 6224, 
93 2004 16650 2.1441 0.6727 0.0173 0.7827 
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6222, 7534, 808, 7532, 81, 7531, 
26520 
GOTERM_BP_FAT GO:0009116 nucleoside 
metabolic process 
10 10.526 4.60E-04 11315, 3251, 2079, 654364, 1329, 
7167, 51727, 2023, 1345, 4710 
93 413 16650 4.3349 0.6845 0.0176 0.8085 
GOTERM_BP_FAT GO:0038095 Fc-epsilon 
receptor signaling 
pathway 
7 7.368 4.71E-04 5687, 5688, 7334, 808, 5721, 5685, 
5684 
93 179 16650 7.0013 0.6934 0.0178 0.8283 
GOTERM_BP_FAT GO:1903362 regulation of 
cellular protein 
catabolic process 
8 8.421 4.80E-04 11315, 5687, 4478, 5688, 302, 5721, 
5685, 5684 
93 251 16650 5.7062 0.6999 0.0178 0.8433 
GOTERM_BP_FAT GO:0019083 viral transcription 7 7.368 5.00E-04 6181, 6132, 6224, 6222, 6154, 6165, 
6156 
93 181 16650 6.9239 0.7145 0.0183 0.8783 
GOTERM_BP_FAT GO:0006518 peptide metabolic 
process 
14 14.737 5.42E-04 1936, 6181, 1933, 6647, 6132, 6154, 
293, 6165, 8665, 6156, 6224, 6222, 
5859, 6576 
93 818 16650 3.0641 0.7430 0.0195 0.9515 
GOTERM_BP_FAT GO:0008104 protein 
localization 
27 28.421 5.74E-04 6181, 9601, 51596, 6165, 29082, 
10016, 4678, 81, 302, 2923, 6132, 
10961, 6154, 293, 5052, 6156, 11315, 
4478, 4082, 6224, 2665, 6222, 7534, 
7532, 7531, 26520, 5878 
93 2448 16650 1.9746 0.7631 0.0204 1.0084 
GOTERM_BP_FAT GO:0098609 cell-cell adhesion 17 17.895 5.93E-04 7112, 1936, 832, 6647, 302, 3385, 
5052, 3383, 11315, 4478, 9124, 8350, 
10606, 7534, 2023, 7531, 3105 
93 1164 16650 2.6147 0.7740 0.0207 1.0412 
GOTERM_BP_FAT GO:0046496 nicotinamide 
nucleotide 
metabolic process 
6 6.316 5.97E-04 7167, 10135, 4190, 7086, 2023, 3945 93 123 16650 8.7333 0.7764 0.0206 1.0486 
GOTERM_BP_FAT GO:0019362 pyridine 
nucleotide 
metabolic process 
6 6.316 5.97E-04 7167, 10135, 4190, 7086, 2023, 3945 93 123 16650 8.7333 0.7764 0.0206 1.0486 
GOTERM_BP_FAT GO:0080134 regulation of 
response to stress 
18 18.947 6.05E-04 6647, 302, 3848, 10961, 3385, 293, 
5721, 5052, 5660, 5034, 5685, 5684, 
5687, 11315, 5688, 7334, 7531, 3105 
93 1285 16650 2.5078 0.7811 0.0206 1.0631 
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GOTERM_BP_FAT GO:0051436 negative 
regulation of 
ubiquitin-protein 
ligase activity 
involved in 
mitotic cell cycle 
5 5.263 6.39E-04 5687, 5688, 5721, 5685, 5684 93 71 16650 12.6079 0.7989 0.0214 1.1221 
GOTERM_BP_FAT GO:1901657 glycosyl 
compound 
metabolic process 
10 10.526 6.67E-04 11315, 3251, 2079, 654364, 1329, 
7167, 51727, 2023, 1345, 4710 
93 435 16650 4.1157 0.8126 0.0221 1.1714 
GOTERM_BP_FAT GO:0051439 regulation of 
ubiquitin-protein 
ligase activity 
involved in 
mitotic cell cycle 
5 5.263 6.74E-04 5687, 5688, 5721, 5685, 5684 93 72 16650 12.4328 0.8157 0.0220 1.1828 
GOTERM_BP_FAT GO:1904667 negative 
regulation of 
ubiquitin protein 
ligase activity 
5 5.263 7.10E-04 5687, 5688, 5721, 5685, 5684 93 73 16650 12.2625 0.8316 0.0229 1.2458 
GOTERM_BP_FAT GO:0043604 amide 
biosynthetic 
process 
13 13.684 7.19E-04 1936, 6181, 1933, 6132, 6224, 6222, 
6154, 293, 6165, 5859, 6576, 8665, 
6156 
93 736 16650 3.1623 0.8354 0.0229 1.2617 
GOTERM_BP_FAT GO:0009967 positive regulation 
of signal 
transduction 
19 20.000 7.25E-04 1936, 6647, 2923, 10961, 5721, 5660, 
5685, 5684, 3383, 5687, 11315, 5688, 
2079, 7334, 7534, 808, 7532, 7531, 
81 
93 1428 16650 2.3821 0.8376 0.0227 1.2709 
GOTERM_BP_FAT GO:0009259 ribonucleotide 
metabolic process 
11 11.579 7.33E-04 11315, 3251, 654364, 1329, 7167, 
10606, 51727, 808, 2023, 1345, 4710 
93 535 16650 3.6810 0.8409 0.0227 1.2851 
GOTERM_BP_FAT GO:0031397 negative 
regulation of 
protein 
ubiquitination 
6 6.316 7.41E-04 11315, 5687, 5688, 5721, 5685, 5684 93 129 16650 8.3271 0.8443 0.0227 1.2999 
GOTERM_BP_FAT GO:0023056 positive regulation 
of signaling 
20 21.053 7.84E-04 1936, 6647, 302, 2923, 10961, 5721, 
5660, 5685, 5684, 3383, 5687, 11315, 
93 1563 16650 2.2909 0.8602 0.0237 1.3750 
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5688, 2079, 7334, 7534, 808, 7532, 
7531, 81 
GOTERM_BP_FAT GO:0072524 pyridine-
containing 
compound 
metabolic process 
6 6.316 7.94E-04 7167, 10135, 4190, 7086, 2023, 3945 93 131 16650 8.2000 0.8638 0.0237 1.3928 
GOTERM_BP_FAT GO:0051437 positive regulation 
of ubiquitin-
protein ligase 
activity involved 
in regulation of 
mitotic cell cycle 
transition 
5 5.263 8.27E-04 5687, 5688, 5721, 5685, 5684 93 76 16650 11.7784 0.8743 0.0244 1.4487 
GOTERM_BP_FAT GO:0009057 macromolecule 
catabolic process 
17 17.895 8.31E-04 6181, 302, 6132, 6154, 6165, 5721, 
5685, 5684, 6156, 11315, 5687, 4478, 
5688, 6224, 7334, 6222, 808 
93 1201 16650 2.5342 0.8757 0.0242 1.4564 
GOTERM_BP_FAT GO:0007155 cell adhesion 21 22.105 8.35E-04 7112, 1936, 832, 654364, 6647, 302, 
3385, 953, 5052, 3383, 11315, 4478, 
9124, 8350, 10606, 396, 7534, 2023, 
81, 7531, 3105 
93 1699 16650 2.2129 0.8769 0.0241 1.4630 
GOTERM_BP_FAT GO:0022610 biological 
adhesion 
21 22.105 8.73E-04 7112, 1936, 832, 654364, 6647, 302, 
3385, 953, 5052, 3383, 11315, 4478, 
9124, 8350, 10606, 396, 7534, 2023, 
81, 7531, 3105 
93 1705 16650 2.2051 0.8880 0.0248 1.5286 
GOTERM_BP_FAT GO:0001738 morphogenesis of 
a polarized 
epithelium 
6 6.316 9.10E-04 5687, 4478, 5688, 5721, 5685, 5684 93 135 16650 7.9570 0.8980 0.0256 1.5933 
GOTERM_BP_FAT GO:0031145 anaphase-
promoting 
complex-
dependent 
catabolic process 
5 5.263 9.56E-04 5687, 5688, 5721, 5685, 5684 93 79 16650 11.3312 0.9091 0.0266 1.6735 
GOTERM_BP_FAT GO:0033036 macromolecule 
localization 
29 30.526 9.61E-04 6181, 9601, 51596, 6165, 5660, 
29082, 10016, 4678, 81, 302, 2923, 
6132, 5243, 10961, 6154, 293, 5052, 
93 2817 16650 1.8431 0.9104 0.0264 1.6830 
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6156, 11315, 4478, 4082, 6224, 6222, 
2665, 7534, 7532, 7531, 26520, 5878 
GOTERM_BP_FAT GO:0000956 nuclear-
transcribed 
mRNA catabolic 
process 
7 7.368 9.83E-04 6181, 6132, 6224, 6222, 6154, 6165, 
6156 
93 206 16650 6.0836 0.9151 0.0267 1.7208 
GOTERM_BP_FAT GO:0046364 monosaccharide 
biosynthetic 
process 
5 5.263 0.001001978 7167, 4190, 7086, 2023, 6576 93 80 16650 11.1895 0.9191 0.0270 1.7536 
GOTERM_BP_FAT GO:0009167 purine 
ribonucleoside 
monophosphate 
metabolic process 
8 8.421 0.001013814 11315, 3251, 1329, 7167, 10606, 
2023, 1345, 4710 
93 285 16650 5.0255 0.9214 0.0270 1.7741 
GOTERM_BP_FAT GO:0009126 purine nucleoside 
monophosphate 
metabolic process 
8 8.421 0.001034643 11315, 3251, 1329, 7167, 10606, 
2023, 1345, 4710 
93 286 16650 5.0079 0.9254 0.0272 1.8102 
GOTERM_BP_FAT GO:0006733 oxidoreduction 
coenzyme 
metabolic process 
6 6.316 0.001036949 7167, 10135, 4190, 7086, 2023, 3945 93 139 16650 7.7280 0.9259 0.0270 1.8142 
GOTERM_BP_FAT GO:0034613 cellular protein 
localization 
20 21.053 0.001039676 6181, 302, 6132, 2923, 10961, 6154, 
293, 6165, 5052, 6156, 29082, 11315, 
4478, 10016, 6224, 6222, 7534, 7532, 
7531, 26520 
93 1600 16650 2.2379 0.9264 0.0268 1.8190 
GOTERM_BP_FAT GO:1903321 negative 
regulation of 
protein 
modification by 
small protein 
conjugation or 
removal 
6 6.316 0.001070723 11315, 5687, 5688, 5721, 5685, 5684 93 140 16650 7.6728 0.9319 0.0273 1.8728 
GOTERM_BP_FAT GO:0043603 cellular amide 
metabolic process 
15 15.789 0.001071749 1936, 6181, 1933, 6647, 6132, 6154, 
293, 6165, 8665, 6156, 6224, 6222, 
10135, 5859, 6576 
93 994 16650 2.7017 0.9321 0.0271 1.8746 
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GOTERM_BP_FAT GO:1904668 positive regulation 
of ubiquitin 
protein ligase 
activity 
5 5.263 0.001098825 5687, 5688, 5721, 5685, 5684 93 82 16650 10.9166 0.9365 0.0275 1.9215 
GOTERM_BP_FAT GO:0070727 cellular 
macromolecule 
localization 
20 21.053 0.001145052 6181, 302, 6132, 2923, 10961, 6154, 
293, 6165, 5052, 6156, 29082, 11315, 
4478, 10016, 6224, 6222, 7534, 7532, 
7531, 26520 
93 1613 16650 2.2199 0.9435 0.0283 2.0016 
GOTERM_BP_FAT GO:2001233 regulation of 
apoptotic 
signaling pathway 
9 9.474 0.001199795 11315, 6647, 2923, 10961, 7534, 
7532, 7531, 5034, 3383 
93 380 16650 4.2402 0.9508 0.0294 2.0963 
GOTERM_BP_FAT GO:0090407 organophosphate 
biosynthetic 
process 
11 11.579 0.001216942 2224, 3251, 2079, 654364, 1329, 
7167, 10606, 51727, 10135, 808, 
7086 
93 572 16650 3.4429 0.9528 0.0295 2.1260 
GOTERM_BP_FAT GO:0043488 regulation of 
mRNA stability 
6 6.316 0.001251986 5687, 5688, 7534, 5721, 5685, 5684 93 145 16650 7.4082 0.9568 0.0300 2.1866 
GOTERM_BP_FAT GO:0098869 cellular oxidant 
detoxification 
5 5.263 0.001256145 11315, 6647, 10935, 9352, 5052 93 85 16650 10.5313 0.9573 0.0299 2.1937 
GOTERM_BP_FAT GO:0009141 nucleoside 
triphosphate 
metabolic process 
8 8.421 0.001286771 11315, 654364, 1329, 7167, 51727, 
2023, 1345, 4710 
93 297 16650 4.8224 0.9604 0.0303 2.2467 
GOTERM_BP_FAT GO:0009119 ribonucleoside 
metabolic process 
9 9.474 0.001303855 11315, 3251, 654364, 1329, 7167, 
51727, 2023, 1345, 4710 
93 385 16650 4.1852 0.9621 0.0304 2.2762 
GOTERM_BP_FAT GO:1904666 regulation of 
ubiquitin protein 
ligase activity 
5 5.263 0.00131191 5687, 5688, 5721, 5685, 5684 93 86 16650 10.4089 0.9628 0.0303 2.2901 
GOTERM_BP_FAT GO:0048584 positive regulation 
of response to 
stimulus 
23 24.211 0.001319694 1936, 6647, 2923, 3848, 10961, 293, 
3385, 5721, 5660, 5685, 5684, 3383, 
5687, 11315, 5688, 2079, 7334, 7534, 
808, 7532, 81, 7531, 3105 
93 2030 16650 2.0284 0.9636 0.0302 2.3035 
GOTERM_BP_FAT GO:1990748 cellular 
detoxification 
5 5.263 0.001369383 11315, 6647, 10935, 9352, 5052 93 87 16650 10.2892 0.9678 0.0310 2.3893 
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GOTERM_BP_FAT GO:0006402 mRNA catabolic 
process 
7 7.368 0.001410314 6181, 6132, 6224, 6222, 6154, 6165, 
6156 
93 221 16650 5.6707 0.9710 0.0317 2.4598 
GOTERM_BP_FAT GO:0061024 membrane 
organization 
15 15.789 0.001463054 6181, 6647, 302, 6132, 5243, 6154, 
6165, 6156, 29082, 6224, 6222, 7534, 
7532, 7531, 26520 
93 1027 16650 2.6149 0.9746 0.0325 2.5507 
GOTERM_BP_FAT GO:0043487 regulation of RNA 
stability 
6 6.316 0.001542674 5687, 5688, 7534, 5721, 5685, 5684 93 152 16650 7.0671 0.9792 0.0340 2.6877 
GOTERM_BP_FAT GO:0015992 proton transport 6 6.316 0.001587931 11315, 1329, 476, 1347, 81, 1345 93 153 16650 7.0209 0.9814 0.0347 2.7656 
GOTERM_BP_FAT GO:0098754 detoxification 5 5.263 0.001616917 11315, 6647, 10935, 9352, 5052 93 91 16650 9.8369 0.9827 0.0350 2.8154 
GOTERM_BP_FAT GO:2000060 positive regulation 
of protein 
ubiquitination 
involved in 
ubiquitin-
dependent protein 
catabolic process 
5 5.263 0.001616917 5687, 5688, 5721, 5685, 5684 93 91 16650 9.8369 0.9827 0.0350 2.8154 
GOTERM_BP_FAT GO:0035567 non-canonical 
Wnt signaling 
pathway 
6 6.316 0.001681367 5687, 5688, 808, 5721, 5685, 5684 93 155 16650 6.9303 0.9853 0.0360 2.9260 
GOTERM_BP_FAT GO:0006818 hydrogen 
transport 
6 6.316 0.001681367 11315, 1329, 476, 1347, 81, 1345 93 155 16650 6.9303 0.9853 0.0360 2.9260 
GOTERM_BP_FAT GO:0009165 nucleotide 
biosynthetic 
process 
8 8.421 0.001736839 3251, 2079, 654364, 1329, 10606, 
51727, 10135, 808 
93 313 16650 4.5759 0.9872 0.0369 3.0212 
GOTERM_BP_FAT GO:0006732 coenzyme 
metabolic process 
8 8.421 0.001800761 7167, 10135, 4190, 4144, 7086, 2023, 
3945, 6576 
93 315 16650 4.5469 0.9891 0.0379 3.1307 
GOTERM_BP_FAT GO:1901293 nucleoside 
phosphate 
biosynthetic 
process 
8 8.421 0.001833401 3251, 2079, 654364, 1329, 10606, 
51727, 10135, 808 
93 316 16650 4.5325 0.9900 0.0383 3.1866 
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GOTERM_BP_FAT GO:0010647 positive regulation 
of cell 
communication 
19 20.000 0.001917745 1936, 6647, 2923, 10961, 5721, 5660, 
5685, 5684, 3383, 5687, 11315, 5688, 
2079, 7334, 7534, 808, 7532, 7531, 
81 
93 1555 16650 2.1875 0.9919 0.0396 3.3308 
GOTERM_BP_FAT GO:0019725 cellular 
homeostasis 
13 13.684 0.002071558 10130, 654364, 6647, 9601, 2923, 
10935, 9352, 808, 476, 5034, 5052, 
1207, 3383 
93 833 16650 2.7940 0.9945 0.0424 3.5934 
GOTERM_BP_FAT GO:0002758 innate immune 
response-
activating signal 
transduction 
7 7.368 0.002277192 5687, 5688, 7334, 3385, 5721, 5685, 
5684 
93 243 16650 5.1573 0.9967 0.0462 3.9434 
GOTERM_BP_FAT GO:0038093 Fc receptor 
signaling pathway 
7 7.368 0.002277192 5687, 5688, 7334, 808, 5721, 5685, 
5684 
93 243 16650 5.1573 0.9967 0.0462 3.9434 
GOTERM_BP_FAT GO:0009150 purine 
ribonucleotide 
metabolic process 
10 10.526 0.002301811 11315, 3251, 654364, 1329, 7167, 
10606, 808, 2023, 1345, 4710 
93 520 16650 3.4429 0.9969 0.0463 3.9852 
GOTERM_BP_FAT GO:0050852 T cell receptor 
signaling pathway 
6 6.316 0.002329105 5687, 5688, 7334, 5721, 5685, 5684 93 167 16650 6.4323 0.9971 0.0464 4.0316 
GOTERM_BP_FAT GO:2000058 regulation of 
protein 
ubiquitination 
involved in 
ubiquitin-
dependent protein 
catabolic process 
5 5.263 0.00236885 5687, 5688, 5721, 5685, 5684 93 101 16650 8.8630 0.9974 0.0468 4.0990 
GOTERM_BP_FAT GO:0006401 RNA catabolic 
process 
7 7.368 0.002571544 6181, 6132, 6224, 6222, 6154, 6165, 
6156 
93 249 16650 5.0330 0.9984 0.0504 4.4423 
GOTERM_BP_FAT GO:0002218 activation of 
innate immune 
response 
7 7.368 0.00262326 5687, 5688, 7334, 3385, 5721, 5685, 
5684 
93 250 16650 5.0129 0.9986 0.0509 4.5297 
GOTERM_BP_FAT GO:0031396 regulation of 
protein 
ubiquitination 
7 7.368 0.002783109 11315, 5687, 5688, 7334, 5721, 5685, 
5684 
93 253 16650 4.9535 0.9991 0.0536 4.7993 
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GOTERM_BP_FAT GO:0060071 Wnt signaling 
pathway, planar 
cell polarity 
pathway 
5 5.263 0.002919943 5687, 5688, 5721, 5685, 5684 93 107 16650 8.3660 0.9993 0.0557 5.0296 
GOTERM_BP_FAT GO:2001235 positive regulation 
of apoptotic 
signaling pathway 
6 6.316 0.002994205 11315, 6647, 2923, 7534, 7532, 7531 93 177 16650 6.0689 0.9995 0.0566 5.1543 
GOTERM_BP_FAT GO:0090175 regulation of 
establishment of 
planar polarity 
5 5.263 0.003225864 5687, 5688, 5721, 5685, 5684 93 110 16650 8.1378 0.9997 0.0604 5.5425 
GOTERM_BP_FAT GO:0006163 purine nucleotide 
metabolic process 
10 10.526 0.0032267 11315, 3251, 654364, 1329, 7167, 
10606, 808, 2023, 1345, 4710 
93 547 16650 3.2730 0.9997 0.0600 5.5439 
GOTERM_BP_FAT GO:0031398 positive regulation 
of protein 
ubiquitination 
6 6.316 0.003373815 5687, 5688, 7334, 5721, 5685, 5684 93 182 16650 5.9022 0.9998 0.0622 5.7896 
GOTERM_BP_FAT GO:0002682 regulation of 
immune system 
process 
17 17.895 0.003421312 654364, 6647, 5243, 3848, 3385, 293, 
5721, 5685, 5684, 3383, 5687, 4478, 
5688, 7334, 8294, 808, 3105 
93 1378 16650 2.2087 0.9998 0.0626 5.8688 
GOTERM_BP_FAT GO:0010941 regulation of cell 
death 
18 18.947 0.003451738 1936, 654364, 6647, 2923, 10961, 
5034, 5660, 3336, 3383, 29082, 
11315, 10016, 10935, 396, 7534, 
7532, 81, 7531 
93 1509 16650 2.1356 0.9998 0.0627 5.9195 
GOTERM_BP_FAT GO:0046128 purine 
ribonucleoside 
metabolic process 
8 8.421 0.003563413 11315, 3251, 654364, 1329, 7167, 
2023, 1345, 4710 
93 356 16650 4.0232 0.9999 0.0642 6.1054 
GOTERM_BP_FAT GO:0023051 regulation of 
signaling 
29 30.526 0.00359071 1936, 5660, 5685, 5684, 3383, 10016, 
7334, 81, 832, 6647, 302, 2923, 
10961, 293, 476, 5721, 5052, 5034, 
5687, 11315, 5688, 4082, 2079, 2665, 
396, 7534, 808, 7532, 7531 
93 3070 16650 1.6912 0.9999 0.0642 6.1508 
GOTERM_BP_FAT GO:0051348 negative 
regulation of 
8 8.421 0.003618618 11315, 5687, 5688, 10935, 7532, 
5721, 5685, 5684 
93 357 16650 4.0119 0.9999 0.0642 6.1972 
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transferase 
activity 
GOTERM_BP_FAT GO:0009205 purine 
ribonucleoside 
triphosphate 
metabolic process 
7 7.368 0.003627631 11315, 654364, 1329, 7167, 2023, 
1345, 4710 
93 267 16650 4.6937 0.9999 0.0639 6.2121 
GOTERM_BP_FAT GO:1903364 positive regulation 
of cellular protein 
catabolic process 
6 6.316 0.003701561 5687, 4478, 5688, 5721, 5685, 5684 93 186 16650 5.7752 0.9999 0.0647 6.3349 
GOTERM_BP_FAT GO:0042278 purine nucleoside 
metabolic process 
8 8.421 0.003730985 11315, 3251, 654364, 1329, 7167, 
2023, 1345, 4710 
93 359 16650 3.9896 0.9999 0.0648 6.3837 
GOTERM_BP_FAT GO:0006364 rRNA processing 7 7.368 0.00376229 6181, 6132, 6224, 6222, 6154, 6165, 
6156 
93 269 16650 4.6588 0.9999 0.0648 6.4356 
GOTERM_BP_FAT GO:0045088 regulation of 
innate immune 
response 
8 8.421 0.003788157 5687, 5688, 7334, 3385, 5721, 5685, 
3105, 5684 
93 360 16650 3.9785 0.9999 0.0648 6.4784 
GOTERM_BP_FAT GO:0009199 ribonucleoside 
triphosphate 
metabolic process 
7 7.368 0.004042723 11315, 654364, 1329, 7167, 2023, 
1345, 4710 
93 273 16650 4.5906 1.0000 0.0686 6.8993 
GOTERM_BP_FAT GO:0031347 regulation of 
defense response 
11 11.579 0.004097381 11315, 5687, 5688, 7334, 3848, 293, 
3385, 5721, 5685, 3105, 5684 
93 676 16650 2.9132 1.0000 0.0690 6.9894 
GOTERM_BP_FAT GO:0009144 purine nucleoside 
triphosphate 
metabolic process 
7 7.368 0.004115192 11315, 654364, 1329, 7167, 2023, 
1345, 4710 
93 274 16650 4.5738 1.0000 0.0688 7.0188 
GOTERM_BP_FAT GO:1903320 regulation of 
protein 
modification by 
small protein 
conjugation or 
removal 
7 7.368 0.004263015 11315, 5687, 5688, 7334, 5721, 5685, 
5684 
93 276 16650 4.5407 1.0000 0.0708 7.2620 
GOTERM_BP_FAT GO:0016072 rRNA metabolic 
process 
7 7.368 0.004263015 6181, 6132, 6224, 6222, 6154, 6165, 
6156 
93 276 16650 4.5407 1.0000 0.0708 7.2620 
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GOTERM_BP_FAT GO:0042176 regulation of 
protein catabolic 
process 
8 8.421 0.004397314 11315, 5687, 4478, 5688, 302, 5721, 
5685, 5684 
93 370 16650 3.8710 1.0000 0.0724 7.4825 
GOTERM_BP_FAT GO:0010035 response to 
inorganic 
substance 
9 9.474 0.004401799 11315, 10016, 6647, 10935, 51596, 
808, 5052, 5660, 3383 
93 469 16650 3.4356 1.0000 0.0720 7.4899 
GOTERM_BP_FAT GO:0072521 purine-containing 
compound 
metabolic process 
10 10.526 0.004474043 11315, 3251, 654364, 1329, 7167, 
10606, 808, 2023, 1345, 4710 
93 575 16650 3.1136 1.0000 0.0727 7.6083 
GOTERM_BP_FAT GO:0052548 regulation of 
endopeptidase 
activity 
8 8.421 0.004527575 11315, 10016, 1476, 10935, 7531, 
5721, 3336, 5684 
93 372 16650 3.8502 1.0000 0.0731 7.6959 
GOTERM_BP_FAT GO:0090263 positive regulation 
of canonical Wnt 
signaling pathway 
5 5.263 0.00453398 5687, 5688, 5721, 5685, 5684 93 121 16650 7.3980 1.0000 0.0727 7.7064 
GOTERM_BP_FAT GO:0032270 positive regulation 
of cellular protein 
metabolic process 
17 17.895 0.004587283 6647, 302, 10961, 5721, 5660, 5685, 
3336, 5684, 3383, 11315, 5687, 4478, 
5688, 10016, 7334, 808, 5859 
93 1420 16650 2.1433 1.0000 0.0731 7.7935 
GOTERM_BP_FAT GO:0001736 establishment of 
planar polarity 
5 5.263 0.004668171 5687, 5688, 5721, 5685, 5684 93 122 16650 7.3374 1.0000 0.0738 7.9257 
GOTERM_BP_FAT GO:0007164 establishment of 
tissue polarity 
5 5.263 0.004668171 5687, 5688, 5721, 5685, 5684 93 122 16650 7.3374 1.0000 0.0738 7.9257 
GOTERM_BP_FAT GO:1903322 positive regulation 
of protein 
modification by 
small protein 
conjugation or 
removal 
6 6.316 0.004821753 5687, 5688, 7334, 5721, 5685, 5684 93 198 16650 5.4252 1.0000 0.0757 8.1761 
GOTERM_BP_FAT GO:0031329 regulation of 
cellular catabolic 
process 
8 8.421 0.004866021 11315, 5687, 4478, 5688, 302, 5721, 
5685, 5684 
93 377 16650 3.7991 1.0000 0.0759 8.2481 
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GOTERM_BP_FAT GO:0097190 apoptotic 
signaling pathway 
10 10.526 0.004892065 11315, 10016, 6647, 2923, 10961, 
7534, 7532, 7531, 5034, 3383 
93 583 16650 3.0709 1.0000 0.0758 8.2905 
GOTERM_BP_FAT GO:0006091 generation of 
precursor 
metabolites and 
energy 
8 8.421 0.005006625 11315, 1329, 7167, 808, 4190, 2023, 
1345, 4710 
93 379 16650 3.7790 1.0000 0.0770 8.4767 
GOTERM_BP_FAT GO:0022613 ribonucleoprotein 
complex 
biogenesis 
9 9.474 0.005051978 6181, 6132, 6224, 6222, 6154, 6165, 
1207, 8665, 6156 
93 480 16650 3.3569 1.0000 0.0772 8.5502 
GOTERM_BP_FAT GO:0034655 nucleobase-
containing 
compound 
catabolic process 
8 8.421 0.005078067 6181, 3251, 6132, 6224, 6222, 6154, 
6165, 6156 
93 380 16650 3.7691 1.0000 0.0772 8.5926 
GOTERM_BP_FAT GO:0034614 cellular response 
to reactive oxygen 
species 
5 5.263 0.005086743 11315, 6647, 10935, 5052, 5660 93 125 16650 7.1613 1.0000 0.0768 8.6066 
GOTERM_BP_FAT GO:0044093 positive regulation 
of molecular 
function 
20 21.053 0.005115516 6647, 302, 10961, 5721, 5660, 5685, 
3336, 5684, 3383, 11315, 5687, 5688, 
10016, 7334, 10935, 2665, 396, 808, 
81, 6742 
93 1840 16650 1.9460 1.0000 0.0768 8.6533 
GOTERM_BP_FAT GO:0051186 cofactor metabolic 
process 
8 8.421 0.005446882 7167, 10135, 4190, 4144, 7086, 2023, 
3945, 6576 
93 385 16650 3.7202 1.0000 0.0811 9.1887 
GOTERM_BP_FAT GO:0045089 positive regulation 
of innate immune 
response 
7 7.368 0.005591102 5687, 5688, 7334, 3385, 5721, 5685, 
5684 
93 292 16650 4.2919 1.0000 0.0827 9.4208 
GOTERM_BP_FAT GO:0030162 regulation of 
proteolysis 
11 11.579 0.005650545 11315, 5687, 5688, 10016, 1476, 
10935, 7531, 5721, 5685, 3336, 5684 
93 708 16650 2.7816 1.0000 0.0830 9.5163 
GOTERM_BP_FAT GO:0010646 regulation of cell 
communication 
28 29.474 0.005741003 1936, 5660, 5685, 5684, 3383, 10016, 
7334, 81, 832, 6647, 302, 2923, 
10961, 293, 5721, 5052, 5034, 11315, 
5687, 5688, 4082, 2079, 2665, 396, 
7534, 808, 7532, 7531 
93 3020 16650 1.6599 1.0000 0.0838 9.6615 
254 
 
GOTERM_BP_FAT GO:0009966 regulation of 
signal 
transduction 
26 27.368 0.005938727 1936, 5660, 5685, 5684, 3383, 10016, 
7334, 81, 832, 6647, 302, 2923, 
10961, 5721, 5052, 5034, 11315, 
5687, 5688, 2079, 2665, 396, 7534, 
808, 7532, 7531 
93 2728 16650 1.7063 1.0000 0.0861 9.9780 
GOTERM_BP_FAT GO:0030048 actin filament-
based movement 
5 5.263 0.006159717 4637, 7171, 476, 81, 7170 93 132 16650 6.7815 1.0000 0.0886 10.3305 
GOTERM_BP_FAT GO:0000302 response to 
reactive oxygen 
species 
6 6.316 0.006164486 11315, 6647, 10935, 5034, 5052, 
5660 
93 210 16650 5.1152 1.0000 0.0882 10.3381 
GOTERM_BP_FAT GO:0045087 innate immune 
response 
12 12.632 0.006288685 5687, 5688, 8339, 7334, 3848, 3385, 
5721, 5052, 5685, 3105, 5684, 3383 
93 836 16650 2.5698 1.0000 0.0894 10.5356 
GOTERM_BP_FAT GO:0052547 regulation of 
peptidase activity 
8 8.421 0.006328939 11315, 10016, 1476, 10935, 7531, 
5721, 3336, 5684 
93 396 16650 3.6168 1.0000 0.0894 10.5996 
GOTERM_BP_FAT GO:0002768 immune response-
regulating cell 
surface receptor 
signaling pathway 
8 8.421 0.006587051 5687, 5688, 7334, 808, 3385, 5721, 
5685, 5684 
93 399 16650 3.5896 1.0000 0.0924 11.0085 
GOTERM_BP_FAT GO:0031349 positive regulation 
of defense 
response 
8 8.421 0.00685295 5687, 5688, 7334, 293, 3385, 5721, 
5685, 5684 
93 402 16650 3.5628 1.0000 0.0954 11.4279 
GOTERM_BP_FAT GO:0033209 tumor necrosis 
factor-mediated 
signaling pathway 
5 5.263 0.007373761 5687, 5688, 5721, 5685, 5684 93 139 16650 6.4400 1.0000 0.1017 12.2440 
GOTERM_BP_FAT GO:0044772 mitotic cell cycle 
phase transition 
9 9.474 0.007535185 5687, 5688, 5243, 808, 7532, 7531, 
5721, 5685, 5684 
93 514 16650 3.1348 1.0000 0.1033 12.4955 
GOTERM_BP_FAT GO:0046700 heterocycle 
catabolic process 
8 8.421 0.007698774 6181, 3251, 6132, 6224, 6222, 6154, 
6165, 6156 
93 411 16650 3.4848 1.0000 0.1048 12.7497 
GOTERM_BP_FAT GO:0032268 regulation of 
cellular protein 
metabolic process 
23 24.211 0.007897456 6647, 1476, 302, 10961, 5721, 5052, 
5660, 5685, 3336, 5684, 8665, 3383, 
5687, 11315, 5688, 4478, 10016, 
7334, 10935, 808, 7532, 5859, 7531 
93 2346 16650 1.7552 1.0000 0.1068 13.0575 
255 
 
GOTERM_BP_FAT GO:0051247 positive regulation 
of protein 
metabolic process 
17 17.895 0.008103349 6647, 302, 10961, 5721, 5660, 5685, 
3336, 5684, 3383, 11315, 5687, 4478, 
5688, 10016, 7334, 808, 5859 
93 1508 16650 2.0183 1.0000 0.1089 13.3754 
GOTERM_BP_FAT GO:0044270 cellular nitrogen 
compound 
catabolic process 
8 8.421 0.008408394 6181, 3251, 6132, 6224, 6222, 6154, 
6165, 6156 
93 418 16650 3.4265 1.0000 0.1122 13.8443 
GOTERM_BP_FAT GO:0050851 antigen receptor-
mediated 
signaling pathway 
6 6.316 0.008642865 5687, 5688, 7334, 5721, 5685, 5684 93 228 16650 4.7114 1.0000 0.1145 14.2031 
GOTERM_BP_FAT GO:0042180 cellular ketone 
metabolic process 
6 6.316 0.008798073 11315, 5687, 5688, 5721, 5685, 5684 93 229 16650 4.6908 1.0000 0.1159 14.4399 
GOTERM_BP_FAT GO:0006457 protein folding 6 6.316 0.008798073 10130, 9601, 2923, 10961, 9352, 
3336 
93 229 16650 4.6908 1.0000 0.1159 14.4399 
GOTERM_BP_FAT GO:0051347 positive regulation 
of transferase 
activity 
10 10.526 0.008820658 11315, 5687, 5688, 6647, 7334, 
10961, 808, 5721, 5685, 5684 
93 640 16650 2.7974 1.0000 0.1155 14.4742 
GOTERM_BP_FAT GO:0019439 aromatic 
compound 
catabolic process 
8 8.421 0.008944084 6181, 3251, 6132, 6224, 6222, 6154, 
6165, 6156 
93 423 16650 3.3860 1.0000 0.1164 14.6620 
GOTERM_BP_FAT GO:1903050 regulation of 
proteolysis 
involved in 
cellular protein 
catabolic process 
6 6.316 0.008955203 11315, 5687, 5688, 5721, 5685, 5684 93 230 16650 4.6704 1.0000 0.1160 14.6789 
GOTERM_BP_FAT GO:0016310 phosphorylation 22 23.158 0.009079375 654364, 6647, 302, 1329, 10961, 
5721, 5052, 5660, 5685, 5684, 4710, 
3383, 5687, 11315, 5688, 7167, 
51727, 10935, 808, 2023, 7532, 1345 
93 2229 16650 1.7670 1.0000 0.1169 14.8674 
GOTERM_BP_FAT GO:0010033 response to 
organic substance 
26 27.368 0.009149939 10130, 1933, 5660, 3336, 5685, 5684, 
3383, 10016, 10135, 4678, 3105, 
3251, 654364, 6647, 302, 6132, 476, 
5721, 11315, 5687, 4478, 5688, 
10935, 396, 808, 7532 
93 2822 16650 1.6495 1.0000 0.1172 14.9743 
256 
 
GOTERM_BP_FAT GO:0006334 nucleosome 
assembly 
5 5.263 0.009804026 8339, 8350, 4673, 8294, 4678 93 151 16650 5.9282 1.0000 0.1244 15.9594 
GOTERM_BP_FAT GO:0051641 cellular 
localization 
24 25.263 0.00992952 6181, 6647, 302, 2923, 6132, 1329, 
10961, 6154, 293, 6165, 5052, 6156, 
29082, 11315, 4478, 10016, 6224, 
6222, 7534, 808, 7532, 81, 7531, 
26520 
93 2541 16650 1.6910 1.0000 0.1253 16.1471 
GOTERM_BP_FAT GO:0030177 positive regulation 
of Wnt signaling 
pathway 
5 5.263 0.010483725 5687, 5688, 5721, 5685, 5684 93 154 16650 5.8127 1.0000 0.1312 16.9716 
GOTERM_BP_FAT GO:0042254 ribosome 
biogenesis 
7 7.368 0.010639501 6181, 6132, 6224, 6222, 6154, 6165, 
6156 
93 335 16650 3.7410 1.0000 0.1323 17.2020 
GOTERM_BP_FAT GO:0044770 cell cycle phase 
transition 
9 9.474 0.01073764 5687, 5688, 5243, 808, 7532, 7531, 
5721, 5685, 5684 
93 547 16650 2.9457 1.0000 0.1328 17.3468 
GOTERM_BP_FAT GO:0043085 positive regulation 
of catalytic 
activity 
17 17.895 0.010980235 6647, 10961, 5721, 5660, 5685, 3336, 
5684, 3383, 11315, 5687, 5688, 
10016, 7334, 2665, 396, 808, 6742 
93 1559 16650 1.9522 1.0000 0.1350 17.7038 
GOTERM_BP_FAT GO:0046034 ATP metabolic 
process 
6 6.316 0.011177965 11315, 1329, 7167, 2023, 1345, 4710 93 243 16650 4.4205 1.0000 0.1366 17.9936 
GOTERM_BP_FAT GO:0071356 cellular response 
to tumor necrosis 
factor 
6 6.316 0.011363187 5687, 5688, 5721, 5685, 5684, 3383 93 244 16650 4.4024 1.0000 0.1380 18.2643 
GOTERM_BP_FAT GO:0010565 regulation of 
cellular ketone 
metabolic process 
5 5.263 0.011436496 5687, 5688, 5721, 5685, 5684 93 158 16650 5.6656 1.0000 0.1382 18.3712 
GOTERM_BP_FAT GO:1901361 organic cyclic 
compound 
catabolic process 
8 8.421 0.011603843 6181, 3251, 6132, 6224, 6222, 6154, 
6165, 6156 
93 445 16650 3.2186 1.0000 0.1394 18.6147 
GOTERM_BP_FAT GO:0050776 regulation of 
immune response 
12 12.632 0.011685485 5687, 5688, 7334, 3848, 808, 293, 
3385, 5721, 5685, 3105, 5684, 3383 
93 912 16650 2.3557 1.0000 0.1396 18.7333 
GOTERM_BP_FAT GO:0016071 mRNA metabolic 
process 
10 10.526 0.011888562 6181, 3189, 6132, 6224, 6222, 6154, 
6165, 1207, 6156, 51691 
93 672 16650 2.6642 1.0000 0.1412 19.0274 
257 
 
GOTERM_BP_FAT GO:0000209 protein 
polyubiquitination 
6 6.316 0.012921023 5687, 5688, 7334, 5721, 5685, 5684 93 252 16650 4.2627 1.0000 0.1519 20.5076 
GOTERM_BP_FAT GO:0090090 negative 
regulation of 
canonical Wnt 
signaling pathway 
5 5.263 0.013234772 5687, 5688, 5721, 5685, 5684 93 165 16650 5.4252 1.0000 0.1546 20.9523 
GOTERM_BP_FAT GO:0044085 cellular 
component 
biogenesis 
26 27.368 0.013573988 6181, 8339, 6165, 3383, 29082, 4678, 
81, 3251, 654364, 832, 302, 6132, 
4673, 6154, 8665, 4710, 6156, 11315, 
4478, 8350, 6224, 6222, 8294, 7534, 
4144, 1207 
93 2914 16650 1.5974 1.0000 0.1575 21.4305 
GOTERM_BP_FAT GO:0043065 positive regulation 
of apoptotic 
process 
9 9.474 0.013767865 11315, 10016, 6647, 2923, 7534, 
7532, 7531, 3336, 3383 
93 572 16650 2.8169 1.0000 0.1588 21.7026 
GOTERM_BP_FAT GO:0031497 chromatin 
assembly 
5 5.263 0.013779796 8339, 8350, 4673, 8294, 4678 93 167 16650 5.3602 1.0000 0.1583 21.7193 
GOTERM_BP_FAT GO:0045732 positive regulation 
of protein 
catabolic process 
6 6.316 0.013964905 5687, 4478, 5688, 5721, 5685, 5684 93 257 16650 4.1797 1.0000 0.1595 21.9782 
GOTERM_BP_FAT GO:0009260 ribonucleotide 
biosynthetic 
process 
6 6.316 0.014180305 3251, 654364, 1329, 10606, 51727, 
808 
93 258 16650 4.1635 1.0000 0.1610 22.2784 
GOTERM_BP_FAT GO:0045862 positive regulation 
of proteolysis 
7 7.368 0.014380113 5687, 5688, 10016, 5721, 5685, 3336, 
5684 
93 358 16650 3.5006 1.0000 0.1624 22.5560 
GOTERM_BP_FAT GO:0043068 positive regulation 
of programmed 
cell death 
9 9.474 0.014442365 11315, 10016, 6647, 2923, 7534, 
7532, 7531, 3336, 3383 
93 577 16650 2.7925 1.0000 0.1623 22.6422 
GOTERM_BP_FAT GO:0031400 negative 
regulation of 
protein 
modification 
process 
9 9.474 0.01458012 11315, 5687, 5688, 808, 7532, 7531, 
5721, 5685, 5684 
93 578 16650 2.7877 1.0000 0.1630 22.8328 
258 
 
GOTERM_BP_FAT GO:0046390 ribose phosphate 
biosynthetic 
process 
6 6.316 0.014839931 3251, 654364, 1329, 10606, 51727, 
808 
93 261 16650 4.1157 1.0000 0.1650 23.1911 
GOTERM_BP_FAT GO:1903052 positive regulation 
of proteolysis 
involved in 
cellular protein 
catabolic process 
5 5.263 0.014912274 5687, 5688, 5721, 5685, 5684 93 171 16650 5.2349 1.0000 0.1650 23.2906 
GOTERM_BP_FAT GO:0034612 response to tumor 
necrosis factor 
6 6.316 0.015290964 5687, 5688, 5721, 5685, 5684, 3383 93 263 16650 4.0844 1.0000 0.1681 23.8093 
GOTERM_BP_FAT GO:0010608 posttranscriptional 
regulation of gene 
expression 
8 8.421 0.015602898 5687, 5688, 7534, 5721, 5859, 5685, 
5684, 8665 
93 472 16650 3.0344 1.0000 0.1705 24.2341 
GOTERM_BP_FAT GO:0045333 cellular respiration 5 5.263 0.015799204 11315, 1329, 4190, 1345, 4710 93 174 16650 5.1446 1.0000 0.1717 24.5003 
GOTERM_BP_FAT GO:0051338 regulation of 
transferase 
activity 
12 12.632 0.016020593 11315, 5687, 5688, 6647, 7334, 
10961, 10935, 808, 7532, 5721, 5685, 
5684 
93 955 16650 2.2496 1.0000 0.1732 24.7995 
GOTERM_BP_FAT GO:0002429 immune response-
activating cell 
surface receptor 
signaling pathway 
7 7.368 0.016066863 5687, 5688, 7334, 3385, 5721, 5685, 
5684 
93 367 16650 3.4148 1.0000 0.1729 24.8618 
GOTERM_BP_FAT GO:0050790 regulation of 
catalytic activity 
22 23.158 0.016556598 6647, 1476, 302, 10961, 5721, 5660, 
5685, 3336, 5684, 3383, 5687, 11315, 
5688, 10016, 7334, 10935, 2665, 396, 
808, 7532, 7531, 6742 
93 2357 16650 1.6711 1.0000 0.1770 25.5191 
GOTERM_BP_FAT GO:0051246 regulation of 
protein metabolic 
process 
23 24.211 0.01695505 6647, 1476, 302, 10961, 5721, 5052, 
5660, 5685, 3336, 5684, 8665, 3383, 
5687, 11315, 5688, 4478, 10016, 
7334, 10935, 808, 7532, 5859, 7531 
93 2512 16650 1.6392 1.0000 0.1801 26.0498 
GOTERM_BP_FAT GO:0034728 nucleosome 
organization 
5 5.263 0.017032567 8339, 8350, 4673, 8294, 4678 93 178 16650 5.0290 1.0000 0.1801 26.1527 
GOTERM_BP_FAT GO:0015980 energy derivation 
by oxidation of 
6 6.316 0.01718697 11315, 1329, 808, 4190, 1345, 4710 93 271 16650 3.9638 1.0000 0.1808 26.3571 
259 
 
organic 
compounds 
GOTERM_BP_FAT GO:0043086 negative 
regulation of 
catalytic activity 
11 11.579 0.017288684 11315, 5687, 5688, 1476, 302, 10935, 
7532, 7531, 5721, 5685, 5684 
93 839 16650 2.3473 1.0000 0.1810 26.4915 
GOTERM_BP_FAT GO:0031331 positive regulation 
of cellular 
catabolic process 
6 6.316 0.017434456 5687, 4478, 5688, 5721, 5685, 5684 93 272 16650 3.9492 1.0000 0.1817 26.6837 
GOTERM_BP_FAT GO:0000165 MAPK cascade 11 11.579 0.017549109 5687, 5688, 6647, 10961, 808, 5721, 
5052, 5660, 5685, 5684, 3383 
93 841 16650 2.3417 1.0000 0.1820 26.8345 
GOTERM_BP_FAT GO:0044283 small molecule 
biosynthetic 
process 
8 8.421 0.018391588 2224, 11315, 6647, 7167, 4190, 7086, 
2023, 6576 
93 488 16650 2.9350 1.0000 0.1892 27.9339 
GOTERM_BP_FAT GO:0006839 mitochondrial 
transport 
6 6.316 0.018707452 1329, 7534, 293, 7532, 26520, 7531 93 277 16650 3.8780 1.0000 0.1913 28.3420 
GOTERM_BP_FAT GO:0010942 positive regulation 
of cell death 
9 9.474 0.019007367 11315, 10016, 6647, 2923, 7534, 
7532, 7531, 3336, 3383 
93 607 16650 2.6545 1.0000 0.1933 28.7275 
GOTERM_BP_FAT GO:1901135 carbohydrate 
derivative 
metabolic process 
14 14.737 0.01930743 3251, 654364, 1329, 5660, 4710, 
11315, 2079, 7167, 10606, 51727, 
808, 7086, 2023, 1345 
93 1247 16650 2.0100 1.0000 0.1953 29.1113 
GOTERM_BP_FAT GO:0072655 establishment of 
protein 
localization to 
mitochondrion 
5 5.263 0.020374809 7534, 293, 7532, 26520, 7531 93 188 16650 4.7615 1.0000 0.2042 30.4606 
GOTERM_BP_FAT GO:0032269 negative 
regulation of 
cellular protein 
metabolic process 
12 12.632 0.020641929 11315, 5687, 5688, 1476, 302, 10935, 
808, 7532, 7531, 5721, 5685, 5684 
93 992 16650 2.1657 1.0000 0.2058 30.7945 
GOTERM_BP_FAT GO:0042981 regulation of 
apoptotic process 
15 15.789 0.021186504 654364, 6647, 2923, 10961, 5034, 
3336, 3383, 11315, 10016, 10935, 
7534, 396, 7532, 7531, 81 
93 1400 16650 1.9182 1.0000 0.2099 31.4705 
260 
 
GOTERM_BP_FAT GO:0006333 chromatin 
assembly or 
disassembly 
5 5.263 0.021450825 8339, 8350, 4673, 8294, 4678 93 191 16650 4.6867 1.0000 0.2114 31.7963 
GOTERM_BP_FAT GO:0070585 protein 
localization to 
mitochondrion 
5 5.263 0.021450825 7534, 293, 7532, 26520, 7531 93 191 16650 4.6867 1.0000 0.2114 31.7963 
GOTERM_BP_FAT GO:0009894 regulation of 
catabolic process 
8 8.421 0.022563486 11315, 5687, 4478, 5688, 302, 5721, 
5685, 5684 
93 509 16650 2.8139 1.0000 0.2203 33.1520 
GOTERM_BP_FAT GO:0043067 regulation of 
programmed cell 
death 
15 15.789 0.022746632 654364, 6647, 2923, 10961, 5034, 
3336, 3383, 11315, 10016, 10935, 
7534, 396, 7532, 7531, 81 
93 1413 16650 1.9006 1.0000 0.2211 33.3727 
GOTERM_BP_FAT GO:0023014 signal 
transduction by 
protein 
phosphorylation 
11 11.579 0.022752415 5687, 5688, 6647, 10961, 808, 5721, 
5052, 5660, 5685, 5684, 3383 
93 877 16650 2.2456 1.0000 0.2203 33.3797 
GOTERM_BP_FAT GO:0031401 positive regulation 
of protein 
modification 
process 
13 13.684 0.023213773 5687, 11315, 5688, 6647, 302, 7334, 
10961, 808, 5721, 5660, 5685, 5684, 
3383 
93 1143 16650 2.0362 1.0000 0.2234 33.9325 
GOTERM_BP_FAT GO:0016051 carbohydrate 
biosynthetic 
process 
5 5.263 0.023320608 7167, 4190, 7086, 2023, 6576 93 196 16650 4.5671 1.0000 0.2235 34.0599 
GOTERM_BP_FAT GO:0065003 macromolecular 
complex assembly 
17 17.895 0.02446403 3251, 832, 654364, 302, 8339, 4673, 
4710, 8665, 3383, 29082, 11315, 
4478, 8350, 8294, 4678, 4144, 1207 
93 1710 16650 1.7799 1.0000 0.2323 35.4091 
GOTERM_BP_FAT GO:0043281 regulation of 
cysteine-type 
endopeptidase 
activity involved 
in apoptotic 
process 
5 5.263 0.024885848 11315, 10016, 10935, 7531, 3336 93 200 16650 4.4758 1.0000 0.2349 35.9002 
261 
 
GOTERM_BP_FAT GO:0030178 negative 
regulation of Wnt 
signaling pathway 
5 5.263 0.025286866 5687, 5688, 5721, 5685, 5684 93 201 16650 4.4535 1.0000 0.2374 36.3638 
GOTERM_BP_FAT GO:0009636 response to toxic 
substance 
5 5.263 0.025691782 11315, 6647, 10935, 9352, 5052 93 202 16650 4.4315 1.0000 0.2399 36.8287 
GOTERM_BP_FAT GO:0034470 ncRNA 
processing 
7 7.368 0.02630744 6181, 6132, 6224, 6222, 6154, 6165, 
6156 
93 411 16650 3.0492 1.0000 0.2440 37.5295 
GOTERM_BP_FAT GO:0006323 DNA packaging 5 5.263 0.026929988 8339, 8350, 4673, 8294, 4678 93 205 16650 4.3666 1.0000 0.2482 38.2306 
GOTERM_BP_FAT GO:0006461 protein complex 
assembly 
15 15.789 0.026957351 3251, 832, 654364, 302, 8339, 4673, 
4710, 3383, 29082, 11315, 4478, 
8350, 8294, 4678, 4144 
93 1445 16650 1.8585 1.0000 0.2475 38.2612 
GOTERM_BP_FAT GO:0070271 protein complex 
biogenesis 
15 15.789 0.027097733 3251, 832, 654364, 302, 8339, 4673, 
4710, 3383, 29082, 11315, 4478, 
8350, 8294, 4678, 4144 
93 1446 16650 1.8572 1.0000 0.2478 38.4182 
GOTERM_BP_FAT GO:0002764 immune response-
regulating 
signaling pathway 
8 8.421 0.027597257 5687, 5688, 7334, 808, 3385, 5721, 
5685, 5684 
93 531 16650 2.6973 1.0000 0.2509 38.9738 
GOTERM_BP_FAT GO:0007005 mitochondrion 
organization 
9 9.474 0.027897372 11315, 10935, 7534, 293, 7532, 
26520, 7531, 6742, 4710 
93 653 16650 2.4675 1.0000 0.2524 39.3054 
GOTERM_BP_FAT GO:0010038 response to metal 
ion 
6 6.316 0.027977156 11315, 10016, 6647, 51596, 808, 
3383 
93 308 16650 3.4876 1.0000 0.2521 39.3932 
GOTERM_BP_FAT GO:0070887 cellular response 
to chemical 
stimulus 
23 24.211 0.029390706 654364, 10130, 6647, 6132, 9352, 
476, 5721, 5034, 5052, 5660, 5685, 
5684, 3383, 5687, 11315, 5688, 4478, 
10016, 10935, 396, 10135, 7532, 
3105 
93 2648 16650 1.5550 1.0000 0.2622 40.9299 
GOTERM_BP_FAT GO:0051248 negative 
regulation of 
protein metabolic 
process 
12 12.632 0.029608854 11315, 5687, 5688, 1476, 302, 10935, 
808, 7532, 7531, 5721, 5685, 5684 
93 1049 16650 2.0480 1.0000 0.2630 41.1638 
GOTERM_BP_FAT GO:0022603 regulation of 
anatomical 
12 12.632 0.029967652 5687, 4478, 5688, 10016, 832, 3848, 
396, 81, 5721, 5685, 5684, 3383 
93 1051 16650 2.0441 1.0000 0.2649 41.5465 
262 
 
structure 
morphogenesis 
GOTERM_BP_FAT GO:1901700 response to 
oxygen-containing 
compound 
15 15.789 0.030021775 654364, 6647, 1933, 476, 5052, 5660, 
5034, 3383, 11315, 4478, 10935, 
10135, 808, 4678, 7532 
93 1466 16650 1.8318 1.0000 0.2644 41.6040 
GOTERM_BP_FAT GO:1902589 single-organism 
organelle 
organization 
16 16.842 0.030510155 832, 6647, 302, 3383, 29082, 11315, 
83473, 7534, 396, 7171, 7532, 7531, 
26520, 81, 6742, 7170 
93 1612 16650 1.7770 1.0000 0.2672 42.1207 
GOTERM_BP_FAT GO:0051336 regulation of 
hydrolase activity 
14 14.737 0.031915947 11315, 10016, 6647, 1476, 10935, 
2665, 396, 808, 5721, 7531, 6742, 
3336, 5684, 3383 
93 1337 16650 1.8747 1.0000 0.2768 43.5841 
GOTERM_BP_FAT GO:0002253 activation of 
immune response 
8 8.421 0.032522411 5687, 5688, 7334, 3848, 3385, 5721, 
5685, 5684 
93 550 16650 2.6041 1.0000 0.2804 44.2045 
GOTERM_BP_FAT GO:0033554 cellular response 
to stress 
17 17.895 0.032866322 10130, 654364, 6647, 9601, 2923, 
10961, 9352, 5034, 5052, 5660, 3383, 
11315, 10016, 7334, 10935, 8294, 
7531 
93 1773 16650 1.7166 1.0000 0.2820 44.5535 
GOTERM_BP_FAT GO:0072593 reactive oxygen 
species metabolic 
process 
5 5.263 0.034618071 11315, 6647, 10935, 5052, 3383 93 222 16650 4.0323 1.0000 0.2938 46.2994 
GOTERM_BP_FAT GO:0042787 protein 
ubiquitination 
involved in 
ubiquitin-
dependent protein 
catabolic process 
5 5.263 0.034618071 5687, 5688, 5721, 5685, 5684 93 222 16650 4.0323 1.0000 0.2938 46.2994 
GOTERM_BP_FAT GO:0050778 positive regulation 
of immune 
response 
9 9.474 0.035316596 5687, 5688, 7334, 3848, 3385, 5721, 
5685, 3105, 5684 
93 684 16650 2.3557 1.0000 0.2979 46.9810 
GOTERM_BP_FAT GO:2000116 regulation of 
cysteine-type 
endopeptidase 
activity 
5 5.263 0.035598253 11315, 10016, 10935, 7531, 3336 93 224 16650 3.9963 1.0000 0.2989 47.2535 
263 
 
GOTERM_BP_FAT GO:0042592 homeostatic 
process 
16 16.842 0.035641704 10130, 654364, 6647, 9601, 2923, 
3848, 9352, 476, 5034, 5052, 94081, 
3383, 10935, 8294, 808, 1207 
93 1645 16650 1.7413 1.0000 0.2982 47.2954 
GOTERM_BP_FAT GO:0006936 muscle 
contraction 
6 6.316 0.036468057 6647, 4637, 808, 7171, 476, 7170 93 331 16650 3.2453 1.0000 0.3031 48.0868 
GOTERM_BP_FAT GO:0044257 cellular protein 
catabolic process 
9 9.474 0.036628028 11315, 5687, 4478, 5688, 302, 7334, 
5721, 5685, 5684 
93 689 16650 2.3386 1.0000 0.3033 48.2386 
GOTERM_BP_FAT GO:0009896 positive regulation 
of catabolic 
process 
6 6.316 0.03727382 5687, 4478, 5688, 5721, 5685, 5684 93 333 16650 3.2258 1.0000 0.3068 48.8476 
GOTERM_BP_FAT GO:0034660 ncRNA metabolic 
process 
8 8.421 0.038312893 6181, 6132, 6224, 6222, 6154, 6165, 
5859, 6156 
93 570 16650 2.5127 1.0000 0.3130 49.8132 
GOTERM_BP_FAT GO:0008219 cell death 18 18.947 0.038623652 654364, 6647, 2923, 10961, 293, 
5034, 5660, 3336, 3383, 29082, 
11315, 10016, 10935, 396, 7534, 
7532, 7531, 81 
93 1958 16650 1.6459 1.0000 0.3141 50.0986 
GOTERM_BP_FAT GO:0031399 regulation of 
protein 
modification 
process 
16 16.842 0.038870462 5687, 11315, 5688, 6647, 302, 7334, 
10961, 808, 7532, 5721, 7531, 5660, 
5052, 5685, 5684, 3383 
93 1664 16650 1.7215 1.0000 0.3148 50.3242 
GOTERM_BP_FAT GO:0002684 positive regulation 
of immune system 
process 
11 11.579 0.038906381 5687, 5688, 5243, 7334, 3848, 3385, 
5721, 5685, 3105, 5684, 3383 
93 960 16650 2.0514 1.0000 0.3141 50.3569 
GOTERM_BP_FAT GO:0044092 negative 
regulation of 
molecular 
function 
12 12.632 0.039770833 11315, 5687, 5688, 1476, 302, 10935, 
808, 7532, 7531, 5721, 5685, 5684 
93 1100 16650 1.9531 1.0000 0.3189 51.1391 
GOTERM_BP_FAT GO:0051091 positive regulation 
of sequence-
specific DNA 
binding 
transcription 
factor activity 
5 5.263 0.040207683 11315, 5687, 7334, 10935, 3383 93 233 16650 3.8419 1.0000 0.3209 51.5299 
264 
 
GOTERM_BP_FAT GO:0007596 blood coagulation 6 6.316 0.041035431 832, 302, 8350, 3848, 7534, 953 93 342 16650 3.1409 1.0000 0.3254 52.2623 
GOTERM_BP_FAT GO:0065004 protein-DNA 
complex assembly 
5 5.263 0.041276209 8339, 8350, 4673, 8294, 4678 93 235 16650 3.8092 1.0000 0.3260 52.4734 
GOTERM_BP_FAT GO:0080135 regulation of 
cellular response 
to stress 
8 8.421 0.041771254 11315, 6647, 7334, 10961, 7531, 
5034, 5052, 5660 
93 581 16650 2.4652 1.0000 0.3282 52.9046 
GOTERM_BP_FAT GO:0060828 regulation of 
canonical Wnt 
signaling pathway 
5 5.263 0.044578327 5687, 5688, 5721, 5685, 5684 93 241 16650 3.7144 1.0000 0.3453 55.2808 
GOTERM_BP_FAT GO:0006955 immune response 15 15.789 0.045102661 8339, 3848, 931, 3385, 293, 5721, 
5052, 5685, 5684, 3383, 5687, 5688, 
7334, 808, 3105 
93 1551 16650 1.7315 1.0000 0.3476 55.7119 
GOTERM_BP_FAT GO:0005996 monosaccharide 
metabolic process 
5 5.263 0.045711204 7167, 4190, 7086, 2023, 6576 93 243 16650 3.6838 1.0000 0.3504 56.2074 
GOTERM_BP_FAT GO:0009152 purine 
ribonucleotide 
biosynthetic 
process 
5 5.263 0.046860155 3251, 654364, 1329, 10606, 808 93 245 16650 3.6537 1.0000 0.3565 57.1286 
GOTERM_BP_FAT GO:0051259 protein 
oligomerization 
7 7.368 0.047005405 29082, 3251, 654364, 302, 8350, 
8294, 4144 
93 473 16650 2.6495 1.0000 0.3564 57.2437 
GOTERM_BP_FAT GO:0010638 positive regulation 
of organelle 
organization 
8 8.421 0.048214351 11315, 4478, 302, 7334, 7534, 7532, 
7531, 3383 
93 600 16650 2.3871 1.0000 0.3628 58.1909 
GOTERM_BP_FAT GO:0050817 coagulation 6 6.316 0.0482759 832, 302, 8350, 3848, 7534, 953 93 358 16650 3.0005 1.0000 0.3621 58.2386 
GOTERM_BP_FAT GO:0007599 hemostasis 6 6.316 0.0482759 832, 302, 8350, 3848, 7534, 953 93 358 16650 3.0005 1.0000 0.3621 58.2386 
GOTERM_BP_FAT GO:0034622 cellular 
macromolecular 
complex assembly 
11 11.579 0.050119056 29082, 832, 8339, 8350, 4673, 8294, 
4678, 1207, 8665, 4710, 3383 
93 1004 16650 1.9615 1.0000 0.3722 59.6431 
GOTERM_BP_FAT GO:0006164 purine nucleotide 
biosynthetic 
process 
5 5.263 0.051007881 3251, 654364, 1329, 10606, 808 93 252 16650 3.5522 1.0000 0.3764 60.3043 
265 
 
GOTERM_BP_FAT GO:2000027 regulation of 
organ 
morphogenesis 
5 5.263 0.051007881 5687, 5688, 5721, 5685, 5684 93 252 16650 3.5522 1.0000 0.3764 60.3043 
GOTERM_BP_FAT GO:0071310 cellular response 
to organic 
substance 
19 20.000 0.052212466 10130, 654364, 6647, 6132, 476, 
5721, 5660, 5685, 5684, 3383, 5687, 
11315, 4478, 5688, 10016, 10135, 
396, 7532, 3105 
93 2186 16650 1.5561 1.0000 0.3825 61.1842 
GOTERM_BP_FAT GO:0015672 monovalent 
inorganic cation 
transport 
7 7.368 0.052348837 11315, 1329, 476, 1347, 7531, 81, 
1345 
93 486 16650 2.5787 1.0000 0.3822 61.2826 
GOTERM_BP_FAT GO:0035556 intracellular signal 
transduction 
22 23.158 0.053124928 1936, 832, 6647, 10961, 5721, 5034, 
5052, 5660, 5685, 5684, 3383, 5687, 
11315, 5688, 10016, 7334, 2665, 396, 
808, 7531, 81, 5878 
93 2657 16650 1.4824 1.0000 0.3857 61.8384 
GOTERM_BP_FAT GO:0043161 proteasome-
mediated 
ubiquitin-
dependent protein 
catabolic process 
6 6.316 0.056751806 11315, 5687, 5688, 5721, 5685, 5684 93 375 16650 2.8645 1.0000 0.4053 64.3374 
GOTERM_BP_FAT GO:1903047 mitotic cell cycle 
process 
10 10.526 0.057115731 5687, 29082, 5688, 5243, 808, 7532, 
7531, 5721, 5685, 5684 
93 890 16650 2.0116 1.0000 0.4062 64.5794 
GOTERM_BP_FAT GO:0071824 protein-DNA 
complex subunit 
organization 
5 5.263 0.057272898 8339, 8350, 4673, 8294, 4678 93 262 16650 3.4166 1.0000 0.4060 64.6835 
GOTERM_BP_FAT GO:0002757 immune response-
activating signal 
transduction 
7 7.368 0.057600108 5687, 5688, 7334, 3385, 5721, 5685, 
5684 
93 498 16650 2.5165 1.0000 0.4067 64.8992 
GOTERM_BP_FAT GO:0072522 purine-containing 
compound 
biosynthetic 
process 
5 5.263 0.057921267 3251, 654364, 1329, 10606, 808 93 263 16650 3.4037 1.0000 0.4074 65.1097 
266 
 
GOTERM_BP_FAT GO:0060548 negative 
regulation of cell 
death 
10 10.526 0.059431665 11315, 29082, 654364, 6647, 10935, 
396, 7534, 7531, 5660, 3383 
93 897 16650 1.9959 1.0000 0.4146 66.0838 
GOTERM_BP_FAT GO:0055085 transmembrane 
transport 
13 13.684 0.059759516 1329, 5243, 293, 476, 94081, 11315, 
808, 7531, 26520, 81, 1347, 1345, 
6576 
93 1322 16650 1.7605 1.0000 0.4153 66.2918 
GOTERM_BP_FAT GO:0034976 response to 
endoplasmic 
reticulum stress 
5 5.263 0.061894458 11315, 10130, 9601, 2923, 5034 93 269 16650 3.3277 1.0000 0.4256 67.6173 
GOTERM_BP_FAT GO:0065009 regulation of 
molecular 
function 
23 24.211 0.062078531 6647, 1476, 302, 10961, 5721, 5660, 
5685, 3336, 5684, 3383, 5687, 11315, 
5688, 10016, 7334, 10935, 2665, 396, 
808, 7532, 7531, 81, 6742 
93 2863 16650 1.4383 1.0000 0.4255 67.7292 
GOTERM_BP_FAT GO:0006396 RNA processing 10 10.526 0.063893096 6181, 3189, 6132, 6224, 6222, 6154, 
6165, 1207, 6156, 51691 
93 910 16650 1.9674 1.0000 0.4339 68.8134 
GOTERM_BP_FAT GO:1901701 cellular response 
to oxygen-
containing 
compound 
10 10.526 0.064598087 11315, 4478, 654364, 6647, 10935, 
10135, 7532, 5052, 5660, 3383 
93 912 16650 1.9631 1.0000 0.4365 69.2253 
GOTERM_BP_FAT GO:0060429 epithelium 
development 
11 11.579 0.067309492 5687, 4478, 5688, 654364, 3189, 
6647, 5721, 5660, 5685, 5684, 3383 
93 1060 16650 1.8579 1.0000 0.4492 70.7622 
GOTERM_BP_FAT GO:0060070 canonical Wnt 
signaling pathway 
5 5.263 0.072443197 5687, 5688, 5721, 5685, 5684 93 284 16650 3.1520 1.0000 0.4735 73.4757 
GOTERM_BP_FAT GO:0071103 DNA 
conformation 
change 
5 5.263 0.072443197 8339, 8350, 4673, 8294, 4678 93 284 16650 3.1520 1.0000 0.4735 73.4757 
GOTERM_BP_FAT GO:0010498 proteasomal 
protein catabolic 
process 
6 6.316 0.072474493 11315, 5687, 5688, 5721, 5685, 5684 93 403 16650 2.6655 1.0000 0.4725 73.4915 
GOTERM_BP_FAT GO:0048585 negative 
regulation of 
13 13.684 0.073660851 5687, 11315, 5688, 10016, 302, 3848, 
808, 5721, 5660, 5685, 3105, 5684, 
3383 
93 1369 16650 1.7001 1.0000 0.4771 74.0835 
267 
 
response to 
stimulus 
GOTERM_BP_FAT GO:0003012 muscle system 
process 
6 6.316 0.073680998 6647, 4637, 808, 7171, 476, 7170 93 405 16650 2.6523 1.0000 0.4760 74.0935 
GOTERM_BP_FAT GO:0006952 defense response 14 14.737 0.073831264 8339, 3848, 3385, 293, 5721, 5052, 
5685, 5684, 3383, 11315, 5687, 5688, 
7334, 3105 
93 1518 16650 1.6512 1.0000 0.4756 74.1675 
GOTERM_BP_FAT GO:0071822 protein complex 
subunit 
organization 
15 15.789 0.075500329 3251, 832, 654364, 302, 8339, 4673, 
4710, 3383, 29082, 11315, 4478, 
8350, 8294, 4678, 4144 
93 1674 16650 1.6042 1.0000 0.4824 74.9769 
GOTERM_BP_FAT GO:1901615 organic hydroxy 
compound 
metabolic process 
6 6.316 0.076745527 2224, 11315, 3251, 6647, 7167, 808 93 410 16650 2.6200 1.0000 0.4870 75.5650 
GOTERM_BP_FAT GO:0030029 actin filament-
based process 
8 8.421 0.078218289 832, 4637, 396, 7171, 476, 81, 7170, 
3383 
93 672 16650 2.1313 1.0000 0.4927 76.2438 
GOTERM_BP_FAT GO:0030163 protein catabolic 
process 
9 9.474 0.07934631 11315, 5687, 4478, 5688, 302, 7334, 
5721, 5685, 5684 
93 811 16650 1.9868 1.0000 0.4967 76.7517 
GOTERM_BP_FAT GO:0012501 programmed cell 
death 
16 16.842 0.082980733 654364, 6647, 2923, 10961, 293, 
5034, 3336, 3383, 11315, 10016, 
10935, 396, 7534, 7532, 7531, 81 
93 1852 16650 1.5467 1.0000 0.5118 78.3192 
GOTERM_BP_FAT GO:0032880 regulation of 
protein 
localization 
10 10.526 0.083856467 11315, 4478, 4082, 10961, 396, 7534, 
293, 7532, 7531, 5052 
93 962 16650 1.8610 1.0000 0.5145 78.6817 
GOTERM_BP_FAT GO:0010467 gene expression 37 38.947 0.084339108 1936, 6181, 1933, 6165, 5685, 5684, 
3383, 51691, 9124, 7334, 3012, 
10135, 7112, 654364, 6132, 10961, 
6154, 293, 5721, 8665, 6156, 5687, 
11315, 5688, 4478, 3189, 3182, 8350, 
6224, 10935, 6222, 7534, 8294, 2023, 
5859, 1207, 6576 
93 5306 16650 1.2484 1.0000 0.5154 78.8790 
GOTERM_BP_FAT GO:0019221 cytokine-mediated 
signaling pathway 
7 7.368 0.086185876 5687, 5688, 5721, 5685, 3105, 5684, 
3383 
93 554 16650 2.2621 1.0000 0.5223 79.6183 
268 
 
GOTERM_BP_FAT GO:0000278 mitotic cell cycle 10 10.526 0.086380059 5687, 29082, 5688, 5243, 808, 7532, 
7531, 5721, 5685, 5684 
93 968 16650 1.8495 1.0000 0.5219 79.6946 
GOTERM_BP_FAT GO:1902531 regulation of 
intracellular signal 
transduction 
15 15.789 0.08777809 1936, 832, 6647, 10961, 5052, 5660, 
5034, 3383, 11315, 10016, 7334, 
2665, 396, 808, 81 
93 1714 16650 1.5668 1.0000 0.5267 80.2360 
GOTERM_BP_FAT GO:0006812 cation transport 10 10.526 0.089382026 11315, 1329, 808, 476, 1347, 7531, 
81, 1345, 94081, 3383 
93 975 16650 1.8362 1.0000 0.5323 80.8403 
GOTERM_BP_FAT GO:1901990 regulation of 
mitotic cell cycle 
phase transition 
5 5.263 0.094414626 5687, 5688, 5721, 5685, 5684 93 312 16650 2.8691 1.0000 0.5517 82.6254 
GOTERM_BP_FAT GO:0030111 regulation of Wnt 
signaling pathway 
5 5.263 0.09778665 5687, 5688, 5721, 5685, 5684 93 316 16650 2.8328 1.0000 0.5639 83.7324 
GOTERM_BP_FAT GO:0010604 positive regulation 
of macromolecule 
metabolic process 
22 23.158 0.098263848 654364, 6647, 302, 10961, 5721, 
5660, 5685, 3336, 5684, 3383, 5687, 
11315, 5688, 4478, 10016, 3182, 
7334, 8350, 8294, 10135, 808, 5859 
93 2856 16650 1.3791 1.0000 0.5646 83.8836 
GOTERM_BP_FAT GO:0006915 apoptotic process 15 15.789 0.098828425 654364, 6647, 2923, 10961, 293, 
5034, 3336, 3383, 11315, 10016, 
10935, 7534, 396, 7532, 7531 
93 1747 16650 1.5372 1.0000 0.5656 84.0608 
GOTERM_BP_FAT GO:0006511 ubiquitin-
dependent protein 
catabolic process 
7 7.368 0.099857191 11315, 5687, 5688, 7334, 5721, 5685, 
5684 
93 577 16650 2.1720 1.0000 0.5684 84.3788 
GOTERM_CC_FAT GO:0070062 extracellular 
exosome 
71 74.737 5.45E-31 10130, 1476, 552900, 3385, 6165, 
5685, 3336, 5684, 3383, 7167, 3012, 
51727, 10135, 1347, 81, 3105, 3251, 
832, 654364, 6647, 1329, 302, 10961, 
931, 9352, 4190, 6154, 476, 5034, 
6156, 5687, 5688, 4082, 6224, 8350, 
6222, 2665, 8294, 7171, 2023, 5878, 
6742, 7170, 6181, 8339, 3848, 51596, 
5660, 29082, 10016, 4637, 7334, 
7086, 3945, 2923, 5243, 953, 5721, 
5052, 4710, 11315, 4478, 10606, 
95 2811 14527 3.8623 0.0000 0.0000 0.0000 
269 
 
10935, 396, 7534, 808, 7532, 7531, 
1632, 6576 
GOTERM_CC_FAT GO:1903561 extracellular 
vesicle 
71 74.737 7.53E-31 10130, 1476, 552900, 3385, 6165, 
5685, 3336, 5684, 3383, 7167, 3012, 
51727, 10135, 1347, 81, 3105, 3251, 
832, 654364, 6647, 1329, 302, 10961, 
931, 9352, 4190, 6154, 476, 5034, 
6156, 5687, 5688, 4082, 6224, 8350, 
6222, 2665, 8294, 7171, 2023, 5878, 
6742, 7170, 6181, 8339, 3848, 51596, 
5660, 29082, 10016, 4637, 7334, 
7086, 3945, 2923, 5243, 953, 5721, 
5052, 4710, 11315, 4478, 10606, 
10935, 396, 7534, 808, 7532, 7531, 
1632, 6576 
95 2825 14527 3.8432 0.0000 0.0000 0.0000 
GOTERM_CC_FAT GO:0043230 extracellular 
organelle 
71 74.737 7.70E-31 10130, 1476, 552900, 3385, 6165, 
5685, 3336, 5684, 3383, 7167, 3012, 
51727, 10135, 1347, 81, 3105, 3251, 
832, 654364, 6647, 1329, 302, 10961, 
931, 9352, 4190, 6154, 476, 5034, 
6156, 5687, 5688, 4082, 6224, 8350, 
6222, 2665, 8294, 7171, 2023, 5878, 
6742, 7170, 6181, 8339, 3848, 51596, 
5660, 29082, 10016, 4637, 7334, 
7086, 3945, 2923, 5243, 953, 5721, 
5052, 4710, 11315, 4478, 10606, 
10935, 396, 7534, 808, 7532, 7531, 
1632, 6576 
95 2826 14527 3.8418 0.0000 0.0000 0.0000 
GOTERM_CC_FAT GO:0031988 membrane-
bounded vesicle 
73 76.842 5.66E-26 10130, 9601, 1476, 552900, 3385, 
6165, 5685, 3336, 5684, 3383, 7167, 
3012, 51727, 10135, 81, 1347, 3105, 
3251, 832, 654364, 6647, 1329, 302, 
10961, 931, 9352, 4190, 6154, 476, 
5034, 6156, 5687, 5688, 4082, 6224, 
8350, 6222, 2665, 8294, 7171, 2023, 
5878, 6742, 7170, 6181, 8339, 3848, 
51596, 5660, 29082, 10016, 4637, 
7334, 7086, 3945, 2923, 5243, 4673, 
953, 5721, 5052, 4710, 11315, 4478, 
95 3611 14527 3.0913 0.0000 0.0000 0.0000 
270 
 
10606, 10935, 396, 7534, 808, 7532, 
7531, 1632, 6576 
GOTERM_CC_FAT GO:0044421 extracellular 
region part 
71 74.737 4.23E-22 10130, 1476, 552900, 3385, 6165, 
5685, 3336, 5684, 3383, 7167, 3012, 
51727, 10135, 1347, 81, 3105, 3251, 
832, 654364, 6647, 1329, 302, 10961, 
931, 9352, 4190, 6154, 476, 5034, 
6156, 5687, 5688, 4082, 6224, 8350, 
6222, 2665, 8294, 7171, 2023, 5878, 
6742, 7170, 6181, 8339, 3848, 51596, 
5660, 29082, 10016, 4637, 7334, 
7086, 3945, 2923, 5243, 953, 5721, 
5052, 4710, 11315, 4478, 10606, 
10935, 396, 7534, 808, 7532, 7531, 
1632, 6576 
95 3878 14527 2.7996 0.0000 0.0000 0.0000 
GOTERM_CC_FAT GO:0005576 extracellular 
region 
71 74.737 1.80E-17 10130, 1476, 552900, 3385, 6165, 
5685, 3336, 5684, 3383, 7167, 3012, 
51727, 10135, 1347, 81, 3105, 3251, 
832, 654364, 6647, 1329, 302, 10961, 
931, 9352, 4190, 6154, 476, 5034, 
6156, 5687, 5688, 4082, 6224, 8350, 
6222, 2665, 8294, 7171, 2023, 5878, 
6742, 7170, 6181, 8339, 3848, 51596, 
5660, 29082, 10016, 4637, 7334, 
7086, 3945, 2923, 5243, 953, 5721, 
5052, 4710, 11315, 4478, 10606, 
10935, 396, 7534, 808, 7532, 7531, 
1632, 6576 
95 4623 14527 2.3485 0.0000 0.0000 0.0000 
GOTERM_CC_FAT GO:0005912 adherens junction 25 26.316 8.33E-12 1936, 6181, 3383, 9124, 81, 7112, 
832, 302, 2923, 6132, 5052, 5034, 
6156, 11315, 4478, 4082, 8350, 
10606, 2665, 6222, 7534, 7171, 2023, 
7532, 7531 
95 694 14527 5.5085 0.0000 0.0000 0.0000 
GOTERM_CC_FAT GO:0070161 anchoring junction 25 26.316 1.39E-11 1936, 6181, 3383, 9124, 81, 7112, 
832, 302, 2923, 6132, 5052, 5034, 
6156, 11315, 4478, 4082, 8350, 
10606, 2665, 6222, 7534, 7171, 2023, 
7532, 7531 
95 711 14527 5.3768 0.0000 0.0000 0.0000 
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GOTERM_CC_FAT GO:0042470 melanosome 12 12.632 7.67E-11 10130, 9601, 302, 2923, 10961, 4673, 
7534, 476, 7531, 5034, 5878, 5052 
95 106 14527 17.3112 0.0000 0.0000 0.0000 
GOTERM_CC_FAT GO:0048770 pigment granule 12 12.632 7.67E-11 10130, 9601, 302, 2923, 10961, 4673, 
7534, 476, 7531, 5034, 5878, 5052 
95 106 14527 17.3112 0.0000 0.0000 0.0000 
GOTERM_CC_FAT GO:0043209 myelin sheath 14 14.737 8.63E-11 654364, 6647, 302, 10963, 2923, 
4190, 476, 5052, 4478, 10935, 2665, 
7086, 7532, 3945 
95 174 14527 12.3036 0.0000 0.0000 0.0000 
GOTERM_CC_FAT GO:0005925 focal adhesion 16 16.842 2.89E-08 6181, 6132, 2923, 5034, 3383, 6156, 
4478, 4082, 9124, 2665, 6222, 7534, 
7171, 7532, 7531, 81 
95 391 14527 6.2574 0.0000 0.0000 0.0000 
GOTERM_CC_FAT GO:0005924 cell-substrate 
adherens junction 
16 16.842 3.20E-08 6181, 6132, 2923, 5034, 3383, 6156, 
4478, 4082, 9124, 2665, 6222, 7534, 
7171, 7532, 7531, 81 
95 394 14527 6.2098 0.0000 0.0000 0.0000 
GOTERM_CC_FAT GO:0030055 cell-substrate 
junction 
16 16.842 3.78E-08 6181, 6132, 2923, 5034, 3383, 6156, 
4478, 4082, 9124, 2665, 6222, 7534, 
7171, 7532, 7531, 81 
95 399 14527 6.1320 0.0000 0.0000 0.0001 
GOTERM_CC_FAT GO:0005829 cytosol 47 49.474 5.48E-08 1936, 6181, 1933, 6165, 5685, 5684, 
2224, 29082, 7167, 7334, 4637, 
51727, 10135, 7086, 3945, 3251, 
654364, 832, 6647, 302, 6132, 6154, 
4190, 5721, 5052, 8665, 6156, 5687, 
11315, 56896, 5688, 6224, 10606, 
10935, 6222, 2665, 7534, 396, 7171, 
4144, 808, 2023, 7532, 7531, 5859, 
1207, 7170 
95 3399 14527 2.1145 0.0000 0.0000 0.0001 
GOTERM_CC_FAT GO:0030054 cell junction 27 28.421 3.84E-07 1936, 6181, 3383, 9124, 10135, 81, 
7112, 832, 302, 2923, 6132, 476, 
5052, 5034, 6156, 11315, 4478, 4082, 
8350, 10606, 2665, 6222, 7534, 7171, 
2023, 7532, 7531 
95 1379 14527 2.9940 0.0001 0.0000 0.0005 
GOTERM_CC_FAT GO:0005913 cell-cell adherens 
junction 
12 12.632 9.58E-06 11315, 1936, 7112, 832, 9124, 302, 
8350, 10606, 7534, 2023, 7531, 5052 
95 332 14527 5.5271 0.0031 0.0002 0.0129 
GOTERM_CC_FAT GO:0005739 mitochondrion 26 27.368 5.55E-05 6165, 5660, 3336, 2224, 1347, 3945, 
1345, 654364, 6647, 1329, 9352, 
95 1700 14527 2.3387 0.0176 0.0010 0.0749 
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4190, 293, 5052, 94081, 4710, 11315, 
10935, 7534, 7532, 1632, 7531, 5859, 
26520, 6742, 6576 
GOTERM_CC_FAT GO:0000502 proteasome 
complex 
6 6.316 6.67E-05 5687, 5688, 9352, 5721, 5685, 5684 95 66 14527 13.9014 0.0211 0.0012 0.0899 
GOTERM_CC_FAT GO:0044445 cytosolic part 9 9.474 1.57E-04 6181, 6132, 6224, 10935, 6222, 6154, 
2023, 6165, 6156 
95 239 14527 5.7583 0.0491 0.0026 0.2121 
GOTERM_CC_FAT GO:0022626 cytosolic 
ribosome 
7 7.368 1.58E-04 6181, 6132, 6224, 6222, 6154, 6165, 
6156 
95 125 14527 8.5633 0.0493 0.0025 0.2129 
GOTERM_CC_FAT GO:0005911 cell-cell junction 14 14.737 2.49E-04 11315, 1936, 7112, 832, 9124, 302, 
8350, 10606, 7534, 2023, 476, 81, 
7531, 5052 
95 644 14527 3.3243 0.0767 0.0038 0.3360 
GOTERM_CC_FAT GO:0031012 extracellular 
matrix 
12 12.632 6.13E-04 6647, 302, 4637, 6224, 3848, 6222, 
8294, 293, 6165, 5034, 5052, 6156 
95 530 14527 3.4622 0.1783 0.0089 0.8245 
GOTERM_CC_FAT GO:0022625 cytosolic large 
ribosomal subunit 
5 5.263 9.76E-04 6181, 6132, 6154, 6165, 6156 95 68 14527 11.2438 0.2683 0.0135 1.3086 
GOTERM_CC_FAT GO:0030017 Sarcomere 7 7.368 0.001375839 5687, 832, 808, 7171, 2023, 81, 7170 95 188 14527 5.6937 0.3563 0.0182 1.8407 
GOTERM_CC_FAT GO:0016023 cytoplasmic, 
membrane-
bounded vesicle 
18 18.947 0.001405836 10130, 832, 6647, 9601, 302, 2923, 
10961, 4673, 476, 5034, 5052, 29082, 
7534, 7532, 81, 7531, 5878, 3105 
95 1183 14527 2.3267 0.3625 0.0178 1.8805 
GOTERM_CC_FAT GO:0044391 ribosomal subunit 7 7.368 0.00141365 6181, 6132, 6224, 6222, 6154, 6165, 
6156 
95 189 14527 5.6635 0.3641 0.0173 1.8909 
GOTERM_CC_FAT GO:0030529 intracellular 
ribonucleoprotein 
complex 
14 14.737 0.001601561 6181, 6132, 6154, 6165, 5685, 8665, 
6156, 51691, 5687, 3189, 3182, 6224, 
6222, 81 
95 786 14527 2.7237 0.4012 0.0188 2.1397 
GOTERM_CC_FAT GO:1990904 ribonucleoprotein 
complex 
14 14.737 0.001619842 6181, 6132, 6154, 6165, 5685, 8665, 
6156, 51691, 5687, 3189, 3182, 6224, 
6222, 81 
95 787 14527 2.7202 0.4047 0.0184 2.1639 
GOTERM_CC_FAT GO:0044429 mitochondrial part 16 16.842 0.001652483 654364, 6647, 1329, 293, 3336, 
94081, 4710, 11315, 10935, 1347, 
5859, 26520, 1632, 6742, 1345, 6576 
95 990 14527 2.4714 0.4109 0.0181 2.2071 
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GOTERM_CC_FAT GO:0044449 contractile fiber 
part 
7 7.368 0.002133423 5687, 832, 808, 7171, 2023, 81, 7170 95 205 14527 5.2215 0.4951 0.0225 2.8409 
GOTERM_CC_FAT GO:0030016 Myofibril 7 7.368 0.00252352 5687, 832, 808, 7171, 2023, 81, 7170 95 212 14527 5.0491 0.5545 0.0257 3.3522 
GOTERM_CC_FAT GO:0019866 organelle inner 
membrane 
11 11.579 0.003181315 11315, 7112, 1329, 293, 1347, 1632, 
26520, 1345, 94081, 6576, 4710 
95 557 14527 3.0199 0.6393 0.0314 4.2087 
GOTERM_CC_FAT GO:0043292 contractile fiber 7 7.368 0.003314209 5687, 832, 808, 7171, 2023, 81, 7170 95 224 14527 4.7786 0.6543 0.0317 4.3809 
GOTERM_CC_FAT GO:0005743 mitochondrial 
inner membrane 
10 10.526 0.004962268 11315, 1329, 293, 1347, 1632, 26520, 
1345, 94081, 6576, 4710 
95 499 14527 3.0644 0.7965 0.0457 6.4926 
GOTERM_CC_FAT GO:0005840 Ribosome 7 7.368 0.005975961 6181, 6132, 6224, 6222, 6154, 6165, 
6156 
95 253 14527 4.2309 0.8531 0.0533 7.7700 
GOTERM_CC_FAT GO:0015934 large ribosomal 
subunit 
5 5.263 0.007196283 6181, 6132, 6154, 6165, 6156 95 118 14527 6.4795 0.9009 0.0622 9.2862 
GOTERM_CC_FAT GO:0005740 mitochondrial 
envelope 
12 12.632 0.007547774 11315, 654364, 6647, 1329, 293, 
1347, 1632, 26520, 1345, 94081, 
6576, 4710 
95 732 14527 2.5068 0.9115 0.0634 9.7187 
GOTERM_CC_FAT GO:0044455 mitochondrial 
membrane part 
6 6.316 0.01000643 11315, 1329, 293, 1347, 26520, 4710 95 202 14527 4.5421 0.9600 0.0812 12.6906 
GOTERM_CC_FAT GO:0098800 inner 
mitochondrial 
membrane protein 
complex 
5 5.263 0.010859403 11315, 1329, 293, 26520, 4710 95 133 14527 5.7487 0.9696 0.0857 13.7002 
GOTERM_CC_FAT GO:0031966 mitochondrial 
membrane 
11 11.579 0.013748384 11315, 654364, 1329, 293, 1347, 
1632, 26520, 1345, 94081, 6576, 
4710 
95 691 14527 2.4343 0.9881 0.1048 17.0402 
GOTERM_CC_FAT GO:0005615 extracellular space 17 17.895 0.022374487 6647, 1476, 302, 8339, 3848, 931, 
4190, 5052, 5660, 3383, 4478, 7167, 
7534, 10135, 396, 2023, 81 
95 1444 14527 1.8003 0.9993 0.1619 26.3143 
GOTERM_CC_FAT GO:0098798 mitochondrial 
protein complex 
5 5.263 0.023557666 11315, 1329, 293, 26520, 4710 95 168 14527 4.5511 0.9995 0.1661 27.5086 
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GOTERM_CC_FAT GO:0031967 organelle 
envelope 
14 14.737 0.033439041 7112, 654364, 6647, 1329, 293, 
94081, 4710, 11315, 10016, 26520, 
1632, 1347, 1345, 6576 
95 1149 14527 1.8632 1.0000 0.2236 36.8059 
GOTERM_CC_FAT GO:0031975 Envelope 14 14.737 0.03446355 7112, 654364, 6647, 1329, 293, 
94081, 4710, 11315, 10016, 26520, 
1632, 1347, 1345, 6576 
95 1154 14527 1.8551 1.0000 0.2251 37.7038 
GOTERM_CC_FAT GO:0005788 endoplasmic 
reticulum lumen 
5 5.263 0.042063147 10130, 9601, 2923, 10961, 5034 95 202 14527 3.7850 1.0000 0.2633 44.0048 
GOTERM_CC_FAT GO:0099568 cytoplasmic 
region 
6 6.316 0.044590952 4082, 832, 6647, 302, 7171, 81 95 299 14527 3.0685 1.0000 0.2719 45.9662 
GOTERM_CC_FAT GO:0005759 mitochondrial 
matrix 
7 7.368 0.057437985 11315, 6647, 10935, 1632, 5859, 
6742, 3336 
95 425 14527 2.5186 1.0000 0.3315 54.9882 
GOTERM_CC_FAT GO:0005938 cell cortex 5 5.263 0.076285371 4082, 832, 302, 7171, 81 95 247 14527 3.0955 1.0000 0.4108 65.7271 
GOTERM_CC_FAT GO:0000785 Chromatin 7 7.368 0.085446603 11315, 7112, 3012, 8339, 8350, 8294, 
4678 
95 472 14527 2.2678 1.0000 0.4420 70.0403 
GOTERM_MF_FAT GO:0003723 RNA binding 39 41.053 2.74E-14 1936, 6181, 1933, 1476, 9601, 6165, 
3336, 51691, 2224, 7334, 81, 3105, 
302, 10963, 2923, 6132, 4673, 6154, 
5034, 5052, 8665, 6156, 5687, 11315, 
4478, 2079, 3189, 3182, 6224, 6222, 
2665, 7534, 8294, 7532, 2023, 7531, 
5859, 6742, 1207 
93 1656 15478 3.9195 0.0000 0.0000 0.0000 
GOTERM_MF_FAT GO:0044822 poly(A) RNA 
binding 
32 33.684 6.87E-13 1476, 9601, 6165, 3336, 51691, 2224, 
7334, 81, 3105, 302, 2923, 6132, 
10963, 4673, 6154, 5034, 5052, 6156, 
11315, 2079, 3189, 3182, 6224, 6222, 
2665, 7534, 8294, 7532, 2023, 7531, 
6742, 1207 
93 1196 15478 4.4530 0.0000 0.0000 0.0000 
GOTERM_MF_FAT GO:0050839 cell adhesion 
molecule binding 
17 17.895 1.17E-08 7112, 1936, 832, 302, 3385, 5034, 
5052, 3383, 11315, 4478, 9124, 8350, 
10606, 7534, 2023, 7531, 81 
93 461 15478 6.1373 0.0000 0.0000 0.0000 
275 
 
GOTERM_MF_FAT GO:0016860 intramolecular 
oxidoreductase 
activity 
7 7.368 7.68E-07 10130, 9601, 2923, 7167, 10961, 
1632, 5034 
93 54 15478 21.5743 0.0003 0.0001 0.0011 
GOTERM_MF_FAT GO:0098641 cadherin binding 
involved in cell-
cell adhesion 
12 12.632 1.16E-06 11315, 1936, 7112, 832, 9124, 302, 
8350, 10606, 7534, 2023, 7531, 5052 
93 290 15478 6.8868 0.0005 0.0001 0.0016 
GOTERM_MF_FAT GO:0098632 protein binding 
involved in cell-
cell adhesion 
12 12.632 1.66E-06 11315, 1936, 7112, 832, 9124, 302, 
8350, 10606, 7534, 2023, 7531, 5052 
93 301 15478 6.6351 0.0007 0.0001 0.0024 
GOTERM_MF_FAT GO:0098631 protein binding 
involved in cell 
adhesion 
12 12.632 1.95E-06 11315, 1936, 7112, 832, 9124, 302, 
8350, 10606, 7534, 2023, 7531, 5052 
93 306 15478 6.5267 0.0009 0.0001 0.0028 
GOTERM_MF_FAT GO:0045296 cadherin binding 12 12.632 2.01E-06 11315, 1936, 7112, 832, 9124, 302, 
8350, 10606, 7534, 2023, 7531, 5052 
93 307 15478 6.5054 0.0009 0.0001 0.0028 
GOTERM_MF_FAT GO:0016864 intramolecular 
oxidoreductase 
activity, 
transposing S-S 
bonds 
5 5.263 7.88E-06 10130, 9601, 2923, 10961, 5034 93 22 15478 37.8250 0.0034 0.0004 0.0111 
GOTERM_MF_FAT GO:0003756 protein disulfide 
isomerase activity 
5 5.263 7.88E-06 10130, 9601, 2923, 10961, 5034 93 22 15478 37.8250 0.0034 0.0004 0.0111 
GOTERM_MF_FAT GO:0003676 nucleic acid 
binding 
44 46.316 2.26E-05 1936, 6181, 1933, 9601, 1476, 8339, 
6165, 3336, 51691, 2224, 3012, 7334, 
81, 3105, 7112, 654364, 302, 10963, 
6132, 2923, 4673, 6154, 5034, 5052, 
8665, 6156, 5687, 11315, 4478, 2079, 
3189, 3182, 8350, 6224, 6222, 2665, 
7534, 8294, 7532, 2023, 7531, 5859, 
6742, 1207 
93 4097 15478 1.7874 0.0099 0.0010 0.0320 
GOTERM_MF_FAT GO:0003735 structural 
constituent of 
ribosome 
9 9.474 5.22E-05 6181, 6132, 6224, 6222, 6154, 293, 
6165, 6576, 6156 
93 222 15478 6.7472 0.0226 0.0021 0.0738 
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GOTERM_MF_FAT GO:1901363 heterocyclic 
compound binding 
55 57.895 7.05E-05 1936, 1933, 9601, 1476, 6165, 3336, 
3012, 51727, 81, 3105, 3251, 654364, 
10963, 302, 4190, 6154, 476, 5034, 
6156, 5687, 3189, 3182, 8350, 6224, 
6222, 2665, 8294, 2023, 5878, 6742, 
6181, 8339, 51691, 2224, 7334, 3945, 
7112, 6132, 2923, 5243, 4673, 953, 
5052, 8665, 11315, 4478, 2079, 
83473, 10606, 7534, 4144, 7532, 
5859, 7531, 1207 
93 5971 15478 1.5330 0.0304 0.0026 0.0996 
GOTERM_MF_FAT GO:0097159 organic cyclic 
compound binding 
55 57.895 1.07E-04 1936, 1933, 9601, 1476, 6165, 3336, 
3012, 51727, 81, 3105, 3251, 654364, 
10963, 302, 4190, 6154, 476, 5034, 
6156, 5687, 3189, 3182, 8350, 6224, 
6222, 2665, 8294, 2023, 5878, 6742, 
6181, 8339, 51691, 2224, 7334, 3945, 
7112, 6132, 2923, 5243, 4673, 953, 
5052, 8665, 11315, 4478, 2079, 
83473, 10606, 7534, 4144, 7532, 
5859, 7531, 1207 
93 6052 15478 1.5125 0.0459 0.0036 0.1516 
GOTERM_MF_FAT GO:0051087 chaperone binding 6 6.316 1.19E-04 6647, 10963, 10961, 476, 26520, 
3336 
93 81 15478 12.3282 0.0509 0.0037 0.1685 
GOTERM_MF_FAT GO:0016853 isomerase activity 7 7.368 4.48E-04 10130, 9601, 2923, 7167, 10961, 
1632, 5034 
93 165 15478 7.0607 0.1784 0.0130 0.6319 
GOTERM_MF_FAT GO:0005198 structural 
molecule activity 
14 14.737 7.01E-04 6181, 6132, 3848, 6154, 293, 6165, 
6156, 4478, 6224, 4637, 6222, 7171, 
6576, 7170 
93 782 15478 2.9796 0.2646 0.0190 0.9866 
GOTERM_MF_FAT GO:0046983 protein 
dimerization 
activity 
17 17.895 0.001242935 3251, 6647, 8339, 10961, 5034, 
29082, 11315, 10016, 3012, 8350, 
8294, 10135, 7086, 7531, 26520, 81, 
1207 
93 1160 15478 2.4391 0.4200 0.0315 1.7423 
GOTERM_MF_FAT GO:0016209 antioxidant 
activity 
5 5.263 0.001371502 11315, 6647, 10935, 9352, 5052 93 81 15478 10.2735 0.4518 0.0328 1.9209 
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GOTERM_MF_FAT GO:0032403 protein complex 
binding 
13 13.684 0.001887506 832, 4082, 8350, 931, 7171, 3385, 
4678, 81, 7531, 5034, 7170, 3105, 
3383 
93 766 15478 2.8245 0.5629 0.0426 2.6346 
GOTERM_MF_FAT GO:0042802 identical protein 
binding 
18 18.947 0.002457616 3251, 6647, 10961, 5721, 5052, 
29082, 11315, 5688, 10016, 10606, 
10935, 7534, 10135, 4144, 7086, 81, 
26520, 3945 
93 1358 15478 2.2060 0.6596 0.0525 3.4177 
GOTERM_MF_FAT GO:0019899 enzyme binding 21 22.105 0.003727522 6647, 1476, 302, 51596, 476, 5034, 
29082, 11315, 4478, 4082, 7167, 
7334, 10935, 2665, 6222, 7534, 808, 
2023, 7532, 7531, 3945 
93 1789 15478 1.9536 0.8052 0.0749 5.1408 
GOTERM_MF_FAT GO:0051015 actin filament 
binding 
5 5.263 0.007921699 4082, 832, 7171, 81, 7170 93 132 15478 6.3042 0.9693 0.1464 10.6310 
GOTERM_MF_FAT GO:0019900 kinase binding 10 10.526 0.008810583 11315, 4478, 4082, 10935, 6222, 
7534, 808, 476, 7532, 3945 
93 595 15478 2.7971 0.9793 0.1551 11.7560 
GOTERM_MF_FAT GO:0008092 cytoskeletal 
protein binding 
11 11.579 0.02842315 56896, 4478, 4082, 832, 302, 83473, 
808, 7171, 476, 81, 7170 
93 846 15478 2.1640 1.0000 0.4092 33.4688 
GOTERM_MF_FAT GO:0042803 protein 
homodimerization 
activity 
10 10.526 0.029314969 11315, 29082, 3251, 10016, 6647, 
10961, 10135, 7086, 26520, 81 
93 730 15478 2.2799 1.0000 0.4062 34.3267 
GOTERM_MF_FAT GO:0019901 protein kinase 
binding 
8 8.421 0.038649177 4478, 4082, 10935, 6222, 7534, 808, 
476, 7532 
93 531 15478 2.5074 1.0000 0.4852 42.7093 
GOTERM_MF_FAT GO:0044877 macromolecular 
complex binding 
14 14.737 0.044779149 832, 4082, 8350, 931, 7171, 3385, 
4678, 81, 7531, 5034, 6742, 3105, 
7170, 3383 
93 1306 15478 1.7841 1.0000 0.5244 47.6612 
GOTERM_MF_FAT GO:0046982 protein 
heterodimerization 
activity 
7 7.368 0.058561408 3012, 8339, 8350, 8294, 7531, 5034, 
1207 
93 465 15478 2.5054 1.0000 0.6109 57.3790 
GOTERM_MF_FAT GO:0003779 actin binding 6 6.316 0.087674464 4478, 4082, 832, 7171, 81, 7170 93 397 15478 2.5153 1.0000 0.7499 72.6580 
KEGG_PATHWAY hsa04260:Cardiac muscle 
contraction 
6 6.316 0.001045987 1329, 7171, 476, 1347, 1345, 7170 73 75 6910 7.5726 0.1272 0.1272 1.2113 
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KEGG_PATHWAY hsa03050:Proteasome 5 5.263 0.001073877 5687, 5688, 5721, 5685, 5684 73 44 6910 10.7565 0.1304 0.0675 1.2435 
KEGG_PATHWAY hsa03010:Ribosome 7 7.368 0.002804538 6181, 6132, 6224, 6222, 6154, 6165, 
6156 
73 136 6910 4.8721 0.3059 0.1146 3.2177 
KEGG_PATHWAY hsa01130:Biosynthesis of 
antibiotics 
8 8.421 0.006297631 2224, 654364, 7167, 10606, 4190, 
7086, 2023, 3945 
73 212 6910 3.5720 0.5601 0.1856 7.0930 
KEGG_PATHWAY hsa05012:Parkinson's disease 6 6.316 0.015884239 11315, 1329, 293, 1347, 1345, 4710 73 142 6910 3.9996 0.8753 0.3405 17.0112 
KEGG_PATHWAY hsa05203:Viral carcinogenesis 7 7.368 0.019509958 8339, 7534, 8294, 7532, 7531, 81, 
3105 
73 205 6910 3.2322 0.9228 0.3475 20.5028 
KEGG_PATHWAY hsa05169:Epstein-Barr virus 
infection 
6 6.316 0.047436263 7534, 953, 7532, 7531, 3105, 3383 73 190 6910 2.9892 0.9982 0.5945 43.2180 
KEGG_PATHWAY hsa05016:Huntington's disease 6 6.316 0.049232298 6647, 1329, 293, 1347, 1345, 4710 73 192 6910 2.9580 0.9986 0.5597 44.4523 
KEGG_PATHWAY hsa05322:Systemic lupus 
erythematosus 
5 5.263 0.050598681 3012, 8339, 8350, 8294, 81 73 134 6910 3.5320 0.9988 0.5276 45.3749 
KEGG_PATHWAY hsa05010:Alzheimer's disease 5 5.263 0.097452179 1329, 808, 1347, 1345, 4710 73 168 6910 2.8172 1.0000 0.7363 69.7010 
KEGG_PATHWAY hsa04141:Protein processing in 
endoplasmic reticulum 
5 5.263 0.099063949 10130, 9601, 2923, 10961, 5034 73 169 6910 2.8005 1.0000 0.7085 70.3251 
 
Appendix 3: Up-regulated proteins in REC1 CYR61/CCN1 KD model. 
 
Category Term GO TERM Coun
t 
% PValue Genes List 
Tota
l 
Pop 
Hits 
Pop 
Total 
Fold 
Enrichment 
Bonferroni Benjamini FDR 
GOTERM_BP_FAT GO:001607
1 
mRNA metabolic 
process 
23 29.11
4 
1.43E-13 23020, 4670, 26528, 6637, 6635, 
6124, 6133, 3303, 6161, 10236, 
1660, 6421, 9045, 6228, 27339, 
11338, 22913, 9775, 10949, 
1655, 3191, 6050, 6191 
77 672 1665
0 
7.4009 0.0000 0.0000 0.0000 
279 
 
GOTERM_BP_FAT GO:000639
6 
RNA processing 25 31.64
6 
9.30E-13 6637, 6635, 6124, 6161, 10521, 
3028, 6421, 9045, 27339, 9775, 
10949, 3191, 23020, 26528, 
4670, 6133, 3303, 10236, 1660, 
6228, 11338, 22913, 1655, 9188, 
6191 
77 910 1665
0 
5.9405 0.0000 0.0000 0.0000 
GOTERM_BP_FAT GO:000039
8 
mRNA splicing, via 
spliceosome 
15 18.98
7 
6.78E-11 23020, 4670, 6637, 26528, 6635, 
10236, 1660, 6421, 11338, 
27339, 22913, 9775, 10949, 
1655, 3191 
77 299 1665
0 
10.8478 0.0000 0.0000 0.0000 
GOTERM_BP_FAT GO:000037
7 
RNA splicing, via 
transesterification 
reactions with 
bulged adenosine as 
nucleophile 
15 18.98
7 
6.78E-11 23020, 4670, 6637, 26528, 6635, 
10236, 1660, 6421, 11338, 
27339, 22913, 9775, 10949, 
1655, 3191 
77 299 1665
0 
10.8478 0.0000 0.0000 0.0000 
GOTERM_BP_FAT GO:000037
5 
RNA splicing, via 
transesterification 
reactions 
15 18.98
7 
8.08E-11 23020, 4670, 6637, 26528, 6635, 
10236, 1660, 6421, 11338, 
27339, 22913, 9775, 10949, 
1655, 3191 
77 303 1665
0 
10.7046 0.0000 0.0000 0.0000 
GOTERM_BP_FAT GO:000838
0 
RNA splicing 16 20.25
3 
2.95E-10 23020, 4670, 6637, 26528, 6635, 
3303, 10236, 1660, 6421, 11338, 
27339, 22913, 9775, 10949, 
1655, 3191 
77 400 1665
0 
8.6494 0.0000 0.0000 0.0000 
GOTERM_BP_FAT GO:000639
7 
mRNA processing 16 20.25
3 
2.78E-09 23020, 4670, 6637, 26528, 6635, 
3303, 10236, 1660, 6421, 11338, 
27339, 22913, 9775, 10949, 
1655, 3191 
77 471 1665
0 
7.3455 0.0000 0.0000 0.0000 
GOTERM_BP_FAT GO:004408
5 
cellular component 
biogenesis 
33 41.77
2 
4.39E-07 55920, 6637, 6635, 6124, 9380, 
10856, 6161, 3842, 9361, 38, 
9045, 27339, 9775, 6472, 4905, 
23020, 6133, 3303, 1731, 55937, 
5701, 5341, 3615, 4282, 6228, 
81876, 10938, 1213, 70, 6191, 
9188, 83706, 2058 
77 2914 1665
0 
2.4488 0.0009 0.0001 0.0008 
280 
 
GOTERM_BP_FAT GO:190156
6 
organonitrogen 
compound 
biosynthetic process 
22 27.84
8 
5.39E-07 8565, 6124, 6133, 10236, 2618, 
7284, 6161, 51520, 51649, 3615, 
38, 790, 9045, 6228, 10128, 
9775, 1213, 539, 4677, 6472, 
6191, 2058 
77 1375 1665
0 
3.4597 0.0011 0.0001 0.0009 
GOTERM_BP_FAT GO:004360
4 
amide biosynthetic 
process 
16 20.25
3 
9.57E-07 8565, 6124, 6133, 10236, 6161, 
7284, 51649, 51520, 790, 9045, 
6228, 10128, 9775, 4677, 6191, 
2058 
77 736 1665
0 
4.7007 0.0020 0.0002 0.0017 
GOTERM_BP_FAT GO:000641
2 
translation 15 18.98
7 
1.03E-06 8565, 6124, 6133, 6161, 7284, 
10236, 51649, 51520, 9045, 
6228, 10128, 9775, 4677, 6191, 
2058 
77 641 1665
0 
5.0601 0.0022 0.0002 0.0018 
GOTERM_BP_FAT GO:004304
3 
peptide biosynthetic 
process 
15 18.98
7 
1.65E-06 8565, 6124, 6133, 6161, 7284, 
10236, 51649, 51520, 9045, 
6228, 10128, 9775, 4677, 6191, 
2058 
77 667 1665
0 
4.8628 0.0035 0.0003 0.0029 
GOTERM_BP_FAT GO:002261
3 
ribonucleoprotein 
complex biogenesis 
13 16.45
6 
1.67E-06 23020, 6637, 6635, 6133, 6124, 
6161, 10856, 9045, 6228, 27339, 
9775, 9188, 6191 
77 480 1665
0 
5.8563 0.0035 0.0003 0.0029 
GOTERM_BP_FAT GO:000640
1 
RNA catabolic 
process 
10 12.65
8 
1.93E-06 9045, 6228, 10128, 9775, 6124, 
6133, 10236, 6161, 6050, 6191 
77 249 1665
0 
8.6841 0.0041 0.0003 0.0033 
GOTERM_BP_FAT GO:190331
1 
regulation of mRNA 
metabolic process 
8 10.12
7 
2.45E-06 27339, 11338, 26528, 9775, 
3303, 10236, 1655, 3191 
77 133 1665
0 
13.0065 0.0051 0.0004 0.0042 
GOTERM_BP_FAT GO:004690
7 
intracellular 
transport 
22 27.84
8 
5.82E-06 6637, 1434, 6635, 6124, 7846, 
6133, 10960, 6161, 1314, 3842, 
9045, 6228, 11338, 10128, 
81876, 9775, 10938, 1213, 539, 
6191, 4905, 10452 
77 1594 1665
0 
2.9844 0.0122 0.0008 0.0101 
GOTERM_BP_FAT GO:000640
2 
mRNA catabolic 
process 
9 11.39
2 
7.37E-06 9045, 6228, 9775, 6124, 6133, 
10236, 6161, 6050, 6191 
77 221 1665
0 
8.8059 0.0154 0.0010 0.0128 
GOTERM_BP_FAT GO:003312
0 
positive regulation 
of RNA splicing 
5 6.329 7.55E-06 27339, 11338, 26528, 9775, 3303 77 28 1665
0 
38.6132 0.0158 0.0009 0.0131 
281 
 
GOTERM_BP_FAT GO:005068
4 
regulation of mRNA 
processing 
7 8.861 7.88E-06 27339, 11338, 26528, 9775, 
3303, 1655, 3191 
77 104 1665
0 
14.5542 0.0165 0.0009 0.0136 
GOTERM_BP_FAT GO:004360
3 
cellular amide 
metabolic process 
17 21.51
9 
8.41E-06 8565, 6124, 6133, 10236, 6161, 
7284, 51649, 51520, 790, 9045, 
6228, 10128, 9775, 4677, 6472, 
6191, 2058 
77 994 1665
0 
3.6982 0.0176 0.0009 0.0146 
GOTERM_BP_FAT GO:003466
0 
ncRNA metabolic 
process 
13 16.45
6 
9.69E-06 8565, 6133, 6124, 6161, 51520, 
3028, 9045, 6228, 9775, 4677, 
9188, 6191, 2058 
77 570 1665
0 
4.9316 0.0202 0.0010 0.0168 
GOTERM_BP_FAT GO:004348
4 
regulation of RNA 
splicing 
7 8.861 1.03E-05 27339, 11338, 26528, 9775, 
3303, 1655, 3191 
77 109 1665
0 
13.8866 0.0215 0.0010 0.0179 
GOTERM_BP_FAT GO:005164
1 
cellular localization 28 35.44
3 
1.06E-05 55920, 6637, 1434, 6635, 6124, 
7846, 6133, 10856, 10960, 6161, 
1731, 1314, 1660, 3842, 9045, 
6228, 27339, 11338, 10128, 
81876, 9775, 10938, 4627, 1213, 
539, 6191, 4905, 10452 
77 2541 1665
0 
2.3827 0.0220 0.0010 0.0183 
GOTERM_BP_FAT GO:004802
4 
regulation of mRNA 
splicing, via 
spliceosome 
6 7.595 1.67E-05 27339, 11338, 26528, 9775, 
1655, 3191 
77 70 1665
0 
18.5343 0.0345 0.0015 0.0288 
GOTERM_BP_FAT GO:000651
8 
peptide metabolic 
process 
15 18.98
7 
1.71E-05 8565, 6124, 6133, 6161, 7284, 
10236, 51649, 51520, 9045, 
6228, 10128, 9775, 4677, 6191, 
2058 
77 818 1665
0 
3.9652 0.0355 0.0015 0.0296 
GOTERM_BP_FAT GO:005164
9 
establishment of 
localization in cell 
24 30.38
0 
1.82E-05 6637, 1434, 6635, 6124, 7846, 
6133, 10960, 6161, 1731, 1314, 
3842, 9045, 6228, 11338, 10128, 
81876, 9775, 10938, 4627, 1213, 
539, 6191, 4905, 10452 
77 2004 1665
0 
2.5896 0.0377 0.0015 0.0315 
GOTERM_BP_FAT GO:000018
4 
nuclear-transcribed 
mRNA catabolic 
process, nonsense-
mediated decay 
7 8.861 2.06E-05 9045, 6228, 9775, 6124, 6133, 
6161, 6191 
77 123 1665
0 
12.3060 0.0425 0.0017 0.0356 
282 
 
GOTERM_BP_FAT GO:000608
2 
organic acid 
metabolic process 
15 18.98
7 
5.34E-05 8565, 9380, 47, 2618, 51520, 
3028, 38, 790, 4282, 9775, 
51144, 4677, 6472, 10728, 2058 
77 907 1665
0 
3.5761 0.1065 0.0042 0.0923 
GOTERM_BP_FAT GO:001060
8 
posttranscriptional 
regulation of gene 
expression 
11 13.92
4 
5.45E-05 10128, 9775, 3303, 10949, 
10236, 51520, 6191, 3842, 1660, 
5701, 2058 
77 472 1665
0 
5.0393 0.1085 0.0041 0.0942 
GOTERM_BP_FAT GO:003465
5 
nucleobase-
containing 
compound catabolic 
process 
10 12.65
8 
5.65E-05 9045, 6228, 10128, 9775, 6124, 
6133, 10236, 6161, 6050, 6191 
77 380 1665
0 
5.6904 0.1123 0.0041 0.0977 
GOTERM_BP_FAT GO:000661
4 
SRP-dependent 
cotranslational 
protein targeting to 
membrane 
6 7.595 7.67E-05 9045, 6228, 6124, 6133, 6161, 
6191 
77 96 1665
0 
13.5146 0.1493 0.0054 0.1326 
GOTERM_BP_FAT GO:190331
3 
positive regulation 
of mRNA metabolic 
process 
5 6.329 8.51E-05 27339, 26528, 9775, 3303, 10236 77 51 1665
0 
21.1994 0.1643 0.0058 0.1472 
GOTERM_BP_FAT GO:004670
0 
heterocycle 
catabolic process 
10 12.65
8 
1.03E-04 9045, 6228, 10128, 9775, 6124, 
6133, 10236, 6161, 6050, 6191 
77 411 1665
0 
5.2612 0.1951 0.0068 0.1779 
GOTERM_BP_FAT GO:000661
3 
cotranslational 
protein targeting to 
membrane 
6 7.595 1.07E-04 9045, 6228, 6124, 6133, 6161, 
6191 
77 103 1665
0 
12.5961 0.2022 0.0068 0.1852 
GOTERM_BP_FAT GO:004504
7 
protein targeting to 
ER 
6 7.595 1.12E-04 9045, 6228, 6124, 6133, 6161, 
6191 
77 104 1665
0 
12.4750 0.2106 0.0069 0.1939 
GOTERM_BP_FAT GO:004427
0 
cellular nitrogen 
compound catabolic 
process 
10 12.65
8 
1.17E-04 9045, 6228, 10128, 9775, 6124, 
6133, 10236, 6161, 6050, 6191 
77 418 1665
0 
5.1731 0.2186 0.0070 0.2022 
GOTERM_BP_FAT GO:001943
9 
aromatic compound 
catabolic process 
10 12.65
8 
1.28E-04 9045, 6228, 10128, 9775, 6124, 
6133, 10236, 6161, 6050, 6191 
77 423 1665
0 
5.1119 0.2365 0.0075 0.2212 
GOTERM_BP_FAT GO:007259
9 
establishment of 
protein localization 
6 7.595 1.34E-04 9045, 6228, 6124, 6133, 6161, 
6191 
77 108 1665
0 
12.0130 0.2462 0.0076 0.2316 
283 
 
to endoplasmic 
reticulum 
GOTERM_BP_FAT GO:006500
3 
macromolecular 
complex assembly 
20 25.31
6 
1.86E-04 23020, 6637, 6635, 9380, 10856, 
55937, 9361, 3842, 5701, 5341, 
3615, 38, 4282, 27339, 81876, 
10938, 6472, 83706, 4905, 2058 
77 1710 1665
0 
2.5290 0.3238 0.0102 0.3206 
GOTERM_BP_FAT GO:190136
1 
organic cyclic 
compound catabolic 
process 
10 12.65
8 
1.87E-04 9045, 6228, 10128, 9775, 6124, 
6133, 10236, 6161, 6050, 6191 
77 445 1665
0 
4.8592 0.3261 0.0101 0.3234 
GOTERM_BP_FAT GO:003303
6 
macromolecule 
localization 
27 34.17
7 
1.91E-04 55920, 1434, 6124, 6133, 10856, 
6161, 10960, 55937, 1314, 1660, 
3842, 5341, 4282, 9045, 6228, 
27339, 11338, 10128, 81876, 
9775, 27159, 10938, 4627, 1213, 
6191, 4905, 10452 
77 2817 1665
0 
2.0725 0.3319 0.0100 0.3304 
GOTERM_BP_FAT GO:004518
4 
establishment of 
protein localization 
22 27.84
8 
2.00E-04 55920, 1434, 6124, 6133, 10856, 
6161, 10960, 1314, 3842, 5341, 
4282, 9045, 6228, 11338, 81876, 
27159, 10938, 4627, 1213, 6191, 
4905, 10452 
77 2021 1665
0 
2.3539 0.3438 0.0102 0.3452 
GOTERM_BP_FAT GO:003336
5 
protein localization 
to organelle 
14 17.72
2 
2.02E-04 55920, 1434, 6124, 6133, 6161, 
10856, 3842, 1660, 9045, 6228, 
11338, 10938, 6191, 10452 
77 902 1665
0 
3.3562 0.3473 0.0101 0.3495 
GOTERM_BP_FAT GO:000636
4 
rRNA processing 8 10.12
7 
2.25E-04 9045, 6228, 9775, 6124, 6133, 
6161, 9188, 6191 
77 269 1665
0 
6.4307 0.3772 0.0110 0.3878 
GOTERM_BP_FAT GO:001607
2 
rRNA metabolic 
process 
8 10.12
7 
2.63E-04 9045, 6228, 9775, 6124, 6133, 
6161, 9188, 6191 
77 276 1665
0 
6.2676 0.4252 0.0125 0.4533 
GOTERM_BP_FAT GO:007097
2 
protein localization 
to endoplasmic 
reticulum 
6 7.595 2.96E-04 9045, 6228, 6124, 6133, 6161, 
6191 
77 128 1665
0 
10.1360 0.4647 0.0138 0.5115 
GOTERM_BP_FAT GO:000905
7 
macromolecule 
catabolic process 
16 20.25
3 
2.97E-04 6124, 6133, 3303, 6161, 10236, 
9361, 5701, 9045, 6228, 10128, 
77 1201 1665
0 
2.8807 0.4655 0.0135 0.5127 
284 
 
27339, 9775, 27159, 6050, 6191, 
4905 
GOTERM_BP_FAT GO:001046
7 
gene expression 40 50.63
3 
3.27E-04 6637, 6635, 6124, 6161, 10856, 
3842, 10521, 3028, 6421, 9045, 
27339, 9775, 10949, 3191, 4677, 
6749, 23020, 4670, 26528, 8565, 
6133, 3303, 10236, 7284, 51520, 
51649, 1660, 5701, 4282, 6228, 
10128, 11338, 22913, 4627, 
1655, 70, 6191, 9188, 5591, 2058 
77 5306 1665
0 
1.6301 0.4976 0.0145 0.5633 
GOTERM_BP_FAT GO:001975
2 
carboxylic acid 
metabolic process 
13 16.45
6 
3.40E-04 4282, 790, 8565, 47, 9380, 2618, 
51144, 4677, 51520, 6472, 
10728, 2058, 38 
77 826 1665
0 
3.4032 0.5120 0.0148 0.5870 
GOTERM_BP_FAT GO:000095
6 
nuclear-transcribed 
mRNA catabolic 
process 
7 8.861 3.55E-04 9045, 6228, 9775, 6124, 6133, 
6161, 6191 
77 206 1665
0 
7.3477 0.5268 0.0152 0.6121 
GOTERM_BP_FAT GO:004343
6 
oxoacid metabolic 
process 
13 16.45
6 
3.59E-04 4282, 790, 8565, 47, 9380, 2618, 
51144, 4677, 51520, 6472, 
10728, 2058, 38 
77 831 1665
0 
3.3827 0.5313 0.0150 0.6199 
GOTERM_BP_FAT GO:000810
4 
protein localization 24 30.38
0 
4.05E-04 55920, 1434, 6124, 6133, 10856, 
6161, 10960, 1314, 1660, 3842, 
5341, 4282, 9045, 6228, 27339, 
11338, 81876, 27159, 10938, 
4627, 1213, 6191, 4905, 10452 
77 2448 1665
0 
2.1199 0.5741 0.0166 0.6980 
GOTERM_BP_FAT GO:002260
7 
cellular component 
assembly 
25 31.64
6 
4.18E-04 55920, 23020, 6637, 6635, 3303, 
9380, 10856, 1731, 55937, 9361, 
3842, 5701, 5341, 3615, 38, 
4282, 27339, 81876, 10938, 
1213, 70, 6472, 83706, 4905, 
2058 
77 2618 1665
0 
2.0649 0.5854 0.0168 0.7200 
GOTERM_BP_FAT GO:004426
5 
cellular 
macromolecule 
catabolic process 
14 17.72
2 
4.34E-04 6124, 6133, 3303, 6161, 10236, 
9361, 5701, 9045, 6228, 10128, 
27339, 9775, 6050, 6191 
77 976 1665
0 
3.1017 0.5995 0.0171 0.7482 
285 
 
GOTERM_BP_FAT GO:001003
3 
response to organic 
substance 
26 32.91
1 
5.11E-04 10856, 6161, 10521, 9361, 38, 
9775, 10949, 6472, 4670, 3303, 
2618, 7284, 55937, 5701, 3615, 
4282, 790, 10938, 1655, 10148, 
70, 6191, 9188, 5591, 10728, 
2058 
77 2822 1665
0 
1.9922 0.6598 0.0198 0.8808 
GOTERM_BP_FAT GO:004348
8 
regulation of mRNA 
stability 
6 7.595 5.26E-04 3303, 10949, 10236, 3842, 1660, 
5701 
77 145 1665
0 
8.9476 0.6699 0.0199 0.9054 
GOTERM_BP_FAT GO:001503
1 
protein transport 20 25.31
6 
5.44E-04 1434, 6124, 6133, 6161, 10960, 
1314, 3842, 5341, 9045, 4282, 
6228, 11338, 81876, 27159, 
10938, 4627, 1213, 6191, 4905, 
10452 
77 1860 1665
0 
2.3251 0.6821 0.0203 0.9360 
GOTERM_BP_FAT GO:003447
0 
ncRNA processing 9 11.39
2 
5.60E-04 9045, 6228, 9775, 6124, 6133, 
6161, 9188, 6191, 3028 
77 411 1665
0 
4.7350 0.6933 0.0205 0.9651 
GOTERM_BP_FAT GO:004348
7 
regulation of RNA 
stability 
6 7.595 6.51E-04 3303, 10949, 10236, 3842, 1660, 
5701 
77 152 1665
0 
8.5355 0.7467 0.0234 1.1205 
GOTERM_BP_FAT GO:000688
6 
intracellular protein 
transport 
14 17.72
2 
6.58E-04 1434, 6124, 6133, 6161, 1314, 
3842, 9045, 6228, 11338, 10938, 
1213, 6191, 4905, 10452 
77 1020 1665
0 
2.9679 0.7505 0.0233 1.1329 
GOTERM_BP_FAT GO:003461
3 
cellular protein 
localization 
18 22.78
5 
7.32E-04 55920, 1434, 6124, 6133, 10856, 
6161, 1314, 3842, 1660, 9045, 
6228, 11338, 27339, 10938, 
1213, 6191, 4905, 10452 
77 1600 1665
0 
2.4326 0.7865 0.0254 1.2593 
GOTERM_BP_FAT GO:007072
7 
cellular 
macromolecule 
localization 
18 22.78
5 
8.03E-04 55920, 1434, 6124, 6133, 10856, 
6161, 1314, 3842, 1660, 9045, 
6228, 11338, 27339, 10938, 
1213, 6191, 4905, 10452 
77 1613 1665
0 
2.4130 0.8159 0.0274 1.3792 
GOTERM_BP_FAT GO:004225
4 
ribosome biogenesis 8 10.12
7 
8.34E-04 9045, 6228, 9775, 6124, 6133, 
6161, 9188, 6191 
77 335 1665
0 
5.1638 0.8279 0.0280 1.4337 
GOTERM_BP_FAT GO:007259
4 
establishment of 
protein localization 
to organelle 
11 13.92
4 
8.63E-04 9045, 6228, 11338, 1434, 6124, 
6133, 10856, 6161, 6191, 3842, 
10452 
77 666 1665
0 
3.5714 0.8381 0.0285 1.4829 
286 
 
GOTERM_BP_FAT GO:000652
0 
cellular amino acid 
metabolic process 
7 8.861 9.81E-04 790, 8565, 2618, 4677, 51520, 
6472, 2058 
77 250 1665
0 
6.0545 0.8737 0.0318 1.6833 
GOTERM_BP_FAT GO:001905
8 
viral life cycle 9 11.39
2 
0.00108458
1 
9045, 6228, 81876, 6124, 6133, 
3303, 1655, 6161, 6191 
77 455 1665
0 
4.2772 0.8985 0.0346 1.8597 
GOTERM_BP_FAT GO:190258
2 
single-organism 
intracellular 
transport 
11 13.92
4 
0.00119251
4 
9045, 6228, 10128, 1434, 6124, 
6133, 6161, 539, 6191, 3842, 
10452 
77 695 1665
0 
3.4224 0.9192 0.0374 2.0430 
GOTERM_BP_FAT GO:001607
0 
RNA metabolic 
process 
35 44.30
4 
0.00123791 6637, 6635, 6124, 10856, 6161, 
10521, 3028, 6421, 9045, 27339, 
9775, 10949, 3191, 4677, 6749, 
23020, 4670, 26528, 8565, 6133, 
3303, 10236, 51520, 1660, 5701, 
6228, 10128, 11338, 22913, 
1655, 6050, 6191, 9188, 5591, 
2058 
77 4648 1665
0 
1.6283 0.9265 0.0382 2.1200 
GOTERM_BP_FAT GO:190258
0 
single-organism 
cellular localization 
14 17.72
2 
0.00134229
5 
1434, 6133, 6124, 6161, 3842, 
9045, 6228, 10128, 4627, 1213, 
539, 6191, 4905, 10452 
77 1102 1665
0 
2.7471 0.9411 0.0408 2.2968 
GOTERM_BP_FAT GO:001908
3 
viral transcription 6 7.595 0.00142273
4 
9045, 6228, 6124, 6133, 6161, 
6191 
77 181 1665
0 
7.1680 0.9503 0.0426 2.4328 
GOTERM_BP_FAT GO:004428
3 
small molecule 
biosynthetic process 
9 11.39
2 
0.00169131
7 
4282, 790, 47, 51144, 6472, 
50814, 10728, 5341, 38 
77 488 1665
0 
3.9879 0.9718 0.0497 2.8858 
GOTERM_BP_FAT GO:000641
3 
translational 
initiation 
6 7.595 0.00172120
3 
9045, 6228, 6124, 6133, 6161, 
6191 
77 189 1665
0 
6.8646 0.9735 0.0499 2.9361 
GOTERM_BP_FAT GO:000661
2 
protein targeting to 
membrane 
6 7.595 0.00176150
8 
9045, 6228, 6124, 6133, 6161, 
6191 
77 190 1665
0 
6.8284 0.9757 0.0503 3.0038 
GOTERM_BP_FAT GO:001908
0 
viral gene 
expression 
6 7.595 0.00184419
1 
9045, 6228, 6124, 6133, 6161, 
6191 
77 192 1665
0 
6.7573 0.9796 0.0519 3.1427 
GOTERM_BP_FAT GO:004393
3 
macromolecular 
complex subunit 
organization 
22 27.84
8 
0.00269781
6 
23020, 6637, 6635, 9380, 10856, 
55937, 51649, 9361, 3842, 5701, 
5341, 6421, 3615, 38, 4282, 
77 2461 1665
0 
1.9330 0.9966 0.0741 4.5657 
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27339, 81876, 10938, 6472, 
83706, 4905, 2058 
GOTERM_BP_FAT GO:004403
3 
multi-organism 
metabolic process 
6 7.595 0.00295197
2 
9045, 6228, 6124, 6133, 6161, 
6191 
77 214 1665
0 
6.0626 0.9980 0.0797 4.9855 
GOTERM_BP_FAT GO:001603
2 
viral process 12 15.19
0 
0.00424898
3 
9045, 6228, 81876, 6124, 6133, 
3303, 1655, 6161, 9188, 6191, 
3842, 5701 
77 966 1665
0 
2.6861 0.9999 0.1114 7.1011 
GOTERM_BP_FAT GO:004476
4 
multi-organism 
cellular process 
12 15.19
0 
0.00448570
1 
9045, 6228, 81876, 6124, 6133, 
3303, 1655, 6161, 9188, 6191, 
3842, 5701 
77 973 1665
0 
2.6668 0.9999 0.1158 7.4824 
GOTERM_BP_FAT GO:000660
5 
protein targeting 10 12.65
8 
0.00452747
2 
9045, 6228, 11338, 1434, 6124, 
6133, 6161, 6191, 3842, 10452 
77 701 1665
0 
3.0846 0.9999 0.1154 7.5496 
GOTERM_BP_FAT GO:004441
9 
interspecies 
interaction between 
organisms 
12 15.19
0 
0.00541877
3 
9045, 6228, 81876, 6124, 6133, 
3303, 1655, 6161, 9188, 6191, 
3842, 5701 
77 998 1665
0 
2.6000 1.0000 0.1350 8.9711 
GOTERM_BP_FAT GO:004440
3 
symbiosis, 
encompassing 
mutualism through 
parasitism 
12 15.19
0 
0.00541877
3 
9045, 6228, 81876, 6124, 6133, 
3303, 1655, 6161, 9188, 6191, 
3842, 5701 
77 998 1665
0 
2.6000 1.0000 0.1350 8.9711 
GOTERM_BP_FAT GO:004424
8 
cellular catabolic 
process 
16 20.25
3 
0.00578324
9 
6124, 6133, 3303, 6161, 10236, 
9361, 3028, 5701, 38, 9045, 
6228, 10128, 27339, 9775, 6050, 
6191 
77 1616 1665
0 
2.1409 1.0000 0.1417 9.5464 
GOTERM_BP_FAT GO:009015
0 
establishment of 
protein localization 
to membrane 
7 8.861 0.00667348
2 
9045, 6228, 6124, 6133, 6161, 
6191, 4905 
77 368 1665
0 
4.1131 1.0000 0.1599 10.937
3 
GOTERM_BP_FAT GO:007265
7 
protein localization 
to membrane 
8 10.12
7 
0.00689237 9045, 6228, 6124, 6133, 1213, 
6161, 6191, 4905 
77 489 1665
0 
3.5376 1.0000 0.1629 11.276
2 
GOTERM_BP_FAT GO:004639
4 
carboxylic acid 
biosynthetic process 
6 7.595 0.00692085
8 
4282, 790, 47, 51144, 6472, 
10728 
77 262 1665
0 
4.9519 1.0000 0.1617 11.320
3 
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GOTERM_BP_FAT GO:005126
0 
protein 
homooligomerizatio
n 
6 7.595 0.00748029
9 
4282, 10938, 6472, 9361, 38, 
3615 
77 267 1665
0 
4.8592 1.0000 0.1717 12.180
5 
GOTERM_BP_FAT GO:001605
3 
organic acid 
biosynthetic process 
6 7.595 0.00882099
4 
4282, 790, 47, 51144, 6472, 
10728 
77 278 1665
0 
4.6669 1.0000 0.1973 14.210
1 
GOTERM_BP_FAT GO:000639
9 
tRNA metabolic 
process 
5 6.329 0.01016929
1 
8565, 4677, 51520, 3028, 2058 77 185 1665
0 
5.8442 1.0000 0.2216 16.206
7 
GOTERM_BP_FAT GO:000916
1 
ribonucleoside 
monophosphate 
metabolic process 
6 7.595 0.01151439
3 
790, 3303, 2618, 539, 29789, 
3615 
77 297 1665
0 
4.3684 1.0000 0.2447 18.154
8 
GOTERM_BP_FAT GO:000164
9 
osteoblast 
differentiation 
5 6.329 0.01215407
9 
23020, 1213, 9188, 1660, 5701 77 195 1665
0 
5.5445 1.0000 0.2539 19.066
2 
GOTERM_BP_FAT GO:190160
5 
alpha-amino acid 
metabolic process 
5 6.329 0.01215407
9 
790, 9775, 2618, 6472, 38 77 195 1665
0 
5.5445 1.0000 0.2539 19.066
2 
GOTERM_BP_FAT GO:000646
1 
protein complex 
assembly 
14 17.72
2 
0.01319040
5 
9380, 3842, 9361, 5701, 5341, 
3615, 38, 4282, 81876, 10938, 
6472, 83706, 4905, 2058 
77 1445 1665
0 
2.0950 1.0000 0.2698 20.522
5 
GOTERM_BP_FAT GO:007027
1 
protein complex 
biogenesis 
14 17.72
2 
0.01326133
5 
9380, 3842, 9361, 5701, 5341, 
3615, 38, 4282, 81876, 10938, 
6472, 83706, 4905, 2058 
77 1446 1665
0 
2.0935 1.0000 0.2685 20.621
3 
GOTERM_BP_FAT GO:000912
3 
nucleoside 
monophosphate 
metabolic process 
6 7.595 0.01382613
5 
790, 3303, 2618, 539, 29789, 
3615 
77 311 1665
0 
4.1717 1.0000 0.2757 21.403
6 
GOTERM_BP_FAT GO:002261
8 
ribonucleoprotein 
complex assembly 
5 6.329 0.01606853
4 
23020, 27339, 6637, 6635, 10856 77 212 1665
0 
5.0999 1.0000 0.3101 24.438
5 
GOTERM_BP_FAT GO:006102
4 
membrane 
organization 
11 13.92
4 
0.01796315
5 
9045, 6228, 81876, 6124, 6133, 
4627, 3303, 1213, 6161, 6191, 
4905 
77 1027 1665
0 
2.3160 1.0000 0.3369 26.916
4 
GOTERM_BP_FAT GO:007182
2 
protein complex 
subunit organization 
15 18.98
7 
0.01825407
1 
9380, 51649, 3842, 9361, 5701, 
5341, 3615, 38, 4282, 81876, 
10938, 6472, 83706, 4905, 2058 
77 1674 1665
0 
1.9376 1.0000 0.3384 27.290
0 
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GOTERM_BP_FAT GO:007182
6 
ribonucleoprotein 
complex subunit 
organization 
5 6.329 0.01897995
9 
23020, 27339, 6637, 6635, 10856 77 223 1665
0 
4.8483 1.0000 0.3464 28.214
4 
GOTERM_BP_FAT GO:000641
7 
regulation of 
translation 
6 7.595 0.02024260
6 
10128, 9775, 10236, 51520, 
6191, 2058 
77 343 1665
0 
3.7825 1.0000 0.3618 29.796
0 
GOTERM_BP_FAT GO:005125
9 
protein 
oligomerization 
7 8.861 0.02090936
3 
4282, 10938, 9380, 6472, 9361, 
38, 3615 
77 473 1665
0 
3.2001 1.0000 0.3682 30.617
9 
GOTERM_BP_FAT GO:000150
3 
ossification 6 7.595 0.02408129
3 
23020, 1213, 1655, 9188, 1660, 
5701 
77 359 1665
0 
3.6139 1.0000 0.4080 34.405
3 
GOTERM_BP_FAT GO:003424
8 
regulation of cellular 
amide metabolic 
process 
6 7.595 0.02808273 10128, 9775, 10236, 51520, 
6191, 2058 
77 374 1665
0 
3.4690 1.0000 0.4548 38.905
5 
GOTERM_BP_FAT GO:000700
5 
mitochondrion 
organization 
8 10.12
7 
0.02927297 10128, 11338, 3303, 7284, 
51649, 9361, 3028, 10452 
77 653 1665
0 
2.6491 1.0000 0.4654 40.187
0 
GOTERM_BP_FAT GO:000926
0 
ribonucleotide 
biosynthetic process 
5 6.329 0.03032928
3 
790, 2618, 539, 38, 3615 77 258 1665
0 
4.1906 1.0000 0.4742 41.302
9 
GOTERM_BP_FAT GO:000911
9 
ribonucleoside 
metabolic process 
6 7.595 0.03127194
3 
790, 3303, 539, 29789, 38, 3615 77 385 1665
0 
3.3699 1.0000 0.4814 42.282
3 
GOTERM_BP_FAT GO:004639
0 
ribose phosphate 
biosynthetic process 
5 6.329 0.03145409
6 
790, 2618, 539, 38, 3615 77 261 1665
0 
4.1424 1.0000 0.4801 42.469
7 
GOTERM_BP_FAT GO:000181
9 
positive regulation 
of cytokine 
production 
6 7.595 0.03157273
4 
4282, 27159, 3303, 10148, 1660, 
5591 
77 386 1665
0 
3.3611 1.0000 0.4781 42.591
5 
GOTERM_BP_FAT GO:000925
9 
ribonucleotide 
metabolic process 
7 8.861 0.03529385
4 
790, 3303, 2618, 539, 29789, 38, 
3615 
77 535 1665
0 
2.8292 1.0000 0.5139 46.290
2 
GOTERM_BP_FAT GO:000919
9 
ribonucleoside 
triphosphate 
metabolic process 
5 6.329 0.03619808
3 
790, 3303, 539, 29789, 3615 77 273 1665
0 
3.9603 1.0000 0.5196 47.154
5 
GOTERM_BP_FAT GO:009860
9 
cell-cell adhesion 11 13.92
4 
0.03829786
1 
9045, 55379, 10938, 4627, 3303, 
10148, 83706, 5591, 10598, 
29789, 5341 
77 1164 1665
0 
2.0434 1.0000 0.5367 49.111
1 
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GOTERM_BP_FAT GO:009719
3 
intrinsic apoptotic 
signaling pathway 
5 6.329 0.03871759
5 
4282, 3303, 1655, 5591, 6421 77 279 1665
0 
3.8752 1.0000 0.5373 49.494
0 
GOTERM_BP_FAT GO:001969
3 
ribose phosphate 
metabolic process 
7 8.861 0.03925364 790, 3303, 2618, 539, 29789, 38, 
3615 
77 549 1665
0 
2.7571 1.0000 0.5390 49.979
0 
GOTERM_BP_FAT GO:000911
6 
nucleoside 
metabolic process 
6 7.595 0.04039119
8 
790, 3303, 539, 29789, 38, 3615 77 413 1665
0 
3.1414 1.0000 0.5462 50.993
7 
GOTERM_BP_FAT GO:000916
7 
purine 
ribonucleoside 
monophosphate 
metabolic process 
5 6.329 0.04133579 3303, 2618, 539, 29789, 3615 77 285 1665
0 
3.7936 1.0000 0.5514 51.821
5 
GOTERM_BP_FAT GO:001062
8 
positive regulation 
of gene expression 
14 17.72
2 
0.04174911
3 
26528, 3303, 10856, 10521, 
5701, 11338, 27339, 9775, 4627, 
1655, 70, 9188, 6191, 5591 
77 1692 1665
0 
1.7892 1.0000 0.5519 52.179
6 
GOTERM_BP_FAT GO:000912
6 
purine nucleoside 
monophosphate 
metabolic process 
5 6.329 0.04178175
9 
3303, 2618, 539, 29789, 3615 77 286 1665
0 
3.7803 1.0000 0.5490 52.207
8 
GOTERM_BP_FAT GO:004480
2 
single-organism 
membrane 
organization 
9 11.39
2 
0.04336906 9045, 6228, 6124, 6133, 3303, 
1213, 6161, 6191, 4905 
77 866 1665
0 
2.2472 1.0000 0.5595 53.559
0 
GOTERM_BP_FAT GO:000914
1 
nucleoside 
triphosphate 
metabolic process 
5 6.329 0.04686853
6 
790, 3303, 539, 29789, 3615 77 297 1665
0 
3.6403 1.0000 0.5852 56.411
8 
GOTERM_BP_FAT GO:190165
7 
glycosyl compound 
metabolic process 
6 7.595 0.04858844
9 
790, 3303, 539, 29789, 38, 3615 77 435 1665
0 
2.9825 1.0000 0.5955 57.752
6 
GOTERM_BP_FAT GO:000989
3 
positive regulation 
of metabolic process 
21 26.58
2 
0.05357765
9 
26528, 47, 3303, 10856, 10236, 
10521, 5701, 5341, 4282, 27339, 
11338, 81876, 9775, 4627, 1655, 
10148, 70, 9188, 6191, 5591, 
4905 
77 3052 1665
0 
1.4878 1.0000 0.6292 61.425
6 
GOTERM_BP_FAT GO:001407
0 
response to organic 
cyclic compound 
9 11.39
2 
0.05396648
3 
790, 9775, 1655, 10856, 6161, 
9188, 10521, 10728, 38 
77 906 1665
0 
2.1480 1.0000 0.6288 61.698
8 
291 
 
GOTERM_BP_FAT GO:001056
4 
regulation of cell 
cycle process 
7 8.861 0.05422084
7 
55920, 4282, 27339, 1213, 5591, 
5701, 6421 
77 595 1665
0 
2.5439 1.0000 0.6275 61.876
6 
GOTERM_BP_FAT GO:004851
1 
rhythmic process 5 6.329 0.05433906
8 
10236, 1655, 1660, 5591, 6421 77 312 1665
0 
3.4653 1.0000 0.6252 61.958
9 
GOTERM_BP_FAT GO:000916
5 
nucleotide 
biosynthetic process 
5 6.329 0.05485892
5 
790, 2618, 539, 38, 3615 77 313 1665
0 
3.4542 1.0000 0.6258 62.319
1 
GOTERM_BP_FAT GO:000673
2 
coenzyme metabolic 
process 
5 6.329 0.05590678
9 
47, 2618, 51144, 6472, 38 77 315 1665
0 
3.4323 1.0000 0.6299 63.035
3 
GOTERM_BP_FAT GO:190129
3 
nucleoside 
phosphate 
biosynthetic process 
5 6.329 0.05643479
2 
790, 2618, 539, 38, 3615 77 316 1665
0 
3.4214 1.0000 0.6305 63.391
3 
GOTERM_BP_FAT GO:000691
3 
nucleocytoplasmic 
transport 
6 7.595 0.06125477
8 
11338, 6637, 1434, 6635, 9775, 
3842 
77 465 1665
0 
2.7901 1.0000 0.6586 66.495
0 
GOTERM_BP_FAT GO:005116
9 
nuclear transport 6 7.595 0.06492339
7 
11338, 6637, 1434, 6635, 9775, 
3842 
77 473 1665
0 
2.7429 1.0000 0.6776 68.689
4 
GOTERM_BP_FAT GO:007131
0 
cellular response to 
organic substance 
16 20.25
3 
0.06744568
7 
4670, 3303, 10856, 6161, 10521, 
5701, 3615, 790, 4282, 9775, 
10938, 1655, 10148, 5591, 
10728, 2058 
77 2186 1665
0 
1.5827 1.0000 0.6891 70.118
7 
GOTERM_BP_FAT GO:003465
4 
nucleobase-
containing 
compound 
biosynthetic process 
27 34.17
7 
0.07378153
4 
6637, 6635, 6124, 10856, 6161, 
10521, 6421, 38, 9045, 9775, 
539, 6749, 6133, 3303, 2618, 
5701, 3615, 790, 6228, 11338, 
10128, 22913, 1655, 9188, 6191, 
5591, 10728 
77 4357 1665
0 
1.3400 1.0000 0.7198 73.442
8 
GOTERM_BP_FAT GO:000697
4 
cellular response to 
DNA damage 
stimulus 
8 10.12
7 
0.07488416
4 
4282, 27339, 1655, 10856, 5965, 
6749, 5591, 6421 
77 807 1665
0 
2.1436 1.0000 0.7225 73.984
4 
GOTERM_BP_FAT GO:000662
9 
lipid metabolic 
process 
11 13.92
4 
0.07972259
8 
4282, 27339, 5049, 47, 51144, 
55937, 50814, 3028, 10728, 
5341, 38 
77 1330 1665
0 
1.7884 1.0000 0.7427 76.240
4 
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GOTERM_BP_FAT GO:004612
8 
purine 
ribonucleoside 
metabolic process 
5 6.329 0.07974553
6 
3303, 539, 29789, 38, 3615 77 356 1665
0 
3.0370 1.0000 0.7401 76.250
7 
GOTERM_BP_FAT GO:005087
8 
regulation of body 
fluid levels 
6 7.595 0.07976441
9 
790, 10938, 4627, 1314, 83706, 
5341 
77 503 1665
0 
2.5793 1.0000 0.7375 76.259
1 
GOTERM_BP_FAT GO:003464
5 
cellular 
macromolecule 
biosynthetic process 
30 37.97
5 
0.08140322
1 
6637, 6635, 6124, 10856, 6161, 
9361, 10521, 6421, 9045, 9775, 
4677, 6749, 8565, 6133, 3303, 
10236, 7284, 51520, 51649, 
5701, 6228, 10128, 11338, 
22913, 1655, 6191, 9188, 5591, 
10728, 2058 
77 5012 1665
0 
1.2943 1.0000 0.7423 76.980
0 
GOTERM_BP_FAT GO:004227
8 
purine nucleoside 
metabolic process 
5 6.329 0.08166259
8 
3303, 539, 29789, 38, 3615 77 359 1665
0 
3.0116 1.0000 0.7408 77.092
2 
GOTERM_BP_FAT GO:007139
6 
cellular response to 
lipid 
6 7.595 0.08293598
7 
4282, 1655, 10856, 6161, 10521, 
10728 
77 509 1665
0 
2.5489 1.0000 0.7438 77.635
5 
GOTERM_BP_FAT GO:000715
5 
cell adhesion 13 16.45
6 
0.08314738
4 
55920, 9045, 55379, 10938, 
4627, 3303, 51144, 10148, 
83706, 10598, 5591, 29789, 5341 
77 1699 1665
0 
1.6545 1.0000 0.7422 77.724
5 
GOTERM_BP_FAT GO:001813
0 
heterocycle 
biosynthetic process 
27 34.17
7 
0.08350226
9 
6637, 6635, 6124, 10856, 6161, 
10521, 6421, 38, 9045, 9775, 
539, 6749, 6133, 3303, 2618, 
5701, 3615, 790, 6228, 11338, 
10128, 22913, 1655, 9188, 6191, 
5591, 10728 
77 4411 1665
0 
1.3236 1.0000 0.7412 77.873
2 
GOTERM_BP_FAT GO:000911
7 
nucleotide metabolic 
process 
7 8.861 0.08384236 790, 3303, 2618, 539, 29789, 38, 
3615 
77 667 1665
0 
2.2693 1.0000 0.7401 78.014
8 
GOTERM_BP_FAT GO:002261
0 
biological adhesion 13 16.45
6 
0.08486445
6 
55920, 9045, 55379, 10938, 
4627, 3303, 51144, 10148, 
83706, 10598, 5591, 29789, 5341 
77 1705 1665
0 
1.6487 1.0000 0.7420 78.435
2 
GOTERM_BP_FAT GO:001943
8 
aromatic compound 
biosynthetic process 
27 34.17
7 
0.08597157
4 
6637, 6635, 6124, 10856, 6161, 
10521, 6421, 38, 9045, 9775, 
539, 6749, 6133, 3303, 2618, 
5701, 3615, 790, 6228, 11338, 
77 4424 1665
0 
1.3197 1.0000 0.7442 78.882
1 
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10128, 22913, 1655, 9188, 6191, 
5591, 10728 
GOTERM_BP_FAT GO:000663
1 
fatty acid metabolic 
process 
5 6.329 0.08622464
3 
4282, 47, 51144, 10728, 38 77 366 1665
0 
2.9540 1.0000 0.7428 78.983
0 
GOTERM_BP_FAT GO:003132
5 
positive regulation 
of cellular metabolic 
process 
19 24.05
1 
0.08633766
7 
26528, 47, 3303, 10856, 10236, 
10521, 5701, 5341, 4282, 11338, 
27339, 81876, 9775, 4627, 1655, 
10148, 6191, 5591, 4905 
77 2839 1665
0 
1.4471 1.0000 0.7407 79.028
0 
GOTERM_BP_FAT GO:007088
7 
cellular response to 
chemical stimulus 
18 22.78
5 
0.08668660
5 
4670, 3303, 10856, 6161, 10521, 
9361, 5701, 6421, 3615, 790, 
4282, 9775, 10938, 1655, 10148, 
5591, 10728, 2058 
77 2648 1665
0 
1.4699 1.0000 0.7397 79.166
1 
GOTERM_BP_FAT GO:000675
3 
nucleoside 
phosphate metabolic 
process 
7 8.861 0.08760232
6 
790, 3303, 2618, 539, 29789, 38, 
3615 
77 675 1665
0 
2.2424 1.0000 0.7411 79.524
5 
GOTERM_BP_FAT GO:000915
0 
purine 
ribonucleotide 
metabolic process 
6 7.595 0.08892406
6 
3303, 2618, 539, 29789, 38, 3615 77 520 1665
0 
2.4950 1.0000 0.7442 80.031
6 
GOTERM_BP_FAT GO:007149
5 
cellular response to 
endogenous stimulus 
10 12.65
8 
0.08978317
2 
790, 4670, 9775, 10938, 3303, 
1655, 6161, 10521, 5591, 10728 
77 1185 1665
0 
1.8248 1.0000 0.7453 80.354
8 
GOTERM_BP_FAT GO:001060
4 
positive regulation 
of macromolecule 
metabolic process 
19 24.05
1 
0.09030921
2 
26528, 3303, 10856, 10236, 
10521, 5701, 4282, 11338, 
27339, 81876, 9775, 4627, 1655, 
10148, 70, 9188, 6191, 5591, 
4905 
77 2856 1665
0 
1.4385 1.0000 0.7450 80.550
3 
GOTERM_BP_FAT GO:000971
9 
response to 
endogenous stimulus 
12 15.19
0 
0.09228426
9 
790, 4670, 9775, 10938, 3303, 
1655, 6161, 10521, 9361, 5591, 
10728, 38 
77 1548 1665
0 
1.6762 1.0000 0.7505 81.268
0 
GOTERM_BP_FAT GO:000972
5 
response to hormone 8 10.12
7 
0.09435022
8 
790, 1655, 6161, 10521, 9361, 
5591, 10728, 38 
77 854 1665
0 
2.0256 1.0000 0.7562 81.992
0 
GOTERM_BP_FAT GO:000628
1 
DNA repair 6 7.595 0.09456058
1 
27339, 10856, 5965, 6749, 5591, 
6421 
77 530 1665
0 
2.4479 1.0000 0.7547 82.064
2 
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GOTERM_BP_FAT GO:004854
5 
response to steroid 
hormone 
5 6.329 0.09641195
8 
790, 1655, 6161, 10521, 10728 77 381 1665
0 
2.8377 1.0000 0.7594 82.688
2 
GOTERM_BP_FAT GO:003399
3 
response to lipid 8 10.12
7 
0.09702415
7 
4282, 790, 10949, 1655, 10856, 
6161, 10521, 10728 
77 860 1665
0 
2.0115 1.0000 0.7594 82.890
0 
GOTERM_BP_FAT GO:005118
6 
cofactor metabolic 
process 
5 6.329 0.09922139
9 
47, 2618, 51144, 6472, 38 77 385 1665
0 
2.8082 1.0000 0.7652 83.596
1 
GOTERM_CC_FA
T 
GO:003052
9 
intracellular 
ribonucleoprotein 
complex 
25 31.64
6 
7.25E-13 6637, 6635, 7846, 6124, 6161, 
9045, 27339, 9775, 10949, 3191, 
23020, 4670, 6133, 10236, 
51649, 1660, 5701, 6228, 10128, 
11338, 22913, 1655, 6191, 
10728, 2058 
77 786 1452
7 
6.0007 0.0000 0.0000 0.0000 
GOTERM_CC_FA
T 
GO:199090
4 
ribonucleoprotein 
complex 
25 31.64
6 
7.45E-13 6637, 6635, 7846, 6124, 6161, 
9045, 27339, 9775, 10949, 3191, 
23020, 4670, 6133, 10236, 
51649, 1660, 5701, 6228, 10128, 
11338, 22913, 1655, 6191, 
10728, 2058 
77 787 1452
7 
5.9931 0.0000 0.0000 0.0000 
GOTERM_CC_FA
T 
GO:007006
2 
extracellular 
exosome 
38 48.10
1 
7.34E-09 1434, 6635, 6124, 7846, 9380, 
10856, 1314, 3842, 38, 9045, 
539, 3191, 4677, 6472, 4905, 
4670, 47, 10960, 2618, 7284, 
55937, 3615, 4282, 790, 81876, 
10938, 5049, 4627, 1213, 1655, 
70, 6050, 6191, 83706, 10598, 
29789, 10728, 10452 
77 2811 1452
7 
2.5504 0.0000 0.0000 0.0000 
GOTERM_CC_FA
T 
GO:190356
1 
extracellular vesicle 38 48.10
1 
8.44E-09 1434, 6635, 6124, 7846, 9380, 
10856, 1314, 3842, 38, 9045, 
539, 3191, 4677, 6472, 4905, 
4670, 47, 10960, 2618, 7284, 
55937, 3615, 4282, 790, 81876, 
10938, 5049, 4627, 1213, 1655, 
70, 6050, 6191, 83706, 10598, 
29789, 10728, 10452 
77 2825 1452
7 
2.5378 0.0000 0.0000 0.0000 
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GOTERM_CC_FA
T 
GO:004323
0 
extracellular 
organelle 
38 48.10
1 
8.53E-09 1434, 6635, 6124, 7846, 9380, 
10856, 1314, 3842, 38, 9045, 
539, 3191, 4677, 6472, 4905, 
4670, 47, 10960, 2618, 7284, 
55937, 3615, 4282, 790, 81876, 
10938, 5049, 4627, 1213, 1655, 
70, 6050, 6191, 83706, 10598, 
29789, 10728, 10452 
77 2826 1452
7 
2.5369 0.0000 0.0000 0.0000 
GOTERM_CC_FA
T 
GO:007101
3 
catalytic step 2 
spliceosome 
9 11.39
2 
2.52E-08 23020, 4670, 27339, 6637, 
22913, 6635, 9775, 10236, 1655 
77 92 1452
7 
18.4561 0.0000 0.0000 0.0000 
GOTERM_CC_FA
T 
GO:004442
1 
extracellular region 
part 
43 54.43
0 
1.23E-07 1434, 6635, 6124, 7846, 9380, 
10856, 1314, 3842, 38, 9045, 
539, 3191, 4677, 6472, 4905, 
4670, 8565, 3303, 47, 10960, 
2618, 7284, 55937, 3615, 4282, 
790, 81876, 27159, 10938, 5049, 
4627, 1213, 1655, 51144, 10148, 
70, 6050, 6191, 83706, 10598, 
29789, 10728, 10452 
77 3878 1452
7 
2.0919 0.0000 0.0000 0.0002 
GOTERM_CC_FA
T 
GO:000568
1 
spliceosomal 
complex 
10 12.65
8 
3.75E-07 23020, 4670, 27339, 11338, 
6637, 22913, 6635, 9775, 10236, 
1655 
77 179 1452
7 
10.5398 0.0001 0.0000 0.0005 
GOTERM_CC_FA
T 
GO:004264
5 
mitochondrial 
nucleoid 
6 7.595 3.56E-06 55379, 10128, 7284, 55210, 
6472, 9361 
77 45 1452
7 
25.1550 0.0013 0.0001 0.0049 
GOTERM_CC_FA
T 
GO:000929
5 
Nucleoid 6 7.595 4.43E-06 55379, 10128, 7284, 55210, 
6472, 9361 
77 47 1452
7 
24.0846 0.0016 0.0002 0.0061 
GOTERM_CC_FA
T 
GO:003198
8 
membrane-bounded 
vesicle 
38 48.10
1 
5.85E-06 1434, 6635, 6124, 7846, 9380, 
10856, 1314, 3842, 38, 9045, 
539, 3191, 4677, 6472, 4905, 
4670, 47, 10960, 2618, 7284, 
55937, 3615, 4282, 790, 81876, 
10938, 5049, 4627, 1213, 1655, 
70, 6050, 6191, 83706, 10598, 
29789, 10728, 10452 
77 3611 1452
7 
1.9854 0.0021 0.0002 0.0080 
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GOTERM_CC_FA
T 
GO:000557
6 
extracellular region 44 55.69
6 
6.93E-06 1434, 6635, 6124, 7846, 9380, 
10856, 1314, 3842, 38, 9045, 
539, 3191, 4677, 6472, 4905, 
4670, 8565, 3303, 47, 10960, 
2618, 7284, 55937, 5341, 3615, 
4282, 790, 81876, 27159, 10938, 
5049, 4627, 1213, 1655, 51144, 
10148, 70, 6050, 6191, 83706, 
10598, 29789, 10728, 10452 
77 4623 1452
7 
1.7956 0.0025 0.0002 0.0095 
GOTERM_CC_FA
T 
GO:000582
9 
Cytosol 36 45.57
0 
1.17E-05 55920, 6637, 1434, 6635, 6124, 
7846, 9380, 6161, 1314, 3842, 
55114, 9045, 9775, 4677, 4905, 
8565, 6133, 3303, 47, 2618, 
51520, 1660, 5701, 5341, 3615, 
790, 6228, 5049, 4627, 1213, 70, 
6191, 10598, 5591, 10728, 2058 
77 3399 1452
7 
1.9982 0.0042 0.0003 0.0160 
GOTERM_CC_FA
T 
GO:000565
4 
nucleoplasm 33 41.77
2 
1.71E-05 6637, 1434, 6635, 10856, 9361, 
10521, 6421, 27339, 9775, 
10949, 3191, 5965, 6749, 23020, 
4670, 26528, 3303, 47, 10236, 
1660, 5701, 4282, 790, 6228, 
11338, 10128, 1655, 6050, 6191, 
9188, 5591, 10728, 10452 
77 2996 1452
7 
2.0781 0.0061 0.0004 0.0234 
GOTERM_CC_FA
T 
GO:002262
6 
cytosolic ribosome 6 7.595 4.94E-04 9045, 6228, 6124, 6133, 6161, 
6191 
77 125 1452
7 
9.0558 0.1633 0.0118 0.6761 
GOTERM_CC_FA
T 
GO:000573
0 
nucleolus 14 17.72
2 
6.02E-04 55920, 4670, 6124, 6133, 10236, 
1660, 10521, 6228, 5049, 1655, 
6749, 9188, 5591, 29789 
77 882 1452
7 
2.9946 0.1954 0.0135 0.8243 
GOTERM_CC_FA
T 
GO:000591
2 
adherens junction 12 15.19
0 
9.20E-04 9045, 55379, 6124, 10938, 6133, 
4627, 3303, 1213, 70, 6191, 
10598, 29789 
77 694 1452
7 
3.2622 0.2826 0.0193 1.2560 
GOTERM_CC_FA
T 
GO:007016
1 
anchoring junction 12 15.19
0 
0.00111962
6 
9045, 55379, 6124, 10938, 6133, 
4627, 3303, 1213, 70, 6191, 
10598, 29789 
77 711 1452
7 
3.1842 0.3326 0.0222 1.5274 
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GOTERM_CC_FA
T 
GO:003577
0 
ribonucleoprotein 
granule 
6 7.595 0.00141771
2 
6637, 7846, 3191, 6191, 1660, 
5701 
77 158 1452
7 
7.1644 0.4008 0.0266 1.9304 
GOTERM_CC_FA
T 
GO:004444
5 
cytosolic part 7 8.861 0.00155827
1 
9045, 6228, 6124, 6133, 6161, 
6191, 5701 
77 239 1452
7 
5.5257 0.4305 0.0278 2.1199 
GOTERM_CC_FA
T 
GO:003101
2 
extracellular matrix 10 12.65
8 
0.00173333
6 
4670, 6133, 4627, 1213, 1655, 
539, 51144, 6191, 5591, 6421 
77 530 1452
7 
3.5597 0.4654 0.0294 2.3554 
GOTERM_CC_FA
T 
GO:000584
0 
ribosome 7 8.861 0.00207759
9 
9045, 6228, 6124, 6133, 6161, 
51649, 6191 
77 253 1452
7 
5.2199 0.5280 0.0336 2.8171 
GOTERM_CC_FA
T 
GO:004320
9 
myelin sheath 6 7.595 0.00216554 4282, 10938, 7846, 1213, 7284, 
4905 
77 174 1452
7 
6.5056 0.5428 0.0335 2.9347 
GOTERM_CC_FA
T 
GO:004439
1 
ribosomal subunit 6 7.595 0.00309651
7 
9045, 6228, 6124, 6133, 6161, 
6191 
77 189 1452
7 
5.9893 0.6736 0.0456 4.1716 
GOTERM_CC_FA
T 
GO:003439
9 
nuclear periphery 5 6.329 0.00392601
5 
790, 4670, 10856, 3842, 6421 77 123 1452
7 
7.6692 0.7583 0.0552 5.2614 
GOTERM_CC_FA
T 
GO:000575
9 
mitochondrial 
matrix 
8 10.12
7 
0.00673224
7 
55379, 10128, 7284, 55210, 
6472, 9361, 3028, 38 
77 425 1452
7 
3.5513 0.9127 0.0895 8.8635 
GOTERM_CC_FA
T 
GO:003646
4 
cytoplasmic 
ribonucleoprotein 
granule 
5 6.329 0.00735114
1 
6637, 7846, 6191, 1660, 5701 77 147 1452
7 
6.4171 0.9303 0.0939 9.6406 
GOTERM_CC_FA
T 
GO:000591
3 
cell-cell adherens 
junction 
7 8.861 0.00778836 9045, 55379, 10938, 4627, 3303, 
10598, 29789 
77 332 1452
7 
3.9778 0.9405 0.0959 10.185
9 
GOTERM_CC_FA
T 
GO:000592
5 
focal adhesion 7 8.861 0.01645229
3 
6124, 6133, 4627, 3303, 1213, 
70, 6191 
77 391 1452
7 
3.3776 0.9975 0.1866 20.382
0 
GOTERM_CC_FA
T 
GO:000592
4 
cell-substrate 
adherens junction 
7 8.861 0.01702046
7 
6124, 6133, 4627, 3303, 1213, 
70, 6191 
77 394 1452
7 
3.3519 0.9980 0.1866 21.011
6 
GOTERM_CC_FA
T 
GO:003005
5 
cell-substrate 
junction 
7 8.861 0.01799741
2 
6124, 6133, 4627, 3303, 1213, 
70, 6191 
77 399 1452
7 
3.3099 0.9986 0.1906 22.083
4 
GOTERM_CC_FA
T 
GO:003005
4 
cell junction 14 17.72
2 
0.02580175
2 
9045, 55379, 6124, 10938, 6133, 
4627, 3303, 1213, 70, 6191, 
83706, 10598, 29789, 55114 
77 1379 1452
7 
1.9154 0.9999 0.2554 30.173
9 
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GOTERM_CC_FA
T 
GO:004442
9 
mitochondrial part 11 13.92
4 
0.03294362
7 
55379, 10128, 7284, 55210, 539, 
51649, 6472, 9361, 3028, 10452, 
38 
77 990 1452
7 
2.0962 1.0000 0.3068 36.888
0 
GOTERM_CC_FA
T 
GO:003196
7 
organelle envelope 12 15.19
0 
0.03601920
7 
55379, 10128, 1434, 7284, 
55210, 539, 51649, 6472, 3842, 
10452, 489, 38 
77 1149 1452
7 
1.9704 1.0000 0.3226 39.590
6 
GOTERM_CC_FA
T 
GO:003197
5 
Envelope 12 15.19
0 
0.03700426
2 
55379, 10128, 1434, 7284, 
55210, 539, 51649, 6472, 3842, 
10452, 489, 38 
77 1154 1452
7 
1.9618 1.0000 0.3222 40.433
3 
GOTERM_CC_FA
T 
GO:000591
1 
cell-cell junction 8 10.12
7 
0.05105085
5 
9045, 55379, 10938, 4627, 3303, 
10598, 29789, 55114 
77 644 1452
7 
2.3436 1.0000 0.4087 51.322
9 
GOTERM_CC_FA
T 
GO:000569
4 
chromosome 10 12.65
8 
0.05510700
3 
55920, 10128, 27339, 1213, 
10856, 5965, 6749, 5591, 10728, 
6421 
77 937 1452
7 
2.0135 1.0000 0.4248 54.105
1 
GOTERM_CC_FA
T 
GO:000573
9 
mitochondrion 15 18.98
7 
0.05610688
8 
3303, 7284, 55210, 51649, 9361, 
3028, 38, 10128, 55379, 81876, 
1213, 539, 4677, 6472, 10452 
77 1700 1452
7 
1.6647 1.0000 0.4222 54.767
9 
GOTERM_CC_FA
T 
GO:001563
0 
microtubule 
cytoskeleton 
11 13.92
4 
0.05992094
1 
55920, 10128, 27339, 7846, 
4627, 3303, 1213, 1731, 6472, 
1660, 29789 
77 1100 1452
7 
1.8866 1.0000 0.4356 57.215
5 
GOTERM_CC_FA
T 
GO:001986
6 
organelle inner 
membrane 
7 8.861 0.07109892
6 
10128, 7284, 55210, 539, 51649, 
6472, 38 
77 557 1452
7 
2.3710 1.0000 0.4860 63.699
7 
GOTERM_CC_FA
T 
GO:000581
9 
Spindle 5 6.329 0.07424049 55920, 27339, 4627, 1213, 1731 77 303 1452
7 
3.1132 1.0000 0.4930 65.350
6 
GOTERM_CC_FA
T 
GO:000563
5 
nuclear envelope 6 7.595 0.07918092
6 
55379, 10128, 1434, 51649, 
3842, 489 
77 438 1452
7 
2.5844 1.0000 0.5079 67.806
7 
GOTERM_MF_FA
T 
GO:000372
3 
RNA binding 37 46.83
5 
7.04E-16 55920, 6637, 6635, 6124, 6161, 
3842, 9361, 10521, 3028, 6421, 
9045, 55379, 9775, 10949, 3191, 
6749, 23020, 4670, 26528, 8565, 
6133, 10236, 7284, 51649, 1660, 
3615, 6228, 10128, 11338, 
77 1656 1547
8 
4.4912 0.0000 0.0000 0.0000 
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22913, 4627, 1213, 1655, 6191, 
9188, 5591, 2058 
GOTERM_MF_FA
T 
GO:004482
2 
poly(A) RNA 
binding 
32 40.50
6 
1.54E-15 55920, 6637, 6124, 6161, 10521, 
3842, 3028, 6421, 9045, 55379, 
9775, 10949, 3191, 6749, 23020, 
4670, 26528, 8565, 10236, 7284, 
51649, 1660, 6228, 11338, 
10128, 22913, 4627, 1213, 1655, 
6191, 9188, 5591 
77 1196 1547
8 
5.3783 0.0000 0.0000 0.0000 
GOTERM_MF_FA
T 
GO:000016
6 
nucleotide binding 40 50.63
3 
3.06E-13 7846, 9380, 55210, 10856, 9361, 
10521, 6421, 489, 9775, 10949, 
3191, 4677, 5965, 4905, 23020, 
4670, 26528, 8565, 3303, 47, 
1731, 10236, 2618, 7284, 51520, 
1660, 5701, 3615, 790, 11338, 
22913, 81876, 10938, 4627, 
1655, 70, 9188, 5591, 29789, 
2058 
77 2389 1547
8 
3.3656 0.0000 0.0000 0.0000 
GOTERM_MF_FA
T 
GO:190126
5 
nucleoside 
phosphate binding 
40 50.63
3 
3.10E-13 7846, 9380, 55210, 10856, 9361, 
10521, 6421, 489, 9775, 10949, 
3191, 4677, 5965, 4905, 23020, 
4670, 26528, 8565, 3303, 47, 
1731, 10236, 2618, 7284, 51520, 
1660, 5701, 3615, 790, 11338, 
22913, 81876, 10938, 4627, 
1655, 70, 9188, 5591, 29789, 
2058 
77 2390 1547
8 
3.3642 0.0000 0.0000 0.0000 
GOTERM_MF_FA
T 
GO:003609
4 
small molecule 
binding 
41 51.89
9 
5.98E-13 7846, 9380, 55210, 10856, 9361, 
10521, 6421, 489, 9775, 10949, 
3191, 4677, 5965, 4905, 23020, 
4670, 26528, 8565, 3303, 47, 
10960, 1731, 10236, 2618, 7284, 
51520, 1660, 5701, 3615, 790, 
11338, 22913, 81876, 10938, 
4627, 1655, 70, 9188, 5591, 
29789, 2058 
77 2571 1547
8 
3.2056 0.0000 0.0000 0.0000 
300 
 
GOTERM_MF_FA
T 
GO:001688
7 
ATPase activity 17 21.51
9 
3.04E-10 23020, 3303, 10856, 9361, 1660, 
10521, 5701, 489, 9775, 4627, 
1655, 539, 5965, 70, 9188, 4905, 
29789 
77 439 1547
8 
7.7841 0.0000 0.0000 0.0000 
GOTERM_MF_FA
T 
GO:004262
3 
ATPase activity, 
coupled 
15 18.98
7 
5.42E-10 23020, 3303, 10856, 9361, 1660, 
10521, 5701, 489, 9775, 4627, 
1655, 539, 5965, 9188, 4905 
77 326 1547
8 
9.2491 0.0000 0.0000 0.0000 
GOTERM_MF_FA
T 
GO:190136
3 
heterocyclic 
compound binding 
56 70.88
6 
2.20E-09 7846, 6124, 9380, 6161, 10856, 
489, 6421, 9045, 55379, 3191, 
23020, 26528, 3303, 7284, 2618, 
10236, 51520, 1660, 5701, 3615, 
11338, 1655, 70, 6191, 5591, 
29789, 2058, 55920, 6637, 6635, 
55210, 3842, 9361, 10521, 3028, 
9775, 10949, 5965, 4677, 6749, 
4905, 4670, 8565, 6133, 47, 
1731, 51649, 790, 6228, 10128, 
22913, 81876, 10938, 4627, 
1213, 9188 
77 5971 1547
8 
1.8852 0.0000 0.0000 0.0000 
GOTERM_MF_FA
T 
GO:003563
9 
purine 
ribonucleoside 
triphosphate binding 
30 37.97
5 
3.68E-09 7846, 55210, 10856, 9361, 
10521, 489, 9775, 5965, 4677, 
4905, 23020, 8565, 3303, 47, 
2618, 7284, 1731, 51520, 1660, 
5701, 790, 81876, 10938, 4627, 
1655, 70, 9188, 5591, 29789, 
2058 
77 1841 1547
8 
3.2756 0.0000 0.0000 0.0000 
GOTERM_MF_FA
T 
GO:009715
9 
organic cyclic 
compound binding 
56 70.88
6 
3.89E-09 7846, 6124, 9380, 6161, 10856, 
489, 6421, 9045, 55379, 3191, 
23020, 26528, 3303, 7284, 2618, 
10236, 51520, 1660, 5701, 3615, 
11338, 1655, 70, 6191, 5591, 
29789, 2058, 55920, 6637, 6635, 
55210, 3842, 9361, 10521, 3028, 
9775, 10949, 5965, 4677, 6749, 
4905, 4670, 8565, 6133, 47, 
1731, 51649, 790, 6228, 10128, 
22913, 81876, 10938, 4627, 
1213, 9188 
77 6052 1547
8 
1.8600 0.0000 0.0000 0.0000 
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GOTERM_MF_FA
T 
GO:003255
0 
purine 
ribonucleoside 
binding 
30 37.97
5 
4.12E-09 7846, 55210, 10856, 9361, 
10521, 489, 9775, 5965, 4677, 
4905, 23020, 8565, 3303, 47, 
2618, 7284, 1731, 51520, 1660, 
5701, 790, 81876, 10938, 4627, 
1655, 70, 9188, 5591, 29789, 
2058 
77 1850 1547
8 
3.2597 0.0000 0.0000 0.0000 
GOTERM_MF_FA
T 
GO:003254
9 
ribonucleoside 
binding 
30 37.97
5 
4.28E-09 7846, 55210, 10856, 9361, 
10521, 489, 9775, 5965, 4677, 
4905, 23020, 8565, 3303, 47, 
2618, 7284, 1731, 51520, 1660, 
5701, 790, 81876, 10938, 4627, 
1655, 70, 9188, 5591, 29789, 
2058 
77 1853 1547
8 
3.2544 0.0000 0.0000 0.0000 
GOTERM_MF_FA
T 
GO:000188
3 
purine nucleoside 
binding 
30 37.97
5 
4.28E-09 7846, 55210, 10856, 9361, 
10521, 489, 9775, 5965, 4677, 
4905, 23020, 8565, 3303, 47, 
2618, 7284, 1731, 51520, 1660, 
5701, 790, 81876, 10938, 4627, 
1655, 70, 9188, 5591, 29789, 
2058 
77 1853 1547
8 
3.2544 0.0000 0.0000 0.0000 
GOTERM_MF_FA
T 
GO:009736
7 
carbohydrate 
derivative binding 
33 41.77
2 
4.42E-09 7846, 55210, 10856, 9361, 
10521, 489, 9775, 5965, 4677, 
4905, 23020, 8565, 3303, 47, 
10960, 2618, 7284, 1731, 51520, 
1660, 5701, 790, 81876, 27159, 
10938, 4627, 1655, 51144, 70, 
9188, 5591, 29789, 2058 
77 2241 1547
8 
2.9600 0.0000 0.0000 0.0000 
GOTERM_MF_FA
T 
GO:000188
2 
nucleoside binding 30 37.97
5 
4.67E-09 7846, 55210, 10856, 9361, 
10521, 489, 9775, 5965, 4677, 
4905, 23020, 8565, 3303, 47, 
2618, 7284, 1731, 51520, 1660, 
5701, 790, 81876, 10938, 4627, 
1655, 70, 9188, 5591, 29789, 
2058 
77 1860 1547
8 
3.2421 0.0000 0.0000 0.0000 
302 
 
GOTERM_MF_FA
T 
GO:003255
5 
purine 
ribonucleotide 
binding 
30 37.97
5 
6.27E-09 7846, 55210, 10856, 9361, 
10521, 489, 9775, 5965, 4677, 
4905, 23020, 8565, 3303, 47, 
2618, 7284, 1731, 51520, 1660, 
5701, 790, 81876, 10938, 4627, 
1655, 70, 9188, 5591, 29789, 
2058 
77 1884 1547
8 
3.2008 0.0000 0.0000 0.0000 
GOTERM_MF_FA
T 
GO:001707
6 
purine nucleotide 
binding 
30 37.97
5 
7.34E-09 7846, 55210, 10856, 9361, 
10521, 489, 9775, 5965, 4677, 
4905, 23020, 8565, 3303, 47, 
2618, 7284, 1731, 51520, 1660, 
5701, 790, 81876, 10938, 4627, 
1655, 70, 9188, 5591, 29789, 
2058 
77 1897 1547
8 
3.1789 0.0000 0.0000 0.0000 
GOTERM_MF_FA
T 
GO:003255
3 
ribonucleotide 
binding 
30 37.97
5 
7.61E-09 7846, 55210, 10856, 9361, 
10521, 489, 9775, 5965, 4677, 
4905, 23020, 8565, 3303, 47, 
2618, 7284, 1731, 51520, 1660, 
5701, 790, 81876, 10938, 4627, 
1655, 70, 9188, 5591, 29789, 
2058 
77 1900 1547
8 
3.1739 0.0000 0.0000 0.0000 
GOTERM_MF_FA
T 
GO:000552
4 
ATP binding 26 32.91
1 
2.09E-08 10856, 55210, 9361, 10521, 489, 
9775, 5965, 4677, 4905, 23020, 
8565, 47, 3303, 2618, 51520, 
1660, 5701, 790, 10938, 4627, 
1655, 70, 9188, 5591, 29789, 
2058 
77 1495 1547
8 
3.4959 0.0000 0.0000 0.0000 
GOTERM_MF_FA
T 
GO:001711
1 
nucleoside-
triphosphatase 
activity 
19 24.05
1 
2.81E-08 23020, 7846, 3303, 10856, 7284, 
10521, 1660, 9361, 5701, 489, 
9775, 4627, 1655, 539, 5965, 70, 
9188, 4905, 29789 
77 779 1547
8 
4.9028 0.0000 0.0000 0.0000 
GOTERM_MF_FA
T 
GO:003255
9 
adenyl 
ribonucleotide 
binding 
26 32.91
1 
3.35E-08 10856, 55210, 9361, 10521, 489, 
9775, 5965, 4677, 4905, 23020, 
8565, 47, 3303, 2618, 51520, 
1660, 5701, 790, 10938, 4627, 
1655, 70, 9188, 5591, 29789, 
2058 
77 1531 1547
8 
3.4137 0.0000 0.0000 0.0000 
303 
 
GOTERM_MF_FA
T 
GO:003055
4 
adenyl nucleotide 
binding 
26 32.91
1 
3.87E-08 10856, 55210, 9361, 10521, 489, 
9775, 5965, 4677, 4905, 23020, 
8565, 47, 3303, 2618, 51520, 
1660, 5701, 790, 10938, 4627, 
1655, 70, 9188, 5591, 29789, 
2058 
77 1542 1547
8 
3.3893 0.0000 0.0000 0.0001 
GOTERM_MF_FA
T 
GO:001646
2 
pyrophosphatase 
activity 
19 24.05
1 
6.62E-08 23020, 7846, 3303, 10856, 7284, 
10521, 1660, 9361, 5701, 489, 
9775, 4627, 1655, 539, 5965, 70, 
9188, 4905, 29789 
77 824 1547
8 
4.6350 0.0000 0.0000 0.0001 
GOTERM_MF_FA
T 
GO:001681
8 
hydrolase activity, 
acting on acid 
anhydrides, in 
phosphorus-
containing 
anhydrides 
19 24.05
1 
6.86E-08 23020, 7846, 3303, 10856, 7284, 
10521, 1660, 9361, 5701, 489, 
9775, 4627, 1655, 539, 5965, 70, 
9188, 4905, 29789 
77 826 1547
8 
4.6238 0.0000 0.0000 0.0001 
GOTERM_MF_FA
T 
GO:001681
7 
hydrolase activity, 
acting on acid 
anhydrides 
19 24.05
1 
7.12E-08 23020, 7846, 3303, 10856, 7284, 
10521, 1660, 9361, 5701, 489, 
9775, 4627, 1655, 539, 5965, 70, 
9188, 4905, 29789 
77 828 1547
8 
4.6126 0.0000 0.0000 0.0001 
GOTERM_MF_FA
T 
GO:000802
6 
ATP-dependent 
helicase activity 
8 10.12
7 
8.04E-07 23020, 9775, 1655, 10856, 5965, 
9188, 10521, 1660 
77 105 1547
8 
15.3153 0.0003 0.0000 0.0011 
GOTERM_MF_FA
T 
GO:007003
5 
purine NTP-
dependent helicase 
activity 
8 10.12
7 
8.04E-07 23020, 9775, 1655, 10856, 5965, 
9188, 10521, 1660 
77 105 1547
8 
15.3153 0.0003 0.0000 0.0011 
GOTERM_MF_FA
T 
GO:000367
6 
nucleic acid binding 40 50.63
3 
3.30E-06 55920, 6637, 6635, 6124, 10856, 
6161, 3842, 9361, 10521, 3028, 
6421, 9045, 55379, 9775, 10949, 
3191, 4677, 5965, 6749, 23020, 
4670, 26528, 8565, 6133, 10236, 
7284, 51649, 1660, 3615, 6228, 
10128, 11338, 22913, 4627, 
1213, 1655, 6191, 9188, 5591, 
2058 
77 4097 1547
8 
1.9625 0.0012 0.0000 0.0045 
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GOTERM_MF_FA
T 
GO:000438
6 
helicase activity 8 10.12
7 
1.28E-05 23020, 9775, 1655, 10856, 5965, 
9188, 10521, 1660 
77 159 1547
8 
10.1139 0.0046 0.0002 0.0175 
GOTERM_MF_FA
T 
GO:000400
4 
ATP-dependent 
RNA helicase 
activity 
6 7.595 1.77E-05 23020, 9775, 1655, 9188, 10521, 
1660 
77 66 1547
8 
18.2739 0.0064 0.0002 0.0243 
GOTERM_MF_FA
T 
GO:000818
6 
RNA-dependent 
ATPase activity 
6 7.595 1.90E-05 23020, 9775, 1655, 9188, 10521, 
1660 
77 67 1547
8 
18.0012 0.0069 0.0002 0.0262 
GOTERM_MF_FA
T 
GO:000372
4 
RNA helicase 
activity 
6 7.595 2.05E-05 23020, 9775, 1655, 9188, 10521, 
1660 
77 68 1547
8 
17.7364 0.0074 0.0002 0.0281 
GOTERM_MF_FA
T 
GO:000373
5 
structural constituent 
of ribosome 
7 8.861 7.71E-04 9045, 6228, 6124, 6133, 6161, 
51649, 6191 
77 222 1547
8 
6.3382 0.2442 0.0090 1.0550 
GOTERM_MF_FA
T 
GO:001989
9 
enzyme binding 19 24.05
1 
0.00216419
3 
55920, 1434, 3303, 3842, 9361, 
5341, 6421, 38, 790, 10128, 
11338, 27159, 10938, 1213, 
10949, 1655, 5591, 4905, 2058 
77 1789 1547
8 
2.1349 0.5445 0.0243 2.9352 
GOTERM_MF_FA
T 
GO:001661
6 
oxidoreductase 
activity, acting on 
the CH-OH group of 
donors, NAD or 
NADP as acceptor 
5 6.329 0.00261737
1 
9380, 51144, 50814, 3028, 3615 77 117 1547
8 
8.5903 0.6138 0.0284 3.5397 
GOTERM_MF_FA
T 
GO:009864
1 
cadherin binding 
involved in cell-cell 
adhesion 
7 8.861 0.00299611
5 
9045, 55379, 10938, 4627, 3303, 
10598, 29789 
77 290 1547
8 
4.8520 0.6635 0.0315 4.0422 
GOTERM_MF_FA
T 
GO:009863
2 
protein binding 
involved in cell-cell 
adhesion 
7 8.861 0.00359779
2 
9045, 55379, 10938, 4627, 3303, 
10598, 29789 
77 301 1547
8 
4.6747 0.7297 0.0367 4.8354 
GOTERM_MF_FA
T 
GO:009863
1 
protein binding 
involved in cell 
adhesion 
7 8.861 0.00389923
6 
9045, 55379, 10938, 4627, 3303, 
10598, 29789 
77 306 1547
8 
4.5983 0.7578 0.0386 5.2305 
GOTERM_MF_FA
T 
GO:001687
4 
ligase activity 8 10.12
7 
0.00389968
2 
790, 27339, 8565, 2618, 4677, 
51520, 2058, 38 
77 409 1547
8 
3.9318 0.7579 0.0376 5.2311 
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GOTERM_MF_FA
T 
GO:004529
6 
cadherin binding 7 8.861 0.00396171
1 
9045, 55379, 10938, 4627, 3303, 
10598, 29789 
77 307 1547
8 
4.5834 0.7633 0.0372 5.3122 
GOTERM_MF_FA
T 
GO:001661
4 
oxidoreductase 
activity, acting on 
CH-OH group of 
donors 
5 6.329 0.00460648
5 
9380, 51144, 50814, 3028, 3615 77 137 1547
8 
7.3362 0.8129 0.0421 6.1516 
GOTERM_MF_FA
T 
GO:005083
9 
cell adhesion 
molecule binding 
8 10.12
7 
0.00740972
4 
9045, 55379, 10938, 4627, 3303, 
83706, 10598, 29789 
77 461 1547
8 
3.4883 0.9328 0.0653 9.7214 
GOTERM_MF_FA
T 
GO:000519
8 
structural molecule 
activity 
10 12.65
8 
0.01411973
7 
9045, 6228, 6124, 6133, 7846, 
1213, 6161, 51649, 1314, 6191 
77 782 1547
8 
2.5705 0.9943 0.1183 17.761
2 
GOTERM_MF_FA
T 
GO:005102
0 
GTPase binding 6 7.595 0.01953406
1 
55920, 1434, 10938, 3842, 4905, 
2058 
77 316 1547
8 
3.8167 0.9992 0.1568 23.758
9 
GOTERM_MF_FA
T 
GO:001990
4 
protein domain 
specific binding 
8 10.12
7 
0.03085376
9 
55920, 4670, 11338, 7846, 4627, 
3303, 4905, 55114 
77 614 1547
8 
2.6191 1.0000 0.2325 35.010
9 
GOTERM_MF_FA
T 
GO:000552
5 
GTP binding 6 7.595 0.04038945
6 
81876, 10938, 7846, 7284, 1731, 
29789 
77 384 1547
8 
3.1408 1.0000 0.2883 43.273
0 
GOTERM_MF_FA
T 
GO:001701
6 
Ras GTPase binding 5 6.329 0.04327477
5 
55920, 1434, 10938, 3842, 4905 77 269 1547
8 
3.7363 1.0000 0.3001 45.574
0 
GOTERM_MF_FA
T 
GO:003256
1 
guanyl 
ribonucleotide 
binding 
6 7.595 0.04882058
6 
81876, 10938, 7846, 7284, 1731, 
29789 
77 405 1547
8 
2.9780 1.0000 0.3263 49.755
5 
GOTERM_MF_FA
T 
GO:001900
1 
guanyl nucleotide 
binding 
6 7.595 0.04924628
7 
81876, 10938, 7846, 7284, 1731, 
29789 
77 406 1547
8 
2.9706 1.0000 0.3230 50.063
8 
GOTERM_MF_FA
T 
GO:004487
7 
macromolecular 
complex binding 
12 15.19
0 
0.05334562
8 
10128, 6637, 9775, 4627, 10856, 
51144, 6749, 6472, 83706, 4905, 
29789, 6421 
77 1306 1547
8 
1.8470 1.0000 0.3394 52.944
5 
GOTERM_MF_FA
T 
GO:003126
7 
small GTPase 
binding 
5 6.329 0.05484535
8 
55920, 1434, 10938, 3842, 4905 77 291 1547
8 
3.4538 1.0000 0.3416 53.959
3 
KEGG_PATHWAY hsa03040:Spliceosome 9 11.39
2 
3.01E-06 23020, 4670, 27339, 11338, 
6637, 6635, 9775, 3303, 1655 
49 133 6910 9.5427 0.0002 0.0002 0.0032 
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KEGG_PATHWAY hsa03010:Ribosome 6 7.595 0.0023817 9045, 6228, 6124, 6133, 6161, 
6191 
49 136 6910 6.2215 0.1658 0.0866 2.4780 
KEGG_PATHWAY hsa01130:Biosynthesis of antibiotics 6 7.595 0.01520988
3 
47, 2618, 6472, 50814, 3028, 38 49 212 6910 3.9911 0.6880 0.3218 14.894
9 
KEGG_PATHWAY hsa01100:Metabolic pathways 14 17.72
2 
0.07142439
9 
9380, 47, 2618, 3028, 3615, 38, 
790, 5049, 539, 51144, 6472, 
50814, 10728, 2058 
49 1228 6910 1.6077 0.9964 0.7554 54.149
8 
 
Appendix 4: Down regulated proteins in JVM2 CYR61/CCN1 OE model.  
Category Term GO TERM Coun
t 
% PValue Genes List 
Tota
l 
Pop 
Hits 
Pop 
Total 
Fold 
Enrichmen
t 
Bonferroni Benjamini FDR 
GOTERM_BP_FA
T 
GO:190170
0 
response to 
oxygen-
containing 
compound 
5 45.4545454
5 
0.00815069
8 
4282, 523, 55937, 4736, 5052 11 146
6 
16650 5.16247054
4 
0.998782504 0.998782504 11.8414847 
GOTERM_BP_FA
T 
GO:004424
8 
cellular 
catabolic 
process 
5 45.4545454
5 
0.01149951
6 
3094, 3303, 4736, 6165, 5052 11 161
6 
16650 4.68328082
8 
0.999923959 0.991279862 16.3155221
4 
GOTERM_BP_FA
T 
GO:004259
2 
homeostatic 
process 
5 45.4545454
5 
0.01223894
8 
4282, 523, 55937, 5052, 
94081 
11 164
5 
16650 4.60071843
1 
0.999958832 0.965470893 17.274359 
GOTERM_BP_FA
T 
GO:003303
6 
macromolecule 
localization 
6 54.5454545
5 
0.01643970
9 
4282, 523, 55937, 4736, 6165, 
5052 
11 281
7 
16650 3.22393261
7 
0.99999875 0.966564926 22.5294870
3 
GOTERM_BP_FA
T 
GO:001503
1 
protein 
transport 
5 45.4545454
5 
0.01873064
1 
4282, 523, 4736, 6165, 5052 11 186
0 
16650 4.06891495
6 
0.999999815 0.954993942 25.2622069
8 
GOTERM_BP_FA
T 
GO:000679
6 
phosphate-
containing 
compound 
metabolic 
process 
6 54.5454545
5 
0.02392546
1 
4282, 2079, 523, 3094, 3303, 
5052 
11 308
3 
16650 2.94577300
7 
0.999999998 0.963467907 31.1284644
2 
GOTERM_BP_FA
T 
GO:000679
3 
phosphorus 
metabolic 
process 
6 54.5454545
5 
0.02411757 4282, 2079, 523, 3094, 3303, 
5052 
11 308
9 
16650 2.94005120
8 
0.999999998 0.942721358 31.3369168
7 
GOTERM_BP_FA
T 
GO:004518
4 
establishment 
of protein 
localization 
5 45.4545454
5 
0.02484213
5 
4282, 523, 4736, 6165, 5052 11 202
1 
16650 3.74477081
6 
0.999999999 0.924110779 32.117823 
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GOTERM_BP_FA
T 
GO:000810
4 
protein 
localization 
5 45.4545454
5 
0.04680027
8 
4282, 523, 4736, 6165, 5052 11 244
8 
16650 3.09157754 1 0.987311139 52.1991366 
GOTERM_BP_FA
T 
GO:000996
6 
regulation of 
signal 
transduction 
5 45.4545454
5 
0.06604963 4282, 2079, 3094, 3303, 5052 11 272
8 
16650 2.77426019
7 
1 0.996314033 65.0866445 
GOTERM_BP_FA
T 
GO:001003
3 
response to 
organic 
substance 
5 45.4545454
5 
0.07340082
1 
4282, 523, 3303, 55937, 4736 11 282
2 
16650 2.68185039
6 
1 0.996596369 69.0870028
6 
GOTERM_BP_FA
T 
GO:004408
5 
cellular 
component 
biogenesis 
5 45.4545454
5 
0.08102963
7 
4282, 3303, 55937, 4736, 
6165 
11 291
4 
16650 2.59717975
9 
1 0.996893513 72.7824214
6 
GOTERM_BP_FA
T 
GO:001064
6 
regulation of 
cell 
communication 
5 45.4545454
5 
0.09034968 4282, 2079, 3094, 3303, 5052 11 302
0 
16650 2.50602047 1 0.997453589 76.7365568
5 
GOTERM_BP_FA
T 
GO:002305
1 
regulation of 
signaling 
5 45.4545454
5 
0.09494181
6 
4282, 2079, 3094, 3303, 5052 11 307
0 
16650 2.46520580
4 
1 0.997099448 78.4808291
6 
GOTERM_CC_FA
T 
GO:000573
9 
mitochondrion 6 54.5454545
5 
0.00330940
2 
8402, 523, 3303, 6165, 5052, 
94081 
11 170
0 
14527 4.66106951
9 
0.235479265 0.235479265 3.47111249
8 
GOTERM_CC_FA
T 
GO:004442
1 
extracellular 
region part 
8 72.7272727
3 
0.00522783
2 
4282, 523, 3094, 3303, 55937, 
4736, 6165, 5052 
11 387
8 
14527 2.72436588
7 
0.345945849 0.191263856 5.43292869
7 
GOTERM_CC_FA
T 
GO:007006
2 
extracellular 
exosome 
7 63.6363636
4 
0.00534770
8 
4282, 523, 3094, 55937, 4736, 
6165, 5052 
11 281
1 
14527 3.28867113 0.352299415 0.13478356 5.55430841
8 
GOTERM_CC_FA
T 
GO:190356
1 
extracellular 
vesicle 
7 63.6363636
4 
0.0054882 4282, 523, 3094, 55937, 4736, 
6165, 5052 
11 282
5 
14527 3.27237329 0.359668034 0.105456847 5.69638174
1 
GOTERM_CC_FA
T 
GO:004323
0 
extracellular 
organelle 
7 63.6363636
4 
0.00549834
3 
4282, 523, 3094, 55937, 4736, 
6165, 5052 
11 282
6 
14527 3.27121533
8 
0.360196824 0.085446158 5.70663177
7 
GOTERM_CC_FA
T 
GO:000557
6 
extracellular 
region 
8 72.7272727
3 
0.01497885 4282, 523, 3094, 3303, 55937, 
4736, 6165, 5052 
11 462
3 
14527 2.28533223
2 
0.705496804 0.184329037 14.8573529
8 
GOTERM_CC_FA
T 
GO:003198
8 
membrane-
bounded 
vesicle 
7 63.6363636
4 
0.01914115
4 
4282, 523, 3094, 55937, 4736, 
6165, 5052 
11 361
1 
14527 2.56008156
9 
0.791009011 0.200395249 18.6143436 
GOTERM_MF_FA
T 
GO:004482
2 
poly(A) RNA 
binding 
5 45.4545454
5 
0.00325896
3 
8402, 2079, 4736, 6165, 5052 10 119
6 
15478 6.47073578
6 
0.278504044 0.278504044 3.55829294
8 
GOTERM_MF_FA
T 
GO:000372
3 
RNA binding 5 45.4545454
5 
0.01056989
3 
8402, 2079, 4736, 6165, 5052 10 165
6 
15478 4.67330917
9 
0.654449021 0.412164156 11.1253588
5 
GOTERM_MF_FA
T 
GO:190136
3 
heterocyclic 
compound 
binding 
8 72.7272727
3 
0.02014108
3 
8402, 2079, 523, 3094, 3303, 
4736, 6165, 5052 
10 597
1 
15478 2.07375649 0.869276124 0.492481779 20.2150151
8 
GOTERM_MF_FA
T 
GO:009715
9 
organic cyclic 
compound 
binding 
8 72.7272727
3 
0.02183307 8402, 2079, 523, 3094, 3303, 
4736, 6165, 5052 
10 605
2 
15478 2.04600132
2 
0.890024074 0.424130064 21.7309076 
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